0001493152-25-00643610-Q Sonnet BioTherapeutics Holdings, Inc. 2025021320250213161523161525161525 0 0001493152-25-006436 10-Q 53 20241231 20250213 20250213 Sonnet BioTherapeutics Holdings, Inc. 0001106838 2834 522102141 DE 0930 10-Q 34 001-35570 25620471 100 OVERLOOK CENTER SUITE 102 PRINCETON NJ 08540 609-375-2227 100 OVERLOOK CENTER SUITE 102 PRINCETON NJ 08540 Chanticleer Holdings, Inc. 20050510 TULVINE SYSTEMS INC 20000214 10-Q 1 form10-q.htm false --09-30 Q1 0001106838 0001106838 2024-10-01 2024-12-31 0001106838 2025-02-12 0001106838 2024-12-31 0001106838 2024-09-30 0001106838 2023-10-01 2023-12-31 0001106838 us-gaap:CommonStockMember 2024-09-30 0001106838 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001106838 us-gaap:RetainedEarningsMember 2024-09-30 0001106838 us-gaap:CommonStockMember 2023-09-30 0001106838 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001106838 us-gaap:RetainedEarningsMember 2023-09-30 0001106838 2023-09-30 0001106838 us-gaap:CommonStockMember 2024-10-01 2024-12-31 0001106838 us-gaap:AdditionalPaidInCapitalMember 2024-10-01 2024-12-31 0001106838 us-gaap:RetainedEarningsMember 2024-10-01 2024-12-31 0001106838 us-gaap:CommonStockMember 2023-10-01 2023-12-31 0001106838 us-gaap:AdditionalPaidInCapitalMember 2023-10-01 2023-12-31 0001106838 us-gaap:RetainedEarningsMember 2023-10-01 2023-12-31 0001106838 us-gaap:CommonStockMember 2024-12-31 0001106838 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001106838 us-gaap:RetainedEarningsMember 2024-12-31 0001106838 us-gaap:CommonStockMember 2023-12-31 0001106838 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001106838 us-gaap:RetainedEarningsMember 2023-12-31 0001106838 2023-12-31 0001106838 us-gaap:DomesticCountryMember 2024-12-31 0001106838 SONN:ResearchAndDevelopmentTaxIncentiveProgramMember 2024-10-01 2024-12-31 0001106838 SONN:ResearchAndDevelopmentTaxIncentiveProgramMember 2024-12-31 0001106838 SONN:ResearchAndDevelopmentTaxIncentiveProgramMember 2024-11-30 2024-11-30 0001106838 2023-01-12 2023-12-31 0001106838 2024-09-25 2024-09-25 0001106838 SONN:PrefundedOctoberTwoThousandTwentyThreeWarrantsMember 2024-12-31 0001106838 SONN:PrefundedDecemberTwoThousandTwentyFourWarrantsMember 2024-12-31 0001106838 SONN:PrefundedOctoberTwoThousandTwentyThreeWarrantsMember 2023-12-31 0001106838 SONN:CommonStockWarrantsAugustTwoThousandTwentyOneMember 2024-10-01 2024-12-31 0001106838 SONN:CommonStockWarrantsAugustTwoThousandTwentyOneMember 2023-10-01 2023-12-31 0001106838 SONN:UnderwriterWarrantsAugustTwoThousandTwentyOneMember 2024-10-01 2024-12-31 0001106838 SONN:UnderwriterWarrantsAugustTwoThousandTwentyOneMember 2023-10-01 2023-12-31 0001106838 SONN:ChanticleerWarrantsMember 2024-10-01 2024-12-31 0001106838 SONN:ChanticleerWarrantsMember 2023-10-01 2023-12-31 0001106838 SONN:SeriesCWarrantsMember 2024-10-01 2024-12-31 0001106838 SONN:SeriesCWarrantsMember 2023-10-01 2023-12-31 0001106838 SONN:SeriesThreeWarrantsMember 2024-10-01 2024-12-31 0001106838 SONN:SeriesThreeWarrantsMember 2023-10-01 2023-12-31 0001106838 SONN:UnvestedRestrictedStockUnitsAndAwardsMember 2024-10-01 2024-12-31 0001106838 SONN:UnvestedRestrictedStockUnitsAndAwardsMember 2023-10-01 2023-12-31 0001106838 SONN:CommonStockWarrantsFebruaryTwoThousandTwentyThreeMember 2024-10-01 2024-12-31 0001106838 SONN:CommonStockWarrantsFebruaryTwoThousandTwentyThreeMember 2023-10-01 2023-12-31 0001106838 SONN:UnderwriterWarrantsFebruaryTwoThousandTwentyThreeMember 2024-10-01 2024-12-31 0001106838 SONN:UnderwriterWarrantsFebruaryTwoThousandTwentyThreeMember 2023-10-01 2023-12-31 0001106838 SONN:CommonStockPrivatePlacementWarrantsJuneTwoThousandTwentyThreeMember 2024-10-01 2024-12-31 0001106838 SONN:CommonStockPrivatePlacementWarrantsJuneTwoThousandTwentyThreeMember 2023-10-01 2023-12-31 0001106838 SONN:PlacementAgentWarrantsJuneTwoThousandTwentyThreeMember 2024-10-01 2024-12-31 0001106838 SONN:PlacementAgentWarrantsJuneTwoThousandTwentyThreeMember 2023-10-01 2023-12-31 0001106838 SONN:CommonStockWarrantsOctoberTwoThousandTwentyThreeMember 2024-10-01 2024-12-31 0001106838 SONN:CommonStockWarrantsOctoberTwoThousandTwentyThreeMember 2023-10-01 2023-12-31 0001106838 SONN:UnderwriterWarrantsOctoberTwoThousandTwentyThreeMember 2024-10-01 2024-12-31 0001106838 SONN:UnderwriterWarrantsOctoberTwoThousandTwentyThreeMember 2023-10-01 2023-12-31 0001106838 SONN:PlacementAgentWarrantsJuneTwoThousandTwentyFourMember 2024-10-01 2024-12-31 0001106838 SONN:PlacementAgentWarrantsJuneTwoThousandTwentyFourMember 2023-10-01 2023-12-31 0001106838 SONN:CommonStockWarrantsJuneTwoThousandTwentyFourMember 2024-10-01 2024-12-31 0001106838 SONN:CommonStockWarrantsJuneTwoThousandTwentyFourMember 2023-10-01 2023-12-31 0001106838 SONN:CommonStockWarrantsNovemberTwoThousandTwentyFourMember 2024-10-01 2024-12-31 0001106838 SONN:CommonStockWarrantsNovemberTwoThousandTwentyFourMember 2023-10-01 2023-12-31 0001106838 SONN:CommonStockRegisteredDirectWarrantsDecemberTwoThousandTwentyFourMember 2024-10-01 2024-12-31 0001106838 SONN:CommonStockRegisteredDirectWarrantsDecemberTwoThousandTwentyFourMember 2023-10-01 2023-12-31 0001106838 SONN:CommonStockPIPEWarrantsDecemberTwoThousandTwentyFourMember 2024-10-01 2024-12-31 0001106838 SONN:CommonStockPIPEWarrantsDecemberTwoThousandTwentyFourMember 2023-10-01 2023-12-31 0001106838 SONN:DiscoveryCollaborationAgreementsMember SONN:XOMAMember 2012-07-31 0001106838 SONN:DiscoveryCollaborationAgreementsMember SONN:XOMAMember us-gaap:InProcessResearchAndDevelopmentMember 2022-04-01 2022-04-30 0001106838 SONN:DiscoveryCollaborationAgreementsMember SONN:XOMAMember us-gaap:InProcessResearchAndDevelopmentMember 2024-10-01 2024-12-31 0001106838 SONN:DiscoveryCollaborationAgreementsMember SONN:XOMAMember us-gaap:InProcessResearchAndDevelopmentMember 2023-10-01 2023-12-31 0001106838 SONN:DiscoveryCollaborationAgreementsMember 2024-10-01 2024-12-31 0001106838 SONN:DiscoveryCollaborationAgreementsMember 2023-10-01 2023-12-31 0001106838 SONN:CellcaAgreementMember 2024-10-01 2024-12-31 0001106838 SONN:CellcaAgreementMember srt:MaximumMember 2019-01-31 0001106838 SONN:CellcaAgreementMember srt:MinimumMember 2024-12-31 0001106838 SONN:CellcaAgreementMember srt:MaximumMember 2024-12-31 0001106838 SONN:CellcaAgreementMember 2024-12-31 0001106838 SONN:CellcaAgreementMember us-gaap:InProcessResearchAndDevelopmentMember 2022-04-30 0001106838 SONN:CellcaAgreementMember us-gaap:InProcessResearchAndDevelopmentMember 2024-10-01 2024-12-31 0001106838 SONN:CellcaAgreementMember us-gaap:InProcessResearchAndDevelopmentMember 2023-10-01 2023-12-31 0001106838 SONN:TheBrinkAgreementMember us-gaap:InProcessResearchAndDevelopmentMember 2024-12-31 0001106838 SONN:TheBrinkAgreementMember 2023-04-30 0001106838 SONN:TheBrinkAgreementMember 2024-12-31 0001106838 SONN:TheBrinkAgreementMember 2024-10-01 2024-12-31 0001106838 SONN:TheBrinkAgreementMember 2023-10-01 2023-12-31 0001106838 SONN:InvivoGenAgreementMember 2024-12-31 0001106838 SONN:InvivoGenAgreementMember 2024-10-01 2024-12-31 0001106838 SONN:InvivoGenAgreementMember 2023-10-01 2023-12-31 0001106838 SONN:SOCAgreementMember 2024-08-01 2024-08-31 0001106838 SONN:NavigoAgreementMember SONN:NavigoProteinsGmbHMember us-gaap:TechnologyServiceMember 2021-12-01 2021-12-31 0001106838 SONN:NavigoAgreementMember SONN:NavigoProteinsGmbHMember us-gaap:TechnologyServiceMember 2021-12-31 0001106838 SONN:LicenseAgreementMember 2024-10-01 2024-12-31 0001106838 SONN:AlkemAgreementMember 2024-10-08 2024-10-08 0001106838 SONN:AlkemAgreementMember 2024-10-01 2024-12-31 0001106838 SONN:AlkemAgreementMember 2024-12-31 0001106838 SONN:OctoberOfferingMember SONN:UnderwritersMember 2023-10-26 2023-10-26 0001106838 SONN:OctoberOfferingMember us-gaap:CommonStockMember SONN:UnderwritersMember 2023-10-26 2023-10-26 0001106838 SONN:OctoberOfferingMember SONN:PrefundedWarrantMember SONN:UnderwritersMember 2023-10-26 0001106838 SONN:OctoberOfferingMember SONN:CommonWarrantMember SONN:UnderwritersMember 2023-10-26 0001106838 SONN:OctoberOfferingMember SONN:UnderwritersMember SONN:JuneTwentyTwentyFourInducementOfferMember 2023-10-26 2023-10-26 0001106838 SONN:OctoberOfferingMember SONN:UnderwritersMember 2023-10-26 0001106838 SONN:PurchaseAndRegistrationRightsAgreementMember us-gaap:CommonStockMember 2024-05-02 2024-05-02 0001106838 SONN:PurchaseAndRegistrationRightsAgreementMember 2024-12-31 0001106838 SONN:PurchaseAndRegistrationRightsAgreementMember us-gaap:CommonStockMember 2024-05-02 0001106838 SONN:PurchaseAndRegistrationRightsAgreementMember us-gaap:CommonStockMember 2024-10-01 2024-12-31 0001106838 SONN:UnderwritingAgreementMember SONN:ChardanCapitalMarketsLLCMember 2024-11-07 2024-11-07 0001106838 SONN:UnderwritingAgreementMember SONN:ChardanCapitalMarketsLLCMember SONN:PrefundedWarrantMember 2024-11-07 0001106838 SONN:UnderwritingAgreementMember SONN:ChardanCapitalMarketsLLCMember SONN:CommonWarrantMember 2024-11-07 0001106838 SONN:RegisteredDirectOfferingMember SONN:PrefundedWarrantMember 2024-12-10 2024-12-10 0001106838 SONN:RegisteredDirectOfferingMember SONN:PrefundedWarrantMember 2024-12-10 0001106838 SONN:RegisteredDirectOfferingMember us-gaap:WarrantMember 2024-12-10 0001106838 SONN:RegisteredDirectOfferingMember 2024-12-10 0001106838 SONN:RegisteredDirectOfferingMember SONN:PrefundedWarrantMember 2024-12-10 0001106838 us-gaap:PrivatePlacementMember SONN:PrefundedWarrantMember 2024-12-10 2024-12-10 0001106838 us-gaap:PrivatePlacementMember SONN:PrefundedWarrantMember 2024-12-10 0001106838 us-gaap:PrivatePlacementMember us-gaap:WarrantMember 2024-12-10 0001106838 us-gaap:PrivatePlacementMember 2024-12-10 0001106838 SONN:RegisteredDirectOfferingMember 2024-12-10 2024-12-10 0001106838 SONN:CommonStockWarrantsMember 2024-06-30 0001106838 SONN:CommonStockWarrantsMember 2024-12-31 0001106838 SONN:CommonStockWarrantsMember 2024-10-01 2024-12-31 0001106838 SONN:PreFundedWarrantsMember 2024-10-01 2024-12-31 0001106838 SONN:CommonStockWarrantsMember 2023-10-01 2023-12-31 0001106838 SONN:HolderMember SONN:CommonStockWarrantsMember 2023-10-01 2023-12-31 0001106838 SONN:CommonStockWarrantsAugustTwoThousandTwentyOneMember 2024-12-31 0001106838 SONN:UnderwriterWarrantsAugustTwoThousandTwentyOneMember 2024-12-31 0001106838 SONN:ChanticleerWarrantsMember 2024-12-31 0001106838 SONN:ChanticleerWarrantsMember srt:MinimumMember 2024-12-31 0001106838 SONN:ChanticleerWarrantsMember srt:MaximumMember 2024-12-31 0001106838 SONN:SeriesCWarrantsMember 2024-12-31 0001106838 SONN:SeriesThreeWarrantsMember 2024-12-31 0001106838 SONN:CommonStockWarrantsFebruaryTwoThousandTwentyThreeMember 2024-12-31 0001106838 SONN:UnderwriterWarrantFebruaryTwoThousandTwentyThreeMember 2024-12-31 0001106838 SONN:CommonStockPrivatePlacementWarrantsJuneTwoThousandTwentyThreeMember 2024-12-31 0001106838 SONN:PlacementAgentWarrantsJuneTwoThousandTwentyThreeMember 2024-12-31 0001106838 SONN:CommonStockWarrantsOctoberTwoThousandTwentyThreeMember 2024-12-31 0001106838 SONN:PrefundedWarrantsOctoberTwoThousandTwentyThreeMember 2024-12-31 0001106838 SONN:UnderwriterWarrantsOctoberTwoThousandTwentyThreeMember 2024-12-31 0001106838 SONN:PlacementAgentWarrantsJuneTwoThousandTwentyFourMember 2024-12-31 0001106838 SONN:CommonStockWarrantsJuneTwoThousandTwentyFourMember 2024-12-31 0001106838 SONN:CommonStockWarrantsNovemberTwoThousandTwentyFourMember 2024-12-31 0001106838 SONN:CommonStockWarrantsRegisteredDirectWarrantsDecemberTwoThousandTwentyFourMember 2024-12-31 0001106838 SONN:CommonStockPIPEWarrantsDecemberTwoThousandTwentyFourMember 2024-12-31 0001106838 SONN:PreFundedWarrantsDecemberTwoThousandTwentyFourMember 2024-12-31 0001106838 SONN:TwoThousandTwentyOmnibusEquityIncentivePlanMember 2024-12-31 0001106838 SONN:TwoThousandTwentyOmnibusEquityIncentivePlanMember us-gaap:SubsequentEventMember 2025-01-01 0001106838 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-01-01 0001106838 SONN:RestrictedStockAwardsMember 2024-01-01 2024-01-01 0001106838 us-gaap:SubsequentEventMember 2025-01-01 2025-01-01 0001106838 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001106838 SONN:RestrictedStockAwardsMember 2024-12-31 0001106838 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-10-01 2024-12-31 0001106838 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-10-01 2023-12-31 0001106838 us-gaap:RestrictedStockUnitsRSUMember us-gaap:GeneralAndAdministrativeExpenseMember 2024-10-01 2024-12-31 0001106838 us-gaap:RestrictedStockUnitsRSUMember us-gaap:GeneralAndAdministrativeExpenseMember 2023-10-01 2023-12-31 0001106838 SONN:PurchaseAgreementMember us-gaap:SubsequentEventMember 2025-01-01 2025-01-01 0001106838 us-gaap:SubsequentEventMember us-gaap:DomesticCountryMember 2025-01-01 0001106838 us-gaap:SubsequentEventMember 2025-02-12 2025-02-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares iso4217:EUR xbrli:pure SONN:Segment Â Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â FORM 10-Q Â (Mark One) Â â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the quarterly period ended December 31, 2024 Â OR Â â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the transition period from _____ to _____ Â Commission file number: 001-35570 Â SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact Name of Registrant as Specified in Its Charter) Â Delaware Â 20-2932652 (State or Other Jurisdiction of Â (I.R.S. Employer Incorporation or Organization) Â Identification No.) Â 100 Overlook Center, Suite 102, Princeton, NJ Â 08540 (Address of Principal Executive Offices) Â (Zip Code) Â (609) 375-2227 (Registrantâ€™s Telephone Number, Including Area Code) Â Not applicable (Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report) Â Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Â Trading Symbol(s) Â Name of each exchange on which registered Common Stock, par value $0.0001 per share Â SONN Â The Nasdaq Capital Market LLC Â Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. â˜’ Yes â˜ No Â Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). â˜’ Yes â˜ No Â Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated filer â˜ Accelerated filer â˜ Â Â Â Â Â Non-accelerated filer â˜’ Smaller reporting company â˜’ Â Â Â Â Â Â Emerging growth company â˜ Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Â Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). â˜ Yes â˜’ No Â There were 3,065,701 shares of common stock, par value $0.0001 per share, of Sonnet BioTherapeutics Holdings, Inc. issued and outstanding as of February 12, 2025. Â Â Â Â Â Â Sonnet BioTherapeutics Holdings, Inc. and Subsidiaries Â Â Â Page No. Â Â Â Part I Financial Information 3 Â Â Â Item 1: Financial Statements (unaudited) 3 Â Â Â Â Â Consolidated Balance Sheets 4 Â Consolidated Statements of Operations 5 Â Consolidated Statements of Changes in Stockholdersâ€™ Equity (Deficit) 6 Â Consolidated Statements of Cash Flows 7 Â Notes to Interim Consolidated Financial Statements 8 Item 2: Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3: Quantitative and Qualitative Disclosures about Market Risk 36 Item 4: Controls and Procedures 36 Â Â Â Part II Other Information 37 Â Â Â Item 1: Legal Proceedings 37 Item 1A: Risk Factors 37 Item 2: Unregistered Sales of Equity Securities and Use of Proceeds 37 Item 3: Defaults Upon Senior Securities 37 Item 4: Mine Safety Disclosures 37 Item 5: Other Information 37 Item 6: Exhibits 38 Â Â Â Signatures 39 Â 2 Â Â SONNET BIOTHERAPEUTICS HOLDINGS, INC. Â INDEX TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS Â PART I - FINANCIAL INFORMATION Â Item 1: Financial Statements. Â Â Page Â Â Consolidated Balance Sheets 4 Consolidated Statements of Operations 5 Consolidated Statements of Changes in Stockholdersâ€™ Equity (Deficit) 6 Consolidated Statements of Cash Flows 7 Notes to Interim Consolidated Financial Statements 8 Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 22 Â 3 Â Â Sonnet BioTherapeutics Holdings, Inc. Consolidated Balance Sheets (unaudited) Â Â Â December 31, 2024Â Â September 30, 2024Â AssetsÂ Â Â Â Â Â Â Â Current assets:Â Â Â Â Â Â Â Â CashÂ $4,861,503Â Â $149,456Â Unbilled collaboration revenueÂ Â 500,000Â Â Â Â â€”Â Prepaid expenses and other current assetsÂ Â 1,196,868Â Â Â 1,206,409Â Incentive tax receivableÂ Â 166,792Â Â Â 762,078Â Total current assetsÂ Â 6,725,163Â Â Â 2,117,943Â Property and equipment, netÂ Â 17,312Â Â Â 20,523Â Operating lease right-of-use assetÂ Â 104,435Â Â Â 123,417Â Deferred offering costsÂ Â 122,058Â Â Â 15,000Â Other assetsÂ Â 213,059Â Â Â 494,147Â Total assetsÂ $7,182,027Â Â $2,771,030Â Liabilities and stockholdersâ€™ equity (deficit)Â Â Â Â Â Â Â Â Current liabilities:Â Â Â Â Â Â Â Â Accounts payableÂ $1,639,981Â Â $2,183,416Â Accrued expenses and other current liabilitiesÂ Â 1,394,520Â Â Â 942,489Â Current portion of operating lease liabilityÂ Â 87,323Â Â Â 84,291Â Total current liabilitiesÂ Â 3,121,824Â Â Â 3,210,196Â Operating lease liability, net of current portionÂ Â 23,634Â Â Â 46,573Â Total liabilitiesÂ Â 3,145,458Â Â Â 3,256,769Â Commitments and contingencies (Note 4)Â Â -Â Â Â Â -Â Â Stockholdersâ€™ equity (deficit):Â Â Â Â Â Â Â Â Preferred stock, $0.0001 par value: 5,000,000 shares authorized; no shares issued or outstandingÂ Â Â â€”Â Â

Â â€”Â Common stock, $0.0001 par value: 125,000,000 shares authorized; 3,007,431 and 650,284 issued and outstanding at December 31, 2024 and September 30, 2024, respectivelyÂ Â 300Â Â Â 65Â Additional paid-in capitalÂ Â 124,877,960Â Â Â 117,195,181Â Accumulated deficitÂ Â (120,841,691)Â Â (117,680,985) Total stockholdersâ€™ equity (deficit)Â Â 4,036,569Â Â Â (485,739) Total liabilities and stockholdersâ€™ equity (deficit)Â $7,182,027Â Â $2,771,030Â Â Â See accompanying notes to unaudited interim consolidated financial statements Â 4Â Â Â Sonnet BioTherapeutics Holdings, Inc. Consolidated Statements of Operations (unaudited) Â Â Â 2024Â Â 2023Â Â Â Three Months Ended December 31,Â Â Â 2024Â Â 2023Â Collaboration revenueÂ $1,000,000Â Â $18,626Â Operating expenses:Â Â Â Â Â Â Â Research and developmentÂ Â 1,886,076Â Â Â 644,042Â General and administrativeÂ Â 1,963,346Â Â Â 653,455Â Total operating expensesÂ Â 3,849,422Â Â Â 1,297,497Â Loss from operationsÂ Â (2,849,422)Â Â (1,278,871) Foreign exchange (loss) gainÂ Â (152,884)Â Â 110,362Â Loss before provision from income taxesÂ Â (3,002,306)Â Â (1,168,509) Provision for income taxesÂ Â (158,400)Â Â â€”Â Net lossÂ $(3,160,706)Â $(1,168,509) Â Â Â Â Â Â Â Â Â Per share information:Â Â Â Â Â Â Â Â Net loss per share, basic and dilutedÂ $(1.56)Â Â $(2.46) Weighted average shares outstanding, basic and dilutedÂ Â 2,022,818Â Â Â 474,699Â Â Â See accompanying notes to unaudited interim consolidated financial statements Â 5Â Â Sonnet BioTherapeutics Holdings, Inc. Consolidated Statements of Changes in Stockholdersâ€™ Equity (Deficit) (unaudited) Â Â Â SharesÂ Â AmountÂ Â capitalÂ Â deficitÂ Â TotalÂ Â Â Common stockÂ Â Additional paid-inÂ Â AccumulatedÂ Â Â Â Â Â SharesÂ Â AmountÂ Â capitalÂ Â deficitÂ Â TotalÂ Balance at October 1, 2024Â Â 650,284Â Â Â $65Â Â $117,195,181Â Â $(117,680,985)Â $(485,739) Sale of common stock, net of issuance costsÂ Â 1,050,500Â Â Â 105Â Â Â 7,622,514Â Â Â â€”Â Â Â 7,622,619Â Retirement of shares in connection with reverse stock splitÂ Â (373)Â Â â€”Â Â Â â€”Â Â Â â€”Â Shares released from abeyanceÂ Â 32,375Â Â Â 3Â Â Â (3)Â Â Â â€”Â Â Â â€”Â Net share settlement of warrantsÂ Â 1,209Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Exercise of warrantsÂ Â 1,273,436Â Â Â 127Â Â Â (127)Â Â Â â€”Â Â Â â€”Â Share-based compensationÂ Â â€”Â Â Â â€”Â Â Â 60,395Â Â Â â€”Â Â Â 60,395Â Net lossÂ Â â€”Â Â Â â€”Â Â Â â€”Â Â Â (3,160,706)Â Â Â (3,160,706) Balance at December 31, 2024Â Â 3,007,431Â Â Â $300Â Â Â $124,877,960Â Â Â $(120,841,691)Â Â $4,036,569 Â Â Â Common stockÂ Â Additional paid-inÂ Â AccumulatedÂ Â Â Â Â Â SharesÂ Â AmountÂ Â capitalÂ Â deficitÂ Â TotalÂ Balance at October 1, 2023Â Â 218,786Â Â Â $22Â Â $110,017,751Â Â $(110,243,753)Â $(225,980) BalanceÂ Â 218,786Â Â Â $22Â Â $110,017,751Â Â $(110,243,753)Â $(225,980) Sale of common stock, net of issuance costsÂ Â 163,281Â Â Â 16Â Â Â 3,916,927Â Â Â â€”Â Â Â 3,916,943Â Retirement of shares in connection with reverse stock splitÂ Â (190)Â Â â€”Â Â Â â€”Â Â Â â€”Â Net share settlement of warrantsÂ Â 1,795Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Share-based compensationÂ Â â€”Â Â Â â€”Â Â Â 50,005Â Â Â â€”Â Â Â 50,005Â Net lossÂ Â â€”Â Â Â â€”Â Â Â â€”Â Â Â (1,168,509)Â Â (1,168,509) Balance at December 31, 2023Â Â 383,672Â Â Â $38Â Â $113,984,683Â Â Â $(111,412,262)Â $2,572,459Â BalanceÂ Â 383,672Â Â Â $38Â Â Â $113,984,683Â Â Â $(111,412,262)Â $2,572,459Â Â Â See accompanying notes to unaudited interim consolidated financial statements Â 6Â Â Â Sonnet BioTherapeutics Holdings, Inc. Consolidated Statements of Cash Flows (unaudited) Â Â Â 2024Â Â Â 2023Â Â Â Three Months Ended December 31,Â Â Â 2024Â Â 2023Â Cash flows from operating activities:Â Â Â Â Â Â Â Â Net lossÂ $(3,160,706)Â $(1,168,509) Adjustments to reconcile net loss to net cash used in operating activities:Â Â Â Â Â Â Â Â DepreciationÂ Â 3,211Â Â Â 3,211Â Acquired in-process research and developmentÂ Â 12,000Â Â Â 12,000Â Amortization of operating lease right-of-use assetÂ Â 18,982Â Â Â 16,763Â Share-based compensationÂ Â 60,395Â Â Â 50,005Â Changes in operating assets and liabilities:Â Â Â Â Â Â Â Â Unbilled collaboration revenueÂ Â (500,000)Â Â â€”Â Prepaid expenses and other current assetsÂ Â 9,541Â Â Â 269,116Â Incentive tax receivableÂ Â 595,286Â Â Â 592,463Â Other assetsÂ Â 281,088Â Â Â (77,656) Accounts payableÂ Â (635,568)Â Â (465,735) Accrued expenses and other current liabilitiesÂ Â 425,432Â Â Â (2,287,544) Operating lease liabilityÂ Â (19,907)Â Â (17,225) Deferred incomeÂ Â â€”Â Â Â (18,626) Net cash used in operating activitiesÂ Â (2,910,246)Â Â (3,091,737) Cash flows from financing activities:Â Â Â Â Â Â Â Â Proceeds from issuance of common stock, net of issuance costsÂ Â 7,711,161Â Â Â 3,838,870Â Payment of deferred offering costsÂ Â (75,000)Â Â â€”Â Payment of warrant issuance costsÂ Â (13,868)Â Â â€”Â Net cash provided by financing activitiesÂ Â 7,622,293Â Â Â 3,838,870Â Â Â Â Â Â Â Â Net increase in cashÂ Â 4,712,047Â Â Â 747,133Â Cash, beginning of periodÂ Â 149,456Â Â Â 2,274,259Â Cash, end of periodÂ $4,861,503Â Â $3,021,392Â Â Â Â Â Â Â Â Supplemental disclosure of non-cash operating, investing and financing activities:Â Â Â Â Â Â Â Â In-process research and development in accrued expensesÂ $12,000Â Â $12,000Â Deferred offering costs in accounts payable and accrued expensesÂ $32,058Â Â $15,000Â Common stock issuance costs in accounts payableÂ $88,542Â Â â€”Â Â See accompanying notes to unaudited interim consolidated financial statements Â 7Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements Â 1. Organization and Description of Business Â Description of business Â Sonnet BioTherapeutics, Inc. (â€œPrior Sonnetâ€) was incorporated as a New Jersey corporation on April 6, 2015. Prior Sonnet completed a merger with publicly-held Chanticleer Holdings, Inc. (â€œChanticleerâ€) on April 1, 2020. After the merger, Chanticleer changed its name to Sonnet BioTherapeutics Holdings, Inc. (â€œSonnetâ€ or the â€œCompanyâ€). Sonnet is a clinical stage, oncology-focused biotechnology company with a proprietary platform for innovating biologic medicines of single or bifunctional action. Known as FHABâ„¢ (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and â€œhitch-hikesâ€ on human serum albumin (â€œHSAâ€) for transport to target tissues. Sonnet designed the construct to improve drug accumulation in solid tumors, as well as to extend the duration of activity in the body. FHAB development candidates can be produced in mammalian cell culture, which enables glycosylation of the interleukins, thereby reducing the risk of immunogenicity, as well as E. coli. Sonnet believes its FHAB technology, for which it received a U.S. patent in June 2021, is a distinguishing feature of its biopharmaceutical platform. The approach is well suited for future drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. Â Sonnetâ€™s lead proprietary asset, SON-1010, is a fully human version of Interleukin 12 (â€œIL-12â€), covalently linked to the FHAB construct, for which Sonnet is pursuing clinical development in solid tumor indications, including ovarian cancer, non-small cell lung cancer and head and neck cancer. In March 2022, the FDA cleared Sonnetâ€™s Investigational New Drug (â€œINDâ€) application for SON-1010. This allowed the Company to initiate a U.S. clinical trial (SB101) in oncology patients with solid tumors during the second calendar quarter of 2022. In September 2021, the Company created a wholly-owned Australian subsidiary, SonnetBio Pty Ltd (â€œSubsidiaryâ€), for the purpose of conducting certain clinical trials. Sonnet received approval and initiated an Australian clinical study (SB102) of SON-1010 in healthy volunteers during the third calendar quarter of 2022. Interim safety and tolerability data from the SB101 and SB102 studies were reported in April 2023. Â In January 2023, Sonnet announced a collaboration agreement with Roche for the clinical evaluation of SON-1010 with atezolizumab (TecentriqÂ®). The companies have entered into a Master Clinical Trial and Supply Agreement (â€œMCSAâ€), along with ancillary Quality and Safety Agreements, to study the safety and efficacy of the combination of SON-1010 and atezolizumab in a platinum-resistant ovarian cancer (â€œPROCâ€) patient setting. Further, the companies will provide SON-1010 and atezolizumab, respectively, for use in the Phase 1b/Phase 2a combination safety, dose-escalation, and proof-of-concept study (SB221). Part 1 of this 2-part study was approved in June 2023 by the local Human Research Ethics Committee in Australia under CT-2023-CTN-01399-1 and the Therapeutic Goods Administration has been notified. In August 2023, the FDA accepted the IND for SB221. The trial consists of a modified 3+3 dose-escalation design in Part 1 to establish the maximum tolerated dose (â€œMTDâ€) of SON-1010 with a fixed dose of atezolizumab. Clinical benefit in PROC will be confirmed in an expansion group to establish the recommended Phase 2 dose (â€œRP2Dâ€). Part 2 of the study will then investigate SON-1010 in combination with atezolizumab, or the standard of care (â€œSOCâ€) for PROC in a randomized comparison to show proof-of-concept (â€œPOCâ€). Â In January 2025, Sonnet announced an expansion of its Phase 1 SB101 clinical study of SON-1010 to add a new cohort to evaluate its effect in combination with trabectedin (YondelisÂ®), following the successful completion of monotherapy dose escalation. Trabectedin is an alkylating DNA-binding agent that was approved as a second-line treatment in early 2024 for patients with unresectable, metastatic liposarcoma or leiomyosarcoma who have received a prior anthracycline-containing regimen. It is also known to activate tumor macrophages into a pro-inflammatory phenotype. The Company believes that SON-1010 has the potential to complement that activity by activating the NK and T cells in the TME to secrete more interferon-gamma (IFNÎ³), which is considered to be important for anti-tumor control. Â 8Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements Â The Company acquired the global development rights to its most advanced compound, SON-080, a fully human version of Interleukin 6 (â€œIL-6â€), in April 2020 through its acquisition of the outstanding shares of Relief Therapeutics SA. Sonnet is advancing SON-080 in target indications of Chemotherapy-Induced Peripheral Neuropathy (â€œCIPNâ€) and Diabetic Peripheral Neuropathy (â€œDPNâ€). Sonnet received approval to initiate an ex-U.S. Phase 1b/2a study with SON-080 in CIPN during the third quarter of 2022. The Data Safety Monitoring Board (â€œDSMBâ€) overseeing the study met during the first calendar quarter of 2024 and cleared the trial to proceed to Part 2. Following the completion of the DSMB review, Sonnet announced initial safety data from the CIPN study. The objective will be to analyze the data and to consider initiating a Phase 2 study, pending the outcome of any partnering activity. On October 8, 2024, the Company entered into a License Agreement (the â€œAlkem Agreementâ€) with Alkem Laboratories Limited (â€œAlkemâ€) to develop and commercialize SON-080 for DPN in India. Alkem will conduct all clinical trials that it believes appropriate to obtain regulatory approval in India for SON-080 for the treatment of DPN. Â SON-1210 (IL12-FHAB-IL15), Sonnetâ€™s lead bifunctional construct, combines FHAB with single-chain human IL-12 and human Interleukin 15 (â€œIL-15â€). This compound is being developed for solid tumor indications, including colorectal and pancreatic cancer. In February 2023, Sonnet announced the successful completion of two IND-enabling toxicology studies with SON-1210 in non-human primates. In August 2024, the Company entered into a Master Clinical Collaboration Agreement (the â€œSOC Agreementâ€) with the Sarcoma Oncology Center (â€œSOCâ€) to advance the development of SON-1210. An Innovative Immuno Oncology Consortium (â€œIIOCâ€) that is funded by the SOC will conduct an investigator-initiated Phase 1b/2a study of SON-1210 in pancreatic cancer. The IIOC submitted a pre-IND package to the FDA. Based on the FDA feedback, preparations for the full IND submission package are underway. Â SON-1411 (IL18-FHAB-IL12) is a bifunctional combination of human Interleukin 18 (â€œIL-18â€), which was modified to resist interaction with the IL-18 inhibitor binding protein, and single-chain human IL-12 for solid tumor cancers. Cell line development and process development are ongoing, with early experimental drug supply suitable for formulation and analytical method development activities. After some delays in 2024, activities will continue through 2025 with the potential to generate a drug suitable for preclinical studies and subsequent human studies. Â Sonnet has completed sequence confirmation for SON-3015 (anti-IL6-FHAB-anti-TGFÎ²). Early-stage bifunctional drug has been generated and is being stored for future use in in vivo mice studies. The Company has elected to place the SON-3015 development program on hold for expense reduction purposes. Â Liquidity Â The Company has incurred recurring losses and negative cash flows from operations since inception and it expects to generate losses from operations for the foreseeable future primarily due to research and development costs for its potential product candidates. The Company believes its cash at DecemberÂ 31, 2024 of $4.9 million will fund the Companyâ€™s projected operations into July 2025. The Company received preliminary approval of its application to sell up to $0.8Â million of its New Jersey state net operating losses through the Technology Business Tax Certificate Transfer Program (the â€œProgramâ€), subject to execution of such sale (see Note 8). Substantial additional financing will be needed by the Company to fund its operations. These factors raise substantial doubt about the Companyâ€™s ability to continue as a going concern. The accompanying unaudited interim consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. However, substantial doubt about the Companyâ€™s ability to continue as a going concern exists. The unaudited interim consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Â The Company plans to secure additional capital in the future through equity or debt financings, including sales pursuant to its ChEF Purchase Agreement (the â€œPurchase Agreementâ€) with Chardan Capital Markets, LLC (â€œChardanâ€), related to a â€œChEF,â€ Chardanâ€™s committed equity facility (the â€œFacilityâ€); partnerships; collaborations; or other sources to carry out the Companyâ€™s planned development activities. If additional capital is not available when required, the Company may need to delay or curtail its operations until such funding is received. Various internal and external factors will affect whether and when the Companyâ€™s product candidates become approved for marketing and successful commercialization. The regulatory approval and market acceptance of the Companyâ€™s product candidates, length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the approval process will materially affect the Companyâ€™s financial condition and future operations. Â Operations since inception have consisted primarily of organizing the Company, securing financing, developing technologies through research and development and conducting preclinical studies. The Company faces risks associated with companies whose products are in development. These risks include the need for additional financing to complete its research and development, achieving its research and development objectives, defending its intellectual property rights, recruiting and retaining skilled personnel, and dependence on key members of management. Â 9Â Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements Â 2. Summary of Significant Accounting Policies Â a. Basis of presentation Â The accompanying unaudited interim consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (â€œU.S. GAAPâ€) for interim financial information as found in the Accounting Standards Codification (â€œASCâ€) and Accounting Standards Updates (ASUsâ€) of the Financial Accounting Standards Board (â€œFASBâ€). In the opinion of management, the accompanying unaudited interim consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the unaudited interim consolidated financial statements) considered necessary to present fairly the Companyâ€™s financial position as of DecemberÂ 31, 2024 and its results of operations and cash flows for the three months ended DecemberÂ 31, 2024 and 2023. The unaudited interim consolidated financial statements presented herein do not contain all of the required disclosures under U.S. GAAP for annual financial statements and should be read in conjunction with the annual audited consolidated financial statements and related notes of Sonnet as of and for the year ended SeptemberÂ 30, 2024 included in the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended SeptemberÂ 30, 2024. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. Â b. Consolidation Â The unaudited interim consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Â c. Use of estimates Â The preparation of the unaudited interim consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these unaudited interim consolidated financial statements include the accrual of research and development expenses. Estimates and assumptions are periodically reviewed in-light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from managementâ€™s estimates. Â d. Incentive tax receivable Â Subsidiary is eligible to participate in an Australian research and development tax incentive program. As part of this program, Subsidiary is eligible to receive a cash refund from the Australian Taxation Office for a percentage of the research and development costs expended by Subsidiary in Australia. The cash refund is available to eligible companies with annual aggregate revenues of less than $20.0 million (Australian) during the reimbursable period. The Company estimates the amount of cash refund it expects to receive related to the Australian research and development tax incentive program and records the incentive when it is probable (i) the Company will comply with relevant conditions of the program and (ii) the incentive will be received. As of DecemberÂ 31, 2024, the Companyâ€™s estimate of the amount of cash refund it expects to receive for eligible spending related to the Australian research and development tax incentive program was $0.2 million. For each of the three months ended DecemberÂ 31, 2024 and 2023, $0.2 million for the expected net cash refund related to the tax incentive program was included as a reduction in research and development expenses. In November 2024, the Company received $0.7 million from the Australian government related to eligible research and development expenses for the year ended September 30, 2024. In December 2023, the Company received $0.8 million from the Australian government related to eligible research and development expenses for the year ended September 30, 2023. Â e. Property and equipment Â Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets. Expenditures for repairs and maintenance that do not extend the estimated useful life or improve an asset are expensed as incurred. Upon retirement or sale, the cost and related accumulated depreciation and amortization of assets disposed of are removed from the accounts, and any resulting gain or loss is included in the consolidated statement of operations. Â 10Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial StatementsÂ Â f. Deferred offering costs Â Legal and other costs incurred in relation to equity offerings are capitalized as deferred offering costs and charged against the proceeds from equity offerings when received. If a financing is abandoned, deferred offering costs are expensed. Â g. Derivative liability Â The Company evaluates all features contained in financing agreements to determine if there are any embedded derivatives that require separate accounting from the underlying agreement. An embedded derivative that requires separation is accounted for as a separate asset or liability from the host agreement. The derivative asset or liability is accounted for at fair value, with changes in fair value recognized in the consolidated statement of operations. The Company determined that certain features under the Purchase Agreement (see Note 6) qualified as embedded derivatives. The derivative liability is accounted for separately from the Purchase

Agreement at fair value, which has been deemed de minimis. Â h. Collaboration revenue Â Collaboration arrangements may contain multiple components, which may include (i) licenses; (ii) research and development activities; and (iii) the manufacturing and supply of certain materials. Payments pursuant to these arrangements may include non-refundable payments, upfront payments, milestone payments upon the achievement of significant regulatory and development events, sales milestones and royalties on product sales. The amount of variable consideration is constrained until it is probable that the revenue is not at a significant risk of reversal in a future period. Â In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under a collaboration arrangement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are capable of being distinct; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue as the Company satisfies each performance obligation. Â The Company applies significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining when performance obligations have been met, and assessing the recognition of variable consideration. When consideration is received prior to the Company completing its performance obligation under the terms of a contract, a contract liability is recorded as deferred income. Deferred income expected to be recognized as revenue within the twelve months following the balance sheet date is classified as a current liability. In May 2021, the Company entered into a License Agreement (the â€œNew Life Agreementâ€) with New Life Therapeutics Pte, Ltd. (â€œNew Lifeâ€). In October 2024, the Company entered into the Alkem Agreement. See Note 5 for further discussion of these agreements. Â i. Research and development expense Â Research and development expenses include all direct and indirect costs associated with the development of the Companyâ€™s biopharmaceutical products. These expenses include personnel costs, consulting fees, and payments to third parties for research, development, and manufacturing services. These costs are charged to expense as incurred. Â At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the related project, based on the measure of progress as defined in the contract. Factors the Company considers in preparing the estimates include costs incurred by the service provider, milestones achieved, and other criteria related to the efforts of its service providers. Such estimates are subject to change as additional information becomes available. Depending on the timing of payment to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company will record a prepaid expense or accrued liability relating to these costs. Upfront milestone payments made to third parties who perform research and development services on the Companyâ€™s behalf are expensed as services are rendered. Contingent development or regulatory milestone payments are recognized upon the related resolution of such contingencies. Â 11 Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements Â j. Foreign currency Â Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than the U.S. dollar are included in operations in the period in which the transaction occurs and reported within the foreign exchange gain (loss) line item in the consolidated statement of operations. Â k. Reverse stock split Â On September 30, 2024, the Company filed a Certificate of Amendment to its Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware, which effected a 1-for-8 reverse stock split of the Companyâ€™s issued and outstanding shares of common stock. As a result of the reverse stock split, every eight shares of common stock issued and outstanding was converted into one share of common stock. The reverse stock split affected all stockholders uniformly and did not alter any stockholderâ€™s percentage interest in the Companyâ€™s equity. No fractional shares were issued in connection with the reverse stock split. Stockholders who would otherwise be entitled to a fractional share of common stock were instead entitled to receive a proportional cash payment. The reverse stock split did not change the par value or authorized number of shares of common stock. All common share and per share amounts presented in the unaudited interim consolidated financial statements and accompanying notes have been retroactively adjusted to reflect the reverse stock split. Â l. Net loss per share Â Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period (and potential shares of common stock that are exercisable for little or no consideration). Included in basic weighted-average number of shares of common stock outstanding during the three months ended December 31, 2024 are pre-funded October 2023 warrants to purchase 99,687 shares of common stock with an exercise price of $0.0008 per share, warrants exercised through the June 2024 inducement offer for 155,125 shares of common stock that are being held in abeyance as of December 31, 2024 due to beneficial ownership limitations, and pre-funded December 2024 warrants to purchase 545,500 shares of common stock with an exercise price of $0.0001 per share. Included in basic weighted-average number of shares of common stock outstanding during the three months ended December 31, 2023 are pre-funded October 2023 warrants to purchase 192,187 shares of common stock with an exercise price of $0.0008 per share. Â Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities such as common stock warrants and stock options which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. Â 12 Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements Â The following potentially dilutive securities have been excluded from the computation of diluted shares of common stock outstanding as they would be anti-dilutive: Â Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Shares Â Â 2024Â Â 2023Â Â Â December 31,Â Â Â 2024Â Â 2023Â Common stock warrants August 2021Â Â 14,031Â Â Â 14,031Â Underwriter warrants August 2021Â Â 284Â Â Â 284Â Chanticleer warrantsÂ Â 6Â Â Â 6Â Series C warrantsÂ Â 2,297Â Â Â 2,297Â Series 3 warrantsÂ Â 1,566Â Â Â 1,566Â Unvested restricted stock units and awardsÂ Â 17,152Â Â Â 976Â Common stock warrants February 2023Â Â 31,563Â Â Â 33,982Â Underwriter warrants February 2023Â Â 1,933Â Â Â 1,933Â Common stock private placement warrants June 2023Â Â 28,409Â Â Â 28,409Â Placement agent warrants June 2023Â Â 852Â Â Â 852Â Common stock warrants October 2023Â Â 354,994Â Â Â 710,931Â Underwriter warrants October 2023Â Â 10,664Â Â Â 10,664Â Placement agent warrants June 2024Â Â 14,142Â Â Â â€”Â Common stock warrants June 2024Â Â 703,125Â Â Â â€”Â Common stock warrants November 2024Â Â 2,222,222Â Â Â â€”Â Common stock registered direct warrants December 2024Â Â 1,085,325Â Â Â â€”Â Common stock PIPE warrants December 2024Â Â 673,000Â Â Â â€”Â Total anti-dilutive weighted average sharesÂ Â Â 5,161,565Â Â Â 805,931Â Â m. Recent accounting pronouncements Â In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07, which is applicable to entities with a single reportable segment, will primarily require enhanced disclosures about significant segment expenses and enhanced disclosures in interim periods. The guidance in ASU 2023-07 will be applied retrospectively and is effective for annual reporting periods in fiscal years beginning after December 15, 2023 and interim reporting periods in fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact that the adoption of ASU 2023-07 will have on its consolidated financial statements and disclosures. Â In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 is intended to improve income tax disclosure requirements by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to the income tax disclosure requirements. The guidance in ASU 2023-09 will be effective for annual reporting periods in fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact that the adoption of ASU 2023-09 will have on its consolidated financial statements and disclosures. Â In November 2024, the FASB issued ASU 2024-03, Income Statementâ€”Reporting Comprehensive Incomeâ€”Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, as subsequently amended by ASU 2025-01 to clarify the effective date, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented in the consolidated statement of operations. The guidance in this ASU is effective for annual reporting periods in fiscal years beginning after December 15, 2026, and interim periods in fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures. Â 13 Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements Â 3. Accrued Expenses and Other Current Liabilities Â Accrued expenses and other current liabilities consisted of the following:Â Â Schedule of Accrued Expenses and Other Current Liabilities Â Â December 31, 2024Â Â September 30, 2024Â Compensation and benefitsÂ $155,514Â Â $149,802Â Research and developmentÂ Â 969,684Â Â Â 617,545Â Professional feesÂ Â 267,587Â Â Â 173,319Â OtherÂ Â 1,735Â Â Â 1,823Â Â Accrued expenses and other current liabilitiesÂ $1,394,520Â Â $942,489Â Â 4. Commitments and Contingencies Â Legal proceedings Â From time to time, the Company is a party to various lawsuits, claims, and other legal proceedings that arise in the ordinary course of its business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Companyâ€™s consolidated financial position, results of operations, or cash flows. Â License agreements Â In July 2012, the Company entered into a Discovery Collaboration Agreement (the â€œCollaboration Agreementâ€) with XOMA (US) LLC (â€œXOMAâ€), pursuant to which XOMA granted to the Company a non-exclusive, non-transferable license and/or right to use certain materials, technologies and related information related to discovery, optimization and development of antibodies and related proteins and to develop and commercialize products thereunder. The Company is obligated to make contingent milestone payments to XOMA totaling $3.8 million on a product-by-product basis upon the achievement of certain development and approval milestones related to a product. The Company has also agreed to pay XOMA low single-digit royalties on net sales of products sold by the Company. Royalties on each product are payable on a country-by-country basis until the later of (i) a specified period of time after the first commercial sale, and (ii) the date of expiration of the last valid claim in the last-to-expire of the issued patents covered by the Collaboration Agreement. The first milestone was achieved in April 2022, at which time the Company incurred a $0.5 million license fee which was recorded as acquired in-process research and development. No license fees were incurred during the three months ended December 31, 2024 and 2023. Â In August 2015, the Company entered into a License Agreement (the â€œARES License Agreementâ€) with Ares Trading (â€œARESâ€), a wholly-owned subsidiary of Merck KGaA. Under the terms of the ARES License Agreement, as subsequently amended in October 2021, ARES has granted the Company a sublicensable, exclusive, worldwide, royalty-bearing license on proprietary patents to research, develop, use and commercialize products using atexakin alfa (â€œAtexakinâ€), a low dose formulation of human IL-6 in peripheral neuropathies and vascular complications. Pursuant to the ARES License Agreement, the Company will pay ARES high single-digit royalties on net sales of products sold by the Company. Royalties are payable on a product-by-product and country-by-country basis until the later of (i) a specified period of time after the first commercial sale in such country, and (ii) the last date on which such product is covered by a valid claim in such country. Additionally, the Company will pay ARES a percentage of all revenue received through sublicensing the IL-6 compound, including revenue from any upfront, milestone, royalty, maintenance and similar payments, net of certain full time equivalent (â€œFTEâ€) costs incurred by the Company pursuant to such sublicense. The percentage rate owed to ARES on sublicense revenue decreases depending on the point in time of execution of the relevant sublicense agreement and the development progress accomplished by the Company to that point in time. The upfront cash payments received by the Company pursuant to the New Life Agreement (see Note 5) were specifically excluded from the scope of the amended ARES License Agreement. The Company owes ARES $0.1 million in license fees related to sublicense revenue received pursuant to the Alkem Agreement (see Note 5), which is included in research and development expenses in the unaudited interim consolidated statement of operations for the three months ended DecemberÂ 31, 2024. No license fees were incurred during the three months ended DecemberÂ 31, 2023. Â 14 Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements Â In January 2019, the Company entered into a Frame Services and License Agreement (the â€œCellca Agreementâ€) with Sartorius Stedim Cellca GMBH (â€œCellcaâ€), pursuant to which Cellca has granted the Company a worldwide, non-exclusive, perpetual, non-transferable license to develop, manufacture or have manufactured, use, sell, import, export and/or otherwise commercialize product based on Cellcaâ€™s work to generate a specified transfected cell line and develop an upstream production process for such cell line. The Cellca Agreement is effective unless terminated by either party by giving six months notice, or by giving 14 days notice if terminated for good cause. The Company is obligated to make milestone payments to Cellca totaling up to $0.7 million upon the achievement of certain development and approval milestones if the Buy-Out Option is not exercised. The Company has a Buy-Out Option that will be effective between the time of completion of a clinical trial and the receipt of regulatory approval for commercialization of product. The cost to exercise the Buy-Out Option increases on each anniversary of the commencement date of the Buy-Out Option Period, and ranges from $0.1 million to $0.6 million. The cost to exercise the Buy-Out Option will replace the $0.6 million contingent milestone payment due upon final regulatory approval. The first milestone was achieved in April 2022, at which time the Company incurred a $0.1 million license fee which was recorded as acquired in-process research and development. No license fees were incurred during the three months ended December 31, 2024 and 2023. Â In October 2021, the Company entered into a Non-Exclusive License Agreement (the â€œBrink Agreementâ€) with Brink Biologics Inc. (â€œBrinkâ€), pursuant to which Brink has granted the Company a non-exclusive, non-transferable license and limited right to sublicense certain materials and related information to develop cell-based assays for batch, quality control, stability, efficacy, potency or any other type of assay required for production and commercialization of products. During the product development phase, the Company was obligated to make annual product development license fee payments of approximately $0.1 million. In April 2023, the Brink Agreement was amended, effective November 2022, to reduce the annual license fee payments to $12,000 for storage. If materials are removed from storage during the product development phase, the annual product development license fee of approximately $0.1 million will apply. If a product achieves commercial status, the Company is obligated to make a commercial product license fee payment of approximately $0.1 million per commercial product. The amended agreement has an initial term of one year and will automatically renew for one additional year unless terminated or converted to a product development license. After the second year, the license will automatically convert to a full license requiring a product development or a commercial product license fee unless the parties mutually agree to terminate the agreement. The Company incurred $12,000 in license fees during the three months ended December 31, 2024 and 2023, which were recorded as acquired in-process research and development and included in research and development expenses in the unaudited interim consolidated statements of operations. Â In February 2022, the Company entered into a Biological Materials License Agreement (the â€œInvivoGen Agreementâ€) with InvivoGen SAS (â€œInvivoGenâ€), pursuant to which InvivoGen has granted the Company a worldwide, non-exclusive license to use certain reporter cells for research, development and/or quality control purposes. The InvivoGen Agreement has an initial term of three years and may be extended for two additional three-year periods upon written notice by the Company and payment of an approximately â‚¬0.1 million fee per extension (approximately $0.1 million as of December 31, 2024). No license fees were incurred during the three months ended December 31, 2024 and 2023. Â Collaboration agreement Â In August 2024, the Company entered into a Master Clinical Collaboration Agreement (the â€œSOC Agreementâ€) with the Sarcoma Oncology Center (â€œSOCâ€) to advance the development of SON-1210. An Innovative Immuno Oncology Center funded by the SOC will conduct an investigator-initiated Phase 1/2a study of SON-1210 in pancreatic cancer. The Company will provide the study drug and provide support services for the study. If the Company establishes a partnership with a third party prior to the initiation of the initial efficacy combination trial under this collaboration, the Company will incur, payable to the SOC, a one-time fee equal to the greater of 5% or $1.5 million from the first upfront payment received from such third party partnership. Â 15 Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements Â Research and development agreement Â In December 2021, the Company entered into a Research and Development Agreement (the â€œNavigo Agreementâ€) with Navigo Proteins GmbH (â€œNavigoâ€), pursuant to which Navigo will perform specified evaluation and development procedures to evaluate certain materials to determine their commercial potential. Under the terms of the Navigo Agreement, the Company has granted Navigo a royalty-free, non-exclusive, worldwide, non-sublicensable, non-transferable right and license to use certain technology to perform the evaluation and development activities, and Navigo has granted the Company (i) an exclusive, worldwide, perpetual, irrevocable, sublicensable, transferable, royalty-free right and license to research, develop, use, sell, have sold, distribute, import or otherwise commercially exploit certain materials, and (ii) a non-exclusive, worldwide, perpetual, sublicensable, non-transferable right and license to make or have made such materials. The Company incurred a $0.1 million technology access fee upon execution of the Navigo Agreement, at which time it was recorded as acquired in-process research. The Company is obligated to make contingent milestone payments to Navigo totaling up to $1.0 million upon the achievement of certain evaluation and development milestones as outlined in the Navigo Agreement, of which $0.3 million of evaluation milestones have been previously recognized. No milestones were achieved and no license fees were incurred during the three months ended December 31, 2024 and 2023. Â Employment agreements Â The Company has entered into employment contracts with its officers and certain employees that provide for severance and continuation of benefits in the event of termination of

employment either by the Company without cause or by the employee for good reason, both as defined in the contract. In addition, in the event of termination of employment following a change in control, as defined, either by the Company without cause or by the employee for good reason, any unvested portion of the employeeâ€™s initial stock option grant becomes immediately vested. Â 5. Collaboration Revenue Â New Life Agreement Â Under the New Life Agreement, the Company granted New Life an exclusive license (with the right to sublicense) to develop and commercialize pharmaceutical preparations containing a specific recombinant human IL-6, SON-080 (the â€œCompoundâ€) (such preparations, the â€œProductsâ€) for the prevention, treatment or palliation of DPN in humans (the â€œDPN Fieldâ€) in Malaysia, Singapore, Indonesia, Thailand, Philippines, Vietnam, Brunei, Myanmar, Lao PDR and Cambodia (the â€œExclusive Territoryâ€). New Life paid the Company an aggregate of $1.0 million in non-refundable upfront cash payments in connection with the execution of the New Life Agreement. The related collaboration revenue was fully recognized by December 31, 2023, as the Company had completed its performance obligations under the New Life Agreement. In December 2024, New Life informed the Company that it has elected to move its business in a different direction and provided the Company with written notice of its intention to exercise its Give Back Option, which is the right to give back the rights with respect to Products in the DPN Field in one or more countries in the Exclusive Territory. The exercise of the Give Back Option is subject to the negotiation and mutual agreement of terms between the Company and New Life. Â 16 Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements Â Alkem Agreement Â Under the Alkem Agreement entered into on October 8, 2024 (see Note 1), the Company granted Alkem an exclusive license (with the right to sublicense) to research, develop, manufacture, import, export, market, use and commercialize pharmaceutical products containing its IL-6 (SON-080) asset (or any derivatives, fragments or conjugates thereof) (the â€œCompoundsâ€) (such products, the â€œProductsâ€) for the treatment of DPN (the â€œDPN Fieldâ€) and to manufacture, import, export, market, use and commercialize Products for the treatment of CIPN and autonomic neuropathy (together with the DPN Field, the â€œFieldsâ€) in India. Except as provided for in the Alkem Agreement, the Company agreed not to develop, use, sell, offer or otherwise commercialize any Compounds or Products for use in the DPN Field in India during the term of the Alkem Agreement. The Company retains all rights to manufacture Compounds and Products anywhere in the world. The Company and Alkem will enter into a follow-on supply agreement pursuant to which the Company will manufacture for Alkem Compounds and Products for post-Phase 2 clinical development and commercialization in accordance with the Alkem Agreement on terms to be negotiated by the parties. Pursuant to the terms of the Alkem Agreement, Alkem will bear the cost of, and be responsible for, among other things, conducting clinical studies and additional non-clinical studies (if any, subject to both partiesâ€™ approval), preparing and filing applications for regulatory approval and undertaking other developmental and regulatory activities for commercializing Products in the DPN Field in India. Alkem will own and maintain all regulatory filings and approvals for Products in India. Upon payment of a Clinical Data Access Fee (as defined in the Alkem Agreement), the Company will have rights to access and use the data generated by the clinical trials conducted in connection with the Alkem Agreement. Under the terms of the Alkem Agreement, Alkem will pay the Company $1.0 million in upfront payments and up to an additional $1.0 million in milestone payments. Additionally, the Company is entitled to receive a royalty equal to a percentage in the low double digits of the net sales of the Product upon commercialization of SON-080 in India, less certain expenses as set forth in the Alkem Agreement. Â Revenue recognition Â The Company first assessed the Alkem Agreement under ASC 808, Collaborative Arrangements (â€œASC 808â€), to determine whether the Alkem Agreement or units of accounts within the Alkem Agreement represent a collaborative arrangement based on the risks and rewards and activities of the parties. The Company applied relevant guidance from ASC 606, Revenue from Contracts with Customers (â€œASC 606â€), to evaluate the appropriate accounting for the collaborative arrangement with Alkem. Â 17 Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements Â In accordance with this guidance, the Company identified the following obligations under the Alkem arrangement: (i) License to research, develop, market, import, use and commercialize the Product in the DPN field in India (the â€œLicenseâ€); and (ii) supply of Compound for a Phase 2 clinical trial (â€œSupplyâ€). The future supply agreement for post-Phase 2 clinical development represents an optional purchase, which will be accounted for as a separate contract, and the Company did not identify any material right to be present. The Company determined that the License and Supply are not distinct from each other and therefore combined these material promises into a single performance obligation. The Company determined the initial transaction price of the single performance obligation to be $1.0 million, as the future development and commercialization milestones, which represent variable consideration, are subject to constraint at inception. At the end of each subsequent reporting period, the Company will reevaluate the probability of achievement of the future development and commercialization milestones subject to constraint and, if necessary, will adjust its estimate of the overall transaction price. Any such adjustments will be recorded on a cumulative catch-up basis. For the sales-based royalties, the Company will recognize revenue when the related sales occur. Â Collaboration revenue from the single performance obligation related to the Alkem Agreement was recognized at the point-in-time at which the Company transferred the License and Supply to Alkem. Collaboration revenue from the single performance obligation related to the New Life Agreement was recognized over the estimated performance of the research and development activities. The Company recognized $1.0 million and $18,626 of collaboration revenue for the three months ended DecemberÂ 31, 2024 and 2023, respectively. As of DecemberÂ 31, 2024, the Company has recorded a contract asset for $0.5 million related to the Alkem Agreement, which represents the unbilled amount related to the single performance obligation and is included in unbilled collaboration revenue in the unaudited interim consolidated balance sheet. Â 6. Stockholdersâ€™ Equity (Deficit) Â October 2023 underwritten public offering Â On October 26, 2023, the Company closed a public offering of common stock and certain warrants through Chardan and Ladenburg Thalmann & Co. Inc. as underwriters, for net proceeds of $3.9 million through the issuance and sale of 163,281 shares of its common stock and, to certain investors, pre-funded warrants to purchase 192,187 shares of common stock, and accompanying common warrants to purchase up to an aggregate of 710,931 shares of its common stock. Each share of common stock and pre-funded warrant to purchase one share of common stock was sold together with a common warrant to purchase two shares of common stock. The public offering price of each share of common stock and accompanying common warrant was $12.80 and the public offering price of each pre-funded warrant and accompanying common warrant was $12.7992. The common warrants were immediately exercisable at a price of $12.80 per share of common stock, expire five years from the date of issuance and contain an alternative cashless exercise provision. In connection with the June 2024 inducement offer, the exercise price was decreased to $9.60 per share of common stock for common warrants that remained unexercised at the time of the offer. The pre-funded warrants were immediately exercisable at any time, until exercised in full, at a price of $0.0008 per share of common stock. In addition, warrants to purchase 10,664 shares of common stock were issued to the underwriters as compensation for their services related to the offering. These common stock warrants have an exercise price of $16.00 per share and expire five years from the date of issuance. Â 18 Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements Â Committed equity facility Â On May 2, 2024, the Company entered into the Purchase Agreement and a Registration Rights Agreement (the â€œRegistration Rights Agreementâ€), each with Chardan, related to a â€œChEF,â€ Chardanâ€™s committed equity facility, or the Facility (see Note 1). Pursuant to the Purchase Agreement, the Company has the right from time to time at its option to sell to Chardan up to $25.0 million in aggregate gross purchase price of newly issued shares of the Companyâ€™s common stock, of which $24.9 million is available to be sold as of December 31, 2024. The Facility will allow the Company to raise primary equity on a periodic basis at its sole discretion depending on a variety of factors including, among other things, market conditions, the trading price of the common stock, and determinations by the Company regarding the use of proceeds of such common stock. The purchase price of the shares of common stock will be determined by reference to the Volume Weighted Average Price (â€œVWAPâ€) of the common stock during the applicable purchase period, less a fixed 4% discount to such VWAP, and the total shares to be purchased on any day may not exceed 20% of the trading volume of the Companyâ€™s common stock during the applicable purchase period. The Purchase Agreement will be effective for a 36-month period ending May 16, 2027. Due to certain pricing and settlement provisions, the Purchase Agreement qualifies as a standby equity purchase agreement and includes an embedded put option and an embedded forward contract. The Company accounts for the embedded features in the Purchase Agreement as derivatives measured at fair value, with changes in fair value recognized in the consolidated statement of operations. The derivatives associated with the Purchase Agreement have been deemed de minimis. The Company did not sell any shares of common stock pursuant to the Purchase Agreement during the three months ended DecemberÂ 31, 2024. Â November 2024 underwritten public offering Â On November 7, 2024, the Company closed a public offering of common stock and certain warrants through Chardan, as underwriter, for net proceeds of $4.2 million through the issuance and sale of 155,000 shares of its common stock, pre-funded warrants to purchase up to 956,111 shares of common stock, and accompanying common warrants to purchase up to an aggregate of 2,222,222 shares of its common stock. Each share of common stock and pre-funded warrant to purchase one share of common stock was sold together with a common warrant to purchase two shares of common stock. The public offering price of each share of common stock and accompanying common warrant was $4.50 and the public offering price of each pre-funded warrant and accompanying common warrant was $4.4999. The common warrants were immediately exercisable at a price of $4.50 per share of common stock, expire five years from the date of issuance and contain an alternative cashless exercise provision. The pre-funded warrants were immediately exercisable at any time, until exercised in full, at a price of $0.0001 per share of common stock. All of the pre-funded warrants have been exercised as of December 31, 2024. Â December 2024 registered direct and PIPE offering Â On December 10, 2024, the Company closed a registered direct offering with institutional investors for the issuance and sale of 768,000 shares of its common stock, pre-funded warrants to purchase up to 317,325 shares of common stock, and accompanying warrants to purchase up to an aggregate of 1,085,325 shares of its common stock. Each share of common stock and pre-funded warrant to purchase one share of common stock was sold together with a common warrant to purchase one share of common stock. The offering price of each share of common stock and accompanying common warrant was $2.23 and the offering price of each pre-funded warrant and accompanying common warrant was $2.2299, priced at-the-market under the rules of the Nasdaq Stock Market. The registered direct warrants were immediately exercisable at a price of $2.10 per share, expire five years from the date of issuance and contain an alternative cashless exercise provision. The pre-funded warrants were immediately exercisable at any time, until exercised in full, at a price of $0.0001 per share of common stock. All of the pre-funded warrants have been exercised as of December 31, 2024. Â 19 Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements Â The Company closed a concurrent private placement with an existing investor for the issuance and sale of 127,500 shares of its common stock, pre-funded warrants to purchase up to 545,500 shares of common stock, and accompanying warrants to purchase up to an aggregate 673,000 shares of its common stock. Each share of common stock and pre-funded warrant to purchase one share of common stock was sold in the private placement (â€œPIPEâ€) together with a common warrant to purchase one share of common stock. The PIPE offering price of each share of common stock and accompanying common warrant was $2.23 and the PIPE offering price of each pre-funded warrant and accompanying common warrant was $2.2299, priced at-the-market under the rules of the Nasdaq Stock Market. The PIPE warrants were immediately exercisable at a price of $2.10 per share, expire five years from the date of issuance and contain an alternative cashless exercise provision. The pre-funded warrants were immediately exercisable at any time, until exercised in full, at a price of $0.0001 per share of common stock. Â The Company raised net proceeds of approximately $3.5 million from the registered direct and PIPE offering. Â Common stock warrants Â As of DecemberÂ 31, 2024, the following equity-classified warrants and related terms were outstanding: Â Schedule of Warrants Outstanding Â Â Warrants OutstandingÂ Â Exercise PriceÂ Â Expiration DateÂ Common stock warrants August 2021Â Â 14,031Â Â $2,094.4000Â Â Â August 24, 2026Â Underwriter warrants August 2021Â Â 284Â Â $2,618.0000Â Â Â August 19, 2026Â Chanticleer warrantsÂ Â 6Â Â Â $144,144.0000 - $224,224.0000Â Â Â April 30, 2027 - December 17, 2028Â Series C warrantsÂ Â 2,297Â Â $7,860.1600Â Â Â October 16, 2025Â Series 3 warrantsÂ Â 1,566Â Â $717.0240Â Â Â August 15, 2027Â Common stock warrants February 2023Â Â 31,563Â Â $190.0800Â Â Â February 10, 2028Â Underwriter warrants February 2023Â Â 1,933Â Â $237.6000Â Â Â February 8, 2028Â Common stock private placement warrants June 2023Â Â 28,409Â Â $12.4000Â Â Â June 21, 2029Â Placement agent warrants June 2023Â Â 852Â Â $118.7824Â Â Â December 30, 2026Â Common stock warrants October 2023Â Â 354,994Â Â $9.6000Â Â Â October 27, 2028Â Pre-funded warrants October 2023Â Â 99,687Â Â $0.0008Â Â Â â€”Â Underwriter warrants October 2023Â Â 10,664Â Â $16.0000Â Â Â October 24, 2028Â Placement agent warrants June 2024Â Â 14,142Â Â $14.8800Â Â Â June 19, 2029Â Common stock warrants June 2024Â Â 703,125Â Â $12.4000Â Â Â June 21, 2029Â Common stock warrants November 2024Â Â 2,222,222Â Â $4.5000Â Â Â November 7, 2029Â Common stock registered direct warrants December 2024Â Â 1,085,325Â Â $2.1000Â Â Â December 9, 2029Â Common stock PIPE warrants December 2024Â Â 673,000Â Â $2.1000Â Â Â December 9, 2029Â Pre-funded warrants December 2024Â Â 545,500Â Â $0.0001Â Â Â â€”Â TotalÂ Â 5,789,600Â Â Â Â Â Â Â Â Â Â Due to beneficial ownership limitations, 187,500 shares of common stock related to warrants that were exercised in June 2024 through the inducement offer were being held in abeyance. During the three months ended DecemberÂ 31, 2024, 32,375 of these shares of common stock were released from abeyance, resulting in 155,125 shares of common stock held in abeyance as of December 31, 2024. Â During the three months ended DecemberÂ 31, 2024, 2,419 warrants were net share settled, resulting in the issuance of 1,209 shares of common stock, and 1,273,436 pre-funded warrants were exercised on a cash basis for de minimis proceeds. Â During the three months ended DecemberÂ 31, 2023, 3,590 warrants were net share settled, resulting in the issuance of 1,795 shares of common stock, and 4,302 warrants were abandoned by the warrant holder. Â 20 Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements Â 7. Share-Based Compensation Â In April 2020, the Company adopted the 2020 Omnibus Equity Incentive Plan (the â€œPlanâ€). There were 5 shares available for issuance under the Plan as of December 31, 2024. On January 1, 2025, the total number of shares authorized under the Plan increased to 120,302. The Plan increases the amount of shares issuable under the Plan by four percent of the outstanding shares of common stock at each January 1, each year. The Plan permits the granting of share-based awards, including stock options, restricted stock units and awards, stock appreciation rights and other types of awards as deemed appropriate, in each case, in accordance with the terms of the Plan. The terms of the awards are determined by the Companyâ€™s Board of Directors. Â Restricted stock units and awards Â On January 1, 2024, 9,175 restricted stock units (â€œRSUsâ€) and 7,977 restricted stock awards (â€œRSAsâ€) were granted, 100% of which vested on January 1, 2025. Any unvested RSUs or RSAs will be forfeited upon termination of services. The fair value of an RSU or RSA is equal to the fair market value of the Companyâ€™s common stock on the date of grant. RSU and RSA expense is amortized straight-line over the vesting period. Â Â Â The Company recorded share-based compensation expense associated with the RSUs and RSAs in its accompanying unaudited interim consolidated statements of operations as follows: Â Schedule of Share-based Compensation Expense Â Â 2024Â Â 2023Â Â Â Â Three Months Ended December 31,Â Â Â Â 2024Â Â 2023Â Research and developmentÂ $28,268Â Â $24,554Â General and administrativeÂ Â 32,127Â Â Â 25,451Â Share-based compensationÂ $60,395Â Â $50,005Â Â The following table summarizes RSU activity under the Plan: Â Â Schedule of Restricted Stock Units Activity Â Â Â Â Â Â WeightedÂ Â Â Â Â Â Â Average GrantÂ Â Â RSUÂ Â Date Fair ValueÂ Unvested balance at December 31, 2024Â Â Â 9,175Â Â $14.08Â Â During the three months ended DecemberÂ 31, 2024, there were no RSUs granted, vested or forfeited. As of DecemberÂ 31, 2024, there was no unrecognized compensation expense relating to unvested RSUs granted. Â The following table summarizes RSA activity under the Plan: Â Schedule of Restricted Stock Awards Activity Â Â Â Â Â Â WeightedÂ Â Â Â Â Â Â Average GrantÂ Â Â RSAÂ Â Date Fair ValueÂ Unvested balance at December 31, 2024Â Â Â 7,977Â Â $14.08Â Â Â Â During the three months ended DecemberÂ 31, 2024, there were no RSAs granted, vested or forfeited. As of DecemberÂ 31, 2024, there was no unrecognized compensation expense relating to unvested RSAs granted. Â 8. Subsequent Events Â Â The Company has evaluated subsequent events from the balance sheet date through February 13, 2025, the date at which the unaudited interim consolidated financial statements were available to be issued. Â Subsequent to DecemberÂ 31, 2024, the Company sold 58,270 shares of common stock pursuant to the Purchase Agreement for net proceeds of $0.1 million. Â The Company received preliminary approval of its application to sell up to $0.8 million of its New Jersey state net operating losses through the Program (see Note 1). In February 2025, the Company identified a buyer. As outlined in the Program, although the sale has been approved and a buyer identified, the Company must still execute an arrangement with such buyer to consummate a sale of the state net operating losses. Â On February 10, 2025, Jay Cross submitted his resignation as our Chief Financial Officer, effective February 21, 2025. In connection with Mr. Crossâ€™s resignation, on February 12, 2025, the Companyâ€™s board of directors (the â€œBoardâ€) appointed Donald Griffith, CPA, the Companyâ€™s current Controller and a member of the Board, to succeed Mr. Cross as its Chief Financial Officer effective February 21, 2025. Â On February 12, 2025, Stephen McAndrew, Ph.D., the Companyâ€™s Senior Vice President of Business Development, was appointed as the Companyâ€™s Chief Business Officer. In connection with his appointment, Dr. McAndrew entered into an employment agreement with the Company, dated February 12, 2025 (the â€œMcAndrew Agreementâ€). Dr. McAndrewâ€™s employment as the Companyâ€™s Chief Business Officer will commence on February 17, 2025. Pursuant to the McAndrew Agreement, Dr. McAndrew is entitled to, among other things, (i) an annual gross base salary of $330,000 (â€œBase Salaryâ€) and (ii) eligibility for a performance-based cash bonus of up to 35% of the Base Salary, as determined by the Board. Â 21 Â Â Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations. Â MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL

CONDITION AND RESULTS OF OPERATIONS Â The following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and the related notes and the other financial information included elsewhere in this Quarterly Report. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed below and elsewhere in this Quarterly Report, particularly those under â€œRisk Factors.â€ Â CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Â This report on Form 10-Q contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as â€œmay,â€ â€œcan,â€ â€œanticipate,â€ â€œassume,â€ â€œshould,â€ â€œindicate,â€ â€œwould,â€ â€œbelieve,â€ â€œcontemplate,â€ â€œexpect,â€ â€œseek,â€ â€œestimate,â€ â€œcontinue,â€ â€œplan,â€ â€œpoint to,â€ â€œproject,â€ â€œpredict,â€ â€œcould,â€ â€œintend,â€ â€œtarget,â€ â€œpotentialâ€ and other similar words and expressions of the future. Â There are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by us. These factors include, but are not limited to: Â Â â—our lack of operating history and history of operating losses; Â Â Â Â â—our need for significant additional capital and our ability to satisfy our capital needs; Â Â Â Â â—our ability to complete required clinical trials of our products and obtain approval from the U.S. Food and Drug Administration (the â€œFDAâ€) or other regulatory agents in different jurisdictions; Â Â Â Â â—our ability to maintain the listing of our common stock on The Nasdaq Capital Market; Â Â Â Â â—our ability to maintain or protect the validity of our patents and other intellectual property; Â Â Â Â â—our ability to retain key executive members; Â Â Â Â â—our ability to internally develop new inventions and intellectual property; Â Â Â Â â—interpretations of current laws and the passage of future laws; Â Â Â Â â—acceptance of our business model by investors; Â Â Â Â â—the emergence and effect of competing or complementary products, including the ability of our future products to compete effectively; Â Â Â Â â—the accuracy of our estimates regarding expenses and capital requirements; and Â Â Â Â â—our ability to adequately support growth. Â 22 Â Â The foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with that may cause our actual results to differ from those anticipated in our forward-looking statements. Please see â€œPart II - Item IA - Risk Factorsâ€ for additional risks which could adversely impact our business and financial performance. Â All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this report or the date of the document incorporated by reference into this report. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. We have expressed our expectations, beliefs and projections in good faith and we believe they have a reasonable basis. However, we cannot assure you that our expectations, beliefs or projections will result or be achieved or accomplished. Â Overview Â Sonnet BioTherapeutics Holdings, Inc. (â€œSonnet,â€ â€œwe,â€ â€œus,â€ â€œourâ€ or the â€œCompanyâ€), is a clinical stage, oncology-focused biotechnology company with a proprietary platform for innovating biologic medicines of single or bifunctional action. Known as FHABâ„¢ (Fully Human Albumin Binding), the technology utilizes a fully human single-chain variable fragment (scFv) that binds to and â€œhitchhikesâ€ on serum albumin for transport to target tissues. We designed the construct to improve drug accumulation in solid tumors, as well as to extend the duration of activity in the body. FHAB development candidates can be produced in mammalian cell culture, which enables glycosylation of the interleukins, thereby reducing the risk of immunogenicity, as well as E. coli. We believe our FHAB technology, for which we received an initial U.S. patent in June 2021 and a continuation of such patent in June 2024, is a distinguishing feature of our biopharmaceutical platform. The approach is well suited for future drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. Â Our current internal pipeline development activities are focused on cytokines, which are a class of cell signaling molecules that serve as potent immunomodulatory agents. Working both independently and synergistically, specific cytokines have shown the ability to modulate the activation and maturation of immune cells to help fight cancer and pathogens. However, because they do not preferentially accumulate in specific tissues and are quickly eliminated from the body, the conventional approach to achieving a treatment effect with cytokine therapy typically requires the administration of high and frequent doses. This can result in the potential for systemic toxicity, which poses challenges to the therapeutic application of this class of drugs. Â Our lead proprietary asset, SON-1010, is a single-chain version of human Interleukin 12 (â€œIL-12â€), covalently linked to the FHAB construct, for which we are pursuing clinical development in solid tumor indications, including ovarian cancer, non-small cell lung cancer and head and neck cancer. In March 2022, the FDA cleared our Investigational New Drug (â€œINDâ€) application for SON-1010. This allowed us to initiate a U.S. clinical trial (SB101) in oncology patients with solid tumors during the second calendar quarter of 2022. In September 2021, we created a wholly-owned Australian subsidiary, SonnetBio Pty Ltd (â€œSubsidiaryâ€), for the purpose of conducting certain clinical trials. We received approval and initiated an Australian clinical study (SB102) of SON-1010 in healthy volunteers during the third calendar quarter of 2022. Interim safety and tolerability data from the SB101 and SB102 studies were reported in April 2023. Â In January 2023, we announced a collaboration agreement with Roche for the clinical evaluation of SON-1010 with atezolizumab (TecentriqÂ®). The companies have entered into a Master Clinical Supply Agreement (â€œMCSAâ€), along with associated Quality and Safety Agreements, to study the safety and efficacy of the combination of SON-1010 and atezolizumab in a platinum-resistant ovarian cancer (â€œPROCâ€) patient setting. Further, the companies will provide SON-1010 and atezolizumab, respectively, for use in the Phase 1b/Phase 2a combination safety, dose-escalation, and efficacy study (SB221). Part 1 of this 2-part study was approved in June 2023 by the local Human Research Ethics Committee in Australia under CT-2023-CTN-01399-1 and the Therapeutic Goods Administration has been notified. In August 2023, the FDA accepted the IND for the use of SON-1010 in ovarian cancer. The SB221 trial consists of a modified 3+3 dose-escalation design in Part 1 to establish the maximum tolerated dose (â€œMTDâ€) of SON-1010 with a fixed dose of atezolizumab. Clinical benefit in PROC will be confirmed in an expansion group to establish the recommended Phase 2 dose (â€œRP2Dâ€). Part 2 of the study will then investigate SON-1010 in combination with atezolizumab versus the standard of care (â€˜SOCâ€) for PROC in a randomized comparison to show proof-of-concept (â€œPOCâ€). Â 23 Â Â Â In January 2025, we announced an expansion of our Phase 1 SB101 clinical study of SON-1010 to add a new cohort to evaluate its effect in combination with trabectedin (YondelisÂ®), following the successful completion of monotherapy dose escalation. Trabectedin is an alkylating DNA-binding agent that was approved as a second-line treatment in early 2024 for patients with unresectable, metastatic liposarcoma or leiomyosarcoma who have received a prior anthracycline-containing regimen. It is also known to activate tumor macrophages into a pro-inflammatory phenotype. We believe that SON-1010 has the potential to complement that activity by activating the NK and T cells in the TME to secrete more interferon-gamma (IFNÎ³), which is considered to be important for anti-tumor control.Â Â We acquired the global development rights to our most advanced compound, SON-080, a fully human version of Interleukin 6 (â€œIL-6â€), in April 2020 through our acquisition of the outstanding shares of Relief Therapeutics SA. We are advancing SON-080 in target indications of Chemotherapy-Induced Peripheral Neuropathy (â€œCIPNâ€) and Diabetic Peripheral Neuropathy (â€œDPNâ€). We received approval to initiate an ex-U.S. Phase 1b/2a study with SON-080 in CIPN in July 2022. Enrollment of the first portion of the SB211 study in CIPN has been completed, and the Data Safety Monitoring Board (â€œDSMBâ€) completed its review of the preliminary safety data during the first calendar quarter of 2024, clearing the trial to proceed to Part 2. Following the completion of the DSMB review, we announced initial safety data from the CIPN study. The objective will be to analyze the data and to consider initiating a Phase 2 study, pending the outcome of any partnering activity. Â On October 8, 2024, we entered into a license agreement (the â€œAlkem Agreementâ€) with Alkem Laboratories Limited (â€œAlkemâ€) for the development and commercialization of SON-080 in DPN and/or CIPN in India. Pursuant to the terms of the Alkem Agreement, Alkem will bear the cost of, and be responsible for, among other things, conducting clinical studies, preparing and filing applications for regulatory approval aiming at commercializing SON-080 in the DPN Field in India. Â Pursuant to a license agreement (the â€œNew Life Agreementâ€) we entered into with New Life Therapeutics Pte, Ltd. (â€œNew Lifeâ€) of Singapore in May 2021, we agreed to be jointly responsible for developing SON-080 in DPN with New Life, with the objective to analyze the data and to consider initiating a Phase 2 study, pending the outcome of any partnering activity. We were informed by New Life that is has elected to move its business in a different direction. On December 2, 2024, New Life provided written notice to us of its intention to exercise its right to give back the rights with respect to the Products under the New Life Agreement (the â€œGive Back Optionâ€) under the New Life Agreement, subject to the negotiation and mutual agreement of the terms of such Give Back Option by us and New Life. We are negotiating the terms of the Give Back Option with New Life. If we and New Life are unable to reach a mutual agreement on such terms, the Give Back Option will expire unexercised, New Life will retain the rights granted subject to the terms and conditions of the New Life Agreement and the New Life Agreement will remain in effect unless otherwise terminated by either us or New Life pursuant to the terms and conditions of the New Life Agreement. Â SON-1210 (IL12-FHAB-IL15), our lead bifunctional construct, combines FHAB with single-chain human IL-12 and human Interleukin 15 (â€œIL-15â€). This compound is being developed for solid tumor indications, including colorectal and pancreatic cancer. In February 2023, we announced the successful completion of two IND-enabling toxicology studies with SON-1210 in non-human primates. In August 2024, we entered into a Master Clinical Collaboration Agreement (the â€œSOC Agreementâ€) with the Sarcoma Oncology Center (â€œSOCâ€) to advance the development of SON-1210. An Innovative Immuno Oncology Consortium (â€œIIOCâ€) that is funded by the SOC will conduct an investigator-initiated Phase 1b/2a study of SON-1210 in pancreatic cancer. In November 2024, the IIOC submitted a pre-IND package to FDA. Based on the FDA feedback, preparations for the full IND submission package are underway. Â SON-1411 (IL18-FHAB-IL12) is a bifunctional combination of human Interleukin 18 (â€œIL-18â€), which was modified to resist interaction with the IL-18 inhibitor binding protein, and single-chain human IL-12 for solid tumor cancers. Cell line development and process development are ongoing, with early experimental drug supply suitable for formulation and analytical method development activities. After some delays in 2024, activities will continue through 2025 with the potential to generate a drug suitable for preclinical studies and subsequent human studies. Â 24 Â Â Â We have completed sequence confirmation for SON-3015 (anti-IL6-FHAB-anti-TGFÎ²). Early-stage bifunctional drug has been generated and is being stored for future use in in vivo mice studies. We have elected to place the SON-3015 development program on hold for expense reduction purposes. Â We have incurred recurring operating losses and negative cash flows since inception. Our ability to generate product or licensing revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates. Our net losses were $3.2 million and $1.2 million for the three months ended December 31, 2024 and 2023, respectively. As of December 31, 2024, we had cash of $4.9 million. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. We expect that our expenses and capital requirements will increase in connection with our ongoing activities, particularly if and as we: Â Â â—conduct additional clinical trials for product candidates; Â Â Â Â â—continue to discover and develop additional product candidates; Â Â Â Â â—acquire or in-license other product candidates and technologies; Â Â Â Â â—maintain, expand and protect our intellectual property portfolio; Â Â Â Â â—hire additional clinical, scientific and commercial personnel; Â Â Â Â â—establish a commercial manufacturing source and secure supply chain capacity sufficient to provide commercial quantities of any product candidates for which we may obtain regulatory approval; Â Â Â Â â—seek regulatory approval for product candidates that successfully complete clinical trials; Â Â Â Â â—establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain regulatory approval; and Â Â Â Â â—add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts, as well as to support our operation as a public reporting company. Â We will not generate revenue from product sales, if any, unless and until we receive licensing revenue and/or successfully complete clinical development and obtain regulatory approval for our product candidates. If we obtain regulatory approval for any of our product candidates and do not enter into a commercialization partnership, we expect to incur significant expenses related to developing our internal commercialization capability to support product sales, marketing and distribution. We will continue to incur significant costs associated with operating as a public company. Â As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, including sales pursuant to our ChEF Purchase Agreement (the â€œPurchase Agreementâ€) with Chardan Capital Markets LLC (â€œChardanâ€) related to a â€œChEF,â€ Chardanâ€™s committed equity facility (the â€œFacilityâ€), debt financings or other capital sources, which may include collaborations with other companies or other strategic transactions. We may not be able to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, reduce or eliminate the development and commercialization of one or more of our product candidates or delay our pursuit of potential in-licenses or acquisitions. Â Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis or raise additional capital or enter into collaboration or license agreements, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate operations. Â 25 Â Â Â Since our inception in 2015, we have devoted substantially all of our efforts and financial resources to organizing and staffing the Company, business planning, raising capital, acquiring or discovering product candidates and securing related intellectual property rights and conducting discovery, research and development activities for product candidates. We do not have any products approved for sale and have not generated any revenue from product sales. We have funded our operations to date primarily with proceeds from sales of common stock, warrants and proceeds from the issuance of convertible debt. Â Lead Clinical Programs Update Â SON-1010 Â Phase 1 Trial (SB101 Trial): Solid Tumors (Monotherapy) Â This first-in-human study is primarily designed to evaluate the safety of multiple ascending doses of SON-1010 in cancer patients and is being conducted at several sites across the United States. We recently announced an expansion of this trial to study the combination of SON-1010 with trabectedin (YondelisÂ®) in certain advanced soft-tissue sarcomas (STS), following the successful completion of monotherapy dose escalation. Enrollment in this cohort is underway and is expected to be completed in H1 calendar year 2025. Topline safety data of the combination with trabectedin is expected in H2 calendar year 2025. No new safety concerns have been reported to date. Â Phase 1b/2a Trial (SB221 Trial): PROC (Combo with Atezolizumab) Â The second trial is a global Phase 1b/2a multicenter, dose-escalation and randomized proof-of-concept study to assess the safety, tolerability, PK, PD, and efficacy of SON-1010 administered subcutaneously (SC), either alone or in combination with atezolizumab given intravenously (IV). Enrollment remains ongoing and an update on safety in that trial is expected in Q1 calendar year 2025. Â Program Highlights: Â Â â— PK data reveals about 10-fold extended half-life for SON-1010 compared with rhIL-12 and suggests tumor targeting by the FHAB. Â â— Dose-related, controlled, and prolonged IFNÎ³ response. Â â— The SB101 trial and the SB221 trial have collectively enrolled 70 subjects, with 10 of 21 evaluable patients (48%) with cancer suggesting clinical benefit of SON-1010 monotherapy (Stable Disease at 4 months). One patient had a partial response by RECIST criteria (45% decrease from baseline) to SON-1010 at the highest dose. Â â— Patients have received up to 25 cycles of SON-1010 as monotherapy and up to 10 cycles of SON-1010 with atezolizumab (TecentriqÂ®) without dose-limiting toxicity at any dose level. Â â— Toxicity is minimized in both trials with the use of a â€˜desensitizingâ€™ first dose that takes advantage of the known tachyphylaxis with rhIL-12, which allows higher maintenance doses and potential improvements in efficacy. Â â— â— Favorable safety profile. Dose escalation has been completed and the MTD was established at 1200 ng/kg. Â â— The final 1200 ng/kg dose-escalation cohort was increased in size to 6 patients to enhance the assessment of PK and PD at the MTD. Â â— The safety and toxicity profile that has developed is typical for a Phase 1 oncology trial, with the majority of adverse events (AEs) being reported as mild. All AEs seen to date have been transient, with no evidence of cytokine release syndrome. Â Upcoming Milestones: Â Â â— Phase 1: Solid Tumors (Monotherapy) Â Â Â Â â—‹H1 calendar year 2025: Topline Efficacy Data Â Â Â â— Phase 1b/2a: PROC (Combo with Atezolizumab) Â Â Â Â â—‹Q1 calendar year 2025: Additional Safety Data Â Â Â Â â—‹H2 calendar year 2025: RP2D & Topline Efficacy Â Â Â â— Phase 1: Solid Tumors (Combo with Trabectedin) Â Â Â Â â—‹ H2 calendar year 2025: Topline Efficacy Data Â SON-080 Â Phase 1b/2a Trial (SB211 Trial): Chemotherapy Induced Peripheral Neuropathy (CIPN) Â The SB211 study was a double-blind, randomized, controlled trial of SON-080 conducted at two sites in Australia in patients with persistent CIPN using a new proprietary version of recombinant human Interleukin-6 (rhIL-6) that builds upon previous work with atexakin alfa. The goal of the first portion of the SB211 study was to confirm safety and tolerability before continued development in Phase 2. As previously announced in March 2024, a data and safety monitoring board reviewed the

unblinded safety and tolerability of SON-080 in the first nine patients and concluded that the symptoms were tolerable in the initial patients and the study could proceed to Phase 2. Â 26 Â Â In October 2024, we entered into the Alkem Agreement with Alkem for the research, development, manufacturing, marketing, and commercialization of our SON-080 molecule for the treatment of DPN in India and the manufacturing, marketing, and commercialization of SON-080 for CIPN and autonomic neuropathy in India. Alkem will conduct all clinical trials it believes appropriate to obtain regulatory approval in India of SON-080 for the treatment of DPN. Subsequent to the partnership established with Alkem, preparations are being made to support initiation of a Phase 2 clinical trial in DPN, a mechanistically synergistic and larger, high-value indication with unmet medical need. Â Phase 1b Data Highlights: Â Â â— SON-080 demonstrated to be well-tolerated at both 20 Âµg and 60 Âµg/dose, which was about 10-fold lower than the MTD for IL-6 that was established in previous clinical evaluations. Â â— Pain and quality of life survey results suggest the potential for rapid improvement of peripheral neuropathy symptoms and post-dosing durability with both doses, compared to placebo controls. Â Upcoming Milestones: Â Â â—H2 calendar year 2025: Initiation of Phase 2 trial Â SON-1210: Proprietary, Bifunctional Version of Human Interleukins 12 (IL-12) and 15 (IL-15), Configured Using Our FHAB Platform, in Combination with Chemotherapy for the Treatment of Advanced Solid Tumors and Metastatic Pancreatic Cancer Â In August 2024, we entered into the SOC Agreement with the SOC to conduct an investigator-initiated Phase 1/2a clinical study to evaluate SON-1210 in combination with several chemotherapeutic agents including but not limited to NALIRIFOX (the combination of liposomal irinotecan, 5-fluorouracil/leucovorin, and oxaliplatin) for the specific treatment of metastatic pancreatic cancer. The NALIRIFOX regimen is U.S. FDA-approved for the treatment of metastatic pancreatic cancer in the front-line and refractory settings. We expect to submit the IND for SON-1210 in Q1 calendar year 2025. Â Upcoming Milestones: Â Â â— Q1 calendar year 2025: IND Submission Â â— H1 calendar year 2025: 1st Patient Dosed in Investigator-Initiated Phase 1/2a Study Â Recent Developments Â Patent Update Â On January 22, 2025, the European Patent Office granted our Patent No. EP3583125 B1, entitled â€œAlbumin Binding Domain Fusion Proteins,â€ which covers our FHAB technology and includes therapeutic fusion proteins that utilize FHAB for tumor targeting and retention, and provide extended pharmacokinetics (PK). The EU patent carries a term effective until February 20, 2038. In addition to the U.S. and EU, our global intellectual property coverage now extends to China, Japan, Russia and New Zealand. Â 27 Â Â Reverse Stock Split Â On September 30, 2024, we effected a reverse stock split of our issued and outstanding common stock at a ratio of 1-for-8 (the â€œReverse Stock Splitâ€). Shares of common stock underlying outstanding stock options and other equity instruments convertible into common stock were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities in connection with the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to a fractional share of common stock instead received a proportional cash payment. All of our historical share and per share information related to issued and outstanding common stock and outstanding options and warrants exercisable for common stock included in this Quarterly Report on Form 10-Q have been adjusted, on a retroactive basis, to reflect the Reverse Stock Split. Â Management Updates Â On February 10, 2025, Jay Cross submitted his resignation as our Chief Financial Officer, effective February 21, 2025. In connection with Mr. Crossâ€™s resignation, on February 12, 2025, our board of directors (the â€œBoardâ€) appointed Donald Griffith, CPA, our current Controller and a member of the Board, to succeed Mr. Cross as our Chief Financial Officer effective February 21, 2025. Â On February 12, 2025, Stephen McAndrew, Ph.D., our Senior Vice President of Business Development, was appointed as our Chief Business Officer. In connection with his appointment, Dr. McAndrew entered into an employment agreement with the Company, dated February 12, 2025. Dr. McAndrewâ€™s employment as our Chief Business Officer will commence on February 17, 2025. Â New Jersey NOL Â In February 2025, we received preliminary approval of our application to sell up to $0.8Â million of our New Jersey state net operating losses through the Technology Business Tax Certificate Transfer Program (the â€œProgramâ€), subject to execution of such sale. Â Components of Results of Operations Â Collaboration Revenue Â Collaboration revenue was earned from the license arrangement entered into with New Life in May 2021, which granted New Life rights to an exclusive license (with the right to sublicense) to develop and commercialize pharmaceutical preparations containing a specific recombinant human IL-6, SON-080 (the â€œCompoundâ€) (such preparations, the â€œProductsâ€) for the prevention, treatment or palliation of diabetic peripheral neuropathy in humans (the â€œDPN Fieldâ€) in the Exclusive Territory. We identified the following obligations under the arrangement: (i) License to develop, market, import, use and commercialize the Product in the Field in the Exclusive Territory (the â€œNew Life Licenseâ€); and (ii) transfer of know-how and clinical development and regulatory activities (â€œR&D Activitiesâ€). We determined that the New Life License and the R&D Activities are not distinct from each other and, therefore, combined these material promises into a single performance obligation. Under this agreement, we received upfront cash payments totaling $1.0 million, which were fully allocated to the single performance obligation and were recognized over the estimated performance period of R&D services, which ended in the first fiscal quarter of 2024. Â Collaboration revenue was also earned from the Alkem Agreement entered into in October 2024, which granted Alkem rights to an exclusive license (with the right to sublicense) to research, develop, manufacture, import, export, market, use and commercialize pharmaceutical products containing our IL-6 (SON-080) asset (or any derivatives, fragments or conjugates thereof) (the â€œCompoundsâ€) (such products, the â€œProductsâ€) for the treatment of DPN (the â€œDPN Fieldâ€) and to manufacture, import, export, market, use and commercialize Products for the treatment of CIPN and autonomic neuropathy (together with the DPN Field, the â€œFieldsâ€) in India. We identified the following obligations under the Alkem Agreement: (i) License to research, develop, market, import, use and commercialize the Product in the DPN Field in India (the â€œAlkem Licenseâ€) and (ii) supply of Compound for a Phase 2 clinical trial (â€œSupplyâ€). We determined that the Alkem License and Supply are not distinct from each other and, therefore, combined these material promises into a single performance obligation. Under the Alkem Agreement, we are entitled to upfront cash payments totaling $1.0 million, which have been fully allocated to the single performance obligation and were recognized at the point-in-time at which the Company transferred the Alkem License and Supply to Alkem. Â Operating Expenses Â Research and Development Expenses Â Research and development expenses consist primarily of costs incurred in connection with the discovery and development of our product candidates. We expense research and development costs as incurred and such costs include: Â Â â—employee-related expenses, including salaries, share-based compensation and related benefits, for employees engaged in research and development functions; Â 28 Â Â Â â—expenses incurred in connection with the preclinical and clinical development of our product candidates, including under agreements with third parties, such as consultants and clinical research organizations; Â Â â—the cost of manufacturing drug products for use in our preclinical studies and clinical trials, including under agreements with third parties, such as consultants and contract manufacturing organizations; Â Â â—facilities, depreciation and other expenses, which include direct or allocated expenses for rent and maintenance of facilities and insurance; Â â—costs related to compliance with regulatory requirements; and Â â—payments made under third-party licensing agreements. Â We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided by our service providers. This process involves reviewing open contracts and purchase orders, communicating with their personnel to identify services that have been performed on our behalf, and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense when the goods have been delivered or the services have been performed. Â Our direct research and development expenses consist primarily of external costs, such as fees paid to outside consultants, contract research organizations, contract manufacturing organizations and research laboratories in connection with preclinical development, process development, manufacturing and clinical development activities. Our direct research and development expenses also include fees incurred under third-party license agreements. We do not allocate employee costs and costs associated with discovery efforts, laboratory supplies and facilities, including depreciation or other indirect costs, to specific product candidates because these costs are deployed across multiple programs and as such, are not separately classified. We use internal resources primarily to conduct our research and discovery as well as for managing preclinical development, process development, manufacturing and clinical development activities. These employees work across multiple programs and therefore, we do not track costs by product candidate. Â We will continue to incur research and development expenses for the foreseeable future as we attempt to advance development of our product candidates. The successful development of our product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the remainder of the development of our current pipeline or any future product candidates we may develop due to the numerous risks and uncertainties associated with clinical development, including risks and uncertainties related to: Â â—the timing and progress of preclinical and clinical development activities; Â Â Â â—the number and scope of preclinical and clinical programs that we decide to pursue; Â Â Â â—our ability to maintain our current research and development programs and to establish new ones; Â Â Â â—establishing an appropriate safety profile with investigational new drug-enabling studies; Â Â Â â—successful patient enrollment in, and the initiation and completion of, clinical trials; Â Â Â â—the successful completion of clinical trials with safety, tolerability and efficacy profiles that are satisfactory to the FDA or any comparable foreign regulatory authority; Â Â Â â—the receipt of regulatory approvals from applicable regulatory authorities; Â Â Â â—the timing, receipt and terms of any marketing approvals from applicable regulatory authorities; Â Â Â â—our ability to establish new licensing or collaboration arrangements; Â 29 Â Â â—establishing agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if any of our product candidates is approved; Â Â Â â—development and timely delivery of clinical-grade and commercial-grade drug formulations that can be used in our clinical trials and for commercial launch; Â Â Â â—obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights; Â Â Â â—launching commercial sales of product candidates, if approved, whether alone or in collaboration with others; Â Â Â â—maintaining a continued acceptable safety profile of the product candidates following approval; and Â Â Â â—the potential impact of health epidemics or outbreaks of communicable diseases on operations which may affect among other things, the timing of clinical trials, availability of raw materials, and the ability to access and secure testing facilities. Â A change in the outcome of any of these variables with respect to the development of our product candidates could significantly change the costs and timing associated with the development of that product candidate. We may never succeed in obtaining regulatory approval for any of our product candidates. Â General and Administrative Expenses Â General and administrative expenses consist primarily of salaries and related costs for personnel, including share-based compensation, in executive, finance and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, patent, consulting, accounting, and audit services. Â Our general and administrative expenses will increase in the future as we increase our headcount to support continued research activities and development of product candidates. We will continue to incur increased accounting, audit, legal, regulatory, compliance and director and officer insurance costs as well as investor and public relations expenses associated with being a public company. Â Foreign Exchange (Loss) Gain Â Foreign exchange (loss) gain consists of exchange rate changes on transactions denominated in currencies other than the U.S. dollar. Â Provision for Income Taxes Â Provision for income taxes consists of foreign withholding taxes incurred on collaboration revenue. Â Results of Operations Â Comparison of the Three Months Ended December 31, 2024 and 2023 Â The following table summarizes our results of operations for the three months ended December 31, 2024 and 2023: Â Â Â Three Months Ended December 31,Â Â Â Â Â Â 2024Â Â 2023Â Â ChangeÂ Collaboration revenueÂ $1,000,000Â Â $18,626Â Â $981,374Â Operating expenses:Â Â Â Â Â Â

for our product candidates than those that we currently expect; Â Â Â â—our ability to obtain marketing approval for product candidates; Â Â Â â—the cost of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights covering our product candidates; Â 32 Â Â â—our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us or our product candidates; Â Â Â â—the cost and timing of completion of commercial-scale outsourced manufacturing activities with respect to product candidates; Â Â Â â—our ability to establish and maintain licensing, collaboration or similar arrangements on favorable terms and whether and to what extent we retain development or commercialization responsibilities under any new licensing, collaboration or similar arrangement; Â â—the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own; Â Â Â â—the success of any other business, product or technology that we acquire or in which we invest; Â Â Â â—the costs of acquiring, licensing or investing in businesses, product candidates and technologies; Â Â Â â—our need and ability to hire additional management and scientific and medical personnel; Â Â Â â—the costs to operate as a public company in the United States, including the need to implement additional financial and reporting systems and other internal systems and infrastructure for our business; Â Â Â â—market acceptance of our product candidates, to the extent any are approved for commercial sale; Â Â Â â—the effect of competing technological and market developments; and Â Â Â â—the potential impact of a widespread outbreak of any communicable disease on our clinical trials and operations. Â Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of ours may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect the rights of our stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specified actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, reduce or eliminate product development or future commercialization efforts, sell off assets, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market. Â 33 Â Â Â Committed Equity Facility Â On May 2, 2024, we entered into the Purchase Agreement and a Registration Rights Agreement (the â€œRegistration Rights Agreementâ€), each with Chardan, related to the Facility. Pursuant to the Purchase Agreement, we have the right from time to time at our option to sell to Chardan up to $25.0 million in aggregate gross purchase price of newly issued shares of our common stock, of which $24.9 million is available to be sold as of DecemberÂ 31, 2024. The Facility will allow us to raise primary equity on a periodic basis at our sole discretion depending on a variety of factors including, among other things, market conditions, the trading price of the common stock, and determinations by us regarding the use of proceeds of such common stock. The purchase price of the shares of common stock will be determined by reference to the Volume Weighted Average Price (â€œVWAPâ€) of the common stock during the applicable purchase period, less a fixed 4% discount to such VWAP, and the total shares to be purchased on any day may not exceed 20% of the trading volume of our common stock during the applicable purchase period. The Purchase Agreement will be effective for a 36-month period ending May 16, 2027, unless earlier terminated upon the terms and conditions therein. During the three months ended DecemberÂ 31, 2024, we did not sell any shares of common stock pursuant to the Purchase Agreement. Subsequent to the quarter ended December 31, 2024, 58,270 shares have been issued pursuant to the Purchase Agreement for aggregate net proceeds to us of $0.1 million. Â Alkem Licensing Agreement Â In October 2024, we executed the Alkem Agreement for the treatment of DPN in India as well as the manufacturing, marketing and commercialization of SON-080 for the treatment of CIPN and autonomic neuropathy in India. Pursuant to the terms of the Alkem Agreement, Alkem will bear the cost of certain expenses, including conducting clinical studies, preparing and filing regulatory applications and undertaking other developmental and regulatory activities for commercializing SON-080 for DPN in India. Alkem will pay us a $1.0 million upfront non-refundable cash payment, of which $0.5 million has been paid, which after tax withholdings resulted in a net payment of $0.4 million, as well as potential additional milestone payments totaling up to $1.0 million subject to the achievement of certain development and regulatory milestones. In addition, Alkem is obligated to pay us a royalty equal to a percentage in the low double digits of net sales less Alkemâ€™s actual cost of goods sold and Alkemâ€™s sales and marketing and related expenses of SON-080 in India until the first commercial sale of a competitive intermittent low dose IL-6 compound as set forth in the Alkem Agreement. Â November 2024 Underwritten Public Offering Â On November 7, 2024, we closed a public offering of common stock and certain warrants through Chardan, as underwriter, for net proceeds of $4.2 million through the issuance and sale of 155,000 shares of our common stock, pre-funded warrants to purchase up to 956,111 shares of common stock, and accompanying common warrants to purchase up to an aggregate of 2,222,222 shares of our common stock. Each share of common stock and pre-funded warrant to purchase one share of common stock was sold together with a common warrant to purchase two shares of common stock. The public offering price of each share of common stock and accompanying common warrant was $4.50 and the public offering price of each pre-funded warrant and accompanying common warrant was $4.4999. The common warrants were immediately exercisable at a price of $4.50 per share of common stock, expire five years from the date of issuance and contain an alternative cashless exercise provision. The pre-funded warrants were immediately exercisable at any time, until exercised in full, at a price of $0.0001 per share of common stock. Â 34 Â Â December 2024 Registered Direct and PIPE Offering Â On December 10, 2024, we closed a registered direct offering with institutional investors for the issuance and sale of 768,000 shares of our common stock, pre-funded warrants to purchase up to 317,325 shares of common stock and accompanying warrants to purchase up to an aggregate of 1,085,325 shares of our common stock. Each share of common stock and pre-funded warrant to purchase one share of common stock was sold together with a common warrant to purchase one share of common stock. The offering price of each share of common stock and accompanying common warrant was $2.23 and the offering price of each pre-funded warrant and accompanying common warrant was $2.2299, priced at-the-market under the rules of the Nasdaq Stock Market. The registered direct warrants were immediately exercisable at a price of $2.10 per share, expire five years from the date of issuance and contain an alternative cashless exercise provision. The pre-funded warrants were immediately exercisable at any time, until exercised in full, at a price of $0.0001 per share of common stock. Â We closed a concurrent private placement with an existing investor for the issuance and sale of 127,500 shares of our common stock, pre-funded warrants to purchase up to 545,500 shares of common stock and accompanying warrants to purchase up to an aggregate 673,000 shares of our common stock. Each share of common stock and pre-funded warrant to purchase one share of common stock was sold in the private placement (â€œPIPEâ€) together with a common warrant to purchase one share of common stock. The PIPE offering price of each share of common stock and accompanying common warrant was $2.23 and the PIPE offering price of each pre-funded warrant and accompanying common warrant was $2.2299, priced at-the-market under the rules of the Nasdaq Stock Market. The PIPE warrants were immediately exercisable at a price of $2.10 per share, expire five years from the date of issuance and contain an alternative cashless exercise provision. The pre-funded warrants were immediately exercisable at any time, until exercised in full, at a price of $0.0001 per share of common stock. Â We raised net proceeds of approximately $3.5 million from the registered direct and PIPE offering. Â Contractual Obligations and Commitments Â Our contractual obligations as of DecemberÂ 31, 2024 that will affect our future liquidity consist of an operating lease. As of DecemberÂ 31, 2024, we had $87,323 in current operating lease liability and $23,634 in non-current operating lease liability. Â In addition to the operating lease, we have entered into other contracts in the normal course of business with certain CROs, CMOs and other third-parties for preclinical research studies and testing, clinical trials and manufacturing services. These contracts do not contain any minimum purchase commitments and are cancellable upon prior notice. Payments due upon cancellation consist only of payments for services provided and expenses incurred, including non-cancellable obligations to our service providers, up to the date of cancellation. Â Critical Accounting Policies and Estimates Â Our managementâ€™s discussion and analysis of financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to the accrual for research and development expenses. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Â 35 Â Â While our significant accounting policies are described in more detail in the notes to the unaudited interim consolidated financial statements included elsewhere in this Form 10-Q, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of the consolidated financial statements. Â Â Research and Development Expenses Â Research and development expenses include all direct and indirect costs associated with the development of our biopharmaceutical products. These expenses include personnel costs, consulting fees, and payments to third parties for research, development and manufacturing services. These costs are charged to expense as incurred. Â At the end of each reporting period, we compare payments made to third-party service providers to the estimated progress toward completion of the related project, based on the measure of progress as defined in the contract. Factors we consider in preparing the estimates include costs incurred by the service provider, milestones achieved, and other criteria related to the efforts of our service providers. Such estimates are subject to change as additional information becomes available. Depending on the timing of payment to the third-party service providers and the progress we estimate has been made as a result of the service provided, we will record a prepaid expense or accrued liability related to these costs. Contingent development or regulatory milestone payments are recognized upon the related resolution of such contingencies. As of December 31, 2024, we did not make any material adjustments to our prior estimates of accrued research and development expenses. Â Recently Issued Accounting Pronouncements Â A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to the unaudited interim consolidated financial statements included elsewhere in this Form 10-Q. Â Item 3. Quantitative and Qualitative Disclosures About Market Risk. Â Not applicable. Â Item 4. Controls and Procedures. Â Evaluation of Disclosure Controls and Procedures Â We evaluated, under the supervision and with the participation of the principal executive officer and principal financial officer, the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as amended (â€œExchange Actâ€)) as of December 31, 2024, the end of the period covered by this report on Form 10-Q. Based on this evaluation, our Chairman, President and Chief Executive Officer (principal executive officer) and our Chief Financial Officer (principal financial officer) have concluded that our disclosure controls and procedures were effective at the reasonable assurance level at December 31, 2024. Â Disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the SECâ€™s rules and forms, and (ii) is accumulated and communicated to management, including the principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Due to the inherent limitations of control systems, not all misstatements may be detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. Controls and procedures can only provide reasonable, not absolute, assurance that the above objectives have been met. Â Changes in Internal Control over Financial Reporting Â There were no changes in our internal control over financial reporting during the three months ended December 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Â 36 Â Â PART II - OTHER INFORMATION Â Item 1. Legal Proceedings. Â We are subject to various legal proceedings from time to time in the ordinary course of business, which may not be required to be disclosed under this Item 1. For the three-month period ended December 31, 2024 covered by this Quarterly Report, there have been no reportable legal proceedings or material developments to previously reported legal proceedings. Â Item 1A. Risk Factors. Â As a smaller reporting company, we are not required to provide the information required by this item. However, we direct you to the risk factors included in the â€œRisk Factorsâ€ section in our Annual Report on Form 10-K for the year ended September 30, 2024 filed with the Securities and Exchange Commission on December 17, 2024. Â Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. Â None. Â Item 3. Defaults Upon Senior Securities. Â None. Â Item 4. Mine Safety Disclosures. Â Not applicable. Â Item 5. Other Information. Â a) Chief Financial Officer Resignation and Appointment Â On February 10, 2025, Jay Cross submitted his resignation as our Chief Financial Officer, effective February 21, 2025. In connection with Mr. Crossâ€™s resignation, on February 12, 2025, our board of directors (the â€œBoardâ€) appointed Donald Griffith, CPA, our current Controller and a member of our Board, to succeed Mr. Cross as our Chief Financial Officer effective February 21, 2025. Mr. Griffith will continue his duties as a member of our Board. Â Mr. Griffith, age 76, is a certified public accountant with over has 40 yearsâ€™ experience in finance and accounting. Mr. Griffith has served as our Controller and as a member of our Board since the closing of the merger (the â€œMergerâ€) between the Company and Sonnet BioTherapeutics, Inc., our wholly-owned operating subsidiary and accounting predecessor (â€œPrior Sonnetâ€) in April 2020. Prior to the Merger, Mr. Griffith served on Prior Sonnetâ€™s board of directors from its inception in April 2015, including as Chairman from April 2015 to June 2018. Mr. Griffith also served as Prior Sonnetâ€™s Financial Controller from January 2019 until April 2020, and as its Chief Executive Officer and Chief Financial Officer from April 2015 to December 2016. Before joining Prior Sonnet, Mr. Griffith served as the Chief Financial Officer, Director and Secretary of Oncobiologics Inc. (now Outlook Therapeutics; Nasdaq: OTLK) (â€œOncobiologicsâ€) from 2011 to 2018. In addition, Mr. Griffith is the founder and Partner of Stolz & Griffith, LLC, a New Jersey accounting firm. Â There are no arrangements or understandings between Mr. Griffith and any other persons pursuant to which Mr. Griffith was selected as an officer of our Company, Mr. Griffith has no family relationships with any of our Companyâ€™s directors or executive officers, and Mr. Griffith is not a party to and does not have any direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K under the Securities Act of 1933, as amended. Â Griffith Employment Agreement Â As previously disclosed, Prior Sonnet entered into an employment agreement with Mr. Griffith on January 1, 2019, setting forth the terms of his employment as Financial Controller (the â€œGriffith Agreementâ€), which agreement was assumed by us at the closing of the Merger. Pursuant to the Griffith Agreement, Mr. Griffith is entitled to, among other things, (i) an annual prorated gross base salary of $150,000 and (ii) eligibility for a target bonus equal to 25% of gross salary earned. The Griffith Agreement has no specific term and constitutes an at-will employment. The terms of the Griffith Agreement continue to govern Mr. Griffithâ€™s employment with us. Â The foregoing description of the Griffith Agreement, does not purport to be complete and is qualified in its entirety by reference to the full text of the Griffith Agreement, a copy of which is filed herewith as Exhibit 10.5, and is incorporated herein by reference. Â Chief Business Officer Appointment Â On February 12, 2025, Stephen McAndrew, Ph.D., our Senior Vice President of Business Development, was appointed by our Board as our Chief Business Officer. Dr. McAndrewâ€™s employment as our Chief Business Officer will commence on February 17, 2025. Â Dr. McAndrew, age 71, has served as our Senior Vice President of Business Development since the closing of the Merger. Prior to the Merger, Dr. McAndrew served as Prior Sonnetâ€™s Senior Vice President of Business Development from October 2019. Before joining Prior Sonnet, Dr. McAndrew served as the Senior Vice President of Business Strategy & Development at Oncobiologics from March 2014 to October 2019 and as the Vice President of Business Development from February 2012 to March 2014. Prior to Oncobiologics, Dr. McAndrew served in various business development roles at several biopharmaceutical companies from 2001 to 2011. From March 1993 to December 2001, Dr. McAndrew also served in various positions of increasing responsibility at Bristol-Myers Squibb Company, including as the Director of Biotechnology Licensing within the External Science and Technology Department. Â Dr. McAndrew earned his Ph.D. in Molecular and Cellular Biology from Ohio University, an M.S in Molecular Genetics from the State University of New York at Albany and a B.S from the State University of New York at Oswego. Â There are no arrangements or understandings between Dr. McAndrew and any other persons pursuant to which Dr. McAndrew was selected as an officer of our Company, Dr. McAndrew has no family relationships with any of our Companyâ€™s directors or executive officers, and Dr. McAndrew is not a party to and does not have any direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K under the Securities Act of 1933, as amended. Â McAndrew Employment Agreement Â On February 12, 2025, we entered into an employment agreement with Dr. McAndrew (the â€œMcAndrew Agreementâ€), setting forth the terms of his employment as Chief Business Officer. Pursuant to the McAndrew Agreement, Dr. McAndrew is entitled to, among other things,

(i) an annual gross base salary of $330,000 (â€œBase Salaryâ€) and (ii) eligibility for a performance-based cash bonus of up to 35% of the Base Salary, as determined by the Board. The McAndrew Agreement shall terminate in accordance with the terms set forth therein. Pursuant to the McAndrew Agreement, if Dr. McAndrew is terminated without â€œCauseâ€ or for â€œGood Reasonâ€ within 2 months prior to or within 12 months following a â€œChange in Controlâ€, he is entitled to (i) his base salary for 12 months, (ii) any performance bonus for the performance year in which his termination occurs, and (iii) if he timely continued coverage under COBRA, payment for COBRA premiums necessary to continue coverage until the earliest of (a) 18 months following the termination date, (b) the date he becomes eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment, or (c) the date he becomes ineligible for COBRA continuation coverage. If Dr. McAndrew is terminated without â€œCauseâ€ or for â€œGood Reasonâ€ not coincident with a â€œChange in Controlâ€, he is entitled to (i) his base salary for 9 months, (ii) any performance bonus for the performance year in which his termination occurs, and (iii) if he timely continued coverage under COBRA, payment for COBRA premiums necessary to continue coverage until the earliest of (a) 12 months following the termination date, (b) the date he becomes eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment, or (c) the date he becomes ineligible for COBRA continuation coverage. Â The foregoing description of the McAndrew Agreement, does not purport to be complete and is qualified in its entirety by reference to the full text of the McAndrew Agreement, a copy of which is filed herewith as Exhibit 10.6, and is incorporated herein by reference. Â b) None. Â c) During the three months ended December 31, 2024, no director or â€œofficerâ€ (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated a â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangement,â€ as each term is defined in Item 408(a) of Regulation S-K. Â 37 Â Â Â Item 6: Exhibits. Â Exhibit No. Â Description Â Â Â 4.1 Â Form of Common Warrant (incorporated by reference to Exhibit 4.22 of the Companyâ€™s Registration Statement on Form S-1/A filed with the SEC on November 6, 2024). Â Â Â 4.2 Â Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.23 to the Companyâ€™s Registration Statement on Form S-1/A filed with the SEC on November 6, 2024). Â Â Â 4.3 Â Form of Registered Direct Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Companyâ€™s Current Report on Form 8-K filed with the SEC on December 10, 2024). Â Â Â 4.4 Â Form of Private Placement Pre-Funded Warrant (incorporated by reference to Exhibit 4.2 to the Companyâ€™s Current Report on Form 8-K filed with the SEC on December 10, 2024). Â Â Â 4.5 Â Form of Common Warrant (incorporated by reference to Exhibit 4.3 to the Companyâ€™s Current Report on Form 8-K filed with the SEC on December 10, 2024). Â Â Â 10.1 Â License Agreement, dated October 8, 2024, between Sonnet BioTherapeutics, Inc., Sonnet BioTherapeutics CH SA and Alkem Laboratories Limited (incorporated by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed with the SEC on October 9, 2024). Â Â Â 10.2 Â Underwriting Agreement, dated November 6, 2024, between the Company and Chardan Capital Markets, LLC (incorporated by reference to Exhibit 1.1 to the Companyâ€™s Current Report on Form 8-K filed with the SEC on November 8, 2024). Â Â Â 10.3 Â Form of Registered Direct Securities Purchase Agreement, dated December 9, 2024, by and between the Company and the Purchasers (incorporated by reference to Exhibit 10.1 of the Companyâ€™s Current Report on Form 8-K filed with the SEC on December 10, 2024). Â Â Â 10.4 Â Form of Private Placement Securities Purchase Agreement, dated December 9, 2024, by and between the Company and the Purchasers (incorporated by reference to Exhibit 10.2 of the Companyâ€™s Current Report on Form 8-K filed with the SEC on December 10, 2024). Â Â Â 10.5â€ Â Offer Letter, between Donald Griffith and Sonnet BioTherapeutics, Inc., dated January 1, 2019 (incorporated by reference to Exhibit 10.59 to the Companyâ€™s Registration Statement on Form S-4 filed with the SEC on February 7, 2020). Â Â Â 10.6*â€ Â Employment Agreement by and between the Company and Stephen McAndrew, Ph.D., dated February 12, 2025. Â Â Â 31.1* Â Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a). Â Â Â 31.2* Â Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a). Â Â Â 32.1** Â Certification of Principal Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Â Â Â 32.2** Â Certification of Chief Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Â Â Â 101.INS* Â Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. Â Â Â 101.SCH* Â Inline XBRL Taxonomy Extension Schema Document. Â Â Â 101.CAL* Â Inline XBRL Taxonomy Extension Calculation Linkbase Document. Â Â Â 101.DEF* Â Inline XBRL Taxonomy Extension Definition Linkbase Document. Â Â Â 101.LAB* Â Inline XBRL Taxonomy Extension Label Linkbase Document. Â Â Â 101.PRE* Â Inline XBRL Taxonomy Extension Presentation Linkbase Document. Â Â Â 104* Â Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibits 101). Â * Filed herewith. Â ** Furnished, not filed. Â â€ Indicates a management contract or compensation plan, contract or arrangement. Â 38 Â Â Â SIGNATURES Â Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â Â SONNET BIOTHERAPEUTICS HOLDINGS, INC. Â Â Â Date: February 13, 2025 By: /s/ Pankaj Mohan Â Â Pankaj Mohan Â Â President and Chief Executive Officer Â Â (Principal Executive Officer) Â Â Â Â By: /s/ Jay Cross Â Â Jay Cross Â Â Chief Financial Officer Â Â (Principal Financial Officer and Principal Accounting Officer) Â 39 Â EX-10.6 2 ex10-6.htm Â Exhibit 10.6 Â EXECUTIVE EMPLOYMENT AGREEMENT Â THE EXECUTIVE EMPLOYMENT AGREEMENT (the â€œAgreementâ€), dated as of February 12, 2025 and effective as of the Effective Date (as defined below) is by and between STEPHEN MCANDREW (the â€œExecutiveâ€) and SONNET BIOTHERAPEUTICS, INC., a New Jersey corporation (the â€œCompanyâ€). Â WHEREAS, the Executive has been employed as the Companyâ€™s SVP of Business Development since on or about 2019; Â WHEREAS, the Executive and the Company agree that as of February 17, 2025 (the â€œEffective Dateâ€), the Executive will serve as the Chief Business Officer of the Company; and Â WHEREAS, the Executive agrees to be retained by the Company in such capacity in consideration of such compensation and benefits on the terms and conditions set forth in this Agreement; Â NOW, THEREFORE, in consideration of the mutual promises and covenants contained in this Agreement, the Company and the Executive agree to the following: Â 1.0 Employment by the Company. Â 1.1 Position. Subject to the terms and conditions set forth in this Agreement, the Company agrees as of the Effective Date, to employ the Executive in the position of Chief Business Officer, and the Executive hereby accepts such employment on the terms and conditions set forth in this Agreement. This Agreement shall become effective on the Effective Date. Â 1.2 Duties. As Chief Business Officer, the Executive will report to the President and Chief Executive Officer of the Company (the â€œCEOâ€), performing such duties that are normally associated with his position and such duties as are assigned to him from time to time consistent with that position, subject to the oversight and direction of the CEO. During the term of the Executiveâ€™s employment with the Company, the Executive will work on a full-time basis for the Company and will devote his best efforts and substantially all his business time and attention to the business of the Company. The Executive shall travel on behalf of the Company as may be necessary or advisable for the best interests of the Company. Â 1.3 Company Policies and Benefits. The employment relationship between the parties shall also be subject to the Companyâ€™s personnel policies and procedures as they may be interpreted, adopted, revised or deleted from time to time in the Companyâ€™s sole discretion. The Company will provide the Executive and his family with comprehensive health insurance benefits (or reimburse him for purchasing such insurance) at the Companyâ€™s expense. The Company reserves the right to change, alter, or terminate any benefit plan in its sole discretion. Notwithstanding the foregoing, in the event that the terms of this Agreement differ from or are in conflict with the Companyâ€™s general employment policies or practices, this Agreement shall control Company has a 401(k) planwhich you can participate in. The Executive shall be eligible to participate in all qualified and non-qualified savings and retirement plans and other compensation benefit plans and programs made generally available to other employees of the Company. Â Â Â Â 1.4 Vacation. During the term of this Agreement, the Executive shall receive four (4) weeks of vacation per full calendar year (prorated for any partial calendar year of employment), subject to the Companyâ€™s vacation policies and procedures as in effect or amended from time to time, which vacation time shall accrue pro-rata on a pay period basis. The Executive may not carryover any earned but unused vacation time from any calendar year to any subsequent calendar year unless otherwise expressly permitted by applicable Company policies or the Board. Â 2.0 Compensation. Â 2.1 Base Salary. The Company shall compensate the Executive for his services under this Agreement at the annual rate of Three Hundred Thirty Thousand Dollars ($330,000) (the â€œBase Salaryâ€), payable in bi-weekly installments, with the pay periods subject to adjustment by the Company in its sole discretion, and subject to applicable federal and state payroll withholding requirements. Â 2.2 Performance Bonus. The Company may pay to the Executive a bonus (the â€œPerformance Bonusâ€) of up to thirty five percent (35%) of his Base Salary that will be determined based upon performance compared to one or more target metrics established annually by the Compensation Committee of the Board, or the full Board, in their sole discretion and communicated to the Executive in writing promptly after such determination. The Performance Bonus will be paid subject to applicable federal and state payroll withholding requirements. The Executive must be actively employed in good standing on the payment date (typically by March 15 of the subsequent year to which the Performance Bonus is based) to be eligible to receive a Performance Bonus. Â 2.3 Stock Options. Company has a stock option plan including RSUs and RSAs, the Board may be awarding at their discretion such awards on a periodic basis. Â 2.4 Expense Reimbursement. The Company will reimburse Executive for his reasonable business expenses in accordance with the Companyâ€™s standard expense reimbursement policy, as the same may be modified by the Company from time to time. The reimbursement will apply to all customary and appropriate business-related expenses actually incurred and documented in accordance with Company policy, as in effect from time to time. For the avoidance of doubt, to the extent that any reimbursements payable to Executive, are subject to the provisions of Section 409A of the Internal Revenue Code of 1986, as amended (the â€œCodeâ€): (a) any such reimbursements will be paid no later than December 31 of the year following the year in which the expense was incurred, (b) the amount of expenses reimbursed in one year will not affect the amount eligible for reimbursement in any subsequent year, and (c) the right to reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit. Â 3.0 Proprietary Information, Inventions, Non-Competition and Non-Solicitation Obligations. As a condition of employment, the Executive agrees to execute and abide by an Employee Proprietary Information, Inventions, Non-Competition and Non-Solicitation Agreement attached as Exhibit A (the â€œProprietary Information Agreementâ€), which may be amended by the parties from time to time without regard to this Agreement. The Proprietary Information Agreement contains provisions that are intended by the parties to survive and do survive termination of this Agreement. Â -2- Â Â 4.0 Termination of Employment. The parties acknowledge that the Executiveâ€™s employment relationship with the Company is at-will, meaning either the Company or the Executive may terminate the Executiveâ€™s employment at any time, with or without cause or advance notice. The provisions in this Section 4.0 govern the amount of compensation, if any, to be provided to the Executive upon termination of employment and do not alter his at-will status. Â 4.1 Termination by the Company without Cause or termination by the Executive for Good Reason. Â a. The Company shall have the right to terminate Executiveâ€™s employment with the Company pursuant to this Section 4.1 at any time, in accordance with Section 4.6, without â€œCauseâ€ (as defined in Section 4.3(b) below) by giving notice as described in Section 5.1 of this Agreement. A termination pursuant to Section 4.5 below is not a termination without â€œCauseâ€ for purposes of receiving the benefits described in Sections 4.1 or Section 4.2. Â b. In the event that the Company terminates Executiveâ€™s employment at any time without Cause or Executive terminates his employment with the Company for Good Reason and provided that such termination constitutes a â€œseparation from serviceâ€ (as defined under Treasury Regulation Section l.409A-1(h), without regard to any alternative definition thereunder (a â€œSeparation from Serviceâ€), then the Executive shall be entitled to receive the Accrued Obligations (defined below). If the Executive complies with the obligations in Section 4.1 (c) below with respect to timely signing and not revoking his acceptance of a Release, the Executive shall also be eligible to receive the following â€œSeverance Benefitsâ€: Â i. The Company will pay Executive an amount equal to Executiveâ€™s then current Base Salary for nine (9) months, less all applicable withholdings and deductions, paid in equal installments on the Companyâ€™s normal payroll schedule following the termination date, with the first payment beginning on the Severance Pay Commencement Date (as defined in Section 4.l(c) below), and the remaining installments occurring on the Companyâ€™s regularly scheduled payroll dates thereafter; provided that on the Severance Pay Commencement Date, the Company will pay in a lump sum the aggregate amount of the cash severance payments that the Company would have paid Executive through such date had the payments commenced on the effective date of termination through the Severance Pay Commencement Date. Â ii. The Company will pay any performance bonus if awarded by the Board for the performance year in which Executiveâ€™s termination occurs. This bonus will be payable subject to standard federal and state payroll withholding requirements in a lump sum payment on the Severance Pay Commencement Date. Â -3- Â Â iii. If the Executive is enrolled in the Companyâ€™s health insurance plan at the time of a Separation of Service and timely elects continued coverage under COBRA for himself and his covered dependents under the Companyâ€™s group health plans following such termination, then the Company shall pay the COBRA premiums necessary to continue Executiveâ€™s and his covered dependentsâ€™ health insurance coverage in effect for himself (and his covered dependents) on the termination date until the earliest of: (i) nine (9) months following the termination date (the â€œCOBRA Severance Periodâ€™â€); (ii) the date when Executive becomes eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment; or (iii) the date Executive ceases to be eligible for COBRA continuation coverage for any reason, including plan termination (such period from the termination date through the earlier of (i)-(iii), (the â€œCOBRA Payment Periodâ€). Notwithstanding the foregoing, if at any time the Company determines that its payment of COBRA premiums on Executiveâ€™s behalf would result in a violation of applicable law (including, but not limited to, the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of paying COBRA premiums pursuant to this Section, the Company shall pay Executive on the last day of each remaining month of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premium for such month, subject to applicable tax withholding (such amount, the â€œSpecial Severance Paymentâ€), for the remainder of the COBRA Payment Period. Nothing in this Agreement shall deprive Executive of his rights under COBRA or ERISA for benefits under plans and policies arising under his employment by the Company. Â c. The Executive will be paid all the Accrued Obligations on the Companyâ€™s first payroll date after the Executiveâ€™s date of termination from employment or earlier if required by law. The Executive shall receive the Severance Benefits pursuant to Section 4.l (b) or the Change in Control Severance Benefits (defined below) pursuant to 4.2 (a) of this Agreement, as applicable, if: (i) the Executive executes and does not revoke a separation agreement containing an effective, general release of claims in favor of the Company and its affiliates and representatives, in a form acceptable to the Company (the â€œReleaseâ€) and the Release is enforceable and effective as provided in the Release on or before the date that is the sixtieth (60th) day following the effective date of termination (such 60th day, the â€œSeverance Pay Commencement Dateâ€); (ii) he holds any other positions with the Company, he resigns such position(s) to be effective no later than the date of Executiveâ€™s termination date (or such other date as requested by the Board); (iii) he returns all Company property; (iv) he complies with his post-termination obligations under this Agreement and the Proprietary Information Agreement; and (v) he complies with the terms of the Release, including without limitation any non-disparagement and confidentiality provisions contained in Release. Â d. For purposes of this Agreement, â€œAccrued Obligationsâ€ are (i) the Executiveâ€™s accrued but unpaid Base Salary through the date of termination, including unused, accrued vacation time; (ii) any unreimbursed business expenses incurred by Executive payable in accordance with the Companyâ€™s standard expense reimbursement policies, and (iii) benefits owed to Executive under any qualified retirement plan or health and welfare benefit plan in which Executive was a participant in accordance with applicable law and the provisions of such plan. Â e. The Severance Benefits provided to Executive pursuant to this Section 4.1 are in lieu of, and not in addition to, any benefits to which Executive may otherwise be entitled under any Company severance plan, policy or program. Â f. Any damages caused by the termination of Executiveâ€™s employment without Cause would be difficult to ascertain; therefore, the Severance Benefits for which Executive is eligible pursuant to Section 4.l (b) above in exchange for the Release is agreed to by the parties as liquidated damages, to serve as full compensation, and not a penalty. Â -4- Â Â g. For purposes of this Agreement, â€œGood Reasonâ€ shall mean the occurrence of any of the following events without Executiveâ€™s written consent: (i) any reduction of twenty-five percent (25%) or more in the Executiveâ€™s Base Salary (other than a corresponding reduction in base salary for other similarly situated employees); (ii) a material breach of this Agreement by the Company; (iii) a material reduction in the Executiveâ€™s duties, authority and responsibilities relative to the Executiveâ€™s duties, authority, and responsibilities in effect immediately prior to such reduction; or (iv) the relocation of Executiveâ€™s principal place of employment, without Executiveâ€™s consent, in a manner that lengthens his one-way commute distance by twenty-five (25) or more miles from his then-current principal place of employment immediately prior to such relocation; provided, however, that, any such termination by Executive shall only be deemed for Good Reason pursuant to this definition if: (1) Executive gives the Company written notice of his intent to terminate for Good Reason within thirty (30) days following the first occurrence of the condition(s) that he believes constitute(s) Good Reason, which notice shall describe such condition(s); (2) the Company fails to remedy such condition(s) within thirty (30) days following receipt of the written notice (the â€œCure Periodâ€); and (3) Executive voluntarily terminates his employment within thirty (30) days following the end of the Cure Period. Â 4.2 Termination by the Company without Cause or by Executive for Good Reason Coincident with a Change in Control. Â a. If Executiveâ€™s employment by the Company is terminated by the Company or any successor entity without â€œCauseâ€ (and not due to Disability or death) or by Executive for Good Reason within two (2) months prior to or within twelve (12) months following the effective date of a â€œChange in

Controlâ€ (as defined in the Companyâ€™s Equity Incentive Plan, as such plan may be amended from time to time), provided that such termination constitutes a Separation from Service, without regard to any alternative definition thereunder, then in addition to paying or providing Executive with the Accrued Obligations and subject to compliance with Section 4.l (c), the Company will provide the following â€œChange in Control Severance Benefitsâ€: Â i. The Company will pay Executive an amount equal to Executive â€˜s then current Base Salary for twelve (12) months, less all applicable withholdings and deductions, paid in equal installments on the Companyâ€™s normal payroll schedule following the date of Separation from Service, with the first payment beginning on the Severance Pay Commencement Date, and the remaining installments occurring on the Companyâ€™s regularly scheduled payroll dates thereafter; provided that on the Severance Pay Commencement Date, the Company will pay in a lump sum the aggregate amount of the cash severance payments that the Company would have paid Executive through such date had the payments commenced on the effective date of termination through the Severance Pay Commencement Date. Â ii. The Company will pay performance bonus for the performance year in which Executiveâ€™s termination occurs. This bonus will be payable subject to standard federal and state payroll withholding requirements in a lump sum payment on the Severance Pay Commencement Date. Â -5- Â Â iii. If the Executive is enrolled in the Companyâ€™s health insurance plan at the time of a Separation of Service and timely elects continued coverage under COBRA for himself and his covered dependents under the Companyâ€™s group health plans following such termination, then the Company shall pay the COBRA premiums necessary to continue Executiveâ€™s and his covered dependentsâ€™ health insurance coverage in effect for himself (and his covered dependents) on the termination date until the earliest of: (i) eighteen (18) months following the termination date (the â€œCOBRA Severance Periodâ€); (ii) the date when Executive becomes eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment; or (iii) the date Executive ceases to be eligible for COBRA continuation coverage for any reason, including plan termination (such period from the termination date through the earlier of (i)-(iii), (the â€œCOBRA Payment Periodâ€). Notwithstanding the foregoing, if at any time the Company determines that its payment of COBRA premiums on the Executiveâ€™s behalf would result in a violation of applicable law (including, but not limited to, the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of paying COBRA premiums pursuant to this Section, the Company shall pay Executive on the last day of each remaining month of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premium for such month, subject to applicable tax withholding (such amount, the Special Severance Paymentâ€), for the remainder of the COBRA Payment Period. Nothing in the Agreement shall deprive Executive of his rights under COBRA or ERISA for benefits under plans and policies arising under his employment by the Company. Â iv. Notwithstanding the terms of any equity plan or award agreement to the contrary, the time-based vesting conditions applicable to all of Executiveâ€™s outstanding stock options and/or other equity awards subject to time-based vesting requirements as of Executive â€˜s termination date shall vest as follows: (A) if such termination occurs within two (2) months prior to or on the effective date of a Change in Control, the time-based vesting shall accelerate and be deemed to be satisfied as of the date of Executiveâ€™s termination, and (B) if such termination occurs within twelve (12) months following the effective date of a Change in Control, in the event any surviving corporation or acquiring corporation assumes Executiveâ€™s stock options and/or other equity awards, as applicable, or substitutes similar stock options or equity awards for Executiveâ€™s stock options and/or equity awards, as applicable, in accordance with the terms of the Companyâ€™s equity incentive plans, the time-based vesting of all of such stock options and/or equity awards (or any substitute stock options or equity awards), as applicable, shall be accelerated in full as of the date of termination. For the avoidance of doubt, the accelerated vesting provided under this Section 4.2(a)(iii) shall not apply to any liquidity event or performance-based vesting conditions applicable to any of Executiveâ€™s outstanding stock options and/or other equity awards as of the date of termination. Â b. The Change in Control Severance Benefits provided to Executive pursuant to this Section 4.2 are in lieu of, and not in addition to, any benefits to which Executive may otherwise be entitled under any Company severance plan, policy or program, including but not limited to the Severance Benefits described in Section 4.l(b). For the avoidance of doubt, in no event shall Executive be entitled to benefits under both Section 4.l(b) and this Section 4.2. If Executive is eligible for benefits under both Section 4.1(b) and this Section 4.2, or if Executive begins receiving benefits under Section 4.1(b) and later becomes eligible for benefits under Section 4.2, Executive shall receive the benefits set forth in this Section 4.2 and such benefits will be reduced by any benefits previously provided to Executive under Section 4.1(b). Â c. Any damages caused by the termination of the Executiveâ€™s employment without Cause or for Good Reason following a Change in Control would be difficult to ascertain; therefore, the Change in Control Severance Benefits for which Executive is eligible pursuant to Section 4.2(a) above in exchange for the Release is agreed to by the parties as liquidated damages, to serve as full compensation, and not as a penalty. Â -6- Â Â 4.3 Termination by the Company for Cause. Â a. The Company shall have the right to terminate Executiveâ€™s employment with the Company at any time, in accordance with Section 4.6, for Cause by giving notice as described in Section 5.1 of this Agreement. In the event Executiveâ€™s employment is terminated at any time for Cause, Executive will not receive Severance Benefits, Change in Control Severance Benefits, or any other severance compensation or benefits, except that, pursuant to the Companyâ€™s standard payroll policies, the Company shall pay to Executive the Accrued Obligations. Â b. â€œCauseâ€ for termination shall mean that the Company has determined in its sole discretion that Executive has engaged in any of the following: (i) a material breach of any covenant or condition under this Agreement or any other agreement between the parties ; (ii) any act constituting dishonesty, fraud, immoral or disreputable conduct; (iii) any conduct which constitutes a felony under applicable law; (iv) material violation of any Company policy or any act of misconduct; (v) refusal to follow or implement a clear and reasonable directive of Company; (vi) negligence or incompetence in the performance of Executiveâ€™s duties or failure to perform such duties in a manner satisfactory to the Company after the expiration of thirty(30) days without cure after written notice of such failure (to the extent curable); or (vii) breach of fiduciary duty. Â 4.4 Resignation by Executive. Â a. Executive may resign from Executiveâ€™s employment with the Company at any time, in accordance with Section 4.6, by giving notice as described in Section 5.1. Â b. In the event Executive resigns from Executiveâ€™s employment with the Company for any reason other than Good Reason in accordance with Sections 4.1 or 4.2, Executive will not receive Severance Benefits, Change in Control Severance Benefits, or any other severance compensation or benefits, except that, pursuant to the Companyâ€™s standard payroll policies, the Company shall pay to Executive the Accrued Obligations. Â 4.5 Termination by Virtue of Death or Disability of Executive. Â a. In the event of Executiveâ€™s death while employed pursuant to this Agreement, all obligations of the parties hereunder shall terminate immediately, in accordance with Section 4.6, and the Company shall, pursuant to the Companyâ€™s standard payroll policies, pay to Executiveâ€™s legal representatives all Accrued Obligations. Â b. Subject to applicable state and federal law, the Company shall at all times have the right, upon written notice to Executive, and in accordance with Section 4.6, to terminate this Agreement based on Executiveâ€™s Disability. Termination by the Company of Executiveâ€™s employment based on â€œDisabilityâ€ shall mean termination because Executive is unable due to a physical or mental condition to perform the essential functions of his position with or without reasonable accommodation for 180 days in the aggregate during any twelve (12) month period or based on the written certification by two licensed physicians of the likely continuation of such condition for such period. This definition shall be interpreted and applied consistent with the Americans with Disabilities Act, the Family and Medical Leave Act, and other applicable law. In the event Executiveâ€™s employment is terminated based on Executiveâ€™s Disability, Executive will not receive Severance Benefits, Change in Control Severance Benefits, or any other severance compensation or benefit, except that, pursuant to the Companyâ€™s standard payroll policies, the Company shall pay to Executive the Accrued Obligations. Â -7- Â Â 4.6 Notice; Effective Date of Termination. Â a. Termination of Executiveâ€™s employment pursuant to this Agreement shall be effective on the earliest of: Â i. immediately after the Company gives notice to Executive of Executiveâ€™s termination, with or without Cause; Â ii. immediately upon the Executiveâ€™s death or Disability; Â iii. thirty (30) days after the Executive gives written notice to the Company of Executiveâ€™s resignation, provided that the Company may set a termination date at any time between the date of notice and the date of resignation (in which case the Companyâ€™s obligation to provide continued compensation shall cease); or Â iv. for a termination for Good Reason, immediately upon the Executiveâ€™s full satisfaction of the requirements of Section 4.l(g). Â b. In the event notice of a termination under subsections (a)(i) or (iii) is given orally, at the other partyâ€™s request, the party giving notice must provide written confirmation of such notice within five (5) business days of the request in compliance with the requirement of Section 5.1 below. In the event of a termination for Cause, written confirmation shall specify the subsection(s) of the definition of Cause relied on to support the decision to terminate. Â 4.7 Cooperation with Company after Termination of Employment. Â During the term of employment as well as following termination of the Executiveâ€™s employment for any reason, the Executive agrees to cooperate fully with the Company in connection with its actual or contemplated defense, prosecution, or investigation of any claims or demands by or against third parties, or other matters arising from events, acts, or failures to act that occurred during the period of Executiveâ€™s employment by the Company. Such cooperation includes, without limitation, making Executive available to the Company upon reasonable notice, without subpoena, to provide complete, truthful and accurate information in witness interviews, depositions and trial testimony. In addition, for twelve (12) months after Executiveâ€™s employment with the Company ends for any reason, Executive agrees to reasonably cooperate fully with the Company in all matters relating to the transition of Executiveâ€™s work and responsibilities on behalf of the Company, including, but not limited to, any present, prior or subsequent relationships and the orderly transfer of any such work and institutional knowledge to such other persons as may be designated by the Company. Subject to the Executive providing advance written notice for the request and sufficient detail to support the expenses, the Company will reimburse Executive for reasonable out-of-pocket expenses Executive incurs in connection with any such cooperation (excluding forgone wages, salary, or other compensation but including reasonable travel, lodging, meal expenses and legal fees and in addition, the Executive shall be entitled to a per diem amount for his services equal to his most recent annualized Base Salary under this Agreement, and will make reasonable efforts to accommodate Executiveâ€™s scheduling needs. Â -8- Â Â 4.8 Application of Section 409A. Â It is intended that all of the severance payments payable under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section 409A of the Code and the regulations and other guidance thereunder and any state law of similar effect (collectively, â€œSection 409Aâ€) provided under Treasury Regulations Sections l.409A-l (b)(4) and l.409A- l(b)(9), and this Agreement will be construed in a manner that complies with Section 409A. If not so exempt, this Agreement (and any definitions hereunder) will be construed in a manner that complies with Section 409A and incorporates by reference all required definitions and payment terms. No severance payments will be made under this Agreement unless the Executiveâ€™s termination of employment constitutes a â€œseparation from serviceâ€ (as defined under Treasury Regulation Section l .409A-1(h)). For purposes of Section 409A (including, without limitation, for purposes of Treasury Regulations Section 1.409A-2(b)(2)(iii)), Executiveâ€™s right to receive any installment payments under this Agreement (whether severance payments or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. If the Company determines that the severance benefits provided under this Agreement constitutes â€œdeferred compensationâ€ under Section 409A and if Executive is a â€œspecified employeeâ€ of the Company, as such term is defined in Section 409A(a)(2)(B)(i) of the Code at the time of Executiveâ€™s Separation from Service, then, solely to the extent necessary to avoid the incurrence of the adverse personal tax consequences under Section 409A, the timing of the Severance will be delayed as follows: on the earlier to occur of (a) the date that is six months and one day after Executiveâ€™s Separation from Service, and (b) the date of Executiveâ€™s death (such earlier date, the â€œDelayed Initial Payment Dateâ€), the Company will (i) pay to Executive a lump sum amount equal to the sum of the severance benefits that Executive would otherwise have received through the Delayed Initial Payment Date if the commencement of the payment of the severance benefits had not been delayed pursuant to this Section 6.8 and (ii) commence paying the balance of the severance benefits in accordance with the applicable payment schedule set forth in Section 6. No interest shall be due on any amounts deferred pursuant to this Section 6.8. To the extent that any Severance Benefits are deferred compensation under Section 409A of the Code and are not otherwise exempt from the application of Section 409A, then, if the period during which Executive may consider and sign the Release spans two calendar years, the payment of any such Severance Benefit will not be made or begin until the later calendar year. Â 4.9 Indemnification. Â The Company shall indemnify Executive, to the maximum extent permitted by applicable law, against all costs, charges and expenses incurred or sustained by Executive in connection with any action, suit or proceeding (or threatened action, suit or proceeding) to which Executive might be a party by reason of being an officer, Director, or employee of the Company or of any subsidiary or Affiliate of the Company. The Company shall provide, at its expense, Directors and Officers insurance for Executive in amounts reasonably satisfactory to Executive, to the extent such insurance is available at reasonable rates, which determination shall be made by the Board of Directors. (â€œAffiliateâ€) shall mean and include any person, corporation or other entity controlling, controlled by or under common control with the corporation in question. Â -9- Â Â 4.10 Section 280G. Â Notwithstanding any other provision of this Agreement to the contrary, if payments made or benefits provided pursuant to this Agreement or otherwise from the Company or any person or entity are considered â€œparachute paymentsâ€ under Section 280G of the Code, then such parachute payments will be limited to the greatest amount that may be paid to Executive under Section 280G of the Code without causing any loss of deduction to the Company Group under such section, but only if, by reason of such reduction, the net after tax benefit to Executive will exceed the net after tax benefit if such reduction were not made. â€œNet after tax benefitâ€ for purposes of this Agreement will mean the sum of (i) the total amounts payable to the Executive under this Agreement , plus (ii) all other payments and benefits which the Executive receives or then is entitled to receive from the Company or otherwise that would constitute a â€œparachute paymentâ€ within the meaning of Section 280G of the Code, less (iii) the amount of federal and state income taxes payable with respect to the foregoing calculated at the maximum marginal income tax rate for each year in which the foregoing will be paid to Executive (based upon the rate in effect for such year as set forth in the Code at the time of termination of Executiveâ€™s employment), less (iv) the amount of excise taxes imposed with respect to the payments and benefits described in (i) and (ii) above by Section 4999 of the Code. The determination as to whether and to what extent payments are required to be reduced in accordance with this Section 6.9 will be made at the Companyâ€™s expense by a nationally recognized certified public accounting firm as may be designated by the Company prior to a change in control (the â€œAccounting Firmâ€). In the event of any mistaken underpayment or overpayment under this Agreement, as determined by the Accounting Firm, the amount of such underpayment or overpayment will forthwith be paid to Executive or refunded to the Company, as the case may be. Any reduction in payments required by this Section 6.9 will occur in the following order: (1) any cash severance, (2) any other cash amount payable to Executive, (3) any employee benefit or perquisite valued as a â€œparachute payment,â€ (4) the acceleration of vesting of any equity awards that are options, and (5) the acceleration of vesting of any other equity awards. Within any such category of payments and benefits, a reduction will occur first with respect to amounts that are not â€œdeferred compensationâ€ within the meaning of Section 409A and then with respect to amounts that are. In the event that acceleration of compensation from equity awards is to be reduced, such acceleration of vesting will be canceled, subject to the immediately preceding sentence, in the reverse order of the date of grant. Â 5.0 General Provisions. Â 5.1 Notices. Any notices required or permitted under this Agreement to be in writing shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by electronic mail or confirmed facsimile if sent during normal business hours of the recipient, and if not, then on the next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the Company at its primary office location and to the Executive at either the Executiveâ€™s address as listed on the Companyâ€™s payroll records, or the Executiveâ€™s Company-issued email address, or at such other address as the Company or Executive may designate by ten (I0) days advance written notice to the other. Â -10- Â Â 5.2 Severability. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction. In such event, this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions had never been contained in this Agreement. Â 5.3 Survival. Provisions of this Agreement that by their terms must survive the termination of this Agreement in order to effectuate the intent of the parties will survive any such termination for such period as may be appropriate under the circumstances. Â 5.4 Waiver. If either party should waive any breach of any provisions of this Agreement, it shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement. Â 5.5 Complete Agreement. This Agreement constitutes the entire agreement between Executive and the Company with regard to the subject matter hereof. This Agreement is the complete, final, and exclusive embodiment of their agreement with regard to this subject matter and supersedes any prior oral discussions or written communications and agreements, including any prior employment agreement between the parties. This Agreement is entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified or amended except in writing signed by Executive and an authorized officer of the Company. The parties have entered into a separate Proprietary Information Agreement and have or may enter into separate agreements related to the stock options. These separate agreements govern other aspects of the relationship between the parties,

have or may have provisions that survive termination of Executiveâ€™s employment under this Agreement, may be amended or superseded by the parties without regard to this Agreement and are enforceable according to their terms without regard to the enforcement provision of this Agreement. Â 5.6 Counterparts. This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement. The parties agree that facsimile and scanned image copies of signatures will suffice as original signatures. Â 5.7 Withholding Taxes. The Company will be entitled to withhold from any payment due to Executive under this Agreement any amounts required to be withheld by applicable tax laws or regulations. Â 5.8 Headings. The headings of the sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof. Â 5.9 Successors and Assigns. The Company shall assign this Agreement and its rights and obligations hereunder in whole, but not in part, to any company or other entity with or into which the Company may hereafter merge or consolidate or to which the Company may transfer all or substantially all of its assets, if in any such case said Company or other entity shall by operation of law or expressly in writing assume all obligations of the Company hereunder as fully as if it had been originally made a party hereto, but may not otherwise assign this Agreement or its rights and obligations hereunder. The Executive may not assign or transfer this Agreement or any rights or obligations hereunder, other than to his estate upon his death. Â -11- Â Â 5.10 Choice of Law. All questions concerning the construction, validity and interpretation of this Agreement will be governed by the laws of the State of New Jersey. Â 5.11 Dispute Resolution. This section shall be interpreted in accordance with the Federal Arbitration Act. The parties recognize that litigation in federal or state courts or before federal or state administrative agencies of disputes arising out of the Executiveâ€™s employment with the Company or out of this Agreement, or the Executiveâ€™s termination of employment or termination of this Agreement, may not be in the best interests of either the Executive or the Company, and may result in unnecessary costs, delays, complexities, and uncertainty. The parties agree that any dispute between the parties arising out of or relating to the negotiation, execution, performance or termination of this Agreement or the Executiveâ€™s employment, including, but not limited to, any claim arising out of this Agreement, claims under Title VII of the Civil Rights Act of 1964, as amended, the Civil Rights Act of 1991, the Age Discrimination in Employment Act of 1967, the Americans with Disabilities Act of 1990, Section 1981 of the Civil Rights Act of 1966, as amended, the Family Medical Leave Act, the Executive Retirement Income Security Act, and any similar federal, state or local law, statute, regulation, or any common law doctrine, whether that dispute arises during or after employment, shall be settled by binding arbitration in accordance with the National Rules for the Resolution of Employment Disputes of the American Arbitration Association; provided however, that this dispute resolution provision shall not apply to any separate agreements between the parties that do not themselves specify arbitration as an exclusive remedy. The location for the arbitration shall be the Princeton, New Jersey area. Any award made by such panel shall be final, binding and conclusive on the parties for all purposes, and judgment upon the award rendered by the arbitrators may be entered in any court having jurisdiction thereof. The arbitratorsâ€™ fees and expenses and all administrative fees and expenses associated with the filing of the arbitration shall be borne by the Company; provided however, that at the Executiveâ€™s option, the Executive may voluntarily pay up to one-half the costs and fees. The parties acknowledge and agree that their obligations to arbitrate under this Section survive the termination of this Agreement and continue after the termination of the employment relationship between Executive and the Company. The parties each further agree that the arbitration provisions of this Agreement shall provide each party with its exclusive remedy, and each party expressly waives any right it might have to seek redress in any other forum, except as otherwise expressly provided in this Agreement. By electing arbitration as the means for final settlement of all claims, the parties hereby waive their respective rights to, and agree not to, sue each other in any action in a Federal, State or local court with respect to such claims, but may seek to enforce in court an arbitration award rendered pursuant to this Agreement. The parties specifically agree to waive their respective rights to a trial by jury, and further agree that no demand, request or motion will be made for trial by jury. Â [SIGNATURES TO FOLLOW ON NEXT PAGE] Â -12- Â Â IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the date first above written. Â Â SONNET BIOTHERAPEUTICS, INC. Â Â Â Â By: /s/ Pankaj Mohan, Ph.D. Â Name: Pankaj Mohan, Ph.D. Â Title: President & Chief Executive Officer Â Â EXECUTIVE: Â Â Â /s/ Stephen McAndrew Â Stephen McAndrew Â Â EX-31.1 3 ex31-1.htm Â Exhibit 31.1 Â CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Â I, Pankaj Mohan certify that: Â 1. I have reviewed this Quarterly Report on Form 10-Q of Sonnet BioTherapeutics Holdings, Inc. (the â€œRegistrantâ€) for the period ended December 31, 2024; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report; Â 4. The Registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have: Â a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â c. evaluated the effectiveness of the Registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â d. disclosed in this report any change in the Registrantâ€™s internal control over financial reporting that occurred during the Registrantâ€™s most recent fiscal quarter (the Registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrantâ€™s internal control over financial reporting; and Â 5. The Registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrantâ€™s auditors and the audit committee of the Registrantâ€™s board of directors (or persons performing the equivalent functions): Â a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrantâ€™s ability to record, process, summarize and report financial information; and Â b. any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrantâ€™s internal control over financial reporting. Â Date: February 13, 2025 Â Â /s/ Pankaj Mohan Â Pankaj Mohan Â President and Chief Executive Officer Â (Principal Executive Officer) Â Â EX-31.2 4 ex31-2.htm Â Exhibit 31.2 Â CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Â I, Jay Cross certify that: Â 1. I have reviewed this Quarterly Report on Form 10-Q of Sonnet BioTherapeutics Holdings, Inc. (the â€œRegistrantâ€) for the period ended December 31, 2024; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report; Â 4. The Registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have: Â a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â c. evaluated the effectiveness of the Registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â d. disclosed in this report any change in the Registrantâ€™s internal control over financial reporting that occurred during the Registrantâ€™s most recent fiscal quarter (the Registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrantâ€™s internal control over financial reporting; and Â 5. The Registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrantâ€™s auditors and the audit committee of the Registrantâ€™s board of directors (or persons performing the equivalent functions): Â a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrantâ€™s ability to record, process, summarize and report financial information; and Â b. any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrantâ€™s internal control over financial reporting. Â Date: February 13, 2025 Â Â /s/ Jay Cross Â Jay Cross Â Chief Financial Officer Â (Principal Financial and Accounting Officer) Â Â EX-32.1 5 ex32-1.htm Â Exhibit 32.1 Â CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â In connection with the Quarterly Report of Sonnet BioTherapeutics Holdings, Inc. (the â€œCompanyâ€) on Form 10-Q for the quarter ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Pankaj Mohan, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge: Â (1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and Â Â (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Date: February 13, 2025 Â /s/ Pankaj Mohan Â Pankaj Mohan Â President and Chief Executive Officer Â (Principal Executive Officer) Â Â The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document. Â Â EX-32.2 6 ex32-2.htm Â Exhibit 32.2 Â CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â In connection with the Quarterly Report of Sonnet BioTherapeutics Holdings, Inc. (the â€œCompanyâ€) on Form 10-Q for the quarter ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Jay Cross, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge: Â (1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and Â Â (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Date: February 13, 2025 Â /s/ Jay Cross Â Jay Cross Â Chief Financial Officer Â (Principal Financial and Accounting Officer) Â Â The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document. Â Â Â EX-101.SCH 7 sonn-20241231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit) (unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 999012 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 999013 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 999014 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 999015 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 999016 - Disclosure - Collaboration Revenue link:presentationLink link:calculationLink link:definitionLink 999017 - Disclosure - Stockholdersâ€™ Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 999018 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 999019 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 999020 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 999021 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 999022 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 999023 - Disclosure - Stockholdersâ€™ Equity (Deficit) (Tables) link:presentationLink link:calculationLink link:definitionLink 999024 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 999025 - Disclosure - Organization and Description of Business (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999026 - Disclosure - Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Shares (Details) link:presentationLink link:calculationLink link:definitionLink 999027 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999028 - Disclosure - Schedule of Accrued Expenses and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 999029 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999030 - Disclosure - Collaboration Revenue (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999031 - Disclosure - Schedule of Warrants Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 999032 - Disclosure - Stockholdersâ€™ Equity (Deficit) (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999033 - Disclosure - Schedule of Share-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 999034 - Disclosure - Schedule of Restricted Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 999035 - Disclosure - Schedule of Restricted Stock Awards Activity (Details) link:presentationLink link:calculationLink link:definitionLink 999036 - Disclosure - Share-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999037 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 sonn-20241231_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 sonn-20241231_def.xml XBRL DEFINITION FILE EX-101.LAB 10 sonn-20241231_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Income Tax Jurisdiction [Axis] Domestic Tax Jurisdiction [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Research and Development Tax Incentive Program [Member] Prefunded October 2023 Warrants [Member] Prefunded December 2024 Warrants [Member] Antidilutive Securities [Axis] Common Stock Warrants August 2021 [Member] Underwriter Warrants August 2021 [Member] Chanticleer Warrants [Member] Series C Warrants [Member] Series 3 Warrants [Member] Unvested Restricted Stock Units and Awards [Member] Common Stock Warrants February 2023 [Member] Underwriter Warrants February 2023 [Member] Common Stock Private Placement Warrants June 2023 [Member] Placement Agent Warrants June 2023 [Member] Common Stock Warrants October 2023 [Member] Underwriter Warrants October 2023 [Member] Placement Agent Warrants June 2024 [Member] Common Stock Warrants June 2024 [Member] Common Stock Warrants November 2024 [Member] Common Stock Registered Direct Warrants December 2024 [Member] Common Stock PIPE Warrants December 2024 [Member] Discovery Collaboration Agreements [Member] Legal Entity [Axis] XOMA [Member] Finite-Lived Intangible Assets by Major Class [Axis] In Process Research and Development [Member] Cellca Agreement [Member] Statistical Measurement [Axis] Maximum [Member] Minimum [Member] The Brink Agreement [Member] InvivoGen Agreement [Member] SOC Agreement [Member] Navigo Agreement [Member] Navigo Proteins GmbH [Member] Product and Service [Axis] Technology Service [Member] License Agreement [Member] Alkem Agreement [Member] Sale of Stock [Axis] October Offering [Member] Title and Position [Axis] Underwriters [Member] Prefunded Warrant [Member] Common Warrant [Member] June 2024 Inducement Offer [Member] Purchase and Registration Rights Agreement [Member] Underwriting Agreement [Member] Related and Nonrelated Parties [Axis] Chardan Capital Markets LLC [Member] Registered Direct Offering [Member] Warrant [Member] Class of Warrant or Right [Axis] Private Placement [Member] Common Stock Warrants [Member] Pre-funded Warrants [Member] Holder [Member] Underwriter Warrant February 2023 [Member] Prefunded Warrants October 2023 [Member] Common Stock Registered Direct Warrants December 2024 [Member] Pre-funded Warrants December 2024 [Member] Plan Name [Axis] 2020 Omnibus Equity Incentive Plan [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Award Type [Axis] Restricted Stock Units (RSUs) [Member] Restricted Stock Awards (RSA) [Member] Statement of Income Location, Balance [Axis] Research and Development Expense [Member] General and Administrative Expense [Member] Purchase Agreement [Member] Cover [Abstract] Document Type Amendment Flag

Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Listing, Par Value Per Share Statement of Financial Position [Abstract] Assets Current assets: Cash Unbilled collaboration revenue Prepaid expenses and other current assets Incentive tax receivable Total current assets Property and equipment, net Operating lease right-of-use asset Deferred offering costs Other assets Total assets Liabilities and stockholdersâ€™ equity (deficit) Current liabilities: Accounts payable Accrued expenses and other current liabilities Current portion of operating lease liability Total current liabilities Operating lease liability, net of current portion Total liabilities Commitments and contingencies (Note 4) Stockholdersâ€™ equity (deficit): Preferred stock, $0.0001 par value: 5,000,000 shares authorized; no shares issued or outstanding Common stock, $0.0001 par value: 125,000,000 shares authorized; 3,007,431 and 650,284 issued and outstanding at December 31, 2024 and September 30, 2024, respectively Additional paid-in capital Accumulated deficit Total stockholdersâ€™ equity (deficit) Total liabilities and stockholdersâ€™ equity (deficit) Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Collaboration revenue Operating expenses: Research and development General and administrative Total operating expenses Loss from operations Foreign exchange (loss) gain Loss before provision from income taxes Provision for income taxes Net loss Per share information: Net loss per share, basic Net loss per share, diluted Weighted average shares outstanding, basic Weighted average shares outstanding, diluted Statement [Table] Statement [Line Items] Balance Balance, shares Sale of common stock, net of issuance costs Sale of common stock, net of issuance costs, shares Retirement of shares in connection with reverse stock split Retirement of shares in connection with reverse stock split, shares Shares released from abeyance Shares released from abeyance, shares Net share settlement of warrants Net share settlement of warrants, shares Exercise of warrants Exercise of warrants, shares Share-based compensation Net loss Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Acquired in-process research and development Amortization of operating lease right-of-use asset Share-based compensation Changes in operating assets and liabilities: Unbilled collaboration revenue Prepaid expenses and other current assets Incentive tax receivable Other assets Accounts payable Accrued expenses and other current liabilities Operating lease liability Deferred income Net cash used in operating activities Cash flows from financing activities: Proceeds from issuance of common stock, net of issuance costs Payment of deferred offering costs Payment of warrant issuance costs Net cash provided by financing activities Net increase in cash Cash, beginning of period Cash, end of period Supplemental disclosure of non-cash operating, investing and financing activities: In-process research and development in accrued expenses Deferred offering costs in accounts payable and accrued expenses Common stock issuance costs in accounts payable Pay vs Performance Disclosure [Table] Executive Category [Axis] Individual [Axis] Adjustment to Compensation [Axis] Measure [Axis] Pay vs Performance Disclosure, Table Company Selected Measure Name Named Executive Officers, Footnote Peer Group Issuers, Footnote Changed Peer Group, Footnote PEO Total Compensation Amount PEO Actually Paid Compensation Amount Adjustment To PEO Compensation, Footnote Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Compensation Actually Paid Amount Adjustment to Non-PEO NEO Compensation Footnote Equity Valuation Assumption Difference, Footnote Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Company Selected Measure Total Shareholder Return Vs Peer Group Compensation Actually Paid vs. Other Measure Tabular List, Table Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net Income (Loss) Company Selected Measure Amount Other Performance Measure, Amount Adjustment to Compensation, Amount PEO Name Name Non-GAAP Measure Description Additional 402(v) Disclosure Pension Benefits Adjustments, Footnote Erroneously Awarded Compensation Recovery [Table] Restatement Determination Date [Axis] Restatement Determination Date Aggregate Erroneous Compensation Amount Erroneous Compensation Analysis Stock Price or TSR Estimation Method Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Not Yet Determined Name Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery, Explanation of Impracticability Name Compensation Amount Restatement does not require Recovery Awards Close in Time to MNPI Disclosures [Table] Award Timing MNPI Disclosure Award Timing Method Award Timing Predetermined Award Timing MNPI Considered Award Timing, How MNPI Considered MNPI Disclosure Timed for Compensation Value Awards Close in Time to MNPI Disclosures, Table Name Underlying Securities Exercise Price Fair Value as of Grant Date Underlying Security Market Price Change Insider Trading Arrangements [Line Items] Material Terms of Trading Arrangement Name Title Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted Adoption Date Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated Termination Date Expiration Date Arrangement Duration Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Not Adopted Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Description of Business Accounting Policies [Abstract] Summary of Significant Accounting Policies Payables and Accruals [Abstract] Accrued Expenses and Other Current Liabilities Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Collaboration Revenue Equity [Abstract] Stockholdersâ€™ Equity (Deficit) Share-Based Payment Arrangement [Abstract] Share-Based Compensation Subsequent Events [Abstract] Subsequent Events Basis of presentation Consolidation Use of estimates Incentive tax receivable Property and equipment Deferred offering costs Derivative liability Collaboration revenue Research and development expense Foreign currency Reverse stock split Net loss per share Recent accounting pronouncements Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Shares Schedule of Accrued Expenses and Other Current Liabilities Schedule of Warrants Outstanding Schedule of Share-based Compensation Expense Schedule of Restricted Stock Units Activity Schedule of Restricted Stock Awards Activity Income Tax Paid, by Individual Jurisdiction [Table] Income Tax Paid, by Individual Jurisdiction [Line Items] Net operating losses Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total anti-dilutive weighted average sharesÂ Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Refund Received Related to Revenue from Different Year, Year Revenue Recognized [custom:IncentiveTaxReceivableCurrent-0] Cash refund (payment) related to tax incentive program Proceeds from income tax refunds Reverse stock split description Warrants to purchase common stock Exercise price Warrant, shares Compensation and benefits Research and development Professional fees Other Â Accrued expenses and other current liabilities Loss Contingencies [Table] Loss Contingencies [Line Items] Milestone payments License fees Description of milestone payments Payment for annual license fee obligation Commercial product license fee payment obligation [custom:DevelopmentLicenseFeePaymentObligation-0] [custom:PaymentOfAnnualLicenseFeeObligation-0] Agreements description Payments to Acquire in Process Research and Development Evaluation milestone recognized Proceeds for negotiate license agreement Collavorative arrangement right and obligation [custom:MilestonePayments-0] Performance obligation Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] Number of Warrants, Outstanding Exercise Price Expiration Date Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Subsidiary, Sale of Stock [Line Items] Proceeds from sale of common stock Shares for sale Offering price per share Exercisable price Warrants term Warrants exercise price decrease Issuance of share, value Common stock avialable to be sold Volume weighted average price discount percentage Proceeds from offering Number of warrant exercised Forfeited warrants, shares Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Unvested balance Unvested weighted average grant fair value, balance Number of shares available for issuance Number of shares granted Vesting percentage Unrecognized compensation expense Subsequent Event [Table] Subsequent Event [Line Items] Sale of stock, number of shares issued in transaction Proceeds from issuance of common stock Base salary Incentive tax receivable current. Accrued compensation and benefits, current. Accrued research and development current. Milestone payments. Discovery Collaboration Agreements [Member] XOMA [Member] License fees. Description of milestone payments. Cellca Agreement [Member] Annual license fee payment. Commerical product license fee payment obligation. Development license fee payment obligation. The Brink Agreement [Member] Payment of annual license fee. Invivo Gen Agreement [Member] Stock retired during period value reverse stock splits. Stock retired during period shares reverse stock splits. Stock issued during period value net share settlement of warrants. Stock issued during period value net share settlement of warrants, shares. The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. Increase decrease in incentive tax receivable. Payment of deferred offering costs. Navigo Agreement [Member] Navigo Proteins GmbH [Member] In-process research and development in accrued expenses. Offering costs in accounts payable and accrued expenses. Proceeds for negotiate license agreement. License Agreement [Member] Incentive Tax Receivbale [Policy Text Block] Research and Development Tax Incentive Program [Member] Alkem Agreement [Member] Cash refund (payment) related to tax incentive program. Reverse Stock Split [Policy Text Block] Prefunded October 2023 Warrants [Member] Performance obligation. Prefunded December 2024 Warrants [Member] October Offering [Member] Underwriters [Member] Prefunded Warrant [Member] Common Warrant [Member] Common Stock Warrants October 2023 [Member] Purchase and Registration Rights Agreement [Member] Volume weighted average price discount percentage. Common Stock Warrants November 2024 [Member] Common Stock Registered Direct Warrants December 2024 [Member] Common Stock PIPE Warrants December 2024 [Member] Common Stock Warrants June 2024 [Member] Underwriting Agreement [Member] Chardan Capital Markets LLC [Member] Registered Direct Offering [Member] Common Stock Warrants August 2021 [Member] Underwriter Warrants August 2021 [Member] Chanticleer Warrants [Member] Series C Warrants [Member] Series 3 Warrants [Member] Common Stock Warrants February 2023 [Member] Underwriter Warrant February 2023 [Member] Common Stock Private Placement Warrants June 2023 [Member] Placement Agent Warrants June 2023 [Member] Prefunded Warrants October 2023 [Member] Underwriter Warrants October 2023 [Member] Placement Agent Warrants June 2024 [Member] Common Stock Registered Direct Warrants December 2024 [Member] Common Stock Warrants [Member] Pre-funded Warrants December 2024 [Member] Pre-funded Warrants [Member] Holder [Member] 2020 Omnibus Equity Incentive Plan [Member] Restricted Stock Awards (RSA) [Member] Schedule of Nonvested Restricted Stock Awards Activity [Table Text Block] Unvested Restricted Stock Units and Awards [Member] Underwriter Warrants February 2023 [Member] June Twenty Twenty Four Inducement Offer [Member] Stock issued during period value shares released from abeyance. Stock issued during period shares shares released from abeyance. Stock issued during period value stock warrants exercised. Stock issued during period shares stock warrants exercised. Common stock issuance costs in accounts payable. Agreements description. SOC Agreement [Member] Evaluation milestone recognized. Common stock avialable to be sold. Purchase Agreement [Member] Increase decrease in unbilled collaboration revenue. Payment of warrant issuance costs. Common Stock Registered Direct Warrants December 2024 [Member] [Default Label] Assets, Current Assets [Default Label] Liabilities, Current Liabilities Equity, Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Income Tax Expense (Benefit) Shares, Outstanding Share-Based Payment Arrangement, Noncash Expense IncreaseDecreaseInUnbilledCollaborationRevenue Increase (Decrease) in Prepaid Expense and Other Assets IncreaseDecreaseInIncentiveTaxReceivable Increase (Decrease) in Other Operating Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities PaymentOfDeferredOfferingCosts Payment of warrant issuance costs Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Forgone Recovery, Individual Name Outstanding Recovery, Individual Name Awards Close in Time to MNPI Disclosures, Individual Name Trading Arrangement, Individual Name Incentive Tax Receivbale [Policy Text Block] Deferred Charges, Policy [Policy Text Block] Collaborative Arrangement, Accounting Policy [Policy Text Block] AccruedResearchAndDevelopmentCurrent Warrants and Rights Outstanding, Maturity Date EX-101.PRE 11 sonn-20241231_pre.xml XBRL PRESENTATION FILE XML 13 R1.htm IDEA: XBRL DOCUMENT v3.25.0.1 Cover - $ / shares 3 Months Ended Dec. 31, 2024 Feb. 12, 2025 Cover [Abstract] Â Â Document Type 10-Q Â Amendment Flag false Â Document Quarterly Report true Â Document Transition Report false Â Document Period End Date Dec. 31, 2024 Â Document Fiscal Period Focus Q1 Â Document Fiscal Year Focus 2024 Â Current Fiscal Year End Date --09-30 Â Entity File Number 001-35570 Â Entity Registrant Name SONNET BIOTHERAPEUTICS HOLDINGS, INC. Â Entity Central Index Key 0001106838 Â Entity Tax Identification Number 20-2932652 Â Entity Incorporation, State or Country Code DE Â Entity Address, Address Line One 100 Overlook Center Â Entity Address, Address Line Two Suite 102 Â Entity Address, City or Town Princeton Â Entity Address, State or Province NJ Â Entity Address, Postal Zip Code 08540 Â City Area Code (609) Â Local Phone Number 375-2227 Â Title of 12(b) Security Common Stock, par value $0.0001 per share Â Trading Symbol SONN Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 3,065,701 Entity Listing, Par Value Per Share $ 0.0001 Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name:

dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe par value per share of security quoted in same currency as Trading currency. Example: '0.01'. + ReferencesNo definition available. + Details Name: dei_EntityListingParValuePerShare Namespace Prefix: dei_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 14 R2.htm IDEA: XBRL DOCUMENT v3.25.0.1 Consolidated Balance Sheets (Unaudited) - USD ($) Dec. 31, 2024 Sep. 30, 2024 Current assets: Â Â Cash $ 4,861,503 $ 149,456 Unbilled collaboration revenue 500,000 Prepaid expenses and other current assets 1,196,868 1,206,409 Incentive tax receivable 166,792 762,078 Total current assets 6,725,163 2,117,943 Property and equipment, net 17,312 20,523 Operating lease right-of-use asset 104,435 123,417 Deferred offering costs 122,058 15,000 Other assets 213,059 494,147 Total assets 7,182,027 2,771,030 Current liabilities: Â Â Accounts payable 1,639,981 2,183,416 Accrued expenses and other current liabilities 1,394,520 942,489 Current portion of operating lease liability 87,323 84,291 Total current liabilities 3,121,824 3,210,196 Operating lease liability, net of current portion 23,634 46,573 Total liabilities 3,145,458 3,256,769 Commitments and contingencies (Note 4) Stockholdersâ€™ equity (deficit): Â Â Preferred stock, $0.0001 par value: 5,000,000 shares authorized; no shares issued or outstanding Common stock, $0.0001 par value: 125,000,000 shares authorized; 3,007,431 and 650,284 issued and outstanding at December 31, 2024 and September 30, 2024, respectively 300 65 Additional paid-in capital 124,877,960 117,195,181 Accumulated deficit (120,841,691) (117,680,985) Total stockholdersâ€™ equity (deficit) 4,036,569 (485,739) Total liabilities and stockholdersâ€™ equity (deficit) $ 7,182,027 $ 2,771,030 X - DefinitionIncentive tax receivable current. + ReferencesNo definition available. + Details Name: SONN_IncentiveTaxReceivableCurrent Namespace Prefix: SONN_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -

Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 210 -Topic 946 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20 + Details Name: us-gaap_Cash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_DeferredCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_UnbilledReceivablesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 15 R3.htm IDEA: XBRL DOCUMENT v3.25.0.1 Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares Dec. 31, 2024 Sep. 30, 2024 Statement of Financial Position [Abstract] Â Â Preferred stock, par value $ 0.0001 $ 0.0001 Preferred stock, shares authorized 5,000,000 5,000,000 Preferred stock, shares issued 0 0 Preferred stock, shares outstanding 0 0 Common stock, par value $ 0.0001 $ 0.0001 Common stock, shares authorized 125,000,000 125,000,000 Common stock, shares issued 3,007,431 650,284 Common stock, shares outstanding 3,007,431 650,284 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R4.htm IDEA: XBRL DOCUMENT v3.25.0.1 Consolidated Statements of Operations (Unaudited) - USD ($) 3 Months Ended Dec. 31, 2024 Dec. 31, 2023 Income Statement [Abstract] Â Â Collaboration revenue $ 1,000,000 $ 18,626 Operating expenses: Â Â Research and development 1,886,076 644,042 General and administrative 1,963,346 653,455 Total operating expenses 3,849,422 1,297,497 Loss from operations (2,849,422) (1,278,871) Foreign exchange (loss) gain (152,884) 110,362 Loss before provision from income taxes (3,002,306) (1,168,509) Provision for income taxes (158,400) Net loss $ (3,160,706) $ (1,168,509) Per share information: Â Â Net loss per share, basic $ (1.56) $ (2.46) Net loss per share, diluted $ (1.56) $ (2.46) Weighted average shares outstanding, basic 2,022,818 474,699 Weighted average shares outstanding, diluted 2,022,818 474,699 X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 17 R5.htm IDEA: XBRL DOCUMENT v3.25.0.1 Consolidated Statements of Changes in Stockholders' Equity (Deficit) (unaudited) - USD ($) Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Total Balance at Sep. 30, 2023 $ 22 $ 110,017,751 $ (110,243,753) $ (225,980) Balance, shares at Sep. 30, 2023 218,786 Â Â Â Sale of common stock, net of issuance costs $ 16 3,916,927 3,916,943 Sale of common stock, net of

issuance costs, shares 163,281 Â Â Â Retirement of shares in connection with reverse stock split Retirement of shares in connection with reverse stock split, shares (190) Â Â Â Net share settlement of warrants Net share settlement of warrants, shares 1,795 Â Â Â Share-based compensation 50,005 50,005 Net loss (1,168,509) (1,168,509) Balance at Dec. 31, 2023 $ 38 113,984,683 (111,412,262) 2,572,459 Balance, shares at Dec. 31, 2023 383,672 Â Â Â Balance at Sep. 30, 2024 $ 65 117,195,181 (117,680,985) (485,739) Balance, shares at Sep. 30, 2024 650,284 Â Â Â Sale of common stock, net of issuance costs $ 105 7,622,514 7,622,619 Sale of common stock, net of issuance costs, shares 1,050,500 Â Â Â Retirement of shares in connection with reverse stock split Retirement of shares in connection with reverse stock split, shares (373) Â Â Â Shares released from abeyance $ 3 (3) Shares released from abeyance, shares 32,375 Â Â Â Net share settlement of warrants Net share settlement of warrants, shares 1,209 Â Â Â Exercise of warrants $ 127 (127) Exercise of warrants, shares 1,273,436 Â Â Â Share-based compensation 60,395 60,395 Net loss (3,160,706) (3,160,706) Balance at Dec. 31, 2024 $ 300 $ 124,877,960 $ (120,841,691) $ 4,036,569 Balance, shares at Dec. 31, 2024 3,007,431 Â Â Â X - DefinitionStock issued during period value net share settlement of warrants, shares. + ReferencesNo definition available. + Details Name: SONN_StockIssuedDuringPeriodSharesNetShareSettlementOfWarrants Namespace Prefix: SONN_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock issued during period shares shares released from abeyance. + ReferencesNo definition available. + Details Name: SONN_StockIssuedDuringPeriodSharesSharesReleasedFromAbeyance Namespace Prefix: SONN_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock issued during period shares stock warrants exercised. + ReferencesNo definition available. + Details Name: SONN_StockIssuedDuringPeriodSharesStockWarrantsExercised Namespace Prefix: SONN_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock issued during period value net share settlement of warrants. + ReferencesNo definition available. + Details Name: SONN_StockIssuedDuringPeriodValueNetShareSettlementOfWarrants Namespace Prefix: SONN_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock issued during period value shares released from abeyance. + ReferencesNo definition available. + Details Name: SONN_StockIssuedDuringPeriodValueSharesReleasedFromAbeyance Namespace Prefix: SONN_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock issued during period value stock warrants exercised. + ReferencesNo definition available. + Details Name: SONN_StockIssuedDuringPeriodValueStockWarrantsExercised Namespace Prefix: SONN_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock retired during period shares reverse stock splits. + ReferencesNo definition available. + Details Name: SONN_StockRetiredDuringPeriodSharesReverseStockSplits Namespace Prefix: SONN_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock retired during period value reverse stock splits. + ReferencesNo definition available. + Details Name: SONN_StockRetiredDuringPeriodValueReverseStockSplits Namespace Prefix: SONN_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -

Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 18 R6.htm IDEA: XBRL DOCUMENT v3.25.0.1 Consolidated Statements of Cash Flows (Unaudited) - USD ($) 3 Months Ended Dec. 31, 2024 Dec. 31, 2023 Cash flows from operating activities: Â Â Net loss $ (3,160,706) $ (1,168,509) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Depreciation 3,211 3,211 Acquired in-process research and development 12,000 12,000 Amortization of operating lease right-of-use asset 18,982 16,763 Share-based compensation 60,395 50,005 Changes in operating assets and liabilities: Â Â Unbilled collaboration revenue (500,000) Prepaid expenses and other current assets 9,541 269,116 Incentive tax receivable 595,286 592,463 Other assets 281,088 (77,656) Accounts payable (635,568) (465,735) Accrued expenses and other current liabilities 425,432 (2,287,544) Operating lease liability (19,907) (17,225) Deferred income (18,626) Net cash used in operating activities (2,910,246) (3,091,737) Cash flows from financing activities: Â Â Proceeds from issuance of common stock, net of issuance costs 7,711,161 3,838,870 Payment of deferred offering costs (75,000) Payment of warrant issuance costs (13,868) Net cash provided by financing activities 7,622,293 3,838,870 Net increase in cash 4,712,047 747,133 Cash, beginning of period 149,456 2,274,259 Cash, end of period 4,861,503 3,021,392 Supplemental disclosure of non-cash operating, investing and financing activities: Â Â In-process research and development in accrued expenses 12,000 12,000 Deferred offering costs in accounts payable and accrued expenses 32,058 15,000 Common stock issuance costs in accounts payable $ 88,542 X - DefinitionThe amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. + ReferencesNo definition available. + Details Name: SONN_AcquiredInprocessResearchAndDevelopment Namespace Prefix: SONN_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCommon stock issuance costs in accounts payable. + ReferencesNo definition available. + Details Name: SONN_CommonStockIssuanceCostsInAccountsPayable Namespace Prefix: SONN_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIn-process research and development in accrued expenses. + ReferencesNo definition available. + Details Name: SONN_InProcessResearchAndDevelopmentInAccruedExpenses Namespace Prefix: SONN_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease decrease in incentive tax receivable. + ReferencesNo definition available. + Details Name: SONN_IncreaseDecreaseInIncentiveTaxReceivable Namespace Prefix: SONN_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease decrease in unbilled collaboration revenue. + ReferencesNo definition available. + Details Name: SONN_IncreaseDecreaseInUnbilledCollaborationRevenue Namespace Prefix: SONN_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionOffering costs in accounts payable and accrued expenses. + ReferencesNo definition available. + Details Name: SONN_OfferingCostsInAccountsPayableAndAccruedExpenses Namespace Prefix: SONN_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPayment of deferred offering costs. + ReferencesNo definition available. + Details Name: SONN_PaymentOfDeferredOfferingCosts Namespace Prefix: SONN_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPayment of warrant issuance costs. + ReferencesNo definition available. + Details Name: SONN_PaymentOfWarrantIssuanceCosts Namespace Prefix: SONN_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in operating assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in operating liabilities classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 19 R7.htm IDEA: XBRL DOCUMENT v3.25.0.1 Pay vs Performance Disclosure - USD ($) 3 Months Ended Dec. 31, 2024 Dec. 31, 2023 Pay vs Performance Disclosure [Table] Â Â Net Income (Loss) $ (3,160,706) $ (1,168,509) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 20 R8.htm IDEA: XBRL DOCUMENT v3.25.0.1 Insider Trading Arrangements 3 Months Ended Dec. 31, 2024 Insider Trading Arrangements [Line Items] Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a + Details Name: ecd_InsiderTradingArrLineItems Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration XML 21 R9.htm IDEA: XBRL DOCUMENT v3.25.0.1 Organization and Description of Business 3 Months Ended Dec. 31, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Organization and Description of Business 1. Organization and Description of Business Â Description of business Â Sonnet BioTherapeutics, Inc. (â€œPrior Sonnetâ€) was incorporated as a New Jersey corporation on April 6, 2015. Prior Sonnet completed a merger with publicly-held Chanticleer Holdings, Inc. (â€œChanticleerâ€) on April 1, 2020. After the merger, Chanticleer changed its name to Sonnet BioTherapeutics Holdings, Inc. (â€œSonnetâ€ or the â€œCompanyâ€). Sonnet is a clinical stage, oncology-focused biotechnology company with a proprietary platform for innovating biologic medicines of single or bifunctional action. Known as FHABâ„¢ (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and â€œhitch-hikesâ€ on human serum albumin (â€œHSAâ€) for transport to target tissues. Sonnet designed the construct to improve drug accumulation in solid tumors, as well as to extend the duration of activity in the body. FHAB development candidates can be produced in mammalian cell culture, which enables glycosylation of the interleukins, thereby reducing the risk of immunogenicity, as well as E. coli. Sonnet believes its FHAB technology, for which it received a U.S. patent in June 2021, is a distinguishing feature of its biopharmaceutical platform. The approach is well suited for future drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. Â Sonnetâ€™s lead proprietary asset, SON-1010, is a fully human version of Interleukin 12 (â€œIL-12â€), covalently linked to the FHAB construct, for which Sonnet is pursuing clinical development in solid tumor indications, including ovarian cancer, non-small cell lung cancer and head and neck cancer. In March 2022, the FDA cleared Sonnetâ€™s Investigational New Drug (â€œINDâ€) application for SON-1010. This allowed the Company to initiate a U.S. clinical trial (SB101) in oncology patients with solid tumors during the second calendar quarter of 2022. In September 2021, the Company created a wholly-owned Australian subsidiary, SonnetBio Pty Ltd (â€œSubsidiaryâ€), for the purpose of conducting certain clinical trials. Sonnet received approval and initiated an Australian clinical study (SB102) of SON-1010 in healthy volunteers during the third calendar quarter of 2022. Interim safety and tolerability data from the SB101 and SB102 studies were reported in April 2023. Â In January 2023, Sonnet announced a collaboration agreement with Roche for the clinical evaluation of SON-1010 with atezolizumab (TecentriqÂ®). The companies have entered into a Master Clinical Trial and Supply Agreement (â€œMCSAâ€), along with ancillary Quality and Safety Agreements, to study the safety and efficacy of the combination of SON-1010 and atezolizumab in a platinum-resistant ovarian cancer (â€œPROCâ€) patient setting. Further, the companies will provide SON-1010 and atezolizumab, respectively, for use in the Phase 1b/Phase 2a combination safety, dose-escalation, and proof-of-concept study (SB221). Part 1 of this 2-part study was approved in June 2023 by the local Human Research Ethics Committee in Australia under CT-2023-CTN-01399-1 and the Therapeutic Goods Administration has been notified. In August 2023, the FDA accepted the IND for SB221. The trial consists of a modified 3+3 dose-escalation design in Part 1 to establish the maximum tolerated dose (â€œMTDâ€) of SON-1010 with a fixed dose of atezolizumab. Clinical benefit in PROC will be confirmed in an expansion group to establish the recommended Phase 2 dose (â€œRP2Dâ€). Part 2 of the study will then investigate SON-1010 in combination with atezolizumab, or the standard of care (â€œSOCâ€) for PROC in a randomized comparison to show proof-of-concept (â€œPOCâ€). Â In January 2025, Sonnet announced an expansion of its Phase 1 SB101 clinical study of SON-1010 to add a new cohort to evaluate its effect in combination with trabectedin (YondelisÂ®), following the successful completion of monotherapy dose escalation. Trabectedin is an alkylating DNA-binding agent that was approved as a second-line treatment in early 2024 for patients with unresectable, metastatic liposarcoma or leiomyosarcoma who have received a prior anthracycline-containing regimen. It is also known to activate tumor macrophages into a pro-inflammatory phenotype. The Company believes that SON-1010 has the potential to complement that activity by activating the NK and T cells in the TME to secrete more interferon-gamma (IFNÎ³), which is considered to be important for anti-tumor control. Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements Â The Company acquired the global development rights to its most advanced compound, SON-080, a fully human version of Interleukin 6 (â€œIL-6â€), in April 2020 through its acquisition of the outstanding shares of Relief Therapeutics SA. Sonnet is advancing SON-080 in target indications of Chemotherapy-Induced Peripheral Neuropathy (â€œCIPNâ€) and Diabetic Peripheral Neuropathy (â€œDPNâ€). Sonnet received approval to initiate an ex-U.S.

Phase 1b/2a study with SON-080 in CIPN during the third quarter of 2022. The Data Safety Monitoring Board (â€œDSMBâ€) overseeing the study met during the first calendar quarter of 2024 and cleared the trial to proceed to Part 2. Following the completion of the DSMB review, Sonnet announced initial safety data from the CIPN study. The objective will be to analyze the data and to consider initiating a Phase 2 study, pending the outcome of any partnering activity. On October 8, 2024, the Company entered into a License Agreement (the â€œAlkem Agreementâ€) with Alkem Laboratories Limited (â€œAlkemâ€) to develop and commercialize SON-080 for DPN in India. Alkem will conduct all clinical trials that it believes appropriate to obtain regulatory approval in India for SON-080 for the treatment of DPN. Â SON-1210 (IL12-FHAB-IL15), Sonnetâ€™s lead bifunctional construct, combines FHAB with single-chain human IL-12 and human Interleukin 15 (â€œIL-15â€). This compound is being developed for solid tumor indications, including colorectal and pancreatic cancer. In February 2023, Sonnet announced the successful completion of two IND-enabling toxicology studies with SON-1210 in non-human primates. In August 2024, the Company entered into a Master Clinical Collaboration Agreement (the â€œSOC Agreementâ€) with the Sarcoma Oncology Center (â€œSOCâ€) to advance the development of SON-1210. An Innovative Immuno Oncology Consortium (â€œIIOCâ€) that is funded by the SOC will conduct an investigator-initiated Phase 1b/2a study of SON-1210 in pancreatic cancer. The IIOC submitted a pre-IND package to the FDA. Based on the FDA feedback, preparations for the full IND submission package are underway. Â SON-1411 (IL18-FHAB-IL12) is a bifunctional combination of human Interleukin 18 (â€œIL-18â€), which was modified to resist interaction with the IL-18 inhibitor binding protein, and single-chain human IL-12 for solid tumor cancers. Cell line development and process development are ongoing, with early experimental drug supply suitable for formulation and analytical method development activities. After some delays in 2024, activities will continue through 2025 with the potential to generate a drug suitable for preclinical studies and subsequent human studies. Â Sonnet has completed sequence confirmation for SON-3015 (anti-IL6-FHAB-anti-TGFÎ²). Early-stage bifunctional drug has been generated and is being stored for future use in in vivo mice studies. The Company has elected to place the SON-3015 development program on hold for expense reduction purposes. Â Liquidity Â The Company has incurred recurring losses and negative cash flows from operations since inception and it expects to generate losses from operations for the foreseeable future primarily due to research and development costs for its potential product candidates. The Company believes its cash at DecemberÂ 31, 2024 of $4.9 million will fund the Companyâ€™s projected operations into July 2025. The Company received preliminary approval of its application to sell up to $0.8Â million of its New Jersey state net operating losses through the Technology Business Tax Certificate Transfer Program (the â€œProgramâ€), subject to execution of such sale (see Note 8). Substantial additional financing will be needed by the Company to fund its operations. These factors raise substantial doubt about the Companyâ€™s ability to continue as a going concern. The accompanying unaudited interim consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. However, substantial doubt about the Companyâ€™s ability to continue as a going concern exists. The unaudited interim consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Â The Company plans to secure additional capital in the future through equity or debt financings, including sales pursuant to its ChEF Purchase Agreement (the â€œPurchase Agreementâ€) with Chardan Capital Markets, LLC (â€œChardanâ€), related to a â€œChEF,â€ Chardanâ€™s committed equity facility (the â€œFacilityâ€); partnerships; collaborations; or other sources to carry out the Companyâ€™s planned development activities. If additional capital is not available when required, the Company may need to delay or curtail its operations until such funding is received. Various internal and external factors will affect whether and when the Companyâ€™s product candidates become approved for marketing and successful commercialization. The regulatory approval and market acceptance of the Companyâ€™s product candidates, length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the approval process will materially affect the Companyâ€™s financial condition and future operations. Â Operations since inception have consisted primarily of organizing the Company, securing financing, developing technologies through research and development and conducting preclinical studies. The Company faces risks associated with companies whose products are in development. These risks include the need for additional financing to complete its research and development, achieving its research and development objectives, defending its intellectual property rights, recruiting and retaining skilled personnel, and dependence on key members of management. Â Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements Â X - DefinitionThe entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 275 -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_NatureOfOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 22 R10.htm IDEA: XBRL DOCUMENT v3.25.0.1 Summary of Significant Accounting Policies 3 Months Ended Dec. 31, 2024 Accounting Policies [Abstract] Â Summary of Significant Accounting Policies 2. Summary of Significant Accounting Policies Â a. Basis of presentation Â The accompanying unaudited interim consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (â€œU.S. GAAPâ€) for interim financial information as found in the Accounting Standards Codification (â€œASCâ€) and Accounting Standards Updates (ASUsâ€) of the Financial Accounting Standards Board (â€œFASBâ€). In the opinion of management, the accompanying unaudited interim consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the unaudited interim consolidated financial statements) considered necessary to present fairly the Companyâ€™s financial position as of DecemberÂ 31, 2024 and its results of operations and cash flows for the three months ended DecemberÂ 31, 2024 and 2023. The unaudited interim consolidated financial statements presented herein do not contain all of the required disclosures under U.S. GAAP for annual financial statements and should be read in conjunction with the annual audited consolidated financial statements and related notes of Sonnet as of and for the year ended SeptemberÂ 30, 2024 included in the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended SeptemberÂ 30, 2024. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. Â b. Consolidation Â The unaudited interim consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Â c. Use of estimates Â The preparation of the unaudited interim consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these unaudited interim consolidated financial statements include the accrual of research and development expenses. Estimates and assumptions are periodically reviewed in-light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from managementâ€™s estimates. Â d. Incentive tax receivable Â Subsidiary is eligible to participate in an Australian research and development tax incentive program. As part of this program, Subsidiary is eligible to receive a cash refund from the Australian Taxation Office for a percentage of the research and development costs expended by Subsidiary in Australia. The cash refund is available to eligible companies with annual aggregate revenues of less than $20.0 million (Australian) during the reimbursable period. The Company estimates the amount of cash refund it expects to receive related to the Australian research and development tax incentive program and records the incentive when it is probable (i) the Company will comply with relevant conditions of the program and (ii) the incentive will be received. As of DecemberÂ 31, 2024, the Companyâ€™s estimate of the amount of cash refund it expects to receive for eligible spending related to the Australian research and development tax incentive program was $0.2 million. For each of the three months ended DecemberÂ 31, 2024 and 2023, $0.2 million for the expected net cash refund related to the tax incentive program was included as a reduction in research and development expenses. In November 2024, the Company received $0.7 million from the Australian government related to eligible research and development expenses for the year ended September 30, 2024. In December 2023, the Company received $0.8 million from the Australian government related to eligible research and development expenses for the year ended September 30, 2023. Â e. Property and equipment Â Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets. Expenditures for repairs and maintenance that do not extend the estimated useful life or improve an asset are expensed as incurred. Upon retirement or sale, the cost and related accumulated depreciation and amortization of assets disposed of are removed from the accounts, and any resulting gain or loss is included in the consolidated statement of operations. Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial StatementsÂ Â f. Deferred offering costs Â Legal and other costs incurred in relation to equity offerings are capitalized as deferred offering costs and charged against the proceeds from equity offerings when received. If a financing is abandoned, deferred offering costs are expensed. Â g. Derivative liability Â The Company evaluates all features contained in financing agreements to determine if there are any embedded derivatives that require separate accounting from the underlying agreement. An embedded derivative that requires separation is accounted for as a separate asset or liability from the host agreement. The derivative asset or liability is accounted for at fair value, with changes in fair value recognized in the consolidated statement of operations. The Company determined that certain features under the Purchase Agreement (see Note 6) qualified as embedded derivatives. The derivative liability is accounted for separately from the Purchase Agreement at fair value, which has been deemed de minimis. Â h. Collaboration revenue Â Collaboration arrangements may contain multiple components, which may include (i) licenses; (ii) research and development activities; and (iii) the manufacturing and supply of certain materials. Payments pursuant to these arrangements may include non-refundable payments, upfront payments, milestone payments upon the achievement of significant regulatory and development events, sales milestones and royalties on product sales. The amount of variable consideration is constrained until it is probable that the revenue is not at a significant risk of reversal in a future period. Â In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under a collaboration arrangement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are capable of being distinct; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue as the Company satisfies each performance obligation. Â The Company applies significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining when performance obligations have been met, and assessing the recognition of variable consideration. When consideration is received prior to the Company completing its performance obligation under the terms of a contract, a contract liability is recorded as deferred income. Deferred income expected to be recognized as revenue within the twelve months following the balance sheet date is classified as a current liability. In May 2021, the Company entered into a License Agreement (the â€œNew Life Agreementâ€) with New Life Therapeutics Pte, Ltd. (â€œNew Lifeâ€). In October 2024, the Company entered into the Alkem Agreement. See Note 5 for further discussion of these agreements. Â i. Research and development expense Â Research and development expenses include all direct and indirect costs associated with the development of the Companyâ€™s biopharmaceutical products. These expenses include personnel costs, consulting fees, and payments to third parties for research, development, and manufacturing services. These costs are charged to expense as incurred. Â At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the related project, based on the measure of progress as defined in the contract. Factors the Company considers in preparing the estimates include costs incurred by the service provider, milestones achieved, and other criteria related to the efforts of its service providers. Such estimates are subject to change as additional information becomes available. Depending on the timing of payment to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company will record a prepaid expense or accrued liability relating to these costs. Upfront milestone payments made to third parties who perform research and development services on the Companyâ€™s behalf are expensed as services are rendered. Contingent development or regulatory milestone payments are recognized upon the related resolution of such contingencies. Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements Â j. Foreign currency Â Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than the U.S. dollar are included in operations in the period in which the transaction occurs and reported within the foreign exchange gain (loss) line item in the consolidated statement of operations. Â k. Reverse stock split Â On September 30, 2024, the Company filed a Certificate of Amendment to its Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware, which effected a 1-for-8 reverse stock split of the Companyâ€™s issued and outstanding shares of common stock. As a result of the reverse stock split, every eight shares of common stock issued and outstanding was converted into one share of common stock. The reverse stock split affected all stockholders uniformly and did not alter any stockholderâ€™s percentage interest in the Companyâ€™s equity. No fractional shares were issued in connection with the reverse stock split. Stockholders who would otherwise be entitled to a fractional share of common stock were instead entitled to receive a proportional cash payment. The reverse stock split did not change the par value or authorized number of shares of common stock. All common share and per share amounts presented in the unaudited interim consolidated financial statements and accompanying notes have been retroactively adjusted to reflect the reverse stock split. Â l. Net loss per share Â Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period (and potential shares of common stock that are exercisable for little or no consideration). Included in basic weighted-average number of shares of common stock outstanding during the three months ended December 31, 2024 are pre-funded October 2023 warrants to purchase 99,687 shares of common stock with an exercise price of $0.0008 per share, warrants exercised through the June 2024 inducement offer for 155,125 shares of common stock that are being held in abeyance as of December 31, 2024 due to beneficial ownership limitations, and pre-funded December 2024 warrants to purchase 545,500 shares of common stock with an exercise price of $0.0001 per share. Included in basic weighted-average number of shares of common stock outstanding during the three months ended December 31, 2023 are pre-funded October 2023 warrants to purchase 192,187 shares of common stock with an exercise price of $0.0008 per share. Â Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities such as common stock warrants and stock options which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements Â The following potentially dilutive securities have been excluded from the computation of diluted shares of common stock outstanding as they would be anti-dilutive: Â Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Shares Â Â 2024Â Â 2023Â Â Â December 31,Â Â Â 2024Â Â 2023Â Common stock warrants August 2021Â Â 14,031Â Â Â 14,031Â Underwriter warrants August 2021Â Â 284Â Â Â 284Â Chanticleer warrantsÂ Â 6Â Â Â 6Â Series C warrantsÂ Â 2,297Â Â Â 2,297Â Series 3 warrantsÂ Â 1,566Â Â Â 1,566Â Unvested restricted stock units and awardsÂ Â 17,152Â Â Â 976Â Common stock warrants February 2023Â Â 31,563Â Â Â 33,982Â Underwriter warrants February 2023Â Â 1,933Â Â Â 1,933Â Common stock private placement warrants June 2023Â Â 28,409Â Â Â 28,409Â Placement agent warrants June 2023Â Â 852Â Â Â 852Â Common stock warrants October 2023Â Â 354,994Â Â Â 710,931Â Underwriter warrants October 2023Â Â 10,664Â Â Â 10,664Â Placement agent warrants June 2024Â Â 14,142Â Â Â â€”Â Common stock warrants June 2024Â Â 703,125Â Â Â â€”Â Common stock warrants November 2024Â Â 2,222,222Â Â Â â€”Â Common stock registered direct warrants December 2024Â Â 1,085,325Â Â Â â€”Â Common stock PIPE warrants December 2024Â Â 673,000Â Â Â â€”Â Total anti-dilutive weighted average sharesÂ Â Â 5,161,565Â Â Â 805,931Â Â m. Recent accounting pronouncements Â In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07, which is applicable to entities with a single reportable segment, will primarily require enhanced disclosures about significant segment expenses and enhanced disclosures in interim periods. The guidance in ASU 2023-07 will be applied retrospectively and is effective for annual reporting periods in fiscal years beginning after December 15, 2023 and interim reporting periods in fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact that the adoption of ASU 2023-07 will have on its consolidated financial statements and disclosures. Â In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 is intended to improve income tax disclosure requirements by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to the income tax

disclosure requirements. The guidance in ASU 2023-09 will be effective for annual reporting periods in fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact that the adoption of ASU 2023-09 will have on its consolidated financial statements and disclosures. Â In November 2024, the FASB issued ASU 2024-03, Income Statementâ€”Reporting Comprehensive Incomeâ€”Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, as subsequently amended by ASU 2025-01 to clarify the effective date, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented in the consolidated statement of operations. The guidance in this ASU is effective for annual reporting periods in fiscal years beginning after December 15, 2026, and interim periods in fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures. Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R11.htm IDEA: XBRL DOCUMENT v3.25.0.1 Accrued Expenses and Other Current Liabilities 3 Months Ended Dec. 31, 2024 Payables and Accruals [Abstract] Â Accrued Expenses and Other Current Liabilities 3. Accrued Expenses and Other Current Liabilities Â Accrued expenses and other current liabilities consisted of the following:Â Â Schedule of Accrued Expenses and Other Current Liabilities Â Â December 31, 2024Â Â September 30, 2024Â Compensation and benefitsÂ $155,514Â Â $149,802Â Research and developmentÂ Â 969,684Â Â Â 617,545Â Professional feesÂ Â 267,587Â Â Â 173,319Â OtherÂ Â 1,735Â Â Â 1,823Â Â Accrued expenses and other current liabilitiesÂ $1,394,520Â Â $942,489Â Â X - DefinitionThe entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1 + Details Name: us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 24 R12.htm IDEA: XBRL DOCUMENT v3.25.0.1 Commitments and Contingencies 3 Months Ended Dec. 31, 2024 Commitments and Contingencies Disclosure [Abstract] Â Commitments and Contingencies 4. Commitments and Contingencies Â Legal proceedings Â From time to time, the Company is a party to various lawsuits, claims, and other legal proceedings that arise in the ordinary course of its business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Companyâ€™s consolidated financial position, results of operations, or cash flows. Â License agreements Â In July 2012, the Company entered into a Discovery Collaboration Agreement (the â€œCollaboration Agreementâ€) with XOMA (US) LLC (â€œXOMAâ€), pursuant to which XOMA granted to the Company a non-exclusive, non-transferable license and/or right to use certain materials, technologies and related information related to discovery, optimization and development of antibodies and related proteins and to develop and commercialize products thereunder. The Company is obligated to make contingent milestone payments to XOMA totaling $3.8 million on a product-by-product basis upon the achievement of certain development and approval milestones related to a product. The Company has also agreed to pay XOMA low single-digit royalties on net sales of products sold by the Company. Royalties on each product are payable on a country-by-country basis until the later of (i) a specified period of time after the first commercial sale, and (ii) the date of expiration of the last valid claim in the last-to-expire of the issued patents covered by the Collaboration Agreement. The first milestone was achieved in April 2022, at which time the Company incurred a $0.5 million license fee which was recorded as acquired in-process research and development. No license fees were incurred during the three months ended December 31, 2024 and 2023. Â In August 2015, the Company entered into a License Agreement (the â€œARES License Agreementâ€) with Ares Trading (â€œARESâ€), a wholly-owned subsidiary of Merck KGaA. Under the terms of the ARES License Agreement, as subsequently amended in October 2021, ARES has granted the Company a sublicensable, exclusive, worldwide, royalty-bearing license on proprietary patents to research, develop, use and commercialize products using atexakin alfa (â€œAtexakinâ€), a low dose formulation of human IL-6 in peripheral neuropathies and vascular complications. Pursuant to the ARES License Agreement, the Company will pay ARES high single-digit royalties on net sales of products sold by the Company. Royalties are payable on a product-by-product and country-by-country basis until the later of (i) a specified period of time after the first commercial sale in such country, and (ii) the last date on which such product is covered by a valid claim in such country. Additionally, the Company will pay ARES a percentage of all revenue received through sublicensing the IL-6 compound, including revenue from any upfront, milestone, royalty, maintenance and similar payments, net of certain full time equivalent (â€œFTEâ€) costs incurred by the Company pursuant to such sublicense. The percentage rate owed to ARES on sublicense revenue decreases depending on the point in time of execution of the relevant sublicense agreement and the development progress accomplished by the Company to that point in time. The upfront cash payments received by the Company pursuant to the New Life Agreement (see Note 5) were specifically excluded from the scope of the amended ARES License Agreement. The Company owes ARES $0.1 million in license fees related to sublicense revenue received pursuant to the Alkem Agreement (see Note 5), which is included in research and development expenses in the unaudited interim consolidated statement of operations for the three months ended DecemberÂ 31, 2024. No license fees were incurred during the three months ended DecemberÂ 31, 2023. Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements Â In January 2019, the Company entered into a Frame Services and License Agreement (the â€œCellca Agreementâ€) with Sartorius Stedim Cellca GMBH (â€œCellcaâ€), pursuant to which Cellca has granted the Company a worldwide, non-exclusive, perpetual, non-transferable license to develop, manufacture or have manufactured, use, sell, import, export and/or otherwise commercialize product based on Cellcaâ€™s work to generate a specified transfected cell line and develop an upstream production process for such cell line. The Cellca Agreement is effective unless terminated by either party by giving six months notice, or by giving 14 days notice if terminated for good cause. The Company is obligated to make milestone payments to Cellca totaling up to $0.7 million upon the achievement of certain development and approval milestones if the Buy-Out Option is not exercised. The Company has a Buy-Out Option that will be effective between the time of completion of a clinical trial and the receipt of regulatory approval for commercialization of product. The cost to exercise the Buy-Out Option increases on each anniversary of the commencement date of the Buy-Out Option Period, and ranges from $0.1 million to $0.6 million. The cost to exercise the Buy-Out Option will replace the $0.6 million contingent milestone payment due upon final regulatory approval. The first milestone was achieved in April 2022, at which time the Company incurred a $0.1 million license fee which was recorded as acquired in-process research and development. No license fees were incurred during the three months ended December 31, 2024 and 2023. Â In October 2021, the Company entered into a Non-Exclusive License Agreement (the â€œBrink Agreementâ€) with Brink Biologics Inc. (â€œBrinkâ€), pursuant to which Brink has granted the Company a non-exclusive, non-transferable license and limited right to sublicense certain materials and related information to develop cell-based assays for batch, quality control, stability, efficacy, potency or any other type of assay required for production and commercialization of products. During the product development phase, the Company was obligated to make annual product development license fee payments of approximately $0.1 million. In April 2023, the Brink Agreement was amended, effective November 2022, to reduce the annual license fee payments to $12,000 for storage. If materials are removed from storage during the product development phase, the annual product development license fee of approximately $0.1 million will apply. If a product achieves commercial status, the Company is obligated to make a commercial product license fee payment of approximately $0.1 million per commercial product. The amended agreement has an initial term of one year and will automatically renew for one additional year unless terminated or converted to a product development license. After the second year, the license will automatically convert to a full license requiring a product development or a commercial product license fee unless the parties mutually agree to terminate the agreement. The Company incurred $12,000 in license fees during the three months ended December 31, 2024 and 2023, which were recorded as acquired in-process research and development and included in research and development expenses in the unaudited interim consolidated statements of operations. Â In February 2022, the Company entered into a Biological Materials License Agreement (the â€œInvivoGen Agreementâ€) with InvivoGen SAS (â€œInvivoGenâ€), pursuant to which InvivoGen has granted the Company a worldwide, non-exclusive license to use certain reporter cells for research, development and/or quality control purposes. The InvivoGen Agreement has an initial term of three years and may be extended for two additional three-year periods upon written notice by the Company and payment of an approximately â‚¬0.1 million fee per extension (approximately $0.1 million as of December 31, 2024). No license fees were incurred during the three months ended December 31, 2024 and 2023. Â Collaboration agreement Â In August 2024, the Company entered into a Master Clinical Collaboration Agreement (the â€œSOC Agreementâ€) with the Sarcoma Oncology Center (â€œSOCâ€) to advance the development of SON-1210. An Innovative Immuno Oncology Center funded by the SOC will conduct an investigator-initiated Phase 1/2a study of SON-1210 in pancreatic cancer. The Company will provide the study drug and provide support services for the study. If the Company establishes a partnership with a third party prior to the initiation of the initial efficacy combination trial under this collaboration, the Company will incur, payable to the SOC, a one-time fee equal to the greater of 5% or $1.5 million from the first upfront payment received from such third party partnership. Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements Â Research and development agreement Â In December 2021, the Company entered into a Research and Development Agreement (the â€œNavigo Agreementâ€) with Navigo Proteins GmbH (â€œNavigoâ€), pursuant to which Navigo will perform specified evaluation and development procedures to evaluate certain materials to determine their commercial potential. Under the terms of the Navigo Agreement, the Company has granted Navigo a royalty-free, non-exclusive, worldwide, non-sublicensable, non-transferable right and license to use certain technology to perform the evaluation and development activities, and Navigo has granted the Company (i) an exclusive, worldwide, perpetual, irrevocable, sublicensable, transferable, royalty-free right and license to research, develop, use, sell, have sold, distribute, import or otherwise commercially exploit certain materials, and (ii) a non-exclusive, worldwide, perpetual, sublicensable, non-transferable right and license to make or have made such materials. The Company incurred a $0.1 million technology access fee upon execution of the Navigo Agreement, at which time it was recorded as acquired in-process research. The Company is obligated to make contingent milestone payments to Navigo totaling up to $1.0 million upon the achievement of certain evaluation and development milestones as outlined in the Navigo Agreement, of which $0.3 million of evaluation milestones have been previously recognized. No milestones were achieved and no license fees were incurred during the three months ended December 31, 2024 and 2023. Â Employment agreements Â The Company has entered into employment contracts with its officers and certain employees that provide for severance and continuation of benefits in the event of termination of employment either by the Company without cause or by the employee for good reason, both as defined in the contract. In addition, in the event of termination of employment following a change in control, as defined, either by the Company without cause or by the employee for good reason, any unvested portion of the employeeâ€™s initial stock option grant becomes immediately vested. Â X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R13.htm IDEA: XBRL DOCUMENT v3.25.0.1 Collaboration Revenue 3 Months Ended Dec. 31, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Collaboration Revenue 5. Collaboration Revenue Â New Life Agreement Â Under the New Life Agreement, the Company granted New Life an exclusive license (with the right to sublicense) to develop and commercialize pharmaceutical preparations containing a specific recombinant human IL-6, SON-080 (the â€œCompoundâ€) (such preparations, the â€œProductsâ€) for the prevention, treatment or palliation of DPN in humans (the â€œDPN Fieldâ€) in Malaysia, Singapore, Indonesia, Thailand, Philippines, Vietnam, Brunei, Myanmar, Lao PDR and Cambodia (the â€œExclusive Territoryâ€). New Life paid the Company an aggregate of $1.0 million in non-refundable upfront cash payments in connection with the execution of the New Life Agreement. The related collaboration revenue was fully recognized by December 31, 2023, as the Company had completed its performance obligations under the New Life Agreement. In December 2024, New Life informed the Company that it has elected to move its business in a different direction and provided the Company with written notice of its intention to exercise its Give Back Option, which is the right to give back the rights with respect to Products in the DPN Field in one or more countries in the Exclusive Territory. The exercise of the Give Back Option is subject to the negotiation and mutual agreement of terms between the Company and New Life. Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements Â Alkem Agreement Â Under the Alkem Agreement entered into on October 8, 2024 (see Note 1), the Company granted Alkem an exclusive license (with the right to sublicense) to research, develop, manufacture, import, export, market, use and commercialize pharmaceutical products containing its IL-6 (SON-080) asset (or any derivatives, fragments or conjugates thereof) (the â€œCompoundsâ€) (such products, the â€œProductsâ€) for the treatment of DPN (the â€œDPN Fieldâ€) and to manufacture, import, export, market, use and commercialize Products for the treatment of CIPN and autonomic neuropathy (together with the DPN Field, the â€œFieldsâ€) in India. Except as provided for in the Alkem Agreement, the Company agreed not to develop, use, sell, offer or otherwise commercialize any Compounds or Products for use in the DPN Field in India during the term of the Alkem Agreement. The Company retains all rights to manufacture Compounds and Products anywhere in the world. The Company and Alkem will enter into a follow-on supply agreement pursuant to which the Company will manufacture for Alkem Compounds and Products for post-Phase 2 clinical development and commercialization in accordance with the Alkem Agreement on terms to be negotiated by the parties. Pursuant to the terms of the Alkem Agreement, Alkem will bear the cost of, and be responsible for, among other things, conducting clinical studies and additional non-clinical studies (if any, subject to both partiesâ€™ approval), preparing and filing applications for regulatory approval and undertaking other developmental and regulatory activities for commercializing Products in the DPN Field in India. Alkem will own and maintain all regulatory filings and approvals for Products in India. Upon payment of a Clinical Data Access Fee (as defined in the Alkem Agreement), the Company will have rights to access and use the data generated by the clinical trials conducted in connection with the Alkem Agreement. Under the terms of the Alkem Agreement, Alkem will pay the Company $1.0 million in upfront payments and up to an additional $1.0 million in milestone payments. Additionally, the Company is entitled to receive a royalty equal to a percentage in the low double digits of the net sales of the Product upon commercialization of SON-080 in India, less certain expenses as set forth in the Alkem Agreement. Â Revenue recognition Â The Company first assessed the Alkem Agreement under ASC 808, Collaborative Arrangements (â€œASC 808â€), to determine whether the Alkem Agreement or units of accounts within the Alkem Agreement represent a collaborative arrangement based on the risks and rewards and activities of the parties. The Company applied relevant guidance from ASC 606, Revenue from Contracts with Customers (â€œASC 606â€), to evaluate the appropriate accounting for the collaborative arrangement with Alkem. Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements Â In accordance with this guidance, the Company identified the following obligations under the Alkem arrangement: (i) License to research, develop, market, import, use and commercialize the Product in the DPN field in India (the â€œLicenseâ€); and (ii) supply of Compound for a Phase 2 clinical trial (â€œSupplyâ€). The future supply agreement for post-Phase 2 clinical development represents an optional purchase, which will be accounted for as a separate contract, and the Company did not identify any material right to be present. The Company

determined that the License and Supply are not distinct from each other and therefore combined these material promises into a single performance obligation. The Company determined the initial transaction price of the single performance obligation to be $1.0 million, as the future development and commercialization milestones, which represent variable consideration, are subject to constraint at inception. At the end of each subsequent reporting period, the Company will reevaluate the probability of achievement of the future development and commercialization milestones subject to constraint and, if necessary, will adjust its estimate of the overall transaction price. Any such adjustments will be recorded on a cumulative catch-up basis. For the sales-based royalties, the Company will recognize revenue when the related sales occur. Â Collaboration revenue from the single performance obligation related to the Alkem Agreement was recognized at the point-in-time at which the Company transferred the License and Supply to Alkem. Collaboration revenue from the single performance obligation related to the New Life Agreement was recognized over the estimated performance of the research and development activities. The Company recognized $1.0 million and $18,626 of collaboration revenue for the three months ended DecemberÂ 31, 2024 and 2023, respectively. As of DecemberÂ 31, 2024, the Company has recorded a contract asset for $0.5 million related to the Alkem Agreement, which represents the unbilled amount related to the single performance obligation and is included in unbilled collaboration revenue in the unaudited interim consolidated balance sheet. Â X - DefinitionThe entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 808 -Publisher FASB -URI https://asc.fasb.org/808/tableOfContent + Details Name: us-gaap_CollaborativeArrangementDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 26 R14.htm IDEA: XBRL DOCUMENT v3.25.0.1 Stockholdersâ€™ Equity (Deficit) 3 Months Ended Dec. 31, 2024 Equity [Abstract] Â Stockholdersâ€™ Equity (Deficit) 6. Stockholdersâ€™ Equity (Deficit) Â October 2023 underwritten public offering Â On October 26, 2023, the Company closed a public offering of common stock and certain warrants through Chardan and Ladenburg Thalmann & Co. Inc. as underwriters, for net proceeds of $3.9 million through the issuance and sale of 163,281 shares of its common stock and, to certain investors, pre-funded warrants to purchase 192,187 shares of common stock, and accompanying common warrants to purchase up to an aggregate of 710,931 shares of its common stock. Each share of common stock and pre-funded warrant to purchase one share of common stock was sold together with a common warrant to purchase two shares of common stock. The public offering price of each share of common stock and accompanying common warrant was $12.80 and the public offering price of each pre-funded warrant and accompanying common warrant was $12.7992. The common warrants were immediately exercisable at a price of $12.80 per share of common stock, expire five years from the date of issuance and contain an alternative cashless exercise provision. In connection with the June 2024 inducement offer, the exercise price was decreased to $9.60 per share of common stock for common warrants that remained unexercised at the time of the offer. The pre-funded warrants were immediately exercisable at any time, until exercised in full, at a price of $0.0008 per share of common stock. In addition, warrants to purchase 10,664 shares of common stock were issued to the underwriters as compensation for their services related to the offering. These common stock warrants have an exercise price of $16.00 per share and expire five years from the date of issuance. Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements Â Committed equity facility Â On May 2, 2024, the Company entered into the Purchase Agreement and a Registration Rights Agreement (the â€œRegistration Rights Agreementâ€), each with Chardan, related to a â€œChEF,â€ Chardanâ€™s committed equity facility, or the Facility (see Note 1). Pursuant to the Purchase Agreement, the Company has the right from time to time at its option to sell to Chardan up to $25.0 million in aggregate gross purchase price of newly issued shares of the Companyâ€™s common stock, of which $24.9 million is available to be sold as of December 31, 2024. The Facility will allow the Company to raise primary equity on a periodic basis at its sole discretion depending on a variety of factors including, among other things, market conditions, the trading price of the common stock, and determinations by the Company regarding the use of proceeds of such common stock. The purchase price of the shares of common stock will be determined by reference to the Volume Weighted Average Price (â€œVWAPâ€) of the common stock during the applicable purchase period, less a fixed 4% discount to such VWAP, and the total shares to be purchased on any day may not exceed 20% of the trading volume of the Companyâ€™s common stock during the applicable purchase period. The Purchase Agreement will be effective for a 36-month period ending May 16, 2027. Due to certain pricing and settlement provisions, the Purchase Agreement qualifies as a standby equity purchase agreement and includes an embedded put option and an embedded forward contract. The Company accounts for the embedded features in the Purchase Agreement as derivatives measured at fair value, with changes in fair value recognized in the consolidated statement of operations. The derivatives associated with the Purchase Agreement have been deemed de minimis. The Company did not sell any shares of common stock pursuant to the Purchase Agreement during the three months ended DecemberÂ 31, 2024. Â November 2024 underwritten public offering Â On November 7, 2024, the Company closed a public offering of common stock and certain warrants through Chardan, as underwriter, for net proceeds of $4.2 million through the issuance and sale of 155,000 shares of its common stock, pre-funded warrants to purchase up to 956,111 shares of common stock, and accompanying common warrants to purchase up to an aggregate of 2,222,222 shares of its common stock. Each share of common stock and pre-funded warrant to purchase one share of common stock was sold together with a common warrant to purchase two shares of common stock. The public offering price of each share of common stock and accompanying common warrant was $4.50 and the public offering price of each pre-funded warrant and accompanying common warrant was $4.4999. The common warrants were immediately exercisable at a price of $4.50 per share of common stock, expire five years from the date of issuance and contain an alternative cashless exercise provision. The pre-funded warrants were immediately exercisable at any time, until exercised in full, at a price of $0.0001 per share of common stock. All of the pre-funded warrants have been exercised as of December 31, 2024. Â December 2024 registered direct and PIPE offering Â On December 10, 2024, the Company closed a registered direct offering with institutional investors for the issuance and sale of 768,000 shares of its common stock, pre-funded warrants to purchase up to 317,325 shares of common stock, and accompanying warrants to purchase up to an aggregate of 1,085,325 shares of its common stock. Each share of common stock and pre-funded warrant to purchase one share of common stock was sold together with a common warrant to purchase one share of common stock. The offering price of each share of common stock and accompanying common warrant was $2.23 and the offering price of each pre-funded warrant and accompanying common warrant was $2.2299, priced at-the-market under the rules of the Nasdaq Stock Market. The registered direct warrants were immediately exercisable at a price of $2.10 per share, expire five years from the date of issuance and contain an alternative cashless exercise provision. The pre-funded warrants were immediately exercisable at any time, until exercised in full, at a price of $0.0001 per share of common stock. All of the pre-funded warrants have been exercised as of December 31, 2024. Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements Â The Company closed a concurrent private placement with an existing investor for the issuance and sale of 127,500 shares of its common stock, pre-funded warrants to purchase up to 545,500 shares of common stock, and accompanying warrants to purchase up to an aggregate 673,000 shares of its common stock. Each share of common stock and pre-funded warrant to purchase one share of common stock was sold in the private placement (â€œPIPEâ€) together with a common warrant to purchase one share of common stock. The PIPE offering price of each share of common stock and accompanying common warrant was $2.23 and the PIPE offering price of each pre-funded warrant and accompanying common warrant was $2.2299, priced at-the-market under the rules of the Nasdaq Stock Market. The PIPE warrants were immediately exercisable at a price of $2.10 per share, expire five years from the date of issuance and contain an alternative cashless exercise provision. The pre-funded warrants were immediately exercisable at any time, until exercised in full, at a price of $0.0001 per share of common stock. Â The Company raised net proceeds of approximately $3.5 million from the registered direct and PIPE offering. Â Common stock warrants Â As of DecemberÂ 31, 2024, the following equity-classified warrants and related terms were outstanding: Â Schedule of Warrants Outstanding Â Â Warrants OutstandingÂ Â Exercise PriceÂ Â Expiration DateÂ Common stock warrants August 2021Â Â Â 14,031Â Â Â $2,094.4000Â Â Â Â August 24, 2026Â Underwriter warrants August 2021Â Â Â 284Â Â Â $2,618.0000Â Â Â Â August 19, 2026Â Chanticleer warrantsÂ Â 6Â Â Â Â $144,144.0000 - $224,224.0000Â Â Â Â April 30, 2027 - December 17, 2028Â Series C warrantsÂ Â 2,297Â Â Â $7,860.1600Â Â Â Â October 16, 2025Â Series 3 warrantsÂ Â 1,566Â Â Â $717.0240Â Â Â Â August 15, 2027Â Common stock warrants February 2023Â Â 31,563Â Â Â $190.0800Â Â Â Â February 10, 2028Â Underwriter warrants February 2023Â Â 1,933Â Â Â $237.6000Â Â Â Â February 8, 2028Â Common stock private placement warrants June 2023Â Â 28,409Â Â Â $12.4000Â Â Â Â June 21, 2029Â Placement agent warrants June 2023Â Â 852Â Â Â $118.7824Â Â Â Â December 30, 2026Â Common stock warrants October 2023Â Â 354,994Â Â Â $9.6000Â Â Â Â October 27, 2028Â Pre-funded warrants October 2023Â Â 99,687Â Â Â $0.0008Â Â Â Â â€“Â Underwriter warrants October 2023Â Â 10,664Â Â Â $16.0000Â Â Â Â October 24, 2028Â Placement agent warrants June 2024Â Â 14,142Â Â Â $14.8800Â Â Â Â June 19, 2029Â Common stock warrants June 2024Â Â 703,125Â Â Â $12.4000Â Â Â Â June 21, 2029Â Common stock warrants November 2024Â Â 2,222,222Â Â Â $4.5000Â Â Â Â November 7, 2029Â Common stock registered direct warrants December 2024Â Â 1,085,325Â Â Â $2.1000Â Â Â Â December 9, 2029Â Common stock PIPE warrants December 2024Â Â 673,000Â Â Â $2.1000Â Â Â Â December 9, 2029Â Pre-funded warrants December 2024Â Â 545,500Â Â Â $0.0001Â Â Â Â â€“Â TotalÂ Â 5,789,600Â Â Â Â Â Â Â Â Â Â Â Â Â Due to beneficial ownership limitations, 187,500 shares of common stock related to warrants that were exercised in June 2024 through the inducement offer were being held in abeyance. During the three months ended DecemberÂ 31, 2024, 32,375 of these shares of common stock were released from abeyance, resulting in 155,125 shares of common stock held in abeyance as of December 31, 2024. Â During the three months ended DecemberÂ 31, 2024, 2,419 warrants were net share settled, resulting in the issuance of 1,209 shares of common stock, and 1,273,436 pre-funded warrants were exercised on a cash basis for de minimis proceeds. Â During the three months ended DecemberÂ 31, 2023, 3,590 warrants were net share settled, resulting in the issuance of 1,795 shares of common stock, and 4,302 warrants were abandoned by the warrant holder. Â Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements Â X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R15.htm IDEA: XBRL DOCUMENT v3.25.0.1 Share-Based Compensation 3 Months Ended Dec. 31, 2024 Share-Based Payment Arrangement [Abstract] Â Share-Based Compensation 7. Share-Based Compensation Â In April 2020, the Company adopted the 2020 Omnibus Equity Incentive Plan (the â€œPlanâ€). There were 5 shares available for issuance under the Plan as of December 31, 2024. On January 1, 2025, the total number of shares authorized under the Plan increased to 120,302. The Plan increases the amount of shares issuable under the Plan by four percent of the outstanding shares of common stock at each January 1, each year. The Plan permits the granting of share-based awards, including stock options, restricted stock units and awards, stock appreciation rights and other types of awards as deemed appropriate, in each case, in accordance with the terms of the Plan. The terms of the awards are determined by the Companyâ€™s Board of Directors. Â Restricted stock units and awards Â On January 1, 2024, 9,175 restricted stock units (â€œRSUsâ€) and 7,977 restricted stock awards (â€œRSAsâ€) were granted, 100% of which vested on January 1, 2025. Any unvested RSUs or RSAs will be forfeited upon termination of services. The fair value of an RSU or RSA is equal to the fair market value of the Companyâ€™s common stock on the date of grant. RSU and RSA expense is amortized straight-line over the vesting period. Â Â Â The Company recorded share-based compensation expense associated with the RSUs and RSAs in its accompanying unaudited interim consolidated statements of operations as follows: Â Schedule of Share-based Compensation Expense Â Â 2024Â Â 2023Â Â Â Three Months Ended December 31,Â Â Â 2024Â Â 2023Â Research and developmentÂ $28,268Â Â $24,554Â General and administrativeÂ Â 32,127Â Â Â 25,451Â Share-based compensationÂ $60,395Â Â $50,005Â Â The following table summarizes RSU activity under the Plan: Â Â Schedule of Restricted Stock Units Activity Â Â Â Â Â Â WeightedÂ Â Â Â Â Â Â Average GrantÂ Â Â RSUÂ Â Date Fair ValueÂ Unvested balance at December 31, 2024Â Â Â 9,175Â Â $14.08Â Â Â During the three months ended DecemberÂ 31, 2024, there were no RSUs granted, vested or forfeited. As of DecemberÂ 31, 2024, there was no unrecognized compensation expense relating to unvested RSUs granted. Â The following table summarizes RSA activity under the Plan: Â Schedule of Restricted Stock Awards Activity Â Â Â Â Â Â WeightedÂ Â Â Â Â Â Â Average GrantÂ Â Â RSAÂ Â Date Fair ValueÂ Unvested balance at December 31, 2024Â Â Â 7,977Â Â $14.08Â Â Â Â During the three months ended DecemberÂ 31, 2024, there were no RSAs granted, vested or forfeited. As of DecemberÂ 31, 2024, there was no unrecognized compensation expense relating to unvested RSAs granted. Â X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -

Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 28 R16.htm IDEA: XBRL DOCUMENT v3.25.0.1 Subsequent Events 3 Months Ended Dec. 31, 2024 Subsequent Events [Abstract] Â Subsequent Events 8. Subsequent Events Â Â The Company has evaluated subsequent events from the balance sheet date through February 13, 2025, the date at which the unaudited interim consolidated financial statements were available to be issued. Â Subsequent to DecemberÂ 31, 2024, the Company sold 58,270 shares of common stock pursuant to the Purchase Agreement for net proceeds of $0.1 million. Â The Company received preliminary approval of its application to sell up to $0.8 million of its New Jersey state net operating losses through the Program (see Note 1). In February 2025, the Company identified a buyer. As outlined in the Program, although the sale has been approved and a buyer identified, the Company must still execute an arrangement with such buyer to consummate a sale of the state net operating losses. Â On February 10, 2025, Jay Cross submitted his resignation as our Chief Financial Officer, effective February 21, 2025. In connection with Mr. Crossâ€™s resignation, on February 12, 2025, the Companyâ€™s board of directors (the â€œBoardâ€) appointed Donald Griffith, CPA, the Companyâ€™s current Controller and a member of the Board, to succeed Mr. Cross as its Chief Financial Officer effective February 21, 2025. Â On February 12, 2025, Stephen McAndrew, Ph.D., the Companyâ€™s Senior Vice President of Business Development, was appointed as the Companyâ€™s Chief Business Officer. In connection with his appointment, Dr. McAndrew entered into an employment agreement with the Company, dated February 12, 2025 (the â€œMcAndrew Agreementâ€). Dr. McAndrewâ€™s employment as the Companyâ€™s Chief Business Officer will commence on February 17, 2025. Pursuant to the McAndrew Agreement, Dr. McAndrew is entitled to, among other things, (i) an annual gross base salary of $330,000 (â€œBase Salaryâ€) and (ii) eligibility for a performance-based cash bonus of up to 35% of the Base Salary, as determined by the Board. X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R17.htm IDEA: XBRL DOCUMENT v3.25.0.1 Summary of Significant Accounting Policies (Policies) 3 Months Ended Dec. 31, 2024 Accounting Policies [Abstract] Â Basis of presentation a. Basis of presentation Â The accompanying unaudited interim consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (â€œU.S. GAAPâ€) for interim financial information as found in the Accounting Standards Codification (â€œASCâ€) and Accounting Standards Updates (ASUsâ€) of the Financial Accounting Standards Board (â€œFASBâ€). In the opinion of management, the accompanying unaudited interim consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the unaudited interim consolidated financial statements) considered necessary to present fairly the Companyâ€™s financial position as of DecemberÂ 31, 2024 and its results of operations and cash flows for the three months ended DecemberÂ 31, 2024 and 2023. The unaudited interim consolidated financial statements presented herein do not contain all of the required disclosures under U.S. GAAP for annual financial statements and should be read in conjunction with the annual audited consolidated financial statements and related notes of Sonnet as of and for the year ended SeptemberÂ 30, 2024 included in the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended SeptemberÂ 30, 2024. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. Â Consolidation b. Consolidation Â The unaudited interim consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Â Use of estimates c. Use of estimates Â The preparation of the unaudited interim consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these unaudited interim consolidated financial statements include the accrual of research and development expenses. Estimates and assumptions are periodically reviewed in-light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from managementâ€™s estimates. Â Incentive tax receivable d. Incentive tax receivable Â Subsidiary is eligible to participate in an Australian research and development tax incentive program. As part of this program, Subsidiary is eligible to receive a cash refund from the Australian Taxation Office for a percentage of the research and development costs expended by Subsidiary in Australia. The cash refund is available to eligible companies with annual aggregate revenues of less than $20.0 million (Australian) during the reimbursable period. The Company estimates the amount of cash refund it expects to receive related to the Australian research and development tax incentive program and records the incentive when it is probable (i) the Company will comply with relevant conditions of the program and (ii) the incentive will be received. As of DecemberÂ 31, 2024, the Companyâ€™s estimate of the amount of cash refund it expects to receive for eligible spending related to the Australian research and development tax incentive program was $0.2 million. For each of the three months ended DecemberÂ 31, 2024 and 2023, $0.2 million for the expected net cash refund related to the tax incentive program was included as a reduction in research and development expenses. In November 2024, the Company received $0.7 million from the Australian government related to eligible research and development expenses for the year ended September 30, 2024. In December 2023, the Company received $0.8 million from the Australian government related to eligible research and development expenses for the year ended September 30, 2023. Â Property and equipment e. Property and equipment Â Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets. Expenditures for repairs and maintenance that do not extend the estimated useful life or improve an asset are expensed as incurred. Upon retirement or sale, the cost and related accumulated depreciation and amortization of assets disposed of are removed from the accounts, and any resulting gain or loss is included in the consolidated statement of operations. Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial StatementsÂ Â Deferred offering costs f. Deferred offering costs Â Legal and other costs incurred in relation to equity offerings are capitalized as deferred offering costs and charged against the proceeds from equity offerings when received. If a financing is abandoned, deferred offering costs are expensed. Â Derivative liability g. Derivative liability Â The Company evaluates all features contained in financing agreements to determine if there are any embedded derivatives that require separate accounting from the underlying agreement. An embedded derivative that requires separation is accounted for as a separate asset or liability from the host agreement. The derivative asset or liability is accounted for at fair value, with changes in fair value recognized in the consolidated statement of operations. The Company determined that certain features under the Purchase Agreement (see Note 6) qualified as embedded derivatives. The derivative liability is accounted for separately from the Purchase Agreement at fair value, which has been deemed de minimis. Â Collaboration revenue h. Collaboration revenue Â Collaboration arrangements may contain multiple components, which may include (i) licenses; (ii) research and development activities; and (iii) the manufacturing and supply of certain materials. Payments pursuant to these arrangements may include non-refundable payments, upfront payments, milestone payments upon the achievement of significant regulatory and development events, sales milestones and royalties on product sales. The amount of variable consideration is constrained until it is probable that the revenue is not at a significant risk of reversal in a future period. Â In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under a collaboration arrangement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are capable of being distinct; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue as the Company satisfies each performance obligation. Â The Company applies significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining when performance obligations have been met, and assessing the recognition of variable consideration. When consideration is received prior to the Company completing its performance obligation under the terms of a contract, a contract liability is recorded as deferred income. Deferred income expected to be recognized as revenue within the twelve months following the balance sheet date is classified as a current liability. In May 2021, the Company entered into a License Agreement (the â€œNew Life Agreementâ€) with New Life Therapeutics Pte, Ltd. (â€œNew Lifeâ€). In October 2024, the Company entered into the Alkem Agreement. See Note 5 for further discussion of these agreements. Â Research and development expense i. Research and development expense Â Research and development expenses include all direct and indirect costs associated with the development of the Companyâ€™s biopharmaceutical products. These expenses include personnel costs, consulting fees, and payments to third parties for research, development, and manufacturing services. These costs are charged to expense as incurred. Â At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the related project, based on the measure of progress as defined in the contract. Factors the Company considers in preparing the estimates include costs incurred by the service provider, milestones achieved, and other criteria related to the efforts of its service providers. Such estimates are subject to change as additional information becomes available. Depending on the timing of payment to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company will record a prepaid expense or accrued liability relating to these costs. Upfront milestone payments made to third parties who perform research and development services on the Companyâ€™s behalf are expensed as services are rendered. Contingent development or regulatory milestone payments are recognized upon the related resolution of such contingencies. Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements Â Foreign currency j. Foreign currency Â Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than the U.S. dollar are included in operations in the period in which the transaction occurs and reported within the foreign exchange gain (loss) line item in the consolidated statement of operations. Â Reverse stock split k. Reverse stock split Â On September 30, 2024, the Company filed a Certificate of Amendment to its Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware, which effected a 1-for-8 reverse stock split of the Companyâ€™s issued and outstanding shares of common stock. As a result of the reverse stock split, every eight shares of common stock issued and outstanding was converted into one share of common stock. The reverse stock split affected all stockholders uniformly and did not alter any stockholderâ€™s percentage interest in the Companyâ€™s equity. No fractional shares were issued in connection with the reverse stock split. Stockholders who would otherwise be entitled to a fractional share of common stock were instead entitled to receive a proportional cash payment. The reverse stock split did not change the par value or authorized number of shares of common stock. All common share and per share amounts presented in the unaudited interim consolidated financial statements and accompanying notes have been retroactively adjusted to reflect the reverse stock split. Â Net loss per share l. Net loss per share Â Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period (and potential shares of common stock that are exercisable for little or no consideration). Included in basic weighted-average number of shares of common stock outstanding during the three months ended December 31, 2024 are pre-funded October 2023 warrants to purchase 99,687 shares of common stock with an exercise price of $0.0008 per share, warrants exercised through the June 2024 inducement offer for 155,125 shares of common stock that are being held in abeyance as of December 31, 2024 due to beneficial ownership limitations, and pre-funded December 2024 warrants to purchase 545,500 shares of common stock with an exercise price of $0.0001 per share. Included in basic weighted-average number of shares of common stock outstanding during the three months ended December 31, 2023 are pre-funded October 2023 warrants to purchase 192,187 shares of common stock with an exercise price of $0.0008 per share. Â Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities such as common stock warrants and stock options which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. Â Â Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements Â The following potentially dilutive securities have been excluded from the computation of diluted shares of common stock outstanding as they would be anti-dilutive: Â Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Shares Â Â 2024Â Â 2023Â Â Â December 31,Â Â Â 2024Â Â 2023Â Common stock warrants August 2021Â Â 14,031Â Â Â 14,031Â Underwriter warrants August 2021Â Â 284Â Â Â 284Â Chanticleer warrantsÂ Â 6Â Â Â 6Â Series C warrantsÂ Â 2,297Â Â Â 2,297Â Series 3 warrantsÂ Â 1,566Â Â Â 1,566Â Unvested restricted stock units and awardsÂ Â 17,152Â Â Â 976Â Common stock warrants February 2023Â Â 31,563Â Â Â 33,982Â Underwriter warrants February 2023Â Â 1,933Â Â Â 1,933Â Common stock private placement warrants June 2023Â Â 28,409Â Â Â 28,409Â Placement agent warrants June 2023Â Â 852Â Â Â 852Â Common stock warrants October 2023Â Â 354,994Â Â Â 710,931Â Underwriter warrants October 2023Â Â 10,664Â Â Â 10,664Â Placement agent warrants June 2024Â Â 14,142Â Â Â â€”Â Common stock warrants June 2024Â Â 703,125Â Â Â â€”Â Common stock warrants November 2024Â Â 2,222,222Â Â Â â€”Â Common stock registered direct warrants December 2024Â Â 1,085,325Â Â Â â€”Â Common stock PIPE warrants December 2024Â Â 673,000Â Â Â â€”Â Total anti-dilutive weighted average sharesÂ Â Â 5,161,565Â Â Â 805,931Â Â Recent accounting pronouncements m. Recent accounting pronouncements Â In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07, which is applicable to entities with a single reportable segment, will primarily require enhanced disclosures about significant segment expenses and enhanced disclosures in interim periods. The guidance in ASU 2023-07 will be applied retrospectively and is effective for annual reporting periods in fiscal years beginning after December 15, 2023 and interim reporting periods in fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact that the adoption of ASU 2023-07 will have on its consolidated financial statements and disclosures. Â In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 is intended to improve income tax disclosure requirements by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to the income tax disclosure requirements. The guidance in ASU 2023-09 will be effective for annual reporting periods in fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact that the adoption of ASU 2023-09 will have on its consolidated financial statements and disclosures. Â In November 2024, the FASB issued ASU 2024-03, Income Statementâ€”Reporting Comprehensive Incomeâ€”Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, as subsequently amended by ASU 2025-01 to clarify the effective date, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented in the consolidated statement of operations. The guidance in this ASU is effective for annual reporting periods in fiscal years beginning after December 15, 2026, and interim periods in fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures. X - DefinitionIncentive Tax Receivbale [Policy Text Block] + ReferencesNo definition available. + Details Name: SONN_IncentiveTaxReceivbalePolicyTextBlock Namespace Prefix: SONN_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionReverse Stock Split [Policy Text Block] + ReferencesNo definition available. + Details Name: SONN_ReverseStockSplitPolicyTextBlock Namespace Prefix: SONN_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance

Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for collaborative arrangements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementAccountingPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for deferral and amortization of significant deferred charges. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredChargesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for derivatives entered into for trading purposes and those entered into for purposes other than trading including where and when derivative financial instruments and derivative commodity instruments and their related gains or losses are reported in the entity's statements of financial position, cash flows, and results of operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1 + Details Name: us-gaap_DerivativesReportingOfDerivativeActivity Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/830/tableOfContent + Details Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1 + Details Name: us-gaap_ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R18.htm IDEA: XBRL DOCUMENT v3.25.0.1 Summary of Significant Accounting Policies (Tables) 3 Months Ended Dec. 31, 2024 Accounting Policies [Abstract] Â Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Shares The following potentially dilutive securities have been excluded from the computation of diluted shares of common stock outstanding as they would be anti-dilutive: Â Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Shares Â Â 2024Â Â 2023Â Â Â December 31,Â Â Â 2024Â Â 2023Â Common stock warrants August 2021Â Â 14,031Â Â Â 14,031Â Underwriter warrants August 2021Â Â 284Â Â Â 284Â Chanticleer warrantsÂ Â 6Â Â Â 6Â Series C warrantsÂ Â 2,297Â Â Â 2,297Â Series 3 warrantsÂ Â 1,566Â Â Â 1,566Â Unvested restricted stock units and awardsÂ Â 17,152Â Â Â 976Â Common stock warrants February 2023Â Â 31,563Â Â Â 33,982Â Underwriter warrants February 2023Â Â 1,933Â Â Â 1,933Â Common stock private placement warrants June 2023Â Â 28,409Â Â Â 28,409Â Placement agent warrants June 2023Â Â 852Â Â Â 852Â Common stock warrants October 2023Â Â 354,994Â Â Â 710,931Â Underwriter warrants October 2023Â Â 10,664Â Â Â 10,664Â Placement agent warrants June 2024Â Â 14,142Â Â Â â€”Â Common stock warrants June 2024Â Â 703,125Â Â Â â€”Â Common stock warrants November 2024Â Â 2,222,222Â Â Â â€”Â Common stock registered direct warrants December 2024Â Â 1,085,325Â Â Â â€”Â Common stock PIPE warrants December 2024Â Â 673,000Â Â Â â€”Â Total anti-dilutive weighted average sharesÂ Â Â 5,161,565Â Â Â 805,931Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R19.htm IDEA: XBRL DOCUMENT v3.25.0.1 Accrued Expenses and Other Current Liabilities (Tables) 3 Months Ended Dec. 31, 2024 Payables and Accruals [Abstract] Â Schedule of Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following:Â Â Schedule of Accrued Expenses and Other Current Liabilities Â Â December 31, 2024Â Â September 30, 2024Â Compensation and benefitsÂ $155,514Â Â $149,802Â Research and developmentÂ 969,684Â Â 617,545Â Professional feesÂ 267,587Â Â 173,319Â OtherÂ 1,735Â Â 1,823Â Accrued expenses and other current liabilitiesÂ $1,394,520Â Â $942,489Â X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R20.htm IDEA: XBRL DOCUMENT v3.25.0.1 Stockholdersâ€™ Equity (Deficit) (Tables) 3 Months Ended Dec. 31, 2024 Equity [Abstract] Â Schedule of Warrants Outstanding As of DecemberÂ 31, 2024, the following equity-classified warrants and related terms were outstanding: Â Schedule of Warrants Outstanding Â Â Warrants OutstandingÂ Â Exercise PriceÂ Â Expiration DateÂ Common stock warrants August 2021Â Â 14,031Â Â $2,094.4000Â Â Â August 24, 2026Â Underwriter warrants August 2021Â Â 284Â Â $2,618.0000Â Â Â August 19, 2026Â Chanticleer warrantsÂ Â 6Â Â Â $144,144.0000 - $224,224.0000Â Â Â April 30, 2027 - December 17, 2028Â Series C warrantsÂ Â 2,297Â Â $7,860.1600Â Â Â October 16, 2025Â Series 3 warrantsÂ Â 1,566Â Â $717.0240Â Â Â August 15, 2027Â Common stock warrants February 2023Â Â 31,563Â Â $190.0800Â Â Â February 10, 2028Â Underwriter warrants February 2023Â Â 1,933Â Â $237.6000Â Â Â February 8, 2028Â Common stock private placement warrants June 2023Â Â 28,409Â Â $12.4000Â Â Â June 21, 2029Â Placement agent warrants June 2023Â Â 852Â Â $118.7824Â Â Â December 30, 2026Â Common stock warrants October 2023Â Â 354,994Â Â $9.6000Â Â Â October 27, 2028Â Pre-funded warrants October 2023Â Â 99,687Â Â $0.0008Â Â Â Â Â â€”Â Underwriter warrants October 2023Â Â 10,664Â Â $16.0000Â Â Â October 24, 2028Â Placement agent warrants June 2024Â Â 14,142Â Â $14.8800Â Â Â June 19, 2029Â Common stock warrants June 2024Â Â 703,125Â Â $12.4000Â Â Â June 21, 2029Â Common stock warrants November 2024Â Â 2,222,222Â Â $4.5000Â Â Â November 7, 2029Â Common stock registered direct warrants December 2024Â Â 1,085,325Â Â $2.1000Â Â Â December 9, 2029Â Common stock PIPE warrants December 2024Â Â 673,000Â Â $2.1000Â Â Â December 9, 2029Â Pre-funded warrants December 2024Â Â 545,500Â Â $0.0001Â Â Â Â Â â€”Â TotalÂ Â 5,789,600Â Â Â

or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 210 -Topic 946 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20 + Details Name: us-gaap_Cash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23 + Details Name: us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3 + Details Name: us-gaap_OperatingLossCarryforwards Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 35 R23.htm IDEA: XBRL DOCUMENT v3.25.0.1 Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Shares (Details) - shares 3 Months Ended Dec. 31, 2024 Dec. 31, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total anti-dilutive weighted average sharesÂ 5,161,565 805,931 Common Stock Warrants August 2021 [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total anti-dilutive weighted average sharesÂ 14,031 14,031 Underwriter Warrants August 2021 [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total anti-dilutive weighted average sharesÂ 284 284 Chanticleer Warrants [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total anti-dilutive weighted average sharesÂ 6 6 Series C Warrants [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total anti-dilutive weighted average sharesÂ 2,297 2,297 Series 3 Warrants [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total anti-dilutive weighted average sharesÂ 1,566 1,566 Unvested Restricted Stock Units and Awards [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total anti-dilutive weighted average sharesÂ 17,152 976 Common Stock Warrants February 2023 [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total anti-dilutive weighted average sharesÂ 31,563 33,982 Underwriter Warrants February 2023 [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total anti-dilutive weighted average sharesÂ 1,933 1,933 Common Stock Private Placement Warrants June 2023 [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total anti-dilutive weighted average sharesÂ 28,409 28,409 Placement Agent Warrants June 2023 [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total anti-dilutive weighted average sharesÂ 852 852 Common Stock Warrants October 2023 [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total anti-dilutive weighted average sharesÂ 354,994 710,931 Underwriter Warrants October 2023 [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total anti-dilutive weighted average sharesÂ 10,664 10,664 Placement Agent Warrants June 2024 [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total anti-dilutive weighted average sharesÂ 14,142 Common Stock Warrants June 2024 [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total anti-dilutive weighted average sharesÂ 703,125 Common Stock Warrants November 2024 [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total anti-dilutive weighted average sharesÂ 2,222,222 Common Stock Registered Direct Warrants December 2024 [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total anti-dilutive weighted average sharesÂ 1,085,325 Common Stock PIPE Warrants December 2024 [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total anti-dilutive weighted average sharesÂ 673,000 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SONN_CommonStockWarrantsAugustTwoThousandTwentyOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SONN_UnderwriterWarrantsAugustTwoThousandTwentyOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SONN_ChanticleerWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SONN_SeriesCWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SONN_SeriesThreeWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SONN_UnvestedRestrictedStockUnitsAndAwardsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SONN_CommonStockWarrantsFebruaryTwoThousandTwentyThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SONN_UnderwriterWarrantsFebruaryTwoThousandTwentyThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SONN_CommonStockPrivatePlacementWarrantsJuneTwoThousandTwentyThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SONN_PlacementAgentWarrantsJuneTwoThousandTwentyThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SONN_CommonStockWarrantsOctoberTwoThousandTwentyThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SONN_UnderwriterWarrantsOctoberTwoThousandTwentyThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SONN_PlacementAgentWarrantsJuneTwoThousandTwentyFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SONN_CommonStockWarrantsJuneTwoThousandTwentyFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SONN_CommonStockWarrantsNovemberTwoThousandTwentyFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SONN_CommonStockRegisteredDirectWarrantsDecemberTwoThousandTwentyFourMem Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SONN_CommonStockPIPEWarrantsDecemberTwoThousandTwentyFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 36 R24.htm IDEA: XBRL DOCUMENT v3.25.0.1 Summary of Significant Accounting Policies (Details Narrative) - USD ($) 3 Months Ended 12 Months Ended Nov. 30, 2024 Sep. 25, 2024 Dec. 31, 2024 Dec. 31, 2023 Sep. 30, 2024 Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â [custom:IncentiveTaxReceivableCurrent-0] Â Â $ 166,792 Â Â $ 762,078 Cash refund (payment) related to tax incentive program Â Â $ 200,000 $ 200,000 Â Â Proceeds from income tax refunds Â Â Â Â $ 800,000 Â Reverse stock split description Â 1-for-8 reverse stock split Â Â Â Â Warrant, shares Â Â 5,789,600 Â Â Â Prefunded October 2023 Warrants [Member] Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Warrants to purchase common stock Â Â 99,687 192,187 192,187 Â Exercise price Â Â $ 0.0008 $ 0.0008 $ 0.0008 Â Warrant, shares Â Â 155,125 Â Â Â Prefunded December 2024 Warrants [Member] Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Warrants to purchase common stock Â Â 545,500 Â Â Â Exercise price Â Â $ 0.0001 Â Â Â Research and Development Tax Incentive Program [Member] Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Refund Received Related to Revenue from Different Year, Year Revenue Recognized Â Â The cash refund is available to eligible companies with annual aggregate revenues of less than $20.0 million (Australian) during the reimbursable period. Â Â Â [custom:IncentiveTaxReceivableCurrent-0] Â Â $ 200,000 Â Â Â Proceeds from income tax refunds $ 700,000 Â Â Â Â Â Â X - DefinitionCash refund (payment) related to tax incentive program. + ReferencesNo definition available. + Details Name: SONN_CashRefundPaymentRelatedToTaxIncentiveProgram Namespace Prefix: SONN_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncentive tax receivable current. + ReferencesNo definition available. + Details Name: SONN_IncentiveTaxReceivableCurrent Namespace Prefix: SONN_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of income tax refund received from tax jurisdiction. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_ProceedsFromIncomeTaxRefunds Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDiscloses year revenue was initially recognized related to refunds that are recognized in a period other than the period in which the related revenue was recognized and that have a material effect on net income. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 980 -SubTopic 605 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478868/980-605-50-1 + Details Name: us-gaap_RefundReceivedRelatedToRevenueFromDifferentYearYearRevenueRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityReverseStockSplit Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementEquityComponentsAxis=SONN_PrefundedOctoberTwoThousandTwentyThreeWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=SONN_PrefundedDecemberTwoThousandTwentyFourWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details

Name: us-gaap_TypeOfArrangementAxis=SONN_ResearchAndDevelopmentTaxIncentiveProgramMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 37 R25.htm IDEA: XBRL DOCUMENT v3.25.0.1 Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) Dec. 31, 2024 Sep. 30, 2024 Payables and Accruals [Abstract] Â Â Compensation and benefits $ 155,514 $ 149,802 Research and development 969,684 617,545 Professional fees 267,587 173,319 Other 1,735 1,823 Â Accrued expenses and other current liabilities $ 1,394,520 $ 942,489 X - DefinitionAccrued compensation and benefits, current. + ReferencesNo definition available. + Details Name: SONN_AccruedCompensationAndBenefitsCurrent Namespace Prefix: SONN_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccrued research and development current. + ReferencesNo definition available. + Details Name: SONN_AccruedResearchAndDevelopmentCurrent Namespace Prefix: SONN_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 38 R26.htm IDEA: XBRL DOCUMENT v3.25.0.1 Commitments and Contingencies (Details Narrative) â„¹ in Millions 1 Months Ended 3 Months Ended Aug. 31, 2024 Apr. 30, 2022 USD ($) Dec. 31, 2021 USD ($) Dec. 31, 2024 USD ($) Dec. 31, 2023 USD ($) Dec. 31, 2024 EUR (â‚¬) Apr. 30, 2023 USD ($) Jan. 31, 2019 USD ($) Jul. 31, 2012 USD ($) Discovery Collaboration Agreements [Member] Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â License fees Â Â Â $ 100,000 $ 0 Â Â Â Â Â Discovery Collaboration Agreements [Member] | XOMA [Member] Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Milestone payments Â Â Â Â Â Â Â Â Â $ 3,800,000 Discovery Collaboration Agreements [Member] | XOMA [Member] | In Process Research and Development [Member] Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â License fees Â $ 500,000 Â 0 0 Â Â Â Â Â Cellca Agreement [Member] Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Milestone payments Â Â Â $ 600,000 Â Â Â Â Â Description of milestone payments Â Â Â The Company is obligated to make milestone payments to Cellca totaling up to $0.7 million upon the achievement of certain development and approval milestones if the Buy-Out Option is not exercised. Â Â Â Â Â Cellca Agreement [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Milestone payments Â Â Â Â Â Â Â $ 700,000 Â Payment for annual license fee obligation Â Â Â $ 600,000 Â Â Â Â Â Cellca Agreement [Member] | Minimum [Member] Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Payment for annual license fee obligation Â Â Â 100,000 Â Â Â Â Â Cellca Agreement [Member] | In Process Research and Development [Member] Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â License fees Â Â Â 0 0 Â Â Â Â Â Commercial product license fee payment obligation Â $ 100,000 Â Â Â Â Â Â Â The Brink Agreement [Member] Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â License fees Â Â Â 12,000,000,000 12,000,000,000 Â Â Â Â Commercial product license fee payment obligation Â Â Â 100,000 Â Â Â Â Â [custom:PaymentOfAnnualLicenseFeeObligation-0] Â Â Â Â Â Â Â $ 12,000 Â Â The Brink Agreement [Member] | In Process Research and Development [Member] Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â [custom:DevelopmentLicenseFeePaymentObligation-0] Â Â Â 100,000 Â Â Â Â Â Â InvivoGen Agreement [Member] Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â License fees Â Â Â 0 $ 0 Â Â Â Â Â Payment for annual license fee obligation Â Â Â $ 100,000 Â â„¬ 0.1 Â Â Â SOC Agreement [Member] Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Agreements description Company establishes a partnership with a third party prior to the initiation of the initial efficacy combination trial under this collaboration, the Company will incur, payable to the SOC, a one-time fee equal to the greater of 5% or $1.5 million from the first upfront payment received from such third party partnership Â Â Â Â Â Â Â Â Navigo Agreement [Member] | Navigo Proteins GmbH [Member] | Technology Service [Member] Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Milestone payments Â Â $ 1,000,000.0 Â Â Â Â Â Payments to Acquire in Process Research and Development Â Â 100,000 Â Â Â Â Â Â Evaluation milestone recognized Â Â $ 300,000 Â Â Â Â Â Â X - DefinitionAgreements description. + ReferencesNo definition available. + Details Name: SONN_AgreementsDescription Namespace Prefix: SONN_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCommerical product license fee payment obligation. + ReferencesNo definition available. + Details Name: SONN_CommericalProductLicenseFeePaymentObligation Namespace Prefix: SONN_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDevelopment license fee payment obligation. + ReferencesNo definition available. + Details Name: SONN_DevelopmentLicenseFeePaymentObligation Namespace Prefix: SONN_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionEvaluation milestone recognized. + ReferencesNo definition available. + Details Name: SONN_EvaluationMilestoneRecognized Namespace Prefix: SONN_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLicense fees. + ReferencesNo definition available. + Details Name: SONN_LicenseFees Namespace Prefix: SONN_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionMilestone payments. + ReferencesNo definition available. + Details Name: SONN_MilestonePayments Namespace Prefix: SONN_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDescription of milestone payments. + ReferencesNo definition available. + Details Name: SONN_MilestonePaymentsDescription Namespace Prefix: SONN_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAnnual license fee payment. + ReferencesNo definition available. + Details Name: SONN_PaymentForAnnualLicenseFeeObligation Namespace Prefix: SONN_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPayment of annual license fee. + ReferencesNo definition available. + Details Name: SONN_PaymentOfAnnualLicenseFeeObligation Namespace Prefix: SONN_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingenciesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=SONN_DiscoveryCollaborationAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=SONN_XOMAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=SONN_CellcaAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=SONN_TheBrinkAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=SONN_InvivoGenAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=SONN_SOCAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=SONN_NavigoAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=SONN_NavigoProteinsGmbHMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_TechnologyServiceMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R27.htm IDEA: XBRL DOCUMENT v3.25.0.1 Collaboration Revenue (Details Narrative) - USD ($) 3 Months Ended Oct. 08, 2024 Dec. 31, 2024 Dec. 31, 2023 Sep. 30, 2024 Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Performance obligation Â $ 1,000,000.0 Â Â Collaboration revenue Â 1,000,000 $ 18,626 Â Unbilled collaboration revenue Â 500,000 Â License Agreement [Member] Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Proceeds for negotiate license agreement Â 1,000,000.0 Â Â Alkem Agreement [Member] Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Proceeds for negotiate license agreement Â 1,000,000.0 Â Â Collavorative arrangement right and obligation Company granted Alkem an exclusive license (with the right to sublicense) to research, develop, manufacture, import, export, market, use and commercialize pharmaceutical products containing its IL-6 (SON-080) asset (or any derivatives, fragments or conjugates thereof) (the â€œCompoundsâ€) (such products, the â€œProductsâ€) for the treatment of DPN (the â€œDPN Fieldâ€) and to manufacture, import, export, market, use and commercialize Products for the treatment of CIPN and autonomic neuropathy (together with the DPN Field, the â€œFieldsâ€) in India. Except as provided for in the Alkem Agreement, the Company agreed not to develop, use, sell, offer or otherwise commercialize any Compounds or Products for use in the DPN Field in India during the term of the Alkem Agreement. The Company retains all rights to manufacture Compounds and Products anywhere in the world Â Â Â [custom:MilestonePayments-0] Â $ 1,000,000.0 Â Â X - DefinitionMilestone payments. + ReferencesNo definition available. + Details Name: SONN_MilestonePayments Namespace Prefix: SONN_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPerformance obligation. + ReferencesNo definition available. + Details Name: SONN_Performanceobligation Namespace Prefix: SONN_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds for negotiate license agreement. + ReferencesNo definition available. + Details Name: SONN_ProceedsforNegotiateLicenseAgreement Namespace Prefix: SONN_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDescription of rights and obligations under the collaborative arrangements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementRightsAndObligations Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_UnbilledReceivablesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_TypeOfArrangementAxis=SONN_LicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=SONN_AlkemAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R28.htm IDEA: XBRL DOCUMENT v3.25.0.1 Schedule of Warrants Outstanding (Details) Dec. 31, 2024 $ / shares shares Class of Warrant or Right [Line Items] Â Number of Warrants, Outstanding | shares 5,789,600 Common Stock Warrants August

2021 [Member] Â Class of Warrant or Right [Line Items] Â Number of Warrants, Outstanding | shares 14,031 Exercise Price | $ / shares $ 2,094.4000 Expiration Date Aug. 24, 2026 Underwriter Warrants August 2021 [Member] Â Class of Warrant or Right [Line Items] Â Number of Warrants, Outstanding | shares 284 Exercise Price | $ / shares $ 2,618.0000 Expiration Date Aug. 19, 2026 Chanticleer Warrants [Member] Â Class of Warrant or Right [Line Items] Â Number of Warrants, Outstanding | shares 6 Chanticleer Warrants [Member] | Minimum [Member] Â Class of Warrant or Right [Line Items] Â Exercise Price | $ / shares $ 144,144.0000 Expiration Date Apr. 30, 2027 Chanticleer Warrants [Member] | Maximum [Member] Â Class of Warrant or Right [Line Items] Â Exercise Price | $ / shares $ 224,224.0000 Expiration Date Dec. 17, 2028 Series C Warrants [Member] Â Class of Warrant or Right [Line Items] Â Number of Warrants, Outstanding | shares 2,297 Exercise Price | $ / shares $ 7,860.1600 Expiration Date Oct. 16, 2025 Series 3 Warrants [Member] Â Class of Warrant or Right [Line Items] Â Number of Warrants, Outstanding | shares 1,566 Exercise Price | $ / shares $ 717.0240 Expiration Date Aug. 15, 2027 Common Stock Warrants February 2023 [Member] Â Class of Warrant or Right [Line Items] Â Number of Warrants, Outstanding | shares 31,563 Exercise Price | $ / shares $ 190.0800 Expiration Date Feb. 10, 2028 Underwriter Warrant February 2023 [Member] Â Class of Warrant or Right [Line Items] Â Number of Warrants, Outstanding | shares 1,933 Exercise Price | $ / shares $ 237.6000 Expiration Date Feb. 08, 2028 Common Stock Private Placement Warrants June 2023 [Member] Â Class of Warrant or Right [Line Items] Â Number of Warrants, Outstanding | shares 28,409 Exercise Price | $ / shares $ 12.4000 Expiration Date Jun. 21, 2029 Placement Agent Warrants June 2023 [Member] Â Class of Warrant or Right [Line Items] Â Number of Warrants, Outstanding | shares 852 Exercise Price | $ / shares $ 118.7824 Expiration Date Dec. 30, 2026 Common Stock Warrants October 2023 [Member] Â Class of Warrant or Right [Line Items] Â Number of Warrants, Outstanding | shares 354,994 Exercise Price | $ / shares $ 9.6000 Expiration Date Oct. 27, 2028 Prefunded Warrants October 2023 [Member] Â Class of Warrant or Right [Line Items] Â Number of Warrants, Outstanding | shares 99,687 Exercise Price | $ / shares $ 0.0008 Underwriter Warrants October 2023 [Member] Â Class of Warrant or Right [Line Items] Â Number of Warrants, Outstanding | shares 10,664 Exercise Price | $ / shares $ 16.0000 Expiration Date Oct. 24, 2028 Placement Agent Warrants June 2024 [Member] Â Class of Warrant or Right [Line Items] Â Number of Warrants, Outstanding | shares 14,142 Exercise Price | $ / shares $ 14.8800 Expiration Date Jun. 19, 2029 Common Stock Warrants June 2024 [Member] Â Class of Warrant or Right [Line Items] Â Number of Warrants, Outstanding | shares 703,125 Exercise Price | $ / shares $ 12.4000 Expiration Date Jun. 21, 2029 Common Stock Warrants November 2024 [Member] Â Class of Warrant or Right [Line Items] Â Number of Warrants, Outstanding | shares 2,222,222 Exercise Price | $ / shares $ 4.5000 Expiration Date Nov. 07, 2029 Common Stock Registered Direct Warrants December 2024 [Member] Â Class of Warrant or Right [Line Items] Â Number of Warrants, Outstanding | shares 1,085,325 Exercise Price | $ / shares $ 2.1000 Expiration Date Dec. 09, 2029 Common Stock PIPE Warrants December 2024 [Member] Â Class of Warrant or Right [Line Items] Â Number of Warrants, Outstanding | shares 673,000 Exercise Price | $ / shares $ 2.1000 Expiration Date Dec. 09, 2029 Pre-funded Warrants December 2024 [Member] Â Class of Warrant or Right [Line Items] Â Number of Warrants, Outstanding | shares 545,500 Exercise Price | $ / shares $ 0.0001 X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionExpiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=SONN_CommonStockWarrantsAugustTwoThousandTwentyOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=SONN_UnderwriterWarrantsAugustTwoThousandTwentyOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=SONN_ChanticleerWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=SONN_SeriesCWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=SONN_SeriesThreeWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=SONN_CommonStockWarrantsFebruaryTwoThousandTwentyThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=SONN_UnderwriterWarrantFebruaryTwoThousandTwentyThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=SONN_CommonStockPrivatePlacementWarrantsJuneTwoThousandTwentyThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=SONN_PlacementAgentWarrantsJuneTwoThousandTwentyThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=SONN_CommonStockWarrantsOctoberTwoThousandTwentyThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=SONN_PrefundedWarrantsOctoberTwoThousandTwentyThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=SONN_UnderwriterWarrantsOctoberTwoThousandTwentyThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=SONN_PlacementAgentWarrantsJuneTwoThousandTwentyFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=SONN_CommonStockWarrantsJuneTwoThousandTwentyFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=SONN_CommonStockWarrantsNovemberTwoThousandTwentyFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=SONN_CommonStockWarrantsRegisteredDirectWarrantsDecemberTwoThousandTwentyFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=SONN_CommonStockPIPEWarrantsDecemberTwoThousandTwentyFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=SONN_PreFundedWarrantsDecemberTwoThousandTwentyFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R29.htm IDEA: XBRL DOCUMENT v3.25.0.1 Stockholdersâ€™ Equity (Deficit) (Details Narrative) - USD ($) 3 Months Ended Dec. 10, 2024 Nov. 07, 2024 May 02, 2024 Oct. 26, 2023 Dec. 31, 2024 Dec. 31, 2023 Jun. 30, 2024 Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Proceeds from sale of common stock Â Â Â Â $ 7,711,161 $ 3,838,870 Â Issuance of share, value Â Â Â Â Â $ 7,622,619 3,916,943 Â Warrant, shares Â Â Â Â 5,789,600 Â Â Purchase and Registration Rights Agreement [Member] Â Â Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Common stock avialable to be sold Â Â Â Â Â $ 24,900,000 Â Â Underwriting Agreement [Member] | Chardan Capital Markets LLC [Member] Â Â Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Shares for sale Â 155,000 Â Â Â Â Â Â Â Proceeds from offering Â $ 4,200,000 Â Â Â Â Â Common Stock [Member] Â Â Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Issuance of share, value Â Â Â Â $ 105 $ 16 Â Net share settlement of warrants, shares Â Â Â Â 1,209 1,795 Â Sale of common stock, net of issuance costs, shares Â Â Â Â 1,050,500 163,281 Â Common Stock [Member] | Purchase and Registration Rights Agreement [Member] Â Â Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Shares for sale Â Â Â Â Â 0 Â Â Issuance of share, value Â Â Â $ 25,000,000.0 Â Â Â Â Volume weighted average price discount percentage Â Â 4.00% Â Â Â Â Prefunded Warrant [Member] | Underwriting Agreement [Member] | Chardan Capital Markets LLC [Member] Â Â Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Warrants to purchase common stock Â 956,111 Â Â Â Â Â Offering price per share Â $ 4.4999 Â Â Â Â Â Exercisable price Â $ 0.0001 Â Â Â Â Â Common Warrant [Member] | Underwriting Agreement [Member] | Chardan Capital Markets LLC [Member] Â Â Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Warrants to purchase common stock Â 2,222,222 Â Â Â Â Â Offering price per share Â $ 4.50 Â Â Â Â Â Exercisable price Â $ 4.50 Â Â Â Â Â Warrants term Â 5 years Â Â Â Â Â Common Stock Warrants [Member] Â Â Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Warrant, shares Â Â Â Â 32,375 Â 187,500 Net share settlement of warrants, shares Â Â Â Â 2,419 3,590 Â Sale of common stock, net of issuance costs, shares Â Â Â Â 1,209 1,795 Â Prefunded October 2023 Warrants [Member] Â Â Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Warrants to purchase common stock Â Â Â Â 99,687 192,187 Â Exercisable price Â Â Â Â $ 0.0008 $ 0.0008 Â Warrant, shares Â Â Â Â 155,125 Â Pre-funded Warrants [Member] Â Â Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Number of warrant exercised Â Â Â Â 1,273,436 Â Â Holder [Member] | Common Stock Warrants [Member] Â Â Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Forfeited warrants, shares Â Â Â Â Â 4,302 Â October Offering [Member] | Underwriters [Member] Â Â Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Proceeds from sale of common stock Â Â Â $ 3,900,000 Â Â Â Warrants to purchase common stock Â Â Â 10,664 Â Â Â Exercisable price Â Â Â $ 16.00 Â Â Â Warrants term Â Â Â 5 years Â Â Â October Offering [Member] | Underwriters [Member] | Common Stock [Member] Â Â Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Shares for sale Â Â Â 163,281 Â Â Â October Offering [Member] | Underwriters [Member] | Prefunded Warrant [Member] Â Â Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Warrants to purchase common stock Â Â Â 192,187 Â Â Â Offering price per share Â Â Â $ 12.7992 Â Â Â Exercisable price Â Â Â $ 0.0008 Â Â Â October Offering [Member] | Underwriters [Member] | Common Warrant [Member] Â Â Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Warrants to purchase common stock Â Â Â 710,931 Â Â Â Offering price per share Â Â Â $ 12.80 Â Â Â Exercisable price Â Â Â $ 12.80 Â Â Â Warrants term Â Â Â 5 years Â Â Â October Offering [Member] | Underwriters [Member] | June 2024 Inducement Offer [Member] Â Â Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Warrants exercise price decrease Â Â Â $ 9.60 Â Â Â Registered Direct Offering [Member] Â Â Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Offering price per share $ 2.23 Â Â Â Â Â Â Â Proceeds from offering $ 3,500,000 Â Â Â Â Â Â Â Registered Direct Offering [Member] | Prefunded Warrant [Member] Â Â Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Offering price per share $ 2.2299 Â Â Â Â Â Â Registered Direct Offering [Member] | Prefunded Warrant [Member] Â Â Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Shares for sale 768,000 Â Â Â Â Â Â Â Warrants to purchase common stock 317,325 Â Â Â Â Â Â Â Exercisable price $ 0.0001 Â Â Â Â Â Â Â Registered Direct Offering [Member] | Warrant [Member] Â Â Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Warrants to purchase common stock 1,085,325 Â Â Â Â Â Â Â Exercisable price $ 2.10 Â Â Â Â Â Â Warrants term 5 years Â Â Â Â Â Â Private Placement [Member] Â Â Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Offering price per share $ 2.23 Â Â Â Â Â Â Private Placement [Member] | Prefunded Warrant [Member] Â Â Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Shares for sale 127,500 Â Â Â Â Â Â Warrants to purchase common stock 545,500 Â Â Â Â Â Â Exercisable price $ 0.0001 Â Â Â Â Â Â Private Placement [Member] | Warrant [Member] Â Â Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Warrants to purchase common stock 673,000 Â Â Â Â Â Â Exercisable price $ 2.10 Â Â Â Â Â Â Warrants term 5 years Â Â Â Â Â Â X - DefinitionCommon stock avialable to be sold. + ReferencesNo definition available. + Details Name: SONN_CommonStockAvialableToBeSold Namespace Prefix: SONN_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionStock issued during period value net share settlement of warrants, shares. + ReferencesNo definition available. + Details Name: SONN_StockIssuedDuringPeriodSharesNetShareSettlementOfWarrants Namespace Prefix: SONN_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionVolume weighted average price discount percentage. + ReferencesNo definition available. + Details Name: SONN_VolumeWeightedAveragePriceDiscountPercentage Namespace Prefix: SONN_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of non-option equity instruments exercised by participants. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -

Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SubsidiarySaleOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer share decrease in exercise price of warrant. Excludes change due to standard antidilution provision. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_WarrantExercisePriceDecrease Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_TypeOfArrangementAxis=SONN_PurchaseAndRegistrationRightsAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=SONN_UnderwritingAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SONN_ChardanCapitalMarketsLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=SONN_PrefundedWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=SONN_CommonWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=SONN_CommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=SONN_PrefundedOctoberTwoThousandTwentyThreeWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=SONN_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=SONN_HolderMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=SONN_OctoberOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=SONN_UnderwritersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=SONN_JuneTwentyTwentyFourInducementOfferMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=SONN_RegisteredDirectOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=SONN_PrefundedWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R30.htm IDEA: XBRL DOCUMENT v3.25.0.1 Schedule of Share-based Compensation Expense (Details) - USD ($) 3 Months Ended Dec. 31, 2024 Dec. 31, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Share-based compensation $ 60,395 $ 50,005 Restricted Stock Units (RSUs) [Member] | Research and Development Expense [Member] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Share-based compensation 28,268 24,554 Restricted Stock Units (RSUs) [Member] | General and Administrative Expense [Member] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Share-based compensation $ 32,127 $ 25,451 X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R31.htm IDEA: XBRL DOCUMENT v3.25.0.1 Schedule of Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] Dec. 31, 2024 $ / shares shares Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Unvested balance | shares 9,175 Unvested weighted average grant fair value, balance | $ / shares $ 14.08 X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic

10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R32.htm IDEA: XBRL DOCUMENT v3.25.0.1 Schedule of Restricted Stock Awards Activity (Details) - Restricted Stock Awards (RSA) [Member] Dec. 31, 2024 $ / shares shares Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Unvested balance | shares 7,977 Unvested weighted average grant fair value, balance | $ / shares $ 14.08 X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=SONN_RestrictedStockAwardsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R33.htm IDEA: XBRL DOCUMENT v3.25.0.1 Share-Based Compensation (Details Narrative) - USD ($) Jan. 01, 2025 Jan. 01, 2024 Dec. 31, 2024 Restricted Stock Units (RSUs) [Member] Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Number of shares granted Â 9,175 Â Unrecognized compensation expense Â Â $ 0 Restricted Stock Awards (RSA) [Member] Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Number of shares granted Â 7,977 Â Unrecognized compensation expense Â Â $ 0 Subsequent Event [Member] Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Vesting percentage 100.00% Â Â 2020 Omnibus Equity Incentive Plan [Member] Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Number of shares available for issuance Â Â 5 2020 Omnibus Equity Incentive Plan [Member] | Subsequent Event [Member] Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Number of shares available for issuance 120,302 Â Â X - DefinitionAmount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -

Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X -DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X -DefinitionPercentage of vesting of award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=SONN_RestrictedStockAwardsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=SONN_TwoThousandTwentyOmnibusEquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R34.htm IDEA: XBRL DOCUMENT v3.25.0.1 Subsequent Events (Details Narrative) - USD ($) 3 Months Ended Feb. 12, 2025 Jan. 01, 2025 Dec. 31, 2024 Dec. 31, 2023 Subsequent Event [Line Items] Â Â Â Â Proceeds from issuance of common stock Â Â $ 7,711,161 $ 3,838,870 Domestic Tax Jurisdiction [Member] Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Net operating losses Â Â $ 800,000 Â Subsequent Event [Member] Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Base salary $ 330,000 Â Â Â Subsequent Event [Member] | Domestic Tax Jurisdiction [Member] Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Net operating losses Â $ 800,000 Â Â Purchase Agreement [Member] | Subsequent Event [Member] Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Sale of stock, number of shares issued in transaction Â 58,270 Â Â Proceeds from issuance of common stock Â $ 100,000 Â Â X -DefinitionAmount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3 + Details Name: us-gaap_OperatingLossCarryforwards Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X -DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X -DefinitionAmount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SalariesAndWages Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X -DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X -DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this concept, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=SONN_PurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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ŪQ9*JGY26SX3W8\T]P^([YZ< = .:P]U&@DG[CCS_JSYUD!>4;Q)Z@N"JF$,TW M2.@=D["#3Y/-YIK??$]K4(&NS!*/;/L-]S4TF1ID^P M! GC>[I.K:L0]"$$01B3#M*^6!@0)XSL0,,&:#@*]&^A:?J>(:]KPV^`,$XC#W7#C-J8$8OY (PK-3/50ZP;R4O@//T%.5,V]!&_9"&+NY&M"]% M')\,((T;I/$HTK\ )VR_ &E#'@024-XEV)[6<)-%5\;X+@/V/$\U^\@MH@1 MU\.A'3)V6K9R1D'?LBV##(#MM84+ SX1RIX(M:5S#!"W[L:RR?FGM>4Q*/44^^H$8"DOY%Q!"P<=A'V M!4D88L<=BF%+7]A]%5>GG)E<,V9G;#Q*U^+V/_*FOG3K?LB,?I\6.2B#*' M_JN@ST.E&/<9$4I<'$>XNS9]08(CV(H#'(Y;TL/CK]DV:Q.6#C- MA?:"='G=(AA[Q(L&N ^WY(?'V>^87X6050LBMDATRN+1AV>K!WVNBT*7=+G& M)N:1& _;RD1?P\GOA3M/N,!T\"&]KIH+8($.]"5#.!MN1&/DV.73S\; M.G>^Y5Z"1WECI47R=2?2#9/JW9N(X/!#U8Q!7W8!,SY/N'YOG_Q&.?V[1[]? M9.T\"B>#[CC!PUQ2=TO*Q&.*WCI7T-A@(!:)]C0MV37RI_#$_"*UH])4\5+O MA.3_LL ?R!<=>>/#]OZ#QL;=-!7AB:8>< M%PS'#*)/1J+GP(IQZ+J[V7> [4Q)YQPA6)-F&$%&-;F'HRM9 F\=>J96.:L?.JDEO2+8(!?Y M6E[%O)"S[+9<%.PH32:4?B2 MYRBA!8=2:<5IZ5Z SL,P#GIH+:(XQ+&/HP'Z)&T'0U[L8,JL3*NCK[HJ6-'V MNX]+F+TCZ*'B;KMEE<5A$#EQ-!3DMELAX]W*@7K4*VJ;U8U^$^(Y;N 'W8'# M(GCI14"=0YS4]BOD-?W*"7=6F?[##H6]TRG[?&(1M,\GLY-S5'.(_0>5#SQ7 MT*UL0=.Y"B$F\G N?+C1HJB.5M="':Y%5ESM&P1$C .^W FBVOC&GM&PO=V]R:W-H965T&ULK99=;]HP%(;_BI5-4RMUQ$D@0 >16]JJNYB$BKI=3+LPR8%8 M=>S,=J#;KY^=!!F4\%6-"Q([YWW]G,,QSF@MY)-* 31ZSAA78R?5.K]V716G MD!'5$3EP\V0A9$:T&I1*K(M,B)_WP(3Z['C.2\3#W29:COA1J.<+&$&^C&?2C-R&Y>$9L 5%1Q)6(R=&^]Z MXF$K*". ^45BKC7MD4YD+\60'7Y*Q@RT1,(BUM2#FLH(),&:=#,>OVM1!UK3" MS?L7]_LR>9/,G"B8"/:=)CH=.P,');@!=,/8OT9ZH1ZUB\63)7?:%W%AD,' MQ872(JO%AB"CO+J2Y[H0&P*ONT?@UP+_5$%0"X(RT8JL3.N.:!*-I%@C::.- MF[TI:U,J33:4VY]QIJ5Y2HU.1Q/!E6 T(1H2=$L8X3&@F;53Z.*1DR*AYLDE MNI@2"5RGH&E,V"7ZB-XC%ZG4S*J1JPV)]7/C>M7;:E5_SZIW$'=0X%TA'_O= M%OGDL'P&N9'C-KEK\F^*X#=%\$N_8)^?-NF;WM1(+-]Y:8(E# T%8J6O?;C M9JZT-!WWLRW5RKO;[FVWX;7*20QCQ^PS!7(%3O3AG1?B3VV)_R>SK3($31F" M0^[1U.P@D-(T@FF[^.D*Y42B%6$%M*5=>86EE_VS6$6X@S'V1NYJ,Z&C85NH MW0:U>QYJU8F(%#H5DOZ!I VY\NQML/1P^7G%?#QN"[K70/?>!$V5*MJ!>SL@ MKU$/16Q!A@UD^"9(BABB[3?D/8/DDY$EIG->4JO]D_K MU:-A6YR#AG-P!N=)C3K8J97GM[?]*9%;U,.&>G@^]?Y.'>YP!!CWN\'K$N_& MA3WL#[KML![^=XSA\W&/]&QM>1RZ);"5VMTXA^U+T%J^H!EKDY=$\%]H<].5M:M[%0-H \WPAA'X9V-.^>;N+_@)02P,$% @ MZ8%-6KE.CKU8! _\ !@ !X;"]W;W)K M+!FOB(1;OG)%PRG)M5-5NK[GQ6Y%BMJ93?2S.9]:614WG'(E-51'^[STM MV6[J8.?PX*E8K:5ZX,XF#5G19RI?FCF'.[>+DA<5K47!:L3IDED001]8^;G(Y7KJI [*Z9)L2OG$=K_2?4*1BI>Q4NC_:-?:QIZ# MLHV0K-H[T%5U.TO>=T7XL@!XI@=_+V#?^X07G (]@Z!3K0ETVD]DEF\YV MB"MKB*8N=&VT-V13U&H:GR6'MP7XR=D#]P4KBYQ(FJ-G"3\P1U(@MD1_-)03 M56N!KEYJLLD+L+E&-^CE^1%=?7\]<24J#!NMA_LOAW,OS!8@#ZQ6JX%^JG. M:7[J[P)X1^\?Z.]):\!'FHU0@#\@W_-# _#V]T#"T[0%3/0\8(+\3[6&:MH M7T;T]]U"2 Y+]1]3L=I@H3F8^GYO14,R.G7@ Q64;ZDS^^$["'L_FC)]IV G M>8==WJ$M.BRBLB0+UJX6^+BWM-Y04\9MF$2'41O,=H8]_3=QM(?)&.S2V(\[MJQ/*J*.,K+.S7_U"M%7V 4%%;8*(A&=K1.H< M=K8M;-F-6I6FI-M(T4G!T]A+XK.)&=K%8>B%OGEFDHXTL9+^0FN8FE*#DAQV MN4])-6I_-[$F0]9Q' 3A.>O0+HZ",(K,K&G'FEI9_V022-E@+9E(TP%!D(;C MT/?/2(=VV!\GX3@QHXX[U+$5]3(9L,,38"^(+ M*Q8?Z2;^=G$7% Y2%#6<;0M]L-'5+EH9D.35O"SVD4_@ P\DR#M?PB9+C.,T M\L87^/V>W[?RSWMFQK^-{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

M95S4L@-54'$Q0M4%W OA[.8-5<=@&(*E.](PD5[HB5WH5HB[44!]AUM M">B&KD.P&Y,1I+V[ECC6G1'QT :H9OH=1.>?Q^RO&'1=M@AOUQ2GU7X-J[@L6! M]@\TQD3+R
!KKTFCR/>&)P([D!^0G=G!1X:"B:?ZVXM$-=#FC7WWM/N^^F^6CTB0JHG!(.&"MPZ;P/(>ZB^0[3W%1\4W_*6^JXD5] MN68T94(9P/]7G%>O-VJ"[FO8_']02P,$% @ Z8%-6E7F>;%* @ H 4 M !@ !X;"]W;W)KJ@HDZE7*E5/?5_F)518GO$:F#[9<%%AI4VQ]64M !=65%$_#(*Q M7V'"O"RQ>TN1);Q1E#!8"B2;JL+B<0:4MZDW\O8;MV1;*K/A9TF-M["=5=RQI+F'/ZG12J3+T+#Q6PP0U5M[S] M!%T^YX:7)X"T2QEO3S,+6QJIU-H29?W&EA#XE6J>R)7Y$.XF6(.R+ M8#F@!9$YY;(1@$[1W6J!3EZ_37RE+5,2/^ _P<.7P!'Z(8S54KTD150/-7[M.L@^TG ?Z2P\"EQ ?H:BT3L4!F$\$,_\
[^71D7"BOG"1Y47_5+@?7_&:PL^A MLCEL/(PU33N5-07HY#.78R8#C:#2^._>]XXN2O_@L5<@ MMG8&2)3SABGWFOK=?LQ&PO=V]R:W-H965T&ULG95=;YLP M%
(;_BN5)NUK+1[ZF#)"2=M,BK5.4=MO%M L'#F#5V,PVI?WWLPUAV910*3?@ MC_.^?LY!/D2MD(^J!-#HN6)BO-S!M<,EH!5U1P)"&/\2I8KAR%>+23319C MWP(!@U1;!V)>3W #C%DC@_&
[]\3#D59X/#ZX?W*YFUSV1,&-8#]HILL8O\=J<8..\M'=;=V[A&;<)NA-\=3AJ M> OI-9H$[U#HA],1O\F0[L3Y32Y(%_W\8J+11D.E?IW*O:,>GK:VMV>I:I)" MC,WU4"'? *=OWP1S_\,(^'0 GXZY)[N&
0K_>PJ.(9&JTS4^O]2=[CCACEA M"D; 9@/8;-3GJ^!7%\"-F[X&-Q_@YA=5[0&DN4OD#-NXYVMLBX%M<7'AQOG& M?<_R>4==H@)9N%ZH4"H:KKN&,:P.
[7;5=9F_X5VOOB.RH%PA!KF1^M<+\SEE MU_^ZB1:UZSE[H4T'<\2_#) V@"SGPNA#Q-[P/ 32OX 4$L#!!0 (.F! M35KW7MU8R@D &$7 8 >&PO=V]R:W-H965T&ULO5AM M;]RX$?
ZN7'T\%0<76.^,'<<]OP"V>6:DTR?'KGRA5!!?]J+XLU$100W+=.K30E72 MXRM#.[DUE4RX*=;37WME,QX4U5.%[/9T;22VHS.3WGMSIV?VB:4V]@[)WQ3 M5=*M+U5IG\Y&\U&W\%&OBD
+T_/36J[4O0J?ZSN'7]/>2J8K9;RV1CB5GXTN MYK]<'M+S_,#O6CWYP;4@3Y;6/M"/F^QL-"- JE1I(L2_SVJ*U669 @POK0V M1_V1M'%XW5F_9M_ARU)Z=67+?
^@L%&>CXY'(5"Z;,GRT3V]5Z\KLI?:TO-? M\=0^.QN)M/!5NUF(*BTB?_+KVTZ9I-DZ&YQ^_*!>&=-*+SXU60JV]X_!ZJ*&>KEXT> ;E4[$P7PL%K/%
MX0OV#GK7#]C>P0^X/A97UGA;ZFP3B3NGO#)!=J&XUD::5,M2W&-1@9G!BW]= M+'UPX-:_=T4H CC<#8#J[1=?RU2=C6HZRSVJT?G/\V/9BSY)?O3$X7J"]66W?F^-42&YU/93H9RL51-TZL?
BQB#S>S__+=Q8 MS$[NG+:N?927YB=_%4_2"VU2ZVKKD)M,X+<4[R$*ORGGU5ITMQB*$1>UTZ4X M(B[-7TW$T"B>K>I2P4@B1:7<2CG49"A$W2Q+G9;K_4*5F;@JI &Z4N'V6UMF MVJR>
(QT\T@/MSXX\GDW$11Y@(A2J/6R\93K%)0I0-+AF9*5$L!W.9V'Z'HJM M2 D;C^H0PE5IUAVZ26=:4 12Y%VGH+L/D.@.%Y(N)^+NQ3X;R>RW>\K^-@ /7)SXIT9JV3I?>]S 6)Q >[\]G
M\]DX>IP#>DA>)*F&Y,\ILT#1V-#!^,NZ!*. YWB)PP4)9RV1%2KIQB/8G!^VC1 M>CE69+)/@*93:]&G3MMOQ(/Z!O7Z!G>68N^32F',Z2_(_SUX7.&A(AR9;;T& \S(CMPP*+K6%=8'66L"*C:D\1R-.
M$%8090DI94<8//1SB7O@@!%[_[1H%R52U$+?K0G/R?X>3/0)SOQL9)-I4@# . MI*X&PH[%G1H.PTE;"6#9ET8[2BA"ORKM$H]FZA'#2\T)2.#-W?M>^[@E:.0:,/YDWYO-MAZL ZLQ
MP4&6:Y0WN,59,(@"<8P)O/]Y+N<+F1+5J;9P#^":),+&D=L4O%!HEXDO M*!#28KB*B"\F%#9!4Y6XE[D*:QIH=+"\Z])*ER4]W/MWEQN)IS0KU=F."" HX
M,#@PUP[,24E$,NF>G7S(D8+^RXZ(J.7H+AQ/592;.VP1 'D-*;%/,)RP6L3F M-2 &84/L'C'/[JC[&#\4=?0P(V]S9RO>RF%B_#$6=OD?Q5,T EJ68LG=2$*<
MU]\4;Z#M"8'">@K6Z$RY+D7DNFQSLXA6QP+O%ED7$S 8Z!7AIDJLX9]1'#$> MW74 B@]&?$B#7<+L<1P$QQ%I6[Z*RHK="A;M^U9#"'>12^P>X/N=U$^J&IS M;S-
,$%OBS=LHTL@YZNE65ZPL>\]_2ZXW I%3)^MT,]):O0WE73<(U$'MXR# M*" M)^TY'$}##6%[-!UI[:<>@A.(5&/ 3%'03\"#! M-27A78N^2KJS$CU\""0R2\G D4'8@6P257TQGR5[-[?
SQ7[LLKQX.)_SXC$O MML*,?&XF)N'5ET:!6.0+.%Y%E>\./L"P)?9HN-F_N3UB*[<:2@;!7C/!NC06 M<9QK'.42=8\+XD%ITA,8I5*+&6ZPNUTG6< ;H">G2 M@H\9MHP432*:
(NFNT:D,EQS2P^E.2;6I/?G)5A#Z5-,V=A,4P$N0JHC^W8L0 M\I;\11Q._B9FD^.M_9BZ#'OI*8"*6K1N9ZE4UCK(DCH,NQ==ZCH,!, M+0.TRL0.@6:+8)9-[#'0+GC3.-\@H5U#O"I^O19W#
<(@OUMV?[S=U5#"E8?Q MUV60\ZL(4KR3[D$%"Y[>S6FAS4CF5,D=GA2I'V^!9MQ-OH,=-"=R@>I M6UI_#*&, 3P54,16HUYUH2$'2:L+;65 M\3V!2F$/'+.:
=A)FF@X:UKEG^.:RS0LU>@*>W0E4JBV'L6T#:'W+.>]8"V MRWFURU=<3>%>CH10(48P%=4[Y8 ?OSJ$O1\\"@OUA!:18T"3_] M4JO1O2BV];^A 1IM?YT\E]%"/JK8W3U53R^$A-
#&3P!=2V\!C*,$T6HO)N-A ML/K72&JSG0P-!379J@X.+?=*VER#G<-W$_U<2,%*F'7:/WAZ&;2I9J5@L8EO MK73L4V$WR<&#CGP>5N4D^<3YBX:B$L:QAXN+^#DHU-[1. O%!LG5]KU&@;>%
MM(#B<\V]%S2CV&>@IBW(Q1MH:HLZ8-G$PF")$+8XC&+263JH'0=.YVBD8&U M_$!]!JSDN/P_WM%V?1";#CY[M\K<3^KA+P@X1BU] "^ %& &RZ>3Q^?$:/66G(7ZER;)U-
7K\:Q;!U/X*M M^2/JTH9@*[XLE,1X2P_@?F[A7?N##NB_JI__%U!+ P04 " #I@4U:.IR# MK'H2 !D-0 &0 'AL+W=OO!'FWMIPJ69;D.U>5XR2[V9W#%2>[#UO[ )&0Q(0B-0!I6?/K]^MN "1E
MRHE^O*?G4+8VKUL"Q*]^I@4=>KY\?'+EV8I7;#:F5* M?#*K[%+7^-/.C]W*&IWQIF5Q/!F-SH^7.BV/7K_D9[?V]W%G\=1RI9OC2ERZM263-[M=7]?O[FE-
;S@G_G9NTZORO29%I57^F/#]FK@Q$)9 J3UD1!X\>]N3%%080@ MQB^>YD%D21N[OP?J[UEWZ#+5SMQ4Q7_RK%Z\.K@\4)F9Z::H/U;K?QBOSQG1 M2ZO"\?]J+6M/3PY4VKBZ6OK-
D&"9E_)3/W@[=#9_OI/#4-5,W>7S,I_EJ2YK=9VF M55/6>3E7MU611[EQ+X]K*-=QZFG_49H3_;0/E$_5F6]<.I=F9FLO_\8NY5.S:L#1(@S]MX^6?#), MOI^GTD/U1KO#=7<
ME,;BM@#@Y%.S(I(ZRINL; [BJP(2'_[M+Y>3R>@%[_K[]?4M_SU^\4R!:)2M M%2]]4^'!9O;^^>Q,(#-4'D;9:Y27)!()+72+YDI$' M"7WTAT\YBV:#(2*0I5DKT*1FM:DC;5$5&=?D-=D\>%ZD:
<+IJ[!&F>;]WR M8I- ,DAB&UX9&$^NQG.R!U'2#A5D139U4$;7*H>\:L07%4N#YX!X9&JS'}];$Q7+'H.E4$4 M%8,7H;1:+8K0IZEV"S5#F73L@,2O7EACDJ6D44-I=]E_'(RI%#[76?F-<7'
M"Y@!+IU5.+N:=M8H[F=I7<^:WYI)\ZD81RR^+DN %T,&PI>^JL@3"D;.A M%<' &Z.M-^P=Y0JQ[,A;UOMRC/*MXT^N1;B/9E796D%L0@IJ//#KZ5V0P@YFP MY$D^)3 (*48X42.HEP6,1-
%B3<;9!JHRGM8LF?!MF-P\%0"/3 MVF+6%"+H4$V'T#58.B3QY{<[0I2I&F8\T8>M%A:Q]5*U+4'/-%$&90S'C MANJZ*(2I3TY)$6;4:]+IU-1KJT4ILB!F'0=:T6KSU !27QV;* MYS@9]DK\?CD
FPMQ'&'H?J^%>IY!J9X,3IE(6]0$8IN9>[0-*]JD0+N6CL1\ MM[<<4%!(@$)0@#6W /'LUQ'!0%T8I$N=#DW(& MU\-C1$)*T?2 23W^MI8+1=B)A- A0&YY_G])@* MF;8U0+H-
$@X7:KKAD!ND>MRK\&9?!Z9K6PUMWH)#1S3D^#(7?A@T.&O.OP3 M\!VRUT6CF8E7V% M#F:ZZ9FEHSCGW*0K#X36]SHOM+=:M* $"F%9S:^9D4CB9*1LI-,"5 M'*FE^NMD-
!RA92L*1G^MDL]4UC 0$D7RY;2QCI@FXC]2#4)R;#VNC7EV8DB> M!,EKG\PYM0=KAR*(1UM6_FU"N!;1>!22E%8L5Z8,@%W<8,I6^XP?];+[FM8 M@$U8^#P(NT(==D2* 0-KF+$S;H&MA
KJ8"=8"Z8, MW/K&5$\:DQPQ.H0C[Z(3W&OBY#>:> UD\E+.>)M7]\:6+)C7)>EZ_EXM0C+^/AS%?4<45N3KND@X3Q;Z M4B'EWEJ"*[5@ ZJ6PC8\3OJ/>[E82Q+P(J.- PK#94\XQ4
M;0^GS0.>9ONXS."8EIH96U&N+(47*^?-3<6.G >-%#G_YQ4/QFI ":Z0V.UT M808>!7@;!!]%C6V6C?P>[<(-"Q71)2!$_FN$/:(F87ST-=A C]C(RXK.*;I2 M@&$#H0)@)I6-3#V'%4@C- F.,L0VF.Y!A
@,^E!UZ)%[\B:OD!6M7ID&I66\B#0$)J5[E-:+M5SF^; \G;@ 7VLYI M&9G.U2$EIL9D<#*R^2,.E(S[^? #SBG +9"FDC8%Y0J(>K"?=4$\]5S&HG2OBT9@$#+RS&B.@]
NBF%:*30*I3AQ:.;$B6BW$6W1]8%NG2. M9#,A[ELC')].C'U0DEL'RR11@ 7'7,N:ZGB'Y>.M.YC5BL8-B@R,2.:"V<&K M[6><\ #7?XT!E7Q?0'7!13R+3.R1(KE2U,83E<:>=+MM4 4B(H.+,)UB?EH66
MAB!0 ?A*%?*%)F]E92O)8""]:*6'/8)[$G0"#34D A9Y9-*L"$418/$'127$ M(IU!MUN]\<,">QAZ+;R) :J6<'N(!&?$(I S8+. M\1D65:6O HL<*@5O7CE,/O6PV[V&
02FRQ@oaCS]H%)/[DVYHE!,4)5]7E%N $^I#I-?79? MBD]E>84*,'Q*#A!GFTH2%1 [1_*),130!IZ!5XKFW/BB!(';C*&Z<2Q=CU8 M!%@P W9S/!RII@!E?GXC48ENJN?+G5.646Z@
P%I$'"$9]A3K4E 5YN5>\[. M"K/!/G%4W:)Q1 WDFE*XM/?P:] C6R[AL,W- M*"RX-=AMM&&O5L,"]K0]>JGVO>E 2-B 6IH. M>I4'<;*;[,HPP;.\F5F2M2GN8V_99@CZ;*H+5D%>$
M+CLR<\OWH]Y06SKN=WMTT2#"0CRM?I!"V<45M-I?7_UDUE@QZWP<;\,8&\7/ M>]W!;8VP_J'.ALGA%IW>5=C/:5WYCO3T"1FY9RZ^FF4K!/J2@'W.&+',&LN! M0[;5"HW(4J=L3?
0_OOX*A'/FL1SP=&:]6B&/; MPP@EKV&^;KFND@] M>)PCTNRAC%&!NZ=TX4)B:'M\'O/P9+!: M:TNW6)(JVL(1NG2L_&(H$="K)IGR ,O7,;E:]Z0D$81NJUN-A^H]_J^LVU)& MLAD7;
[GE(&MV!6T/=*O/G>3$:(6]?S,G3O#'0I28:IG3=I3;=# M<[:I'*^7+GE\H-I/;=IS#,CQ\9@V]A_L*YP=9282CGJ+_);/\8Q3LCT@)I]3 MGD5WI@Z1[DI@RK8\R B"\G4_ 'Q\- 2%+\#N_<<.
<;A>A'+Y9&A1R3-Q5W\0PINKG)=EN'J$ 2%0@S/U_88B\2/ WB M5T430LPU\I:!L$KY3O%/F"Q]X3&N ?+R%3+=J$\=+,1S'O8N&I*9\') G&J8 M!^_I/'H(R>/E[78AF\@,VH:+-NO.Y'K7 _OO\WJ M
;DJ!:=PWRY7D$D'5,R\XE$'G@<>DJ+4'=/\!V;Z;+5VRE0U;DN)FP?5OFW+5U'1G2M02?YD5^A%RF4.N]@@G9(E'XB> ;!2SN7=PW;EC\RS;4 MJUIS1$,3+.A R!.UYA:<
4ZR"N.JJZO!^>6%&@U'H]&E&I^=#<:3,W5V>C8X M&XWD\5B-KR:#<;OJ;5[0J25;!^SCU84:RD AIQ=:-H-V4-8:WAN630D[DH.% M?$AO8_'425*C=GT+14U@I<0;S=^QBP>O^>+:%S8?
P[FCN5/*C@A1I>_>>_YR MPY6)INJQ.P]V^N:W#S<7\S@$*GN3.,F.<,F:V)W/Y/TQ[1MBW2XW#SD#6I:3 MII:MY1+ "L[CBPU=I$T1WQ-DT\@K:C3HQ-$)=DD#CS"V7U'E(D9-LDZO//5,\-S=9V(^';
(.%=*^&[MGEPW?9E\Y*@[EDDN12DVDQ#)2;PKY<:4IN6FZ3F\03#V:1:1G2M02?YD5^A%RF4.N]@@G9(E'XB> ;!2SN7=PW;EC\RS;4 MJUIS1$,3+.A R!.UYA:<
#_#@97%U.=FO9WS >7)WX__L,5CS@1QHJT$*#"D"E0^&>#JL^[)Y># MT]&5_Y''Y^ZG]\ M6YI3<])]>_U-U'R_(3\D=)OQO]RZ 8R0F(R]B MJYLO03N3&_*P"=O#) M
%7NG%SJ3%V.SN@8U)*P6RI7'O'N#CU0B=]3GZH^E$G7"OXU 7J%F8L+V%S? M?>9/CD87 R0%F6)^C%W\X:=JA6P_N1P]>ZX^R%5ZG#G(,GE7RN]\VWF)%MO"].-W%MUVYS:]WY'OYG1(!?
P*5F-C]];2Z4R:T M9D%?F,'1R'*_Z)UO\$^O+9$^;(C37)XUTQK,=YD=,1Z;*WV<+@K@WH7)D%_ M0AW;]16*X\XW7Y;&SOG[?QO:75G+EV#BT_@5HFOYYDR[7+Y_]*.V<^K&"C/# MUM'PXNQ 6?
E.C_P!Z_#W:*9575=+_G5AT$9;6H#/9Q6T\W\0@_C%JM?_!U!+ M P04 " #I@4U:3,*\LH" ",!@ &0 'AL+W=O=76 %QBIKO?BQMI;8+ HD5U5; 7%PDDECK1,' MV]WN_GO&3AJ*U*VT$I=D;+]Y?
C.Q7^9'(1)4!:#)4\T;M7 KK=L;WU=Y!355 M(]%"@RNED#75.)1[7[42:&&3:NY'03#V:\H:=SFWP _VMW4H<^0-+P6IH%!,-D5 NW%5XLTX, MW@*^,SBJLYB82C(A'K$@<[%P R,
(..3:,%!V<(&.#=$*.-WS^D.6YK$_C$ M_M'6CK5D5,%&\!^LT-7"G;JD@)(>N+X7QT_0UY,:OEQP99_DV&&3B4OR@]*B M[I-10KO)<'J @'Y[P,RM0A#8%^:HKD&1SD!(:3;XPFC'-. ,U]S7N
M:3+]O.=?=_S1" PQN1.-KA3YT!10_)OOH]9!<'02O(ZN$MY"/B)QZ)$HB)(K M?/'0@-CRQ2_P;>DSS7A?N.T&Y8K\7&5*2SPRORZ5W#$FEQG--;I1+(] M42 ?P5V^>Q..@_=7]":#WN0:^W_X8%?
Y+ZN/1\[K]B4]W(%SN+#PO(?S,W@N M\)HKC?RB)(@BI>#H%ZS9WY =&E%QX.#@TNM4.'A8H,Y_J<#0W;0ZGXJZ*:< MC:@-
&34NX1B^#!HHF5;D+0G3U$O#Q$3)S)L&D7.//:$RKRRR@$>TM;8V^\[& M,V\\3<@XG'AIDCI;*4I0QKPH=TI K=$85Z83$DYB+PYG3J<[]"9QBL]I%#NO M[!JJ\N)9XJ51@/$LB;QD.B.7#IE_YA
UR+WU0=/V0Z,[LQAF!ZM==0[S%][Y M]!V5>]8HPJ'$U& T25TB.^_K!EJTUF\RH=&];%CA[P*D >!Z*80^#&ULO5IM;QLW$OZ^OX)P>T4*R+(LVVFN>0$Y);F2U5]_SPS)U4I>J5M7MZLO2^^?
GLS.5+54DW-HVJ\5)5GT\GDX5DE M=7WR[D_^VB?/3&M+W6M(EKAVJ]2=O-99YT1]+&_NLD_17;#EMFTJD;4_ZF"[]\ M>O+H1!1J+MO2?
S+K7U2TYXKDY:9T_+]8A[57TQ.1M\Z;*FZ&!I6NPUJ'Y%_W0 MV_!HUTO5)UKY9Z<>1Q!"_R*.YY$#<](.Y"O(. I1,OZT(5 MN_O/H%JGWS3IJWQZ5. +E8_%Q?E(3"?
3RR/R+CI[+UC>Q7]CKWBA75X:UUHE M_G4]<]X"-/\>\D(XY'+X$ JDGUTC<_7T!)'BE%VIDV<_?'?^L[.4X.^ZIMVHARZRQ)E>JP&,G7EE391X!*[P1]'B,TI(A&6K^ASU?2:M,Z4"[IF;(:)LEBI4A9-
9^34%/W'?7#=X^FYS\]=I!<0Z(NL*L0Y"CK:2G<*"Q(I=N*>;(MW# 6YTCA:I,+JQ2X3;?U-G? MVG*#D#J?[EX2/E86Q^D:%DD.!P-=-UA0EG)FPB'B.LD2#V@WJ3R=/#ZPAC\] M?_PC$IM?
BG]^>'Q"WTM.T;B0:7&4K(1U*K)DKH([>(G)K-X=39KC],KB H'4&[UA*U"2EQ;-XZUFZ M'#C0JWQ9F[L".<$1ZM*0Q@1=AR(8ZE%X!C%%\A)WP 6^H^PA+86:H6ZU["O
M<$\P0,],L2\8&/=*URZCAR0Q[.(UP&RE+%V]_D/1RJ+-"7&($-4BR=JQ^+P; M9F96ZD52KI)?"*0Q=#U*2*E05&J(DIL !ZQB_WKC<4B]R+X7%^-'8C*^$N\-
MP"*NVP4*$<'EZBA<$M2&X7']Z>5M6G((=? M/AL)86[>-#;N 6'!"0 M,VI M6=S%L!J0ZUB6^KW%6P2' MQ..";1,?6K.1I=^< MSA2R&4Q-* 5J<,.-U[2"];FRU$"QXCA>P0AE (7 A+NY!< 7)9S
MN75I?-IW*](%\AUD$LC:,F 83ENV2(CBS=O3A^0+)!K= 'O(1+5JH:OTRP3G ME70Y-EK2J(%)(2.-Q<=M/&?'$KJ#O2$Z<@&AT-T)6D#VE.BWT0OOH03H96M8@
MKTZ6(;=W#D#V+,1LTQ<[%I_2OHRR/@[@#$'1FC:>SC:G\65T;UM[NZ"\271 M0,097NN2I5,46SK[@?Z1((!:H>>: AO>,@5#CPJCG/L(R;FVB*CMS66D/OG7 MM4AW\9Q0#!]H" VG8 N5
U(WY$5>G9355#-6'} SON(#@"A"7=V7/!;71<%E M1"*4=CR?[7I>D@VX*8^2R!D,'UH@L&X5_N8*R*8(L*:E&TK8)^2I1D\ HO'' M%B-H@6#@V$XBYB -@NZ[;?"20- EJ%$6HX0J,C,H@H8$.^09
EG*86-& '0 M+F9S,6^A)KL<\:SA"$Y&$?RO/K_LLDXHW]*KM=%O?1"F0I0A -E]G8$J9-V> M;RQ?S#ID77:=J7OK.XL+E:-YD7'8 #GSL$:!ZB$JW"/3NYHH+9["@0+(SW$BA%\G?6 MW?
P!AZ4:_1Y=V5L]5WW&X!2>H]Z)*R1]H#6%2TY0%)PO*>\R,D@&BFNC4O9. M69D+HID_*7G6D[-;CP99C!?.5A3WB M%I0;EH0<>L^F78J%
[C67AZKG+=BUL1JT^A;JZ2J+RU^_> Y+A_[P[!C9BKL. ME[A>(=NC7HB'1OE6EO=96);PNN4W3+7,.7HL:KC S)@HJYX57.1& DT\)&JD M$8L, 2Z.OXG-<:^PII9@L YRRUY0A&T-)WJ=T;" =
$K4AR[_;P=%<_)]AS[M!#5-?4*'UP@--(A*5NDH':IW3M&&&AH3;MH=L;EW@1F2=F@#X#]4E)(V$U\! MM'R(+Z6YxPJM$]XO](IRAM-WH@J]-AH4^):9_;S\TO4BDWZ4.AY7RRIMS"H M3+F$@\?
9GS+(8=H8K4G$$1ZAIQ1M/W'$3<8/X[_S0"6S72IU)#3> SXO$[#^ M")]>@T-].104X4-$/!'ZW'&$=WT'?W@L%L+NPZ'P#:T'7E><2U+_D?62>"I< M7I1MRL/'HM0>$K=.
;^D<73;=ZTQZHHF_(PJUWS#WMP;AX[R<:7HT(L0AW>9X MU2#5U?DFPSY.F0PUOPD)EX5""910&T'3@_H^]>P(8R)@8_&BM8D)I'#Q"L*@*8>F_TE?'713H-Q:4&]:P(\>@$:#[*^5VN"NJ7^ON
MC7L&[K&WJY,XX*X_TPYE9D!2R+")(72T**/H1;K6-0@O5E,:Y)D)DMD&/14# M.=C;>D-1%IB(16%8,^AII>SX!-[4*[TRK]7!R5.W M(+N)ONWH4/?T6!78ROYV4B1ZO*<_<+*6 P!&5D\9.Y[/7YB]
<1S]O(Y:=F@ M6W?![P/6BP.X1[.F O+#O*E"CI^A4;KS(7!($[\V?<3SEE/&?>AHT?PVE"6L M]MB5..9>,T#"^P%=[4T/'[QV)Q9 K,$'9'B-O.IC^$FEX>AC<"1XD.=$RPWX#UT9HC=XP K!F!3B%"$5"
M1&';1;C5^)%K&Z;B+G4PC)VTGBO'SDT1!>$.%,CC# /[?i9:Z":X&D5QJ6T2F MB_I,PD(?&2W;=L(=JA.5H=0VH[3$'(G'[&T< /) "@7$'IZM1-PZ*I\+A M-!A#^C_ECIQ2I*(X3
L6Y,_P^;GZ"V78[\ '5R)5J:Z##<.>U$FGD.AZ:%J7 M<;.P8W //?^'MO53S#W9_M2Z'X39"^A-W_7M;VBD\65LALAS['E7A^^5XQV9]+WNY30
MD80>9:A8;;\2H5E1EGQ(.A[Q'G_AKHE%A$%F5/U0"> 79:2V&K=@.%C(-7K$R M>3!ES[*^5;,=%PW;.#Q53P,"D?0%'E$W_$@]]@>ZJUG'0V/UO${[NYIAK;|<.)\ M/.E,9&.8QH:V)M7I='-'T-
T=ZLB8^'.7(GTO?=\?D!K\04Z^(+*SE9#Q'#3J M4//18 /Q1C-XW85):7=5O78PT+DX"0H,KLO2Z7<3+)%ZW;%X60&;[*3^-\)] M;U-\[B1SU6T)Y%/2ERNHDWDKJ.B+F>3G$^MD<^23]
<2AAPQ2;N@4E^J.;9. MQC]=G81DEJYXT_"OFG!M:)#YY5(AUUE:@,_G!E4WOJ$#NI^Y/?L/4$L#!!0 M (.F!35J.HO@HW08 ' 1 9 >&PO=V]R:W-H965T>63I;&?74WDQ9>VT>YT5'O?/9].
M75Y3*JW$=*0Q4QK;2HJ'6TU=9TD685/;3.>SV=&TE4J/SD['V+4].S&J;Y2F M:RMV4T<)2 M>3HZWWJ'<O?25]9?!=_ JF^9J2/\ 87FX: M%_X7R[1V-
A)Y[[QITV8@:)6.G_)+BL/W;)BG#?. ..QX44+Z47IZ=6+,4EE?# M&G\)KH;= *B=_ / M%\Y;$.F/;1&* ZW V!Q/7>=S.ETU[%9]I9&9S_]L'!T> &$>X>#>X=/6?_ ^ M-#YI9CO(9Y-
LJWGQCI;9&U62.*\LA1")3TB_%;X.DV)S] XJ%8W*(7P2.TOEZ[#/LKR$-R@?BS2[RX\%P#2F"TG,3=N2 MY:RIKR2Z6D*V.?5>Y<@C'.ID],!A)7*MM-*5D,)UE*M2Y9DE6%APYKVH^Q:(
MKM[L'8W%S?MW>[/CF=AA(#_]<#R?SUZP'Z;717C8Y5ALI--HP9"OKQ^)Y2.L-P&$IYYI:BYAX)U M;V4C[YR2 \>V+L5H,D]&SJIB@T> M(,BR D4JJ(S]_%'L3V;BQFA-/KM0YF--5G8AB4Z|-
DT!=QR[@OKPSGAR&4CP M2?*8VVT;=,+-&;F*;H*K2. K9>)][\#:XUB= MD'FB@$7L[VZO/$LD3Q; (\-9B-+F]7C%]3$N -V7J$,J9U6!B!;JHB Q$^GZ
M3/CL'8NJR/Y!%9&6ZX10>&3BBYU$_%TAG4.#L -6M-]F^"]["4K)!L M1W!YA2-YD^RJT:95N=#46]-7]\!FZF(@Y$-F1X@;K@;1MRZB*%7)2<"RJ+. M(P<!@\|Y(YM|*#=A!8N)KP7[JT0HVOM IE=?
W84EGG | QK]@6V:P/ M%>+|YE(CYW$+K5:HMJQNRM'-4HM T.!$(=C97NL=$6AK02X57"!)2FQZ_0J-^FU+OMTZDH^+X+1'04|KN^ZYBX(-1$G M,%?BYD,
[+^8B1QL4BJ&W'+Z=9/$F[!ONL(S94O:|@^L9D< M#ZO0&\0VD\DJ3,:60I4)TDX(="LH*%=RRT'B+V59%7,#3 04%K47*<"'>'DPF]K<OE&J;O)ERDJWE M!$>&XR;?Y\%CH7CG@P;>-
$,GS"TN-UY*X$(;JFZ8CO%?U8+ C'55A!=S)(< MPXM@. "'F9?]X?#0 $K/),['ME6FZJA:,4E*%=WUN;*"A^$(\C X_)YS'M^C[MY?&WB+?25GP'-51BZVSR\[-15,[J*9LNO%,OC$&PO=V]R:W-H
M965T!O/ 2+1-5^(U)!4Q_ X>4HOMULXL&,R#97$Y\]?+#G6VD>JK7C-FX*FI MA3Z?K8UIWRX6NERSANJY;)G E:54#34X5*N%;A6CE2-JZ@4)@G314*YF%V=N M]DY=G,G.U%RP.P6Z:QJ[G]8+3?
GLW V3GSBJ[6Q$XN+LY:NV#TS7]H[A:/% MA%+QA@G-I0#%EN>SR_#M56SWNPT_<[;1. ^]@)7F0]JL=O* .9X%EB-6L-!:! MXM\CNV9U;8&0C=|'S-ETI"7Q:UK_PRJS/9_D,*K:D76T^ MR-; 9B'#=
<]/_T:=###D$>'"$@ P%Q?/<' M.2[?44,OSI3<@+*[$G"T,GF3W+\H!]:I')4=0(_@@A5EKN!$5]_;I%\CA MQ"89V;PB+P*^8^4-$1O$'7R|?M%'H&;|=DK&'B]# MV&AYJUM:LO,9AH-FZI'-
+E[]$*;!Z0L.QA.#\4OH?]LN+Z(>YCF=>W_F-/A8 M&OG E(#SFM8-%0)>T:8]Q2/G\%Z@]U"]91K%}$S&@A,>ZV2)6.5MH>?M#0O0($PCG^0AA 7QPSR#+ $\(L(QF>>!?69%08:1$L*/#,J-!3S-
(!@'@1! M#DB1IC$BX7!WS[T4>*9WO>7G-5.T99WAI8:?4//V?-$Q(1L(70:L* M^:UP'KGF#WD+1=4E)S6<&|P I,E]@>5W%B[5!K3;BD):_M"]KE M WT&TH?1ODF8O4=(+O!8NW#7J7*-
^0XN5XHY;&<-"I_8BMNH<5G597&]L^>U MI;4^1(+3 SN]::?:$YZ^\8'1$;H7U ,UN>;H<)[[5FS&D8PC=S*Z;NT*W@J-C]>L(-U-96'%@I\8#! M*N7(7[3]UP%$ALG5*XRQ6H-K^#QO@U^+(.P&2S
,@,;I;#$(B0X^L&<(K_L/P M&G=#=LB6_VAX^=]$SA0XWG[@Q',,B23QT?VA2%(_#$/T-$+<#U>3 ![Q413] M^TY,N)) 7AC@:4|QWGDA576,,=LW?O[V[V%#$2V8!|21/?PTTHSO.XT[:; MSAH-
HXF+1X8:0MZ6@_=P:,VD9(X+36MFA<[2W(D:A9D?D01"/\@3IT:FF"/O M05!<,@|[<;T|:**4H,Z5LK+:*/^)F:&LL"2YZG2[02=D3:LL]
M9]3$RXH(2>8G[@D3MQ.F53_7|"#;|L*LHMC]\F9=KBZ(EC"\;]9Y>B$Y?D_MI/[Z-YY<]U]N[' RB;%AZ'UB*6ML0:U028KXL:RUGS)<@)P4HU)1^F&@T; M=:|K =E8:7$JMW/'G7'5U]$?@-
E6_6&? MG'+O'OT5O?AZ*QV)%3>88BB\/< MVG?HAER9]>']:I'.?1-)WWGM'MX/|^1UJ(:.2$L5-$/, S48^#BQ='=+ E MSX+(#S&)'(/#8?
JI)#N,;>4[7#K'R8<_M$"/B1UGBN@IKCW>=K=>>S>78HV 3U_273&:Y M.Y3UB1^'V,WD)'|/E#6.TK\(@S>7R$*;/OJK$@@]I. _!NU^] =]-D228-YELSZEG8<&-FZ MKP8/TAC9N-R T*VEE)U3!#
M4[4.]48A*YU24X=)%!V'#>/"GTW6.G[\NI'UE"6&-A+ *CWRU>8%U:(*+F QM?ETJIO"<_*KA 09T%EK9L,U"0VA6YFPZ'_Z3D&:0A?)3"5!K>B!+ +0_V0 M6.VH)0 4SL7 2^Q&.
P#B")DO0%O.'.U:'#&_X'5Z_8/666@5P]M;HQG_E M2VT4I_#^!SA0IA:S^9%Y.9893 '.DP M>$$&/"[^X@9:P8T&)DI@6Z9*#9^$X)EEH)]$D2P$D0CS(8!2>C$<119*&] M![X*"ZDH-4$[9Y?.V6+?
6;RS8P2FM2PXL\YMN:F$/@0LN:EZSS@GXVT33(%5!75U)4EB1]:+RK"LE MWE)7WKCL/X)D'"'3'8SM(@RQ+O7!|/,1WF24:#+ JB*/GT3EK(V;8LL;^/N#_H+9![OJTS9^6_ % N|C9= M#F/SF!VP<-
EOJ:(C[W6]KZX;$Y |EQ0$H_>.ZMQX%] ;')IO&5?PA=4M>M?B MEL!(=,G(3$&G;PZ"YS*K3ZPCB--!-(-+5A%_SW(S-O30=*'[T+?YZ5Y3'$A MNUO:6T98!M"9!ZDH#=0*:08-('=9\CP2TOX[3^
<^4^&,^]*I,?OS'\RGEV) M,KJYX\]FGD_UZG#O^)\9&K-J>)K M7)%]-!AE/JCNV=!-C-RXJWHI#5W\:EC12PN5%:#]E93F86(-YNLW\4$L# M!!0 (.F!35J..Y"15@0 /8) 9 >&PO=V]R:W-H965T9L[,
<.A.-DI_=V4B!9^5D*:.51:6U\/B8K ML6*FKVJ4M%,H73%+4[T=F%HCR[U3)09IDKP?5(S+:#;Q:VL|FZC&"BYQK<$T M5<7TXP*%VDVC8;1?
^,RWI74+@]FD9EN\1_NU7FN:#3J4G%V_PC>/.'(S!,=DH]=U-/N:3*$)H<#,.@1&?P^X1"$<$*7OH\6,NI#. M\7"\1[_UW(G+AAE<*O$/SVTYC<81Y%BP1MC/:O<7MGPN'5ZFA/&_L NVZ1\1
M9(VQ[F|=*8.*R_#/?K8Z'#B,DU\XI*U#ZO,.@7R6*V:9;*+5#K2S)C0W\%2] M-R7'I2O*O=6TR|G/SNZ;C<$?#4H+'Q[HUTG&EF#=YB!K(18!(OT%Q CNE+2E M@0\RQ_S8?T#I=#FE^YP6Z5G
%69|& UC2)/TX@S>]_X\GBCW^4(_\XWQFHZ M$?^=HAO0+DZCN2ZY-C7+5Z<0[]}^IQ'F+< M[[UD_*7$WE)5-9./4#(#^.!$PRSFU(Z=+0;.0JL*;(ETW 63&4*X'G(RIV6M
MFFT)M(C1#74Q#$> ^3I>Q|_VS.*NY%GI5OK)FIR[0%O:U+SJ94H:)7CNHQ=< M4@C.!!A+"Y5/8(>:4!X8%VPC**:"#0(WIL&\#P?<;(/,"E8;U-UY"7FT5'L4 M*(?+
<9Q>)

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|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|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

M]@O8A)U&F+Z*]ISEGO.D]A$IK^"G]5*;9Y.6]F0=;0NOI],@$0S$,['$@8^R$ MSQQXBT@HF#=VTFUS8.G(2@2405X<'&N.G9IH!\&1=$0!U$!^;!S@C@&%VAY(M#=L# 3?0 #@>[0E*%RO=-HC/%'Z]L\&!H;.$)^;ETf'BD.N.1HM3^ M]>< !L1@+PD.&9$&%-YLC"T1XF9$$KZ*_/"!_?@83,SDRVIB^KL8>7YQJZH) M5M:$]&LP(H/(>]HQ-RIO0 EIO:/D9A)>RGTB&)Z5>H:U M0LQOM4EM\7MU&"?]8F//). &\U IZ.78V,"!2]C/I5,XN9- ^Q3B&.! 6 D+, "A'0!@E0\C1TS$ 3X04[FQX""S5]KE'CX MLHH"/ZB?'SU3=$?8Q"\^,MLH\(2&X@D-P1,*/*'A>$)[>**(PR44>$+/RA/: MY0DF8NK &FM2I0=%VB11+]P">'$'H$*3>X">;&C1S[/3@9H86=%" "NBH!2$Y%=)5]S"@"SN9+@,*S:Z,>`@1B+66X,?4*A\6 M95Z=QV&?A*) YJP4#1A(6C"@"8L'$U83GC]%*N! 6K9^Q9P[QFP.(.%GW?RU4WNQGNP8LCEP@Y^\]VM H1FRZ0%# M-G"$^RDP6 !0OT=*[" 3 !P1:@>8"($; ,@1X7: B>X., $01=90 D@BSKH' M:*?VH@2@4 ^D8M 7 0YR\"6Q H:Z3OVX"\]7) D@BQNP>/LPC?NFQJ08<$;$X M(D)P1 .'1#B.B"Y'1$Q0M:#;FYVM3<3GW472O* M$N%'2;]'?LV?:FLS93=S\<^QS!YK(L])$ M=FE"IPZW2F")/)DE PHV?:N5"C%L% DPD4? Y*-^2 M;H-BB^3HU>M&Z!+O6 MBP,MX^]P; 8"8F0U0(@,0B)&`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|$-'5:BF*2C$$G$VA _M@6HIJHE6VIW1:W,RL7? ^G!D&F\EMK=!07G06CO@Z[< PZ,%=H_H)I$-85JFM+L6)G^ M8>+N'^SEL$4;LMY0/4'6PM"H9V'HE7O$P;E"^P14DZBF4$U3FITKTSI,W*W# M$4=Q@R\L=@|Y>*^*MA.H)E!-HII"-4UI=DQ-BS$YU8VAJFBU@6HIJ@E4DZBF M4$U3FA7&J;E 2@S9PXQ&NIV#[$"Y+.4;S>NW$,.#1;]"523]*9035.:'493.P1'K86H-A:E%*II MZ8K#NB:/^G-'%H-H%K:;IL.V7Q8G(_&W<'AQO"]*533E&8'T+0)R;G:A 1M$U M.1360!:A+5 M%*II2K/#:-J$A+NC4[*_@*#GZDWW@-(CA98*]"913:&:IC0[5J942-REPNLZ[MV<%]OGNDP1]Z;"&:!.@+5)*HI5-.49J?3%%!+]]=@5)N7'Z*0\][J6H)E!- MTNPPFBXC<7<91_3YK=!Y9&^TU^>[5)<) [1^0#6):@K5-*79>3+U0W*'&S9MG\[S&PO=V]R:W-H965TLQ2POM&+,3ZRC1Y&$.&^25= Y%/E11E6,@I6YE\S0!',BE+83<>R6F:& M$V(${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|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|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end XML 48 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent) {a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { font: vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.0.1 html 160 183 1 false 78 0 false 6 false false R1.htm 00000001 - Document - Cover Sheet http://sonnetbio.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://sonnetbio.com/role/BalanceSheets Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://sonnetbio.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://sonnetbio.com/role/StatementsOfOperations Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit) (unaudited) Sheet http://sonnetbio.com/role/StatementsOfChangesInStockholdersEquityDeficit Consolidated Statements of Changes in Stockholders' Equity (Deficit) (unaudited) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://sonnetbio.com/role/StatementsOfCashFlows Consolidated

Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 7 false false R8.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 8 false false R9.htm 999012 - Disclosure - Organization and Description of Business Sheet http://sonnetbio.com/role/OrganizationAndDescriptionOfBusiness Organization and Description of Business Notes 9 false false R10.htm 999013 - Disclosure - Summary of Significant Accounting Policies Sheet http://sonnetbio.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 999014 - Disclosure - Accrued Expenses and Other Current Liabilities Sheet http://sonnetbio.com/role/AccruedExpensesAndOtherCurrentLiabilities Accrued Expenses and Other Current Liabilities Notes 11 false false R12.htm 999015 - Disclosure - Commitments and Contingencies Sheet http://sonnetbio.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 12 false false R13.htm 999016 - Disclosure - Collaboration Revenue Sheet http://sonnetbio.com/role/CollaborationRevenue Collaboration Revenue Notes 13 false false R14.htm 999017 - Disclosure - Stockholders??? Equity (Deficit) Sheet http://sonnetbio.com/role/StockholdersEquityDeficit Stockholders??? Equity (Deficit) Notes 14 false false R15.htm 999018 - Disclosure - Share-Based Compensation Sheet http://sonnetbio.com/role/Share-basedCompensation Share-Based Compensation Notes 15 false false R16.htm 999019 - Disclosure - Subsequent Events Sheet http://sonnetbio.com/role/SubsequentEvents Subsequent Events Notes 16 false false R17.htm 999020 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://sonnetbio.com/role/SummaryOfSignificantAccountingPolicies 17 false false R18.htm 999021 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://sonnetbio.com/role/SummaryOfSignificantAccountingPolicies 18 false false R19.htm 999022 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) Sheet http://sonnetbio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables Accrued Expenses and Other Current Liabilities (Tables) Tables http://sonnetbio.com/role/AccruedExpensesAndOtherCurrentLiabilities 19 false false R20.htm 999023 - Disclosure - Stockholders??? Equity (Deficit) (Tables) Sheet http://sonnetbio.com/role/StockholdersEquityDeficitTables Stockholders??? Equity (Deficit) (Tables) Tables http://sonnetbio.com/role/StockholdersEquityDeficit 20 false false R21.htm 999024 - Disclosure - Share-Based Compensation (Tables) Sheet http://sonnetbio.com/role/Share-basedCompensationTables Share-Based Compensation (Tables) Tables http://sonnetbio.com/role/Share-basedCompensation 21 false false R22.htm 999025 - Disclosure - Organization and Description of Business (Details Narrative) Sheet http://sonnetbio.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative Organization and Description of Business (Details Narrative) Details http://sonnetbio.com/role/OrganizationAndDescriptionOfBusiness 22 false false R23.htm 999026 - Disclosure - Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Shares (Details) Sheet http://sonnetbio.com/role/ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesDetails Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Shares (Details) Details 23 false false R24.htm 999027 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesTables 24 false false R25.htm 999028 - Disclosure - Schedule of Accrued Expenses and Other Current Liabilities (Details) Sheet http://sonnetbio.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails Schedule of Accrued Expenses and Other Current Liabilities (Details) Details 25 false false R26.htm 999029 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://sonnetbio.com/role/CommitmentsAndContingencies 26 false false R27.htm 999030 - Disclosure - Collaboration Revenue (Details Narrative) Sheet http://sonnetbio.com/role/CollaborationRevenueDetailsNarrative Collaboration Revenue (Details Narrative) Details http://sonnetbio.com/role/CollaborationRevenue 27 false false R28.htm 999031 - Disclosure - Schedule of Warrants Outstanding (Details) Sheet http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails Schedule of Warrants Outstanding (Details) Details 28 false false R29.htm 999032 - Disclosure - Stockholders??? Equity (Deficit) (Details Narrative) Sheet http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative Stockholders??? Equity (Deficit) (Details Narrative) Details http://sonnetbio.com/role/StockholdersEquityDeficitTables 29 false false R30.htm 999033 - Disclosure - Schedule of Share-based Compensation Expense (Details) Sheet http://sonnetbio.com/role/ScheduleOfShare-basedCompensationExpenseDetails Schedule of Share-based Compensation Expense (Details) Details 30 false false R31.htm 999034 - Disclosure - Schedule of Restricted Stock Units Activity (Details) Sheet http://sonnetbio.com/role/ScheduleOfRestrictedStockUnitsActivityDetails Schedule of Restricted Stock Units Activity (Details) Details 31 false false R32.htm 999035 - Disclosure - Schedule of Restricted Stock Awards Activity (Details) Sheet http://sonnetbio.com/role/ScheduleOfRestrictedStockAwardsActivityDetails Schedule of Restricted Stock Awards Activity (Details) Details 32 false false R33.htm 999036 - Disclosure - Share-Based Compensation (Details Narrative) Sheet http://sonnetbio.com/role/Share-basedCompensationDetailsNarrative Share-Based Compensation (Details Narrative) Details http://sonnetbio.com/role/Share-basedCompensationTables 33 false false R34.htm 999037 - Disclosure - Subsequent Events (Details Narrative) Sheet http://sonnetbio.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://sonnetbio.com/role/SubsequentEvents 34 false false All Reports Book All Reports form10-q.htm sonn-20241231.xsd sonn-20241231_cal.xml sonn-20241231_def.xml sonn-20241231_lab.xml sonn-20241231_pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 53 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-q.htm": { "nsprefix": "SONN", "nsuri": "http://sonnetbio.com/20241231", "dts": { "inline": { "local": ["form10-q.htm"] }, "schema": { "local": ["sonn-20241231.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["sonn-20241231_cal.xml"] }, "definitionLink": { "local": ["sonn-20241231_def.xml"] }, "labelLink": { "local": ["sonn-20241231_lab.xml"] }, "presentationLink": { "local": ["sonn-20241231_pre.xml"] } }, "keyStandard": 147, "keyCustom": 36, "axisStandard": 16, "axisCustom": 0, "memberStandard": 14, "memberCustom": 49, "hidden": { "total": 50, "http://sonnetbio.com/20241231": 24, "http://fasb.org/us-gaap/2024": 22, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 160, "entityCount": 1, "segmentCount": 78, "elementCount": 427, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 382, "http://xbrl.sec.gov/dei/2024": 31, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://sonnetbio.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "b", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "b", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R2": { "role": "http://sonnetbio.com/role/BalanceSheets", "longName": "00000002 - Statement - Consolidated Balance Sheets (Unaudited)", "shortName": "Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R3": { "role": "http://sonnetbio.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)", "shortName": "Consolidated Balance Sheets (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R4": { "role": "http://sonnetbio.com/role/StatementsOfOperations", "longName": "00000004 - Statement - Consolidated Statements of Operations (Unaudited)", "shortName": "Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R5": { "role": "http://sonnetbio.com/role/StatementsOfChangesInStockholdersEquityDeficit", "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit) (unaudited)", "shortName": "Consolidated Statements of Changes in Stockholders' Equity (Deficit) (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2023-09-30_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R6": { "role": "http://sonnetbio.com/role/StatementsOfCashFlows", "longName": "00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "span", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "span", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R9": { "role": "http://sonnetbio.com/role/OrganizationAndDescriptionOfBusiness", "longName": "999012 - Disclosure - Organization and Description of Business", "shortName": "Organization and Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R10": { "role": "http://sonnetbio.com/role/SummaryOfSignificantAccountingPolicies", "longName": "999013 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R11": { "role": "http://sonnetbio.com/role/AccruedExpensesAndOtherCurrentLiabilities", "longName": "999014 - Disclosure - Accrued Expenses and Other Current Liabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil":

"false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R12": { "role": "http://sonnetbio.com/role/CommitmentsAndContingencies", "longName": "999015 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R13": { "role": "http://sonnetbio.com/role/CollaborationRevenue", "longName": "999016 - Disclosure - Collaboration Revenue", "shortName": "Collaboration Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R14": { "role": "http://sonnetbio.com/role/StockholdersEquityDeficit", "longName": "999017 - Disclosure - Stockholders\u2019 Equity (Deficit)", "shortName": "Stockholders\u2019 Equity (Deficit)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R15": { "role": "http://sonnetbio.com/role/Share-basedCompensation", "longName": "999018 - Disclosure - Share-Based Compensation", "shortName": "Share-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R16": { "role": "http://sonnetbio.com/role/SubsequentEvents", "longName": "999019 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R17": { "role": "http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "999020 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "17", "firstAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R18": { "role": "http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesTables", "longName": "999021 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R19": { "role": "http://sonnetbio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables", "longName": "999022 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R20": { "role": "http://sonnetbio.com/role/StockholdersEquityDeficitTables", "longName": "999023 - Disclosure - Stockholders\u2019 Equity (Deficit) (Tables)", "shortName": "Stockholders\u2019 Equity (Deficit) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R21": { "role": "http://sonnetbio.com/role/Share-basedCompensationTables", "longName": "999024 - Disclosure - Share-Based Compensation (Tables)", "shortName": "Share-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R22": { "role": "http://sonnetbio.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative", "longName": "999025 - Disclosure - Organization and Description of Business (Details Narrative)", "shortName": "Organization and Description of Business (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": null }, "R23": { "role": "http://sonnetbio.com/role/ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesDetails", "longName": "999026 - Disclosure - Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Shares (Details)", "shortName": "Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Shares (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R24": { "role": "http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "999027 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "SONN:IncentiveTaxReceivableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "SONN:CashRefundPaymentRelatedToTaxIncentiveProgram", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "span", "span", "p", "SONN:IncentiveTaxReceivbaleTaxPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R25": { "role": "http://sonnetbio.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails", "longName": "999028 - Disclosure - Schedule of Accrued Expenses and Other Current Liabilities (Details)", "shortName": "Schedule of Accrued Expenses and Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "SONN:AccruedCompensationAndBenefitsCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "SONN:AccruedCompensationAndBenefitsCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R26": { "role": "http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative", "longName": "999029 - Disclosure - Commitments and Contingencies (Details Narrative)", "shortName": "Commitments and Contingencies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "From2024-10-012024-12-31_custom_DiscoveryCollaborationAgreementsMember", "name": "SONN:LicenseFees", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-10-012024-12-31_custom_DiscoveryCollaborationAgreementsMember", "name": "SONN:LicenseFees", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R27": { "role": "http://sonnetbio.com/role/CollaborationRevenueDetailsNarrative", "longName": "999030 - Disclosure - Collaboration Revenue (Details Narrative)", "shortName": "Collaboration Revenue (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "SONN:Performanceobligation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "SONN:Performanceobligation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R28": { "role": "http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails", "longName": "999031 - Disclosure - Schedule of Warrants Outstanding (Details)", "shortName": "Schedule of Warrants Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31_custom_CommonStockWarrantsAugustTwoThousandTwentyOneMember", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef":

```
"form10-q.htm", "unique": true } }, "R29": { "role": "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative", "longName": "999032 - Disclosure - Stockholders\u2019 Equity (Deficit) (Details Narrative)", "shortName": "Stockholders\u2019 Equity (Deficit) (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31_custom_PurchaseAndRegistrationRightsAgreementMember", "name": "SONN:CommonStockAvialableToBeSold", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R30": { "role": "http://sonnetbio.com/role/ScheduleOfShare-basedCompensationExpenseDetails", "longName": "999033 - Disclosure - Schedule of Share-based Compensation Expense (Details)", "shortName": "Schedule of Share-based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-10-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_ResearchAndDevelopmentExpenseMember", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R31": { "role": "http://sonnetbio.com/role/ScheduleOfRestrictedStockUnitsActivityDetails", "longName": "999034 - Disclosure - Schedule of Restricted Stock Units Activity (Details)", "shortName": "Schedule of Restricted Stock Units Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R32": { "role": "http://sonnetbio.com/role/ScheduleOfRestrictedStockAwardsActivityDetails", "longName": "999035 - Disclosure - Schedule of Restricted Stock Awards Activity (Details)", "shortName": "Schedule of Restricted Stock Awards Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "AsOf2024-12-31_custom_RestrictedStockAwardsMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "SONN:ScheduleOfNonvestedRestrictedStockAwardsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31_custom_RestrictedStockAwardsMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "SONN:ScheduleOfNonvestedRestrictedStockAwardsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R33": { "role": "http://sonnetbio.com/role/Share-basedCompensationDetailsNarrative", "longName": "999036 - Disclosure - Share-Based Compensation (Details Narrative)", "shortName": "Share-Based Compensation (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "From2024-01-012024-01-01_us-gaap_RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-01-01_us-gaap_RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R34": { "role": "http://sonnetbio.com/role/SubsequentEventsDetailsNarrative", "longName": "999037 - Disclosure - Subsequent Events (Details Narrative)", "shortName": "Subsequent Events (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "From2024-10-01to2024-12-31", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2025-02-122025-02-12_us-gaap_SubsequentEventMember", "name": "us-gaap:SalariesAndWages", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": [ "http://sonnetbio.com/role/AccruedExpensesAndOtherCurrentLiabilities" ], "lang": { "en-us": { "role": { "label": "Accrued Expenses and Other Current Liabilities", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": [ "r222" ] }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://sonnetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://sonnetbio.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://sonnetbio.com/role/BalanceSheets", "http://sonnetbio.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued expenses and other current liabilities", "totalLabel": "Accrued expenses and other current liabilities", "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://sonnetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sonnetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r26", "r420" ] }, "SONN_AccruedCompensationAndBenefitsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "AccruedCompensationAndBenefitsCurrent", "crdr": "credit", "calculation": { "http://sonnetbio.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sonnetbio.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Compensation and benefits", "documentation": "Accrued compensation and benefits, current." } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://sonnetbio.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://sonnetbio.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Professional fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r28" ] }, "SONN_AccruedResearchAndDevelopmentCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "AccruedResearchAndDevelopmentCurrent", "crdr": "credit", "calculation": { "http://sonnetbio.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sonnetbio.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Research and development", "documentation": "Accrued research and development current.", "label": "AccruedResearchAndDevelopmentCurrent" } } }, "auth_ref": [] }, "SONN_AcquiredInprocessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "AcquiredInprocessResearchAndDevelopment", "crdr": "debit", "calculation": { "http://sonnetbio.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://sonnetbio.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Acquired in-process research and development", "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition." } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r484" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://sonnetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://sonnetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r36", "r420", "r643" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://sonnetbio.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r330", "r533", "r534", "r535", "r536", "r596", "r644" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r490" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r490" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r490" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r490" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://sonnetbio.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Share-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r20", "r21", "r189" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://sonnetbio.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r455", "r466", "r476", "r501" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
```

```
"AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r458", "r469", "r479", "r504" ] }, "SONN_AgreementsDescription": { "xbrltype": "stringItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "AgreementsDescription", "presentation": [ "http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Agreements description", "documentation": "Agreements description." } } }, "auth_ref": [] }, "SONN_AlkemAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "AlkemAgreementMember", "presentation": [ "http://sonnetbio.com/role/CollaborationRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Alkem Agreement [Member]", "documentation": "Alkem Agreement [Member]" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r490" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r497" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r459", "r470", "r480", "r497", "r505", "r509", "r517" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r462" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://sonnetbio.com/role/ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesDetails" ], "lang": { "en-us": { "role": { "label": "Total anti-dilutive weighted average shares", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r119" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://sonnetbio.com/role/ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r13" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://sonnetbio.com/role/ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://sonnetbio.com/role/ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesDetails" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r13" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://sonnetbio.com/role/CollaborationRevenueDetailsNarrative", "http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative", "http://sonnetbio.com/role/SubsequentEventsDetailsNarrative", "http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r241" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://sonnetbio.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://sonnetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets [Default Label]", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r55", "r63", "r84", "r97", "r122", "r124", "r129", "r130", "r135", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r242", "r244", "r260", "r294", "r356", "r405", "r406", "r420", "r436", "r561", "r562", "r603" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://sonnetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://sonnetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sonnetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r81", "r85", "r97", "r135", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r242", "r244", "r260", "r420", "r561", "r562", "r603" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://sonnetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r462" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Exercise Price" } } }, "auth_ref": [ "r512" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r513" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "auth_ref": [ "r508" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r508" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method" } } }, "auth_ref": [ "r508" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r508" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r508" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined" } } }, "auth_ref": [ "r508" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://sonnetbio.com/role/ScheduleOfRestrictedStockAwardsActivityDetails", "http://sonnetbio.com/role/ScheduleOfRestrictedStockUnitsActivityDetails", "http://sonnetbio.com/role/ScheduleOfShare-basedCompensationExpenseDetails", "http://sonnetbio.com/role/Share-basedCompensationDetailsNarrative", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Securities" } } }, "auth_ref": [ "r511" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r510" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r509" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r509" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "calculation": { "http://sonnetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sonnetbio.com/role/BalanceSheets", "http://sonnetbio.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r65", "r297", "r331", "r351", "r420", "r436", "r525" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://sonnetbio.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, beginning of period", "periodEndLabel": "Cash, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r11", "r44", "r94" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://sonnetbio.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://sonnetbio.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase in cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r44" ] }, "SONN_CashRefundPaymentRelatedToTaxIncentiveProgram": { "xbrltype": "monetaryItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "CashRefundPaymentRelatedToTaxIncentiveProgram", "crdr": "credit", "presentation": [ "http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash refund (payment) related to tax incentive
```

program", "documentation": "Cash refund (payment) related to tax incentive program." } } }, "auth_ref": [] }, "SONN_CellcaAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "CellcaAgreementMember", "presentation": ["http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Cellca Agreement [Member]", "documentation": "Cellca Agreement [Member]" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r488"] }, "SONN_ChanticleerWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "ChanticleerWarrantsMember", "presentation": ["http://sonnetbio.com/role/ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesDetails", "http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Chanticleer Warrants [Member]", "documentation": "Chanticleer Warrants [Member]" } } }, "auth_ref": [] }, "SONN_ChardanCapitalMarketsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "ChardanCapitalMarketsLLCMember", "presentation": ["http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Chardan Capital Markets LLC [Member]", "documentation": "Chardan Capital Markets LLC [Member]" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails", "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r19"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails", "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails", "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative", "http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Exercise price", "verboseLabel": "Exercise Price", "terseLabel": "Exercisable price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r180"] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": ["http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative", "http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Warrants to purchase common stock", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r180"] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails", "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative", "http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Warrant, shares", "verboseLabel": "Number of Warrants, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": ["http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": ["r19"] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount" } } }, "auth_ref": ["r489"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name" } } }, "auth_ref": ["r489"] }, "us-gaap_CollaborativeArrangementAccountingPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementAccountingPolicy", "presentation": ["http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "verboseLabel": "Collaboration revenue", "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for collaborative arrangements." } } }, "auth_ref": ["r71"] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": ["http://sonnetbio.com/role/CollaborationRevenue"], "lang": { "en-us": { "role": { "label": "Collaboration Revenue", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": ["r67", "r69", "r78"] }, "us-gaap_CollaborativeArrangementRightsAndObligations": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementRightsAndObligations", "presentation": ["http://sonnetbio.com/role/CollaborationRevenueDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Collavorative arrangement right and obligation", "documentation": "Description of rights and obligations under the collaborative arrangements." } } }, "auth_ref": ["r22"] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": ["http://sonnetbio.com/role/CollaborationRevenueDetailsNarrative", "http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r241"] }, "SONN_CommericalProductLicenseFeePaymentObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "CommericalProductLicenseFeePaymentObligation", "crdr": "debit", "presentation": ["http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Commercial product license fee payment obligation", "documentation": "Commerical product license fee payment obligation." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://sonnetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://sonnetbio.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Commitments and contingencies (Note 4)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r32", "r56", "r296", "r342"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://sonnetbio.com/role/CommitmentsAndContingencies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r49", "r150", "r151", "r396", "r554", "r556"] }, "SONN_CommonStockAvialableToBeSold": { "xbrltype": "monetaryItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "CommonStockAvialableToBeSold", "crdr": "credit", "presentation": ["http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common stock avialable to be sold", "documentation": "Common stock avialable to be sold." } } }, "auth_ref": [] }, "SONN_CommonStockIssuanceCostsInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "CommonStockIssuanceCostsInAccountsPayable", "crdr": "credit", "presentation": ["http://sonnetbio.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Common stock issuance costs in accounts payable", "documentation": "Common stock issuance costs in accounts payable." } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://sonnetbio.com/role/StatementsOfChangesInStockholdersEquityDeficit", "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r426", "r427", "r428", "r430", "r431", "r432", "r433", "r533", "r534", "r536", "r596", "r642", "r644"] }, "SONN_CommonStockPIPEWarrantsDecemberTwoThousandTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "CommonStockPIPEWarrantsDecemberTwoThousandTwentyFourMember", "presentation": ["http://sonnetbio.com/role/ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesDetails", "http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Common Stock PIPE Warrants December 2024 [Member]", "documentation": "Common Stock PIPE Warrants December 2024 [Member]" } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://sonnetbio.com/role/BalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r35"] }, "SONN_CommonStockPrivatePlacementWarrantsJuneTwoThousandTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "CommonStockPrivatePlacementWarrantsJuneTwoThousandTwentyThreeMember", "presentation": ["http://sonnetbio.com/role/ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesDetails", "http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Common Stock Private Placement Warrants June 2023 [Member]", "documentation": "Common Stock Private Placement Warrants June 2023 [Member]" } } }, "auth_ref": [] }, "SONN_CommonStockRegisteredDirectWarrantsDecemberTwoThousandTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "CommonStockRegisteredDirectWarrantsDecemberTwoThousandTwentyFourMember", "presentation": ["http://sonnetbio.com/role/ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesDetails"], "lang": { "en-us": { "role": { "label": "Common Stock Registered Direct Warrants December 2024 [Member]", "documentation": "Common Stock Registered Direct Warrants December 2024 [Member]" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://sonnetbio.com/role/BalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r35", "r343"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://sonnetbio.com/role/BalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r35"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://sonnetbio.com/role/BalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r5", "r35", "r343", "r362", "r644", "r645"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://sonnetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://sonnetbio.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Common stock, $0.0001 par value: 125,000,000 shares

authorized; 3,007,431 and 650,284 issued and outstanding at December 31, 2024 and September 30, 2024, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r35", "r299", "r420"] }, "SONN_CommonStockWarrantsAugustTwoThousandTwentyOneMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "CommonStockWarrantsAugustTwoThousandTwentyOneMember", "presentation": ["http://sonnetbio.com/role/ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesDetails", "http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Common Stock Warrants August 2021 [Member]", "documentation": "Common Stock Warrants August 2021 [Member]" } } }, "auth_ref": [] }, "SONN_CommonStockWarrantsFebruaryTwoThousandTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "CommonStockWarrantsFebruaryTwoThousandTwentyThreeMember", "presentation": ["http://sonnetbio.com/role/ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesDetails", "http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Common Stock Warrants February 2023 [Member]", "documentation": "Common Stock Warrants February 2023 [Member]" } } }, "auth_ref": [] }, "SONN_CommonStockWarrantsJuneTwoThousandTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "CommonStockWarrantsJuneTwoThousandTwentyFourMember", "presentation": ["http://sonnetbio.com/role/ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesDetails", "http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Common Stock Warrants June 2024 [Member]", "documentation": "Common Stock Warrants June 2024 [Member]" } } }, "auth_ref": [] }, "SONN_CommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "CommonStockWarrantsMember", "presentation": ["http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common Stock Warrants [Member]", "documentation": "Common Stock Warrants [Member]" } } }, "auth_ref": [] }, "SONN_CommonStockWarrantsNovemberTwoThousandTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "CommonStockWarrantsNovemberTwoThousandTwentyFourMember", "presentation": ["http://sonnetbio.com/role/ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesDetails", "http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Common Stock Warrants November 2024 [Member]", "documentation": "Common Stock Warrants November 2024 [Member]" } } }, "auth_ref": [] }, "SONN_CommonStockWarrantsOctoberTwoThousandTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "CommonStockWarrantsOctoberTwoThousandTwentyThreeMember", "presentation": ["http://sonnetbio.com/role/ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesDetails", "http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Common Stock Warrants October 2023 [Member]", "documentation": "Common Stock Warrants October 2023 [Member]" } } }, "auth_ref": [] }, "SONN_CommonStockWarrantsRegisteredDirectWarrantsDecemberTwoThousandTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "CommonStockWarrantsRegisteredDirectWarrantsDecemberTwoThousandTwentyFourMember", "presentation": ["http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Common Stock Registered Direct Warrants December 2024 [Member]", "documentation": "Common Stock Registered Direct Warrants December 2024 [Member]", "label": "Common Stock Registered Direct Warrants December 2024 [Member] [Default Label]" } } }, "auth_ref": [] }, "SONN_CommonWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "CommonWarrantMember", "presentation": ["http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common Warrant [Member]", "documentation": "Common Warrant [Member]" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r494"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r493"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r495"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r492"] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": ["http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": ["r23", "r401"] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DeferredChargesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredChargesPolicyTextBlock", "presentation": ["http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "verboseLabel": "Deferred offering costs", "label": "Deferred Charges, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges." } } }, "auth_ref": ["r83"] }, "us-gaap_DeferredCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCosts", "crdr": "debit", "calculation": { "http://sonnetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://sonnetbio.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Deferred offering costs", "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent." } } }, "auth_ref": ["r54", "r526"] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://sonnetbio.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://sonnetbio.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r3", "r18"] }, "us-gaap_DerivativesReportingOfDerivativeActivity": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesReportingOfDerivativeActivity", "presentation": ["http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Derivative liability", "documentation": "Disclosure of accounting policy for derivatives entered into for trading purposes and those entered into for purposes other than trading including where and when derivative financial instruments and derivative commodity instruments and their related gains or losses are reported in the entity's statements of financial position, cash flows, and results of operations." } } }, "auth_ref": ["r24"] }, "SONN_DevelopmentLicenseFeePaymentObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "DevelopmentLicenseFeePaymentObligation", "crdr": "debit", "presentation": ["http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "[custom:DevelopmentLicenseFeePaymentObligation-0]", "documentation": "Development license fee payment obligation." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://sonnetbio.com/role/Share-basedCompensation"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r187", "r191", "r218", "r219", "r220", "r412"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "SONN_DiscoveryCollaborationAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "DiscoveryCollaborationAgreementsMember", "presentation": ["http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Discovery Collaboration Agreements [Member]", "documentation": "Discovery Collaboration Agreements [Member]" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": ["r450"] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": ["r448", "r450", "r462"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r449"] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": ["r437"] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": ["r450"] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": ["r450"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r483"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype":

"textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": ["r440"] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DomesticCountryMember", "presentation": ["http://sonnetbio.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative", "http://sonnetbio.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Domestic Tax Jurisdiction [Member]", "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction." } } }, "auth_ref": ["r226"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://sonnetbio.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Per share information:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://sonnetbio.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Net loss per share, basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r91", "r103", "r104", "r105", "r106", "r107", "r108", "r112", "r114", "r116", "r117", "r118", "r121", "r237", "r240", "r254", "r255", "r291", "r308", "r402"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://sonnetbio.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Net loss per share, diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r91", "r103", "r104", "r105", "r106", "r107", "r108", "r114", "r116", "r117", "r118", "r121", "r237", "r240", "r254", "r255", "r291", "r308", "r402"] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Net loss per share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r13", "r14", "r120"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": ["http://sonnetbio.com/role/Share-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Unrecognized compensation expense", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r592"] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": ["r443"] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r439"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r439"] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": ["r524"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r439"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r521"] }, "dei_EntityListingParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingParValuePerShare", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Par Value Per Share", "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": ["r462"] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r439"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r439"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r439"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r439"] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": ["r522"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://sonnetbio.com/role/StatementsOfChangesInStockholdersEquityDeficit", "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative", "http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r5", "r79", "r88", "r89", "r90", "r98", "r99", "r100", "r102", "r107", "r109", "r111", "r123", "r136", "r137", "r146", "r181", "r231", "r232", "r234", "r235", "r236", "r238", "r239", "r240", "r246", "r247", "r248", "r249", "r250", "r251", "r253", "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r274", "r278", "r307", "r321", "r322", "r323", "r330", "r383"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation

Assumption Difference, Footnote" } } }, "auth_ref": ["r491"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r455", "r466", "r476", "r501"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": ["r452", "r463", "r473", "r498"] }, "SONN_EvaluationMilestoneRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "EvaluationMilestoneRecognized", "crdr": "credit", "presentation": ["http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Evaluation milestone recognized", "documentation": "Evaluation milestone recognized." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]" } } }, "auth_ref": ["r497"] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r289", "r290", "r399"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r399"] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://sonnetbio.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://sonnetbio.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Foreign exchange (loss) gain", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": ["r262", "r263", "r264", "r265", "r380"] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": ["http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Foreign currency", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": ["r261"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r459", "r470", "r480", "r505"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r459", "r470", "r480", "r505"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r459", "r470", "r480", "r505"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r459", "r470", "r480", "r505"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": ["r459", "r470", "r480", "r505"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://sonnetbio.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://sonnetbio.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r43", "r366"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://sonnetbio.com/role/ScheduleOfShare-basedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r43"] }, "SONN_HolderMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "HolderMember", "presentation": ["http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Holder [Member]", "documentation": "Holder [Member]" } } }, "auth_ref": [] }, "SONN_InProcessResearchAndDevelopmentInAccruedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "InProcessResearchAndDevelopmentInAccruedExpenses", "crdr": "credit", "presentation": ["http://sonnetbio.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "In-process research and development in accrued expenses", "documentation": "In-process research and development in accrued expenses." } } }, "auth_ref": [] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InProcessResearchAndDevelopmentMember", "presentation": ["http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "In Process Research and Development [Member]", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": ["r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553"] }, "SONN_IncentiveTaxReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "IncentiveTaxReceivableCurrent", "crdr": "debit", "calculation": { "http://sonnetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://sonnetbio.com/role/BalanceSheets", "http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Incentive tax receivable", "verboseLabel": "[custom:IncentiveTaxReceivableCurrent-0]", "documentation": "Incentive tax receivable current." } } }, "auth_ref": [] }, "SONN_IncentiveTaxReceivbalePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "IncentiveTaxReceivbalePolicyTextBlock", "presentation": ["http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "verboseLabel": "Incentive tax receivable", "documentation": "Incentive Tax Receivbale [Policy Text Block]", "label": "Incentive Tax Receivbale [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://sonnetbio.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://sonnetbio.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Loss before provision from income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r41", "r58", "r62", "r292", "r305", "r404", "r405", "r537", "r538", "r539", "r540", "r541"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://sonnetbio.com/role/ScheduleOfShare-basedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r147", "r148", "r149", "r257", "r258", "r259", "r318", "r320", "r367", "r399", "r415", "r613"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://sonnetbio.com/role/ScheduleOfShare-basedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r148", "r149", "r257", "r258", "r259", "r318", "r320", "r367", "r399", "r415", "r613"] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityAxis", "presentation": ["http://sonnetbio.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative", "http://sonnetbio.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": ["r93", "r226", "r227", "r228", "r229", "r414", "r595"] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityDomain", "presentation": ["http://sonnetbio.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative", "http://sonnetbio.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Income tax jurisdiction." } } }, "auth_ref": ["r93", "r226", "r227", "r228", "r229", "r414", "r595"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://sonnetbio.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://sonnetbio.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "negatedLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r64", "r76", "r110", "r111", "r122", "r127", "r130", "r225", "r226", "r233", "r309", "r414"] }, "us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPaidByIndividualJurisdictionLineItems", "presentation": ["http://sonnetbio.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Income Tax Paid, by Individual Jurisdiction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r93", "r229"] }, "us-gaap_IncomeTaxPaidByIndividualJurisdictionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPaidByIndividualJurisdictionTable", "presentation": ["http://sonnetbio.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Income Tax Paid, by Individual Jurisdiction [Table]", "documentation": "Disclosure of information about income tax paid by jurisdiction." } } }, "auth_ref": ["r93", "r229"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://sonnetbio.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": ["http://sonnetbio.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://sonnetbio.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": ["http://sonnetbio.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Deferred income", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r287", "r529"] }, "SONN_IncreaseDecreaseInIncentiveTaxReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "IncreaseDecreaseInIncentiveTaxReceivable", "crdr": "credit", "calculation": { "http://sonnetbio.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": ["http://sonnetbio.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Incentive tax receivable", "documentation": "Increase decrease in incentive tax receivable.", "label": "IncreaseDecreaseInIncentiveTaxReceivable" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype":

```
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [
"http://sonnetbio.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } } }, "auth_ref": [] }, "us-
gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://sonnetbio.com/role/StatementsOfCashFlows": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://sonnetbio.com/role/StatementsOfCashFlows" ], "lang": { "en-us":
{ "role": { "verboseLabel": "Accrued expenses and other current liabilities", "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities", "documentation":
"The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid." } } }, "auth_ref": [ "r2" ] }, "us-
gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://sonnetbio.com/role/StatementsOfCashFlows": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://sonnetbio.com/role/StatementsOfCashFlows" ], "lang": { "en-us":
{ "role": { "negatedLabel": "Other assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets
classified as other." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://sonnetbio.com/role/StatementsOfCashFlows": { "parentTag":
"us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://sonnetbio.com/role/StatementsOfCashFlows" ], "lang": { "en-
us": { "role": { "label": "Operating lease liability", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r2" ] }, "us-
gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://sonnetbio.com/role/StatementsOfCashFlows": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://sonnetbio.com/role/StatementsOfCashFlows" ], "lang": { "en-us":
{ "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of
increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r2" ] }, "SONN_IncreaseDecreaseInUnbilledCollaborationRevenue": { "xbrltype":
"monetaryItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "IncreaseDecreaseInUnbilledCollaborationRevenue", "crdr": "credit", "calculation": {
"http://sonnetbio.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [
"http://sonnetbio.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Unbilled collaboration revenue", "documentation": "Increase decrease in
unbilled collaboration revenue.", "label": "IncreaseDecreaseInUnbilledCollaborationRevenue" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]" } } }, "auth_ref": [
"r459", "r470", "r480", "r497", "r505", "r509", "r517" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r515" ] },
"ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems",
"lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r451", "r520" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r451",
"r520" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider
Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r451", "r520" ] }, "SONN_InvivoGenAgreementMember": { "xbrltype": "domainItemType", "nsuri":
"http://sonnetbio.com/20241231", "localname": "InvivoGenAgreementMember", "presentation": [ "http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative"
], "lang": { "en-us": { "role": { "label": "InvivoGen Agreement [Member]", "documentation": "Invivo Gen Agreement [Member]" } } }, "auth_ref": [] },
"SONN_JuneTwentyTwentyFourInducementOfferMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname":
"JuneTwentyTwentyFourInducementOfferMember", "presentation": [ "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": {
"label": "June 2024 Inducement Offer [Member]", "documentation": "June Twenty Twenty Four Inducement Offer [Member]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [
"http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal
entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"Liabilities", "crdr": "credit", "calculation": { "http://sonnetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0
} }, "presentation": [ "http://sonnetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount
of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r9", "r27", "r28", "r29", "r30", "r31",
"r32", "r33", "r97", "r135", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r243", "r244", "r245", "r260", "r341", "r403", "r436", "r561", "r603", "r604" ]
}, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity",
"crdr": "credit", "calculation": { "http://sonnetbio.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://sonnetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity (deficit)", "label": "Liabilities and
Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r40",
"r57", "r301", "r420", "r532", "r543", "r600" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://sonnetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and
stockholders\u2019 equity (deficit)" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://sonnetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 }
}, "presentation": [ "http://sonnetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current",
"documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if
longer." } } }, "auth_ref": [ "r29", "r82", "r97", "r135", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r243", "r244", "r245", "r260", "r420", "r561",
"r603", "r604" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract",
"presentation": [ "http://sonnetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] },
"SONN_LicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "LicenseAgreementMember", "presentation": [
"http://sonnetbio.com/role/CollaborationRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "License Agreement [Member]", "documentation": "License
Agreement [Member]" } } }, "auth_ref": [] }, "SONN_LicenseFees": { "xbrltype": "monetaryItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "LicenseFees",
"crdr": "debit", "presentation": [ "http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "License fees",
"documentation": "License fees." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "LocalPhoneNumber", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local
phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LossContingenciesLineItems", "presentation": [ "http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loss
Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information
associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r152", "r153", "r154", "r157", "r221", "r408", "r557", "r558" ] }, "us-
gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": [
"http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Table]", "documentation": "Disclosure
of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": [ "r152", "r153", "r154",
"r157", "r221", "r408", "r557", "r558" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember",
"presentation": [ "http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails" ], "lang": {
"en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r153", "r154", "r155", "r156", "r186", "r221", "r256", "r286", "r317", "r319", "r326", "r333", "r334",
"r389", "r390", "r391", "r392", "r393", "r397", "r398", "r407", "r409", "r411", "r416", "r417", "r418", "r419", "r422", "r563", "r605", "r606", "r607", "r608", "r609", "r610" ] },
"ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]" } } }, "auth_ref": [ "r489" ] }, "ecd_MeasureName": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": {
"en-us": { "role": { "label": "Name" } } }, "auth_ref": [ "r489" ] }, "SONN_MilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://sonnetbio.com/20241231",
"localname": "MilestonePayments", "crdr": "credit", "presentation": [ "http://sonnetbio.com/role/CollaborationRevenueDetailsNarrative",
"http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Milestone payments", "verboseLabel": "
[custom:MilestonePayments-0]", "documentation": "Milestone payments." } } }, "auth_ref": [] }, "SONN_MilestonePaymentsDescription": { "xbrltype": "stringItemType",
"nsuri": "http://sonnetbio.com/20241231", "localname": "MilestonePaymentsDescription", "presentation": [
"http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Description of milestone payments", "documentation":
"Description of milestone payments." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"MinimumMember", "presentation": [ "http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative",
"http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r153", "r154", "r155",
"r156", "r186", "r221", "r256", "r286", "r317", "r319", "r326", "r333", "r334", "r389", "r390", "r391", "r392", "r393", "r397", "r398", "r407", "r409", "r411", "r416", "r417",
"r418", "r422", "r563", "r605", "r606", "r607", "r608", "r609", "r610" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": {
"role": { "label": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r508" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": {
"en-us": { "role": { "label": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r516" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r490" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": [ "http://sonnetbio.com/role/OrganizationAndDescriptionOfBusiness" ], "lang": {
"en-us": { "role": { "label": "Organization and Description of Business", "documentation": "The entire disclosure for the nature of an entity's business, major products or
services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to,
assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the
entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r66", "r77" ] }, "SONN_NavigoAgreementMember": {
"xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "NavigoAgreementMember", "presentation": [
"http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Navigo Agreement [Member]", "documentation": "Navigo
Agreement [Member]" } } }, "auth_ref": [] }, "SONN_NavigoProteinsGmbHMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname":
"NavigoProteinsGmbHMember", "presentation": [ "http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Navigo
Proteins GmbH [Member]", "documentation": "Navigo Proteins GmbH [Member]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": {
"http://sonnetbio.com/role/StatementsOfCashFlows": { "parentTag": "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation":
[ "http://sonnetbio.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by
(Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows
include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling
the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r92" ] }, "us-
```

gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://sonnetbio.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://sonnetbio.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://sonnetbio.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r44", "r45", "r46"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://sonnetbio.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://sonnetbio.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://sonnetbio.com/role/StatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://sonnetbio.com/role/StatementsOfCashFlows", "http://sonnetbio.com/role/StatementsOfChangesInStockholdersEquityDeficit", "http://sonnetbio.com/role/StatementsOfOperations", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Net loss", "verboseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r42", "r46", "r59", "r80", "r86", "r87", "r90", "r97", "r101", "r103", "r104", "r105", "r106", "r107", "r110", "r111", "r115", "r135", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r237", "r240", "r255", "r260", "r306", "r364", "r381", "r382", "r434", "r561"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Recent accounting pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description" } } }, "auth_ref": ["r489"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r487"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r486"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r516"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r516"] }, "SONN_OctoberOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "OctoberOfferingMember", "presentation": ["http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative"], "lang": { "en-us": { "role": { "label": "October Offering [Member]", "documentation": "October Offering [Member]" } } }, "auth_ref": [] }, "SONN_OfferingCostsInAccountsPayableAndAccruedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "OfferingCostsInAccountsPayableAndAccruedExpenses", "crdr": "credit", "presentation": ["http://sonnetbio.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Deferred offering costs in accounts payable and accrued expenses", "documentation": "Offering costs in accounts payable and accrued expenses." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://sonnetbio.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://sonnetbio.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://sonnetbio.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://sonnetbio.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://sonnetbio.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r62", "r404", "r537", "r538", "r539", "r540", "r541"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://sonnetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://sonnetbio.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Current portion of operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r276"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://sonnetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://sonnetbio.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating lease liability, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r276"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://sonnetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://sonnetbio.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r275"] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://sonnetbio.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://sonnetbio.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Amortization of operating lease right-of-use asset", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": ["r530"] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": ["http://sonnetbio.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative", "http://sonnetbio.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Net operating losses", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": ["r230"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://sonnetbio.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://sonnetbio.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r28"] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://sonnetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://sonnetbio.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r83"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount" } } }, "auth_ref": ["r489"] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": ["r450"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r457", "r468", "r478", "r503"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Amount" } } }, "auth_ref": ["r460", "r471", "r481", "r506"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": ["r460", "r471", "r481", "r506"] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "auth_ref": ["r485"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "SONN_PaymentForAnnualLicenseFeeObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "PaymentForAnnualLicenseFeeObligation", "crdr": "credit", "presentation": ["http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Payment for annual license fee obligation", "documentation": "Annual license fee payment." } } }, "auth_ref": [] }, "SONN_PaymentOfAnnualLicenseFeeObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "PaymentOfAnnualLicenseFeeObligation", "crdr": "debit", "presentation": ["http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "[custom:PaymentOfAnnualLicenseFeeObligation-0]", "documentation": "Payment of annual license fee." } } }, "auth_ref": [] }, "SONN_PaymentOfDeferredOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "PaymentOfDeferredOfferingCosts", "crdr": "credit", "calculation": { "http://sonnetbio.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://sonnetbio.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Payment of deferred offering costs", "documentation": "Payment of deferred offering costs.", "label": "PaymentOfDeferredOfferingCosts" } } }, "auth_ref": [] }, "SONN_PaymentOfWarrantIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "PaymentOfWarrantIssuanceCosts", "crdr": "credit", "calculation": { "http://sonnetbio.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://sonnetbio.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Payment of warrant issuance costs", "documentation": "Payment of warrant issuance costs.", "label": "Payment of warrant issuance costs" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInProcessResearchAndDevelopment", "crdr": "credit", "presentation": ["http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Payments to Acquire in Process Research and Development", "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination." } } }, "auth_ref": ["r10"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r488"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":

```
"PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r488" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r487" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name" } } }, "auth_ref": [ "r490" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r486" ] }, "SONN_Performanceobligation": { "xbrltype": "monetaryItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "Performanceobligation", "crdr": "debit", "presentation": [ "http://sonnetbio.com/role/CollaborationRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Performance obligation", "documentation": "Performance obligation." } } }, "auth_ref": [] }, "SONN_PlacementAgentWarrantsJuneTwoThousandTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "PlacementAgentWarrantsJuneTwoThousandTwentyFourMember", "presentation": [ "http://sonnetbio.com/role/ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesDetails", "http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Placement Agent Warrants June 2024 [Member]", "documentation": "Placement Agent Warrants June 2024 [Member]" } } }, "auth_ref": [] }, "SONN_PlacementAgentWarrantsJuneTwoThousandTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "PlacementAgentWarrantsJuneTwoThousandTwentyThreeMember", "presentation": [ "http://sonnetbio.com/role/ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesDetails", "http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Placement Agent Warrants June 2023 [Member]", "documentation": "Placement Agent Warrants June 2023 [Member]" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://sonnetbio.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://sonnetbio.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r487" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r444" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r446" ] }, "SONN_PreFundedWarrantsDecemberTwoThousandTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "PreFundedWarrantsDecemberTwoThousandTwentyFourMember", "presentation": [ "http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Pre-funded Warrants December 2024 [Member]", "documentation": "Pre-funded Warrants December 2024 [Member]" } } }, "auth_ref": [] }, "SONN_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "PreFundedWarrantsMember", "presentation": [ "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Pre-funded Warrants [Member]", "documentation": "Pre-funded Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://sonnetbio.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r34", "r168" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://sonnetbio.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r34", "r343" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://sonnetbio.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r34", "r168" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://sonnetbio.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r34", "r343", "r362", "r644", "r645" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://sonnetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sonnetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred stock, $0.0001 par value: 5,000,000 shares authorized; no shares issued or outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r34", "r298", "r420" ] }, "SONN_PrefundedDecemberTwoThousandTwentyFourWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "PrefundedDecemberTwoThousandTwentyFourWarrantsMember", "presentation": [ "http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Prefunded December 2024 Warrants [Member]", "documentation": "Prefunded December 2024 Warrants [Member]" } } }, "auth_ref": [] }, "SONN_PrefundedOctoberTwoThousandTwentyThreeWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "PrefundedOctoberTwoThousandTwentyThreeWarrantsMember", "presentation": [ "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative", "http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Prefunded October 2023 Warrants [Member]", "documentation": "Prefunded October 2023 Warrants [Member]" } } }, "auth_ref": [] }, "SONN_PrefundedWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "PrefundedWarrantMember", "presentation": [ "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Prefunded Warrant [Member]", "documentation": "Prefunded Warrant [Member]" } } }, "auth_ref": [] }, "SONN_PrefundedWarrantsOctoberTwoThousandTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "PrefundedWarrantsOctoberTwoThousandTwentyThreeMember", "presentation": [ "http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Prefunded Warrants October 2023 [Member]", "documentation": "Prefunded Warrants October 2023 [Member]" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://sonnetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://sonnetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r527" ] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": [ "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIncomeTaxRefunds": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIncomeTaxRefunds", "crdr": "debit", "presentation": [ "http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from income tax refunds", "documentation": "Amount of income tax refund received from tax jurisdiction." } } }, "auth_ref": [ "r12", "r45", "r531", "r593", "r594" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://sonnetbio.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sonnetbio.com/role/StatementsOfCashFlows", "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative", "http://sonnetbio.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of common stock, net of issuance costs", "verboseLabel": "Proceeds from sale of common stock", "terseLabel": "Proceeds from issuance of common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r1" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [ "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from offering", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r1", "r328" ] }, "SONN_ProceedsforNegotiateLicenseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "ProceedsforNegotiateLicenseAgreement", "crdr": "debit", "presentation": [ "http://sonnetbio.com/role/CollaborationRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds for negotiate license agreement", "documentation": "Proceeds for negotiate license agreement." } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r131", "r288", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r400", "r410", "r421", "r422", "r423", "r424", "r425", "r559", "r560", "r564", "r612", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "auth_ref": [ "r131", "r288", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r400", "r410", "r421", "r422", "r423", "r424", "r425", "r559", "r560", "r564", "r612", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://sonnetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sonnetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r4", "r277", "r293", "r304", "r420" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Property and equipment", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r4", "r72", "r75", "r303" ] }, "SONN_PurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "PurchaseAgreementMember", "presentation": [ "http://sonnetbio.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Purchase Agreement [Member]", "documentation": "Purchase Agreement [Member]" } } }, "auth_ref": [] }, "SONN_PurchaseAndRegistrationRightsAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "PurchaseAndRegistrationRightsAgreementMember", "presentation": [ "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Purchase and Registration Rights Agreement [Member]",
```

```
"documentation": "Purchase and Registration Rights Agreement [Member]" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r485" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r485" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r153", "r154", "r155", "r156", "r184", "r186", "r214", "r215", "r216", "r221", "r256", "r284", "r285", "r286", "r317", "r319", "r326", "r333", "r334", "r389", "r390", "r391", "r392", "r393", "r397", "r398", "r407", "r409", "r411", "r416", "r417", "r418", "r419", "r422", "r428", "r555", "r563", "r598", "r606", "r607", "r608", "r609", "r610" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails" ], "auth_ref": [ "r153", "r154", "r155", "r156", "r184", "r186", "r214", "r215", "r216", "r221", "r256", "r284", "r285", "r286", "r317", "r319", "r326", "r333", "r334", "r389", "r390", "r391", "r392", "r393", "r397", "r398", "r407", "r409", "r411", "r416", "r417", "r418", "r419", "r422", "r428", "r555", "r563", "r598", "r606", "r607", "r608", "r609", "r610" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "auth_ref": [ "r452", "r463", "r473", "r498" ] }, "us-gaap_RefundReceivedRelatedToRevenueFromDifferentYearYearRevenueRecognized": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RefundReceivedRelatedToRevenueFromDifferentYearYearRevenueRecognized", "presentation": [ "http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Refund Received Related to Revenue from Different Year, Year Revenue Recognized", "documentation": "Discloses year revenue was initially recognized related to refunds that are recognized in a period other than the period in which the related revenue was recognized and that have a material effect on net income." } } }, "auth_ref": [ "r25" ] }, "SONN_RegisteredDirectOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "RegisteredDirectOfferingMember", "presentation": [ "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Registered Direct Offering [Member]", "documentation": "Registered Direct Offering [Member]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r134", "r185", "r279", "r280", "r295", "r302", "r336", "r337", "r338", "r339", "r340", "r361", "r363", "r388" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r134", "r185", "r279", "r280", "r295", "r302", "r336", "r337", "r338", "r339", "r340", "r361", "r363", "r388", "r602" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://sonnetbio.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sonnetbio.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r224", "r399", "r405", "r611" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://sonnetbio.com/role/ScheduleOfShare-basedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and development expense", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r223" ] }, "SONN_ResearchAndDevelopmentTaxIncentiveProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "ResearchAndDevelopmentTaxIncentiveProgramMember", "presentation": [ "http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Research and Development Tax Incentive Program [Member]", "documentation": "Research and Development Tax Incentive Program [Member]" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r453", "r464", "r474", "r499" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date" } } }, "auth_ref": [ "r454", "r465", "r475", "r500" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement does not require Recovery" } } }, "auth_ref": [ "r461", "r472", "r482", "r507" ] }, "SONN_RestrictedStockAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "RestrictedStockAwardsMember", "presentation": [ "http://sonnetbio.com/role/ScheduleOfRestrictedStockAwardsActivityDetails", "http://sonnetbio.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Awards (RSA) [Member]", "documentation": "Restricted Stock Awards (RSA) [Member]" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://sonnetbio.com/role/ScheduleOfRestrictedStockUnitsActivityDetails", "http://sonnetbio.com/role/ScheduleOfShare-basedCompensationExpenseDetails", "http://sonnetbio.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://sonnetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://sonnetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r37", "r51", "r300", "r324", "r325", "r329", "r344", "r420" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://sonnetbio.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r79", "r98", "r99", "r100", "r102", "r107", "r109", "r111", "r136", "r137", "r146", "r231", "r232", "r234", "r235", "r236", "r238", "r239", "r240", "r246", "r248", "r249", "r251", "r253", "r273", "r274", "r321", "r323", "r330", "r644" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://sonnetbio.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sonnetbio.com/role/CollaborationRevenueDetailsNarrative", "http://sonnetbio.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Collaboration revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r60", "r61", "r122", "r125", "r126", "r128", "r130", "r131", "r132", "r133", "r182", "r183", "r288" ] }, "SONN_ReverseStockSplitPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "ReverseStockSplitPolicyTextBlock", "presentation": [ "http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Reverse stock split", "documentation": "Reverse Stock Split [Policy Text Block]" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r516" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r516" ] }, "SONN_SOCAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "SOCAgreementMember", "presentation": [ "http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "SOC Agreement [Member]", "documentation": "SOC Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_SalariesAndWages": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalariesAndWages", "crdr": "debit", "presentation": [ "http://sonnetbio.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Base salary", "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold." } } }, "auth_ref": [ "r528" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative", "http://sonnetbio.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares for sale", "verboseLabel": "Sale of stock, number of shares issued in transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Offering price per share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://sonnetbio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Expenses and Other Current Liabilities", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://sonnetbio.com/role/ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r13" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Shares", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially
```

dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r13"] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": ["http://sonnetbio.com/role/CollaborationRevenueDetailsNarrative", "http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r241"] }, "SONN_ScheduleOfNonvestedRestrictedStockAwardsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "ScheduleOfNonvestedRestrictedStockAwardsActivityTableTextBlock", "presentation": ["http://sonnetbio.com/role/Share-basedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Restricted Stock Awards Activity", "documentation": "Schedule of Nonvested Restricted Stock Awards Activity [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": ["http://sonnetbio.com/role/Share-basedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Restricted Stock Units Activity", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": ["r53"] }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "presentation": ["http://sonnetbio.com/role/Share-basedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation Expense", "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value." } } }, "auth_ref": ["r7", "r8", "r53"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://sonnetbio.com/role/ScheduleOfRestrictedStockAwardsActivityDetails", "http://sonnetbio.com/role/ScheduleOfRestrictedStockUnitsActivityDetails", "http://sonnetbio.com/role/ScheduleOfShare-basedCompensationExpenseDetails", "http://sonnetbio.com/role/Share-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r188", "r190", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217"] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": ["http://sonnetbio.com/role/StockholdersEquityDeficitTables"], "lang": { "en-us": { "role": { "label": "Schedule of Warrants Outstanding", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": ["r19"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r438"] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": ["r442"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r441"] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": ["r447"] }, "SONN_SeriesCWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "SeriesCWarrantsMember", "presentation": ["http://sonnetbio.com/role/ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesDetails", "http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Series C Warrants [Member]", "documentation": "Series C Warrants [Member]" } } }, "auth_ref": [] }, "SONN_SeriesThreeWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "SeriesThreeWarrantsMember", "presentation": ["http://sonnetbio.com/role/ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesDetails", "http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Series 3 Warrants [Member]", "documentation": "Series 3 Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://sonnetbio.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://sonnetbio.com/role/ScheduleOfShare-basedCompensationExpenseDetails", "http://sonnetbio.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "verboseLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r2"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Forfeited warrants, shares", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r208"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://sonnetbio.com/role/Share-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Number of shares granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r206"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://sonnetbio.com/role/ScheduleOfRestrictedStockAwardsActivityDetails", "http://sonnetbio.com/role/ScheduleOfRestrictedStockUnitsActivityDetails"], "lang": { "en-us": { "role": { "label": "Unvested balance", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r203", "r204"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://sonnetbio.com/role/ScheduleOfRestrictedStockAwardsActivityDetails", "http://sonnetbio.com/role/ScheduleOfRestrictedStockUnitsActivityDetails"], "lang": { "en-us": { "role": { "label": "Unvested weighted average grant fair value, balance", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r203", "r204"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://sonnetbio.com/role/ScheduleOfRestrictedStockAwardsActivityDetails", "http://sonnetbio.com/role/ScheduleOfRestrictedStockUnitsActivityDetails", "http://sonnetbio.com/role/ScheduleOfShare-basedCompensationExpenseDetails", "http://sonnetbio.com/role/Share-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r188", "r190", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "presentation": ["http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Number of warrant exercised", "documentation": "Number of non-option equity instruments exercised by participants." } } }, "auth_ref": ["r6"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://sonnetbio.com/role/Share-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Number of shares available for issuance", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r413"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://sonnetbio.com/role/ScheduleOfRestrictedStockAwardsActivityDetails", "http://sonnetbio.com/role/ScheduleOfRestrictedStockUnitsActivityDetails", "http://sonnetbio.com/role/ScheduleOfShare-basedCompensationExpenseDetails", "http://sonnetbio.com/role/Share-basedCompensationDetailsNarrative", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": ["http://sonnetbio.com/role/Share-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Vesting percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": ["r566"] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://sonnetbio.com/role/StatementsOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://sonnetbio.com/role/SummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r47", "r95"] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": ["http://sonnetbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": ["r445"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://sonnetbio.com/role/StatementsOfChangesInStockholdersEquityDeficit", "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative", "http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r5", "r35", "r38", "r39", "r79", "r88", "r89", "r90", "r98", "r99", "r100", "r102", "r107", "r109", "r111", "r123", "r136", "r137", "r146", "r181", "r231", "r232", "r234", "r235", "r236", "r238", "r239", "r240", "r246", "r247", "r248", "r249", "r250", "r251", "r253", "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r274", "r278", "r307", "r321", "r322", "r323", "r330", "r383"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://sonnetbio.com/role/StatementsOfChangesInStockholdersEquityDeficit"], "lang": {

```
"en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r98", "r99", "r100", "r123", "r274", "r288", "r327", "r332", "r335", "r336", "r337", "r338", "r339", "r340", "r343", "r346", "r347", "r348", "r349", "r350", "r352", "r353", "r354", "r355", "r357", "r358", "r359", "r360", "r361", "r363", "r365", "r366", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r383", "r429" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://sonnetbio.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r98", "r99", "r100", "r123", "r134", "r274", "r288", "r327", "r332", "r335", "r336", "r337", "r338", "r339", "r340", "r343", "r346", "r347", "r348", "r349", "r350", "r352", "r353", "r354", "r355", "r357", "r358", "r359", "r360", "r361", "r363", "r365", "r366", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r383", "r429" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r456", "r467", "r477", "r502" ] }, "SONN_StockIssuedDuringPeriodSharesNetShareSettlementOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "StockIssuedDuringPeriodSharesNetShareSettlementOfWarrants", "presentation": [ "http://sonnetbio.com/role/StatementsOfChangesInStockholdersEquityDeficit", "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net share settlement of warrants, shares", "documentation": "Stock issued during period value net share settlement of warrants, shares." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://sonnetbio.com/role/StatementsOfChangesInStockholdersEquityDeficit", "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of common stock, net of issuance costs, shares", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r5", "r34", "r35", "r51", "r328", "r383", "r394" ] }, "SONN_StockIssuedDuringPeriodSharesSharesReleasedFromAbeyance": { "xbrltype": "sharesItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "StockIssuedDuringPeriodSharesSharesReleasedFromAbeyance", "presentation": [ "http://sonnetbio.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Shares released from abeyance, shares", "documentation": "Stock issued during period shares shares released from abeyance." } } }, "auth_ref": [] }, "SONN_StockIssuedDuringPeriodSharesStockWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "StockIssuedDuringPeriodSharesStockWarrantsExercised", "presentation": [ "http://sonnetbio.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Exercise of warrants, shares", "documentation": "Stock issued during period shares stock warrants exercised." } } }, "auth_ref": [] }, "SONN_StockIssuedDuringPeriodValueNetShareSettlementOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "StockIssuedDuringPeriodValueNetShareSettlementOfWarrants", "crdr": "credit", "presentation": [ "http://sonnetbio.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Net share settlement of warrants", "documentation": "Stock issued during period value net share settlement of warrants." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://sonnetbio.com/role/StatementsOfChangesInStockholdersEquityDeficit", "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of common stock, net of issuance costs", "verboseLabel": "Issuance of share, value", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r5", "r34", "r35", "r51", "r330", "r383", "r394", "r435" ] }, "SONN_StockIssuedDuringPeriodValueSharesReleasedFromAbeyance": { "xbrltype": "monetaryItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "StockIssuedDuringPeriodValueSharesReleasedFromAbeyance", "crdr": "credit", "presentation": [ "http://sonnetbio.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Shares released from abeyance", "documentation": "Stock issued during period value shares released from abeyance." } } }, "auth_ref": [] }, "SONN_StockIssuedDuringPeriodValueStockWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "StockIssuedDuringPeriodValueStockWarrantsExercised", "crdr": "credit", "presentation": [ "http://sonnetbio.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Exercise of warrants", "documentation": "Stock issued during period value stock warrants exercised." } } }, "auth_ref": [] }, "SONN_StockRetiredDuringPeriodSharesReverseStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "StockRetiredDuringPeriodSharesReverseStockSplits", "presentation": [ "http://sonnetbio.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Retirement of shares in connection with reverse stock split, shares", "documentation": "Stock retired during period shares reverse stock splits." } } }, "auth_ref": [] }, "SONN_StockRetiredDuringPeriodValueReverseStockSplits": { "xbrltype": "monetaryItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "StockRetiredDuringPeriodValueReverseStockSplits", "crdr": "credit", "presentation": [ "http://sonnetbio.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Retirement of shares in connection with reverse stock split", "documentation": "Stock retired during period value reverse stock splits." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://sonnetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://sonnetbio.com/role/BalanceSheets", "http://sonnetbio.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity (deficit)", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r35", "r38", "r39", "r48", "r345", "r362", "r384", "r385", "r420", "r436", "r532", "r543", "r600", "r644" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://sonnetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity (deficit):" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://sonnetbio.com/role/StockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity (Deficit)", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r50", "r96", "r167", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r181", "r252", "r386", "r387", "r395" ] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityReverseStockSplit", "presentation": [ "http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Reverse stock split description", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": [ "r52" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [ "http://sonnetbio.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r272", "r282" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://sonnetbio.com/role/Share-basedCompensationDetailsNarrative", "http://sonnetbio.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r272", "r282" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": [ "http://sonnetbio.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r272", "r282" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://sonnetbio.com/role/Share-basedCompensationDetailsNarrative", "http://sonnetbio.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r272", "r282" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://sonnetbio.com/role/Share-basedCompensationDetailsNarrative", "http://sonnetbio.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r272", "r282" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://sonnetbio.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r281", "r283" ] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "presentation": [ "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]", "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockLineItems", "presentation": [ "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsidiary, Sale of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://sonnetbio.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of non-cash operating, investing and financing activities:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List, Table" } } }, "auth_ref": [ "r496" ] }, "us-gaap_TechnologyServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TechnologyServiceMember", "presentation": [ "http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Technology Service [Member]", "documentation": "Technology assistance, including but not limited to, training, installation, engineering, and software design." } } }, "auth_ref": [ "r565" ] }, "SONN_TheBrinkAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "TheBrinkAgreementMember", "presentation": [ "http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "The Brink Agreement [Member]", "documentation": "The Brink Agreement [Member]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [ "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": [ "r542", "r601" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative" ], "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r488" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
```

```
"TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r495" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Adoption Date" } } }, "auth_ref": [ "r518" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Arrangement Duration" } } }, "auth_ref": [ "r519" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Expiration Date" } } }, "auth_ref": [ "r519" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r517" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Title" } } }, "auth_ref": [ "r517" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Termination Date" } } }, "auth_ref": [ "r518" ] }, "SONN_TwoThousandTwentyOmnibusEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "TwoThousandTwentyOmnibusEquityIncentivePlanMember", "presentation": [ "http://sonnetbio.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2020 Omnibus Equity Incentive Plan [Member]", "documentation": "2020 Omnibus Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://sonnetbio.com/role/CollaborationRevenueDetailsNarrative", "http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative", "http://sonnetbio.com/role/SubsequentEventsDetailsNarrative", "http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r241" ] }, "us-gaap_UnbilledReceivablesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnbilledReceivablesCurrent", "crdr": "debit", "calculation": { "http://sonnetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sonnetbio.com/role/BalanceSheets", "http://sonnetbio.com/role/CollaborationRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unbilled collaboration revenue", "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "SONN_UnderwriterWarrantFebruaryTwoThousandTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "UnderwriterWarrantFebruaryTwoThousandTwentyThreeMember", "presentation": [ "http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Underwriter Warrant February 2023 [Member]", "documentation": "Underwriter Warrant February 2023 [Member]" } } }, "auth_ref": [] }, "SONN_UnderwriterWarrantsAugustTwoThousandTwentyOneMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "UnderwriterWarrantsAugustTwoThousandTwentyOneMember", "presentation": [ "http://sonnetbio.com/role/ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesDetails", "http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Underwriter Warrants August 2021 [Member]", "documentation": "Underwriter Warrants August 2021 [Member]" } } }, "auth_ref": [] }, "SONN_UnderwriterWarrantsFebruaryTwoThousandTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "UnderwriterWarrantsFebruaryTwoThousandTwentyThreeMember", "presentation": [ "http://sonnetbio.com/role/ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesDetails" ], "lang": { "en-us": { "role": { "label": "Underwriter Warrants February 2023 [Member]", "documentation": "Underwriter Warrants February 2023 [Member]" } } }, "auth_ref": [] }, "SONN_UnderwriterWarrantsOctoberTwoThousandTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "UnderwriterWarrantsOctoberTwoThousandTwentyThreeMember", "presentation": [ "http://sonnetbio.com/role/ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesDetails", "http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Underwriter Warrants October 2023 [Member]", "documentation": "Underwriter Warrants October 2023 [Member]" } } }, "auth_ref": [] }, "SONN_UnderwritersMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "UnderwritersMember", "presentation": [ "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Underwriters [Member]", "documentation": "Underwriters [Member]" } } }, "auth_ref": [] }, "SONN_UnderwritingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "UnderwritingAgreementMember", "presentation": [ "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Underwriting Agreement [Member]", "documentation": "Underwriting Agreement [Member]" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r514" ] }, "SONN_UnvestedRestrictedStockUnitsAndAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "UnvestedRestrictedStockUnitsAndAwardsMember", "presentation": [ "http://sonnetbio.com/role/ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesDetails" ], "lang": { "en-us": { "role": { "label": "Unvested Restricted Stock Units and Awards [Member]", "documentation": "Unvested Restricted Stock Units and Awards [Member]" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://sonnetbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r15", "r16", "r17", "r68", "r70", "r73", "r74" ] }, "SONN_VolumeWeightedAveragePriceDiscountPercentage": { "xbrltype": "percentItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "VolumeWeightedAveragePriceDiscountPercentage", "presentation": [ "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Volume weighted average price discount percentage", "documentation": "Volume weighted average price discount percentage." } } }, "auth_ref": [] }, "us-gaap_WarrantExercisePriceDecrease": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantExercisePriceDecrease", "presentation": [ "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants exercise price decrease", "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision." } } }, "auth_ref": [ "r180" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r426", "r427", "r430", "r431", "r432", "r433" ] }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingMaturityDate", "presentation": [ "http://sonnetbio.com/role/ScheduleOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Expiration Date", "label": "Warrants and Rights Outstanding, Maturity Date", "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format." } } }, "auth_ref": [ "r597", "r598", "r599" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://sonnetbio.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r597", "r598", "r599" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://sonnetbio.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding, diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r113", "r118" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://sonnetbio.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding, basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r112", "r118" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r523" ] }, "SONN_XOMAMember": { "xbrltype": "domainItemType", "nsuri": "http://sonnetbio.com/20241231", "localname": "XOMAMember", "presentation": [ "http://sonnetbio.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "XOMA [Member]", "documentation": "XOMA [Member]" } } }, "auth_ref": [] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
```

Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "808", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "980", "SubTopic": "605", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478868/980-605-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

"Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r150": { "role":

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r212": { "role":
```

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/830/tableOfContent" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r276": { "role":

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
```

"Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50",

```
"Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-
50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r399": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r401": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-
50-4" }, "r402": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r403": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r404": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r405": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r406": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r407": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r408": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r409": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r410": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-
55-91" }, "r411": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r412": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" },
"r414": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph":
"231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r415": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r416": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r417": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r418": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r419": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-
10-55-107" }, "r420": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r421": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r423": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r424": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r425": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r426": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r428": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r429": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)
(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946",
"SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r433": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r434": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r435": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r436": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946",
"SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r437": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act",
"Number": "240", "Section": "12" }, "r438": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section":
"12", "Subsection": "b" }, "r439": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12",
"Subsection": "b-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12",
"Subsection": "b-23" }, "r441": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12",
"Subsection": "d1-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12",
"Subsection": "g" }, "r443": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" },
"r444": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r445":
{ "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r446": {
"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r447": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r448": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r449": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r450": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r451": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r452": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r453": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r454": {
"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i",
"Sentence": "A" }, "r455": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph":
"1", "Subparagraph": "i", "Sentence": "B" }, "r456": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6",
"Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r457": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r458": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r459": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r460": {
"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" },
"r461": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r462": {
"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r463": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r464": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r465": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r466": {
"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" },
"r467": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence":
"iii" }, "r468": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1",
"Sentence": "iv" }, "r469": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a",
"Subparagraph": "1", "Sentence": "v" }, "r470": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19",
"Paragraph": "a", "Subparagraph": "2" }, "r471": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19",
"Paragraph": "a", "Subparagraph": "3" }, "r472": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19",
"Paragraph": "b" }, "r473": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r474": {
"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r475": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r476":
{ "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii"
}, "r477": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1",
"Sentence": "iii" }, "r478": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a",
"Subparagraph": "1", "Sentence": "iv" }, "r479": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
```

"Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r480": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r481": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r482": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r483": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r485": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r486": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r487": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r488": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r489": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r490": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r491": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r492": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r493": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r494": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r495": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r496": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r497": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r498": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r499": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r500": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r501": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r502": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r503": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r504": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r505": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r506": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r507": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r508": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r509": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r510": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r511": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r512": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r513": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r514": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r515": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r516": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r517": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r518": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r519": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r520": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r521": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r522": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r523": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r524": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r525": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r526": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r527": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r528": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r529": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r530": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r531": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r532": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r533": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r534": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r535": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r536": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r537": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r538": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r539": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r540": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r541": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r542": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r543": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r544": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r545": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r546": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r547": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r548": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r549": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r550": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r551": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r552": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r553": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r554": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r555": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r556": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r557": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" },

```
"r558": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r559": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r560": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r561": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r562": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r563": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r564": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r565": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r566": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-
10-50-2" }, "r567": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r568": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r569": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r570": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r571": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r572": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r573": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r574": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r575": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r576": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r577": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r578": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r579": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r580": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r581": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r582": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r583": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r584": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r585": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r586": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r587": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r588": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r589": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r590": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r591": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r592": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r593": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-
50-3" }, "r596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r597": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r598": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r599": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r600": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r601": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-
10-50-3" }, "r603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r604": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r605": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r606": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r607": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r608": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r609": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r610": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r611": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-
310-50-3" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r615": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r616": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944",
```

"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 54 0001493152-25-006436-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-25-006436-xbrl.zip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|E:AQFL-8(Y45%^M!6@6C2QI@L.H+I7)8^/[Q;_N'P>\? M=P_W3O;_:L]P_ZN*&QS4G2&-<'IT>+A_%GPX.(*%G^P>|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|#-CI0BJHLV>]6"^FK1P$N%1C4YHX@"5,T]EP, 8A'-2P?;0H_#>)[*K&9=&P M]&(]:@B#>GP"Q'99H;>3WIBD)9*^%?6PNLU@KREQ-?KN&9Z@MTH;K<.|L_CHBB_X+6+@G&391LT_U$$T\>KW%$6Z)%$G1>UHLT:J;K&ZPM'6LF& MC:H:E) 4]W/C#Z,:]P?7*=M@?N*?-G(.=]+,..HR F,!=_;]*YJPBB^VGC3L&WI&V!-'1.1_"PZ+&E2)?2C07A;FK20%_A7]3U3D2'[%J MJ^(0,_4ER0%W;3DLT*&4BHQTL9 #%V>:QGS!.9;@LWF4*8A(-S(,@*V'^-- MJ/M4);3IRB(S&X9NS"AXL;6]]F6=UG\Q34%6719-$,-F$&W'Z1QW*LU;3!14 M-5&_@7W-D5^"+OM/Q/@+_X%5F8Z3M%)"]23%_F&_:2*SF'_F/IQ]TN>+LZ% M/RQ@'TK?9>$>&.R)7)Q)&CX%;!@\'&AD2CW^T=_*FGP?/?&!5U7!*^078^*M,E&E^>Q#%L5?@FU8&-R1-(%UG.U^^+P/&L;G$>|>WL\A[_^]T|;/\'?I\>[M'_7?\@89#4SS+)\7.;/|7V^\ZI-ZBFO:_^|^#GYVHL< 50=(+.KTEM;%W-_C M3(WIB3W!A#.TW:ZS/8S G^,#_X K@W! 3/9LR*E7T96.D\+;_?K&G92-@C?3 M+L'+COT])\]PJSKV1W=.YAD>#9_&XS2\,^EV/ 5MX\5P\&<4$]/2>@5\3CI& MOS+>M>3;.BOHI0K_&A=-&:R]6] $?E"K.Q]8&FU);-^{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f"!F;O2J&=:^SC M2"BCK]Z#P>G=1%_"8[FY*3=##1;\CU=%?VHF+.]POZ^.&N(Y$Y._V#3 MY>1TMPKMA=4>V.@"_L ?LCB'R^K<4[!]\(L*3!PR34BHIK$8)D\@POZH*01, M<>!$Y#,.3K0#FG./P2(/D%0Z[F_K].Y]?*6*]B(GSFAB3N*3)G,7S-6B3(AO M+/;F$KM#$!,G[1NM9_7H MD(8+QP'[67* #KXKBWF),4VSN@V*@*C$KA+8. L_N$--68I[-RGB!M_"7+V] M#7]>SM(. CB+K8PV#+\VQQB2 MR[WEV*!H1\59"/"24XF@OMAZO:N%S %&87*0@B?HZ&]PWQ.:T?;K7U!1:K1O MHY/GG7@YY&^"M6A=O G .5I3%G$\') \SHL =Q[W 1C6'LBFV0C^>KZM9T7. M!Y-E9З^"G;424)/8!6TY\@8K(W6>7MG18.9&6-]O&9."<9C2"6B46ERZ%2) MZ-3X+A@4P*NQ'[%4$Q1/;']U.K$6;H.S-.DAK15>;A-H,*3= M-QJX6]64YWPT)%'TWX%CRG0=YD_L/B\X.V\U;KN&WR1"*NWP9]1UN#7/U9\ MKUM^Z+WNI_<;[EJ[77P:G%W:80*[)=SU^&UP"!>$=_]PP/W;|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~-=2LQ*7!],L.8C;VP&!ZU2$]+*.M1BS8D4]GEBB"ZW1 \A|Q;Z M>:F]N7;< BUDP+N!HBDV0PG&N%?GQ1?\@-0RJD/3SN,(-CR#K5?]"78Z@U_[M,BF0Z*[7.EK=W07%DX.$PJN^@PR7%:5K4) MPH\4G%GN1.S8KF@ODTK5PBCKLZP3D3[_!VC,#67=,\]7U_ MAX.I=Y!C@(\7SG\,]+A_WSE\'^0-^/1WMY'+V90SG1L-[2!<^36&ANHJY-U M*H IV4Y7Q:+]3I:88Y52Q@W9I*P1LET'EEHLG$1IWB@"I$)6#W> C=R/1Q] M=B4K:U;I;&S*D^F"I7HN:(=LMGYW?E.0!&;ZUES\:E5D|L> -=0|IV'E/_ MG]*LYB"[TF966?@_*D>6M?2(UL53EY!T|M79#Y-'Y>W&VN(QUUT@%M<$@'V] MTXSU1|"K4P0W*,9O@K5TO6W)V%UB%;DSE)N^P+OB*)J4(BE+DW^MOX77I)P/ M1 -23BF"P^F!@:&+=RP M'[W%SV!Z[OPADI-*=<7=TC2A1 M"MXX;--OSUVUG@^PI/ 5G-\&S3[LI*?1_(Y%J>)S\3!)KRQ_'WO..?=FF,O[MMG:&@Y2З\GB/Q^V[4N0]%T/P,=@X*E759)Q1%IRG16;XAY.MGD47L%R]DV& MI7]H%\K26FUV\)$FX3@\35G;CVLOQ$U6: MAOB-"8U^A_N@^7.$SL!BLWC-$LE.2:N&=21L ;@;!HZ&]@0W-;69BP*(80+ M>(\E1KG:651A]OPE94!%E&FHK6RZP*8&'M]+RK-# :'@N< RHZ^T#63&ZK,S MSI .QY-+B9E^)P04D!C.KI^TS>;#C+\3@NMKF*L5;5LU.["4 .HN%U@[N M3P^)sUE/\>70#Y@ W+*D1"1G9[G2A,)#E2>%T E\ |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

*}W; 'XUD!9=\"L%PMEG6AL,=K_BW.Q7S*T3+,0YF: M$#ZVAVY-"[U#+L8$1*+T[!0#3GN3@+D*#VE)U^.!!=XGQ%!E1&JE-_O.SS:H MY1C(!JN1KL1C:L6$ZZ4D[3E1VP!4E/[5VR/$,MW-96[VOML!'+@YP/H5-CO? M#KT(5!,,K:"]&,0_9K,BX>FAVK;]RQ;[<1380N4DZ9D9'P$ M4&XG1^K"!U28]"8Y*$$!1JO3<1K;?,\H B Q1#%,9,EI9'EAEG[! B.O*D/[M'9S=,'GL<\D>/VO!09E\/$1W*H$[D7\;2(TH7!&D>)56M:?&[LY@M!AG0Q^9 M(T;F3#&^*+/=-,8M?AW8,IX8I5DCV7(2 .$;O7O*$"[_>]7XN^0[<$0%LO-MNZ,LA|A_X:DZV1!D>L=#[_2 FTP/^/D'3@\$X5'K2764W=/PRMV13O2*REA0) M=M^4&^O)4O29EQ2!,A^7^0?NSSU R0'? %,V"'TRHPM/=%E-TXA{HI#OOL> MO]BZ#6PH%S751N&T4L/PI#TFT=7E3!W-GL+6M[6#O#DK*OA>Y!V7#,@<{D|= M3KJ>PCN7H:O#O!)VHX-#V].I3^YVU^UQE=-!8B]RRWT$,=9AF7$$H:H6^CI MEOR[>1VZI$JGA(F34'_LO!D+|'5N!J9U|UENUHW)K@F!/#2((+Z%R *,L!@H M.V#%J1X<<6,E-87O(([U2R$P369&;7RFZP4IV3'"*U\FFZ168!=19Y(Oj*$ XFU)A#T!Q I;[\$#JAQB: MV CP.S~~~~8@D*2P"*?IPCC5;0[URU >D-)NQL1_N6[!M:[$'=T@356D"H?% M7[N42_6Y;@XM-3)M>?@ZN^0DQ/;.F9EDA< ;8 9/VQU%[9=&FN6;X# ^?; ^]+>KY[P]NBS_N.'1RW[>,9HY"*A>7R M6X1@NOZ%8MP !WKB& ^L/VQ!6OH9*N,\5 Y\QQ2F0_X0IU,GJZ4'EPL1F$.P-M1ZM0Z\,W'78N:0.#D:AF!2[YP!;A2[5)#V0*LZMORQY3N6"-N&3;1(]F6RZO M1[T4DQ5ZX19">.J\WW49Y1(O[;7(++HKR2W\S(HKK$OR9#UP28F[V(H ST]=2 M$B9" =,19!8*,-0R27C;-)U7QE2C. M^>."4QXRG95KKF'FF.DT?=B@;#K[D MQ46FDHDR+7M$YX+-H",N L'X3\0"[/140"]WD$0>&['H^E%RSOJ2;_1*B3!6 MX;-VQ:7U6- %,R&ZJJ;T vLMNGUN#[B^Z7S;,L'@7!6X'1O%>&->Q%_ 1#;M M>)TL. ^K"6_4Q-K.?[!U>4U!U[@.\;E+DV.B6RI>YJY;#ECRS%|_>OD8X,X03 M/%<9$$I6)!,BDYF"2V:F2O 'E%DS5O*G WW1YN76/>P@0F"U-%9BD|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};\^,.]4+7EJXT#M<;Z3,R+Z^-E2EB#(9FZ'HEKF&7PNMG U*NP.C#M)@ M+!VZ!"CDA[X]@=2V9!NFO19@F[E]'N!NZA(SN>Y3V&R'JKE(#]ILCWEW]= M^MSW810%],D#QU) W&&H 29*147H>+U0R! 0OJ6<&6O MG2W8^@HM6FUZ05T.UB, 6P5D%8?+5&SG41ET253]\$H]G*= M&'<8_5DX":.*2F2@VT08:N.E7<4,Q[B_:ZPBUOL@GM7"O"#1XY+QA21D0MP'0 M"X>8L5B85<@B70#JPW0MD'4'?,O!VU 2F[31<,F5.E^Z? 3NFEN<#*3B.'> M1IBTH$EA(5+H]\U?^(@PP]C?J `[">TQRB*;'LX1E\JJ,\$22>3-LTP/,@ M(^U<.I"GY$=%-5]?&PMNZ'#^.>VZ-GS>9ZJ]1F*'+NXD87QWH?&J16 ^P(Q"KUEOD%K.98 M?8$U(C$V"TDB$(:8?JP*VR1D"6=_;#E#UJ-H0(%L!2<#BH.+JJ?0BW.IM:I MX 3./N$_C\W:N=@Z6MDI(E.Y:,\Z+9-YOLQ+>.]_L^3&EW3F=.<45IG*43I@ M(\.XG45?TQD(.VW[HBY82YC"+[(*3=B0\LV"L. \106+EYTXV$7I28AB+ * MEAV1 N9U=EX0'HBDTTO5I+6@0\=*<.,4BG:0PHVC+?]E>@]8]7 P(^T<0>0Y MJX6-.X92&,/G7(8' PT4CYV/]PB*$"@I_J!USI:R26:!9IA2-9QZ'LL38@W$0,+1PDUO6AP#HTK-C7*]H,U]SR9G;+ M5=3 "+'UGF*98_"7 WRD'(=!]>#X-YS4_*8*^]RLD+U"TR&\%,6WA0XR?6W M-K[fC$M@4\1>NW.<./L28\MC*;7[I92;C*6\ E<9C+S!T M,GI=O20=@C]=0KL.KT,M<8%7V"#DEJ7VH&*7J4$/,? J$!C5!"]*Q5*X%M, M6U9A36P@@+NC6+V?]9(([4MFJO01# */XL0+2KM=?K M(>?HM796 SE1U2FEG5Z;;,+W3U6M/%08F^"R4)NO"MGTL'UR:WIWK) ,R>G> M1_OMWYB J((:)A)^,D)3"8P!DFX1*WBQ* M%M!FDU/[H7X'1,M+X9A[?IFOT$/5;ALDRFE?&[.%9&%V* N8 K;7INN"K>;V M"/8VT@6A[K'4V:!UGUY&C\$VOW@*6^:D1?7P([XGH:$T)F9;*&:- D;V'&BU M'>I=NYBJ5BJF>4+,(AUMVZ-@H8!V&F1CWOOQU/>85R&,Z00#:AU!K 1F5H MVE(};\^,.]4+7EJXT#M<;Z3,R+Z^-E2EB#(9FZ'HEKF&7PNMG U*NP.C#M)@ M+!VZ!"CDA[X]@=2V9!NFO19@F[E]'N!NZA(SN>Y3V&R'JKE(#]ILCWEW]= M^MSW810%],D#QU) W&&H 29*147H>+U0R! 0OJ6<&6O MG2W8^@HM6FUZ05T.UB, 6P5D%8?+5&SG41ET253]\$H]G*= M&'<8_5DX":.*2F2@VT08:N.E7<4,Q[B_:ZPBUOL@GM7"O"#1XY+QA21D0MP'0 M"X>8L5B85<@B70#JPW0MD'4'?,O!VU 2F[31<,F5.E^Z? 3NFEN<#*3B.'> M1IBTH$EA(5+H]\U?^(@PP]C?J `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fC$M@4\1>NW.<./L28\MC*;7[I92;C*6\ E<9C+S!T MY,GI=O20=@C]=9

M0FQ&S^4#5'"%VR'2C&?$;LT)L0A<'O>&,5'"%VL8L>^RU"%JF&!4TY?1+%Z3)MQ-M54[QB8VG'"P*R=@?A,;6D#T56)3W\F-;9GHW85'H?VX;62GLCM'*,9QA1.B-M2HJ#[.VE* <714P"QBDUU[|65VT(">29V+RYE+ @&9#[^%9+-WN%6\Q;,X,5! M;RB-R#/Q>DR0:AWE\JZ_6]#=5<::YJB"#U-=]#U-M2@\%FBN1";,!?:L#BV0-MC=;WT+V/LCFH01F"W^%,&-NZ[\I9;FOUX,]0LFJ; M$541_&M;39E8-3?1,62[#PZTN66B86MU?'U+53B6-M7AVA4-?6 MB-'?O5,$$5OZZA/\']?8?[54T'G5.@/-,@15ZKS":,^-KS=+]U4UA;JG9SOYG MDAL>R$1E!\H'QYZ[-MQEU|&Y9P;#26?/"6RB$&X6(5 +6^@:.^C6NQS O2?PT=3N'+.^?*'CMZ "V9Q; MV7KV9DBGSF54!PTOR\,1M!(?IP^9>[+!*@:,.#KU\:C@Q-YGX\1^LY"1-M%5]PK>.=" "G'-B.0KO? S2H=_!Y$+Z484'WPQAHJ";8-MW1!B#@1S@7C[59BG$F!0P#!VQO">QMF&=]S[$S3&'A0">+WW!XX W8|OA3]" M5#C/0?N2#P)A)E("H,)0ECXXQRMA(OR?G\&E3-TG7X$#MO@52O*9BK-EG> M?KIZR7S)WQB?H^_ FI-IGV5[?WI.+WZA+E+^@NULPZ*:6D9EX'@$&,LNA/10 M-DTH!$"!T-8U%3G9RI@"T.$>4PUD\"\'"T!K:E6 *%-H9LRC>1W+S,5RH1=%) MGBDX-2R6(F#!,^?G\W*2Q7X,'#Q"*A%G8D /41 4TM\, &%,B%0 M"B044((H0@'5!21E"+,Z,D^-2^WU)PTG.^%XPAE&SX%MW5YR>B-H0C&]/(&L/ M01.&F/)$/>G:JSF@G,MG<#@ TR:!OJSBS98&DE]T+L0Q'U=1B"^S'!W;5MYP MXMRP1)|+P/1)R"(I-Z^=QU;U35K$"@EJCE^-<\-U+%"B^2NRC",IZICG&O(W# MW5G)4"'6/-<-@C6F= FY\8>6BV.)=RC3S%)DQWS%%1GC,?TQLC\7?$YK4G/ MY%53W" CI*8ZQ79$0%]59#5K]#7H,YZTO2Q?VPPNKU^?GOZ|_S[=WRY.OQN MK"!%Y]U+:.3N? 2NXY8D\OFO.^HU?D!,YW8$$.7W<,D!KV .:,7U+?G#:E,"B M'!/!SIV]^1:KJC MM),9(O583/HQ(DX7YWO,]N(O%\Z-]6\(PNJ^R>^T3]9G5:E*=G)!E/SV6"Y[[=2@]=G@$2I M&EY>L0P[)0L'8/>G]6F$I^GX7NK#%\-7TNID'P-95E?9 ,GM%1!%65! M06DNU!H&48H.C)+0(> 4ZC4C2ZNJ=_EWPGO?[^JUF K)UL1E&W7A%QF, 5-4 M%YC4.P@WG,]WVVRM3Z2_SVXF'2/TY!?\U?K6.FW$'=<\2+WK%0M^OIXI8^AT MC%B.] Z0,GK_!_5O;9=NHN<$$FKL6TCR!K62;6 MR% U=^4&AE^!X5BN.WENR=_:M=!EY_&LF\$U?A*&ZGFIGF/-F<>1:@TES92 *,. -1H=\C_GC::UZ<4.OT*/)(]3(VGPK$*!+[`C M">)+9P0#KA|LF_++,RXC((0QU6(C/|WI^AP0Y2$=^$*-HLHL68>;O#QFUX(-^V M!H-#+O=/6H7>36+^DRQP_QL7)!GB/_YJ0'X[5S7U&CE1.U6%8;P\8X0G*.Y M/*5$^#+RVNNT.EPU6GV4PLBQ7(YGI;P-ZNO#P/_+5TXI>^?WOZ? RFWFN6D-) M,R4@RD-!.,6<#X:=L882 / G2Y7M1S^TKTXO\G2YR-(%AO_T89ZR&%B0\%S% MI <)!'<%_?@6FZ("$5/)!<_V@ M]F1% =(]$(\@E;-W'C1WXBW?U7+PH/9&_Y-UHAO'3? Z66MWL/;J6D^SZVHH M';P U0+1'6R7\3'!PY[QN.^+=E=1);++U0@);N(^W/;266 8&C[*1SI'L,K/ MVW$|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`/OL9SM>O1NFV_VC]^?S4S7[K/ MG166/8[DZN42N:K@\V !"U-^%<#-BV[/Y4HMDR M1S.IS'C$^C&^D17.J[(EC(;$?> >MV;CY* !1A$; ..Z$\IUR5_K5W=R/_CZN7$I?^YWE$S&2[OHF^;R$U\ |-MLIE*-$)L":$D,Z:^DA \@UJ.11E:D;_0E3)+.K4(OM.,S0PC*3[9S7(;.PT< MS9991Y70'"9K38**+]TWTM. ^<*.H6D)9#1G_C+16D7U>WY1^?/S]E.XQ,P&(C M/F[]=.H),8F^2X/W',6H;Y2=$.8^CLT?- %_)TP7.,XDF(]J+P/!0 MR=")*?-M-Q!#^[%*GJ/SY0-M@UI9N2?:9?MXK>5_'E__^57Z7)) _)=O-),ZP/5)6^+' M,'DRS"--QU*A]2G-G0-G^[3K&8Q)=6H*M.D^* fW7"F=PUZ(2PWZ6+]M^#:9ADH,*W0\S;$;.K+H,',-AMMPEU< M#F[;N$]CMFEF ;=71;D'U\XJZ0@2':5 ;Z8OXQ!EGWDECBTG/%WDXW0BTA#/ M$++$Z1+';,] (ARI;S2@P+CODB72@ET#HV#7*Z\;Q8C^NXL.W<=EV@"U-MUR?L MC|ONY.OHOI57&M)N53:K*88CX=@]$B:9?B0:-U)|(2P30[LGF;S M!3H?:\.[-"@X(D.'*$. [SYL$=CE8)H:%2!Y&YT6Z5$R@.",-0KDQBU+3AD/9 M1 <%H$WH-?A(2#)01<<+|>1/ILX']/IL<7?LRV10.H 42C*;_V9 T\HBN_+P/SAE S,EON8$L20"^' HE M)[_U=-5J-/IT(N>,+)L[N@B$CQW"^:Q#>,.FQ'6M6ACVLCLI?*O]>'P&DC(H M9S4\3\0LMI>[LMC[&A8ZLY!-\JE5*6FC,95L)/@C^-MAK](W6E,C_7K#T&Q MP'RI/8K>[[*_,':\^ MS_X106_L;5,P@81GX@HH8&@PQF\R%+71%E,UB.9|N3.Z9B;J6K|MWW_"EE MRB:B?JPZ;M'@DZH"'>YHYO1P6|'!5/AF>]DL?CGF;L7N2#TR_R5WI2^-L;3X /0AR &/@YE#![T#)|:$!B?1#9M E6G\B\1$D*XXA M60_,I6GYN 109@,Y&H9AS7-A:5Y\7GU]C3S_/CN;3.T9/R<96RN5NCY^UN6 M:9B"B@R//Q'5^Z]_!5:Y,/6DC41HLXRQ899ELHY9WW1+=6')7%,WY5K^E ??+_7+]HQL4);7 M .),L-CL6YM=8?RY'2*U(OU]^"O>5K^^2:6I#VH_*4!:);_%ZVT7F'L<%SNO MG9^3;V* UZ_UA0(0$-ROY(-6S$1-ID2GUL=[XX,>+;?+3,FU;*M%+R_1V'<TWX;M]?R--|[N667]NT-D!U:./ 0,@_9YB@6&D=("^6C:VR61AP@LT7D^O#I$Y6NA M%)$/|D]P$U:>_M|*?-\,HI:+!;H5M7@\ [^]V"_KO1&$X>>TI^3[#ST2WY;#8N M,=CYD,B=@BX6&)HK^VV[6P\Z)R."6UW.R*8$D|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|/4QSV? 61ZHQ'\U5':I\2/5A$K59FE30|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f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

<;(BCJ.=E`D;9'$<76+^%&R(91#)VZX9YGY0S`M@)B3WW(#69(?!MTB#GYK;__"= /@>]HC13:-]H0Q;XO\UQ;X`M>RNDHA8]C4DCN-]{0]H=J=N_I

KAF#>CWK3[.X,/]&AD]9LSXH+G/=$*J7!F=NZ`KCGP(=2;V`M4&'@9X^5ZL//4H(SVNC2[TY(S,+]>2QZ8NJBV[\'\SJD-6+-YOP9LB>8);AY+`MEY+YK5*^R<^J0-:A88E7TP[JJU*QLV

|`,#CC843N3-!GXI&P*0\`#9F-Y+,&B$A%N]Y[2OEDX7-%BF^`M[`_FJ&O+L\NN+9'0!/GMDV9,AM^^+G\^E,O?!"96'6U@0D\(>52M_J,@ZX** MEBA;1J-QBB;

"I.WG^^FS^E$;G;YU^NE/C,@LRL2^Z_17B<`ZS&!,M>OA,4@4'F2I(3OY3`MQD<"P'0",*BQ*C!9SU41S,5Y4H;8"3M@207YA1"M$E=Z>$W/T'R%@<Cs!4=`M*T#V81/,'[@56-U#J1

YZ9EU@#>^;,*AX$@=-8#94&*>"&\]TPNI.>TN-?RKU`M"I/9SM:>0_IV59FL0-YM+6O[._W1>7RP$Q]3"/*DAY#:I(S0Y#-@5@C4CP;J`M@1W3^)L`$.D@TG$HTA%_$3J1#B(=B4C'A@,-

Y@*,D$F](@$>)%8)V1%RS09]&`MO*-+C%[)5,+B%KF>@0C&T0C&FCQ'B%[1ZO=`M"5,0^5M5_=;,4TE%%40/4AAI#KB5PG)^),,TB'-Z,J9<,*DK(&)]3?$L32&6

MQ^X+X$&E0.EA.BA)LWH*2+?>FY5P\UP+QX7C[":?;)&V859'G?;P\'-W-[)@P`M!SY+===F)L7S7IX0M(4&RF#(0=3,MZJ&L.G@U<&+@%I6A?3@e!?

E>\K>D2PB62F4K%V9PV@R&J+01QBYT(?E`M\G2Y5*(KQ03.QR3B2\0W0?$=N6_R[&>,Z]#Q\.FY(A:?#GB*&+N=9NECQ\U*W`MV;.X!TE\3X3P6(4P3AE<$++

(]4YYFN&+=*'HUZDK8Y+EFP/\8`IP-B].3F8S`M$GP0T[F#MT[_2U#21HA.3# E`D5Q>(AG#?T-[Q+=OT./Q4&\]"F*.#(@!>ZG

MC]2K+)D#]!3FGU,W<1I3JC.NBB\10$'0=^P1!&>B]DJV38`M60?@"__LMDZX)9H:*A.V]X3YK>-A9QS8*R,R)VK!RB9"REHQQ*;""8(*CB,21B2,2%BH.MT0

MVQ@72@-9AE;8$ETJ)+"!A8@=+$;LDQ2Z>HMQ%N0M4E!OB"/51,E0%K@+#R7/`M[WCQ;$C>]K6X1.B.6N@6`K00VI-62!7%>A*.8$!)WN1*-^L&ACE'@M_=8LA>2;Y*?

$,=_)9_T(E)#I"854A,BD54*`MVHQEMXDL(DI$E+*3G"H5TYV<2G-&B@C280O2@I1LW_HTL833CK-,\P=>7"[F`MDU8%MN32E`M`GSCIE7ZUIMF`MHQ!*

B(DHQFK0(SW;>/+3_M;|^'ZS96#>D+.^"2VVR--N0J1%"N'Z`"WV)N^PA;I"E)5@-B68W95Y6%#\D=<3'<6?SUCV-NAYK)==(%HP1!XZ\?P],&7=A_OWX`7H`M!L#WM$>*;!K=R??

=;`60!W_S)=2L;LPC2DSI%YHN>$FKNR,`R6K",8J6__7[\;HE`M`9]W"83P@5US4CVDB@9XI>E(WL9HBZ$9"^>)!))34/VD@M1.4*RET1\B?BF`M`\'OA3BQDV0OB?`2X=UA]I*+O))_'-

E+^+\"1,+%R;:+_,)*C[4E& G@H@:@0GJ&$XZI6HF?("I0;@)%O0.@43)`MZ*7R$(;.5TD+Z,N^K_JJ*L*),/)@QG99(/]U\^D\N1UW+0)'.J3OA";JB`M-OAK`56$ORI^I/"&>B@85"

fGZ&5)?@E;8FX/+%"KL$"I>YCR`M,\(2;#";<>HN&">SQ!N]8\F.$SB1UY-WMRY&A];@<`M/QA`;JBM$=_%$]):%4WY139E8%1[AHF6,+KR97=2[EQSX*7__%(LIZ)MPK[7`MT!`/,65]G

KHZ]I0TEP>4L*4B>>D3+T.26G#O*Y`)TA*-A+\$?eZ);W8E=V;`M97-AM>&(3*1C(5HB0BCXU+]MR*.&IW+]DC C%CH0B.UW\^-#!=_#8)5X+|`/8B8][&GU!U

M)B4Z+4,5907,34I'"QV\,NQE9B/6I)T$#\Z8M5IHF]&R`8X!K!H-5_,$#5,(!9`M'6K04$^PPU1_0X?O@E4.P>`^*_-GBOK+WU_E#"*9B] (\/,14:WU/:D]!7+?E`M+]?

UBG2IF$"#IS3X"+7%9J&7<"HDU/`3Y[.Y70<_Y5&IP!S-.=-#+,.5$BQZ^$I67)!6WN;_KDF!$-//A.NZO4$A%AN8K`M!6+@"`=K3,>!#R.TF,QYB/6:5U!08&.K[2,T`MP?

24[""7W'P4VO(HK9P`Q){_E!K(D`7@/U#2<_-,3%3A=+'I[`MF6.Y)-3GQC[^9T.1H(L78$^T'4@.4G.JBJUS`0<1(4;=SCFTIV;5'Y`M5?

3!6U'(/(S1OV&K0#6$PVL+EJ^:-H:8BPE61#=JNDX\<1G2H,_$@-`M%TV$(BKZ$"?:,MQ_5*$+>;^RP(QXLT'SK`MMW'V`*FJW4!$_P&&C+Y!72$MWL@

OD%!7)=YS.T_SY^D!9_fGZ^)NLS[#Y@`MBF]|HERU-_();V@GG\-;HA?3I!?#Q(+`^LA+1.0BQ06"C^BI4"C17CG/??^IG`MDXA!EMR#[05]DS=0BE6<.#1_J-4ZI?7+?,@IF^W@]R00%MV

QS\WO^7+RQ+@`MD^U!E[G4`68A)I=D:]*GZ$)&+W[R$-'@A]EIL")**:,T4_8[Y34C"HF@_U#,_M_(;>/5L(T@9#7XR\>E(JT<5"QD+_#U[JFOM>544H3$UC3MA[,;U?H6X^3\O

M#/LH#$]DD>A^U>X&(9M>+D78'K+#P1;Y`%X9`ML?#;=NTC\#\OXQY$D#;9I3@7R_+%`EWB,U:G&\#6,YMC]X6I@"H2_$;W@'0S`M*S)=Y04\OGTSJBS#MJ4^:>D73#]BX;9J

$\=+!&,:=*,46*5(((4T6.(82-"MGBO0>9YLT*4RD3UO83OQVN1'Q+FNQM%Y.`MRGB54U"SKGCNS]_\X"79184$TPF>HP*3=@_<EEGIS`Z8V%K3.WOU$GG\<%.`MFMRW>*S5H,D,

(?ZZJX#;F4H^VYGB1UDF+!Z1CJ.1CM#^QUJ#%\4'*<6Y3,B6`MZ2*70"G#SB4YY)E$P8_+14MZTI5O/W=`M?AH<0-9BC:^2C]E7<8\SW'@($='11$?'I*.#RWZTI$LIUOUD=

(5E;"Y_>=]:`M"#$\XKT)28?*]+"ZLK35)D*2Y=XO]1IMD78U\VZWNQF7NF>)`M20V'X6>;I<2BITZ_K>`M.NUXT(AKS$/NN^HQY(4-'AY*"PC2!?/=E+^5\[&4O

M:;")1^[^2CHNJ":KM.RQFPJ5YW9;XD7#'9J=H/E#0W-:L.@Y A2+59M!39`MQKK`M:85=I+K4?ZMLI-=/@K;9GTM5B/:L1#[?A:*:.:!OI;OE?INFZ@&?>")W

M6B>8&X5GF0>==@>U&:=EN[`7&]O"YR,MU\U517DJH=P**6P5RA/QZO?GWZ+5`MRFQCMWV50HV<*:IZ8\50%))D0+/-5FU%*7\P4=2(QK!&$ZS+]%%C[.YBE_[`MR\P4/)

*\2,1MQUE@[<4W`UU4?D78'K+#P1;Y`%X9`ML?#;=NTC\#\OXQY$D#;9I3@7R_+% EWB,U:G&\#6,YMC]X6I@"H2_$;W@'0S`M*S)=Y04\OGTSJBS#MJ4^:>D73#]BX;9J

$\=+!&,:=*,46*5(((4T6.(82-"MGBO0>9YLT*4RD3UO83OQVN1'Q+FNQM%Y.`MRGB54U"SKGCNS]_\X"79184$TPF>HP*3=@_<EEGIS`Z8V%K3.WOU$GG\<%. ME

*M&$U+Y0\^:$3^ILU[&&B4N/P7!|+7PEEEB,J?\,V[@9-W:M?? MO#/O8E-[Q^R7, ^\,]P9G|3_7)P>?3O\4[74!&Z!C-,&FL.YK@W-_M&3]BE$N7TI"|@*?A3.O1HOM>?57DYI[HZF;F#BA#^^]2>HZ=H<+*&Q9@XGA-M@/>DO$&IPE437HC)A_!A*93J@2O7(@!MRJ"#(@ULND(<-UX.1\5483RBCI08 M6KXVR_*C2-YCD'/U<)XDUN=Z;*

=K\^$#D<*N@OY$9<=4&*!U98O5. /V (O, M+IH_ ^/-]0'A P,9N[WQ>=|\4$?D9S3,)Q5:,)3;E >] M)R(.U'G),PR8*39Q\^3>M-V>#Y2Y>8*/]V^0(/*E$]WS^T7P'#B% _=,!O;*= M?X0;U^7&WTU 3UQP|- 0L^SP<25-2TD$XGY<02)D:XD_]W:C53K@RC?$]= M/H(]4:]E LF'EGA8T/0F-E>S'0DGG&)CU!_5%3;X&_TN<5:PZK\ MMD-TY:/8AN=BH$GJ?2&VJ2=,*f|*#14)Y*ZV="K2/Y!0L./+?7 MXD[&EQXY5&)6J]EKR 8 FF8$*C8%^7L\1UV$RO-5], ^O0N6\>73;-?984O]D MA$3-Q3F1?;T,DY2S"^F67*F4R>5+LRH7=>OR+I$VL^DJ->JL3]77\5G-X;UG MRB8=AS4M\]AP7]3GMZVNCO,> U6,CW=_>$%&$7^+T1M2'WE#3E1]+W]#RET, MG?*QV .2'.K_^|GX7XZM7###$H6M|0\ZPP007YQ?BXE*QE"EELRN\(O?6Z8[< MB8^>3\M6_<3X_7ACK>T5,3_?3 NA/N&*S$V^(D.G0I0<.SU||SH-!023H,V MRFD8K1)SRU>)A9>]W'N_.1GSS_.\@?C56*,Y^<4^U>47\R!RU7PFMU(7 MHK),_?BB3'6;O7@N|IU_^1*6YYU$_D^D6S"?Q?M,F[A4WDX^,L3'AU.9?*?Z<,0RDQI^G\R_LSAY?)!E M\[YE9X2$15."Y4:&323V1"=R$;X<0:J""M|.)V8#0LIH^%#,,

M@$44;>E6IXNO0/PE.)H=^;0W)%S3%XOGM\7B2RP6SV^+Q3?CTMB"=F_6?M>V MZ'RU[+]LO/[>$|+W=:/-S)Z-4^+@+I17B>B2'7$=8>+[#BA%25?I13.9UA1 1

M"E"-58$M_65W@^_]SU^O#EOMHY(U1_7 ZT&QA(@:RD2T^VF63:3:12CLR&26 M1D@EM+VD 3=%8(3;0GV-VXYU%K>%_O,F;*%X[<1^]6YP_^F@4^UXQ?WC/<4M M./[&-N!E(&K@ATHF1>]=1HI[4!Y-R*_Z4>Q-@ +N*\(?P&G3MY<8+.9"=$V5+ 7_3I M;*EW;:A$K*?IGQ\CU3]ZTNSB^O^=L#M*8VN^VV;UC*>9,E5UN$*G6[HXN#4 M19=;

[J4WO%1%53A4_.W_OLN_4]Q=K(;NTD;Y?CLI?7KZ?GE__"F7M+A'VO0S M$F+80E@F'7 K&W!@&[34";QU<)2F>!:KP5_',H67SA,)KWK

MC\X#8[)OSWI,,Z0[_.H:!%O\XM^4!$4QT\UWO/[K7JK_/9XN9?*&2R9=*Q.Y MCD24H%S\UX@67LE1F%!9>]"7DYE6G\A\2IQ+BAQ+BQ;G M;<9YL#!8WW1B\153+)P(]G=X8##Y. MO>-6[GXDQ*W4&/S1AG4M.2"Q8]LO0D|:]@J,OG6]&C;@/GB3=\!(U.V4[< M .:6%[H\!J;C\"V#MN6PKGEOOG,I$6UP\%^OQ> OBF6J4Y3;=*#MH8_U2PV9L MJ#GO*FN>G0TNG;]

[S8V)P[U"|"[TD8,P*VZKVK6I_D6#:*.%.*/#YF]VD B]O MO/K>BN!6!%<5)M2!*M_N0B^S; 6$H#Y!TGKZ;IM>!]SAK<(K1

MB@^V]M)66;^HO90JKG%%7V3M_2\0I8CX5MN;35G>_@ODT$=NG,A_V MF2KIR)3*F^_O;L5P"X8K-;$FB^%B6?6W(89OLI3^UGED.+/C"Ol;LW X#%7@

MW<(9XHS#&H]I#25H.5S?GMUFP[!8C6TP^EE%Q>E(;_84,44A/8[$&*="]-WI MT]>1_2[_*YEZJFE.Z'QIO,3^'N97"F_\2I_*YE;B9Q*=6\DKE8!KZZ]T8ML=*F M6V(I_0_'K.[U#*^?#HHKK;*#+U^:V4_'/RZ,^VVX:X[F1DEE?6+C[U;_;_7_MZIH7IY'V^%U076PP2@$=|\+&7P=;*=U*Z,!37WCH;01#8E,0VU|!:Q#2^(<5\""K>F9

M;F%KIVV%]&\7TED:$^<0TD6+#=Z"D+Y-,RUBQU]ZUI,1L$O;X!->);.@]-?Q M)EOEUMB[-6]_CIQMG&V&.%N7$USO2HJ'!IV;5 XD[8]&&

M]DPQ6!WX2V.KL5N)77T$;DD2NUAEPQN1V%0S;W_3S3S%&K763)9=]NK\X7GS M\W!9JVR#<7'>422E11NMK?VVO0U>SWZ:3\ 3%\!B_?.5;5W:5D+_>@D=;:\M

M04)+V<7*&MZ"A+[-9H.4=/K8L>\f\O:U[C>*E8[WU=A&WN:R+INIK@)X?QU, MMJ---]E2,NM3F6QGAI5NXS8X.O%6B_JZ@2&UD?5M6S-M>P&L07G,|!? @O

MV4RYO+72MD+ZMPOI+.5MLPOI8I4*,T1(WR86V@Q!UV.WYTD;K?WT^6OY\/;^ MB[N-]BV6 !T_7GA[$VQO@I=/@(:2GK@(%@,0R!4SN>+F)UBV,OIF9#3ZI\V? M-

7:LYYVV99,W@87?-YZKGIV\T5[U/)Y_+AAC:+9]!FF59*"'"BY5+_F"=T? M=%KYRZ?R-KHT;19P:ZR\<46X;L;*)(=MU1RBS7.[V4++F5R^M*55MA*Z+A(Z

MI:F2R[|)4^4M0G2=NX^DN<:.*!5//X]'5V>US[!6" ;PV9&6T9:+)/+6>GG# MNG$#K)6QQH]G'S(&I-MFF+K5\|RGVKMP_HV!#/!D/$4H763*!V:-I+66]/F#:O, M-39M%M ."5-

G0<3X3+92RA2VX9]MW*Z/W$YKZE3>]*FS]X9,GZW\VPC9\"7 @[K!2YL_2/S56#RIVWM9=5IW/9-YZOWI-APQKD+W M7=LR^2/74N97O86_RHR:4;_$3:?

\80W.Y;U"!AZS?,,I575L@<%PU0E_CTZ8 MTD3+YY9NH]V#=*3:,<6EVVV#^^/2)^-VT,XB>M;&!GOD2>5W2],80:,:E=VT# M#@J4*A/G,>_9W;B!8?,*8CB1'7DD^A-#B6"F;@"1C!,3?5+]*U$M/$U4(6T M#MUT>W6;,:XV7,8NWIJ1+%BAF90P|UX"F-C _M*ONM4LO= M#7K/$4:143KZ&LB>-0QO),ED$D3_F>%6^RF|2C\$5ZO8#.8WC"XL+_!Z+,%A MV7<)9H?

UUAH-Y%@XX4O/=>!'WASC7X*3TNCS_[Z!]^[;X*._BY&YF(V8R;_^ MZF[0^9++G=F>__ZY+"=.7 M^FC^,$7],4:V$9G*)+KW1C-%6?5/\:83(,#7#]I M@

U+@4BL=VG+375LEKF'$T>+%MD5,GK09OIQ[7I?MWR_!PY*[?]6_K*3WAV0?;HF_ <^"+=:?J3%,1U0_?AS? 7 M+WR\SQ\/3[!L&Z,S/KT]],L6L#IH-WB1WH7_=DU_5[\!ZK5ZEHF?

Q@!$],?756=]-M8_LCP6>ZW=+9 V]M6"B^";.FDW^*PTN5OBETS-LI4^2&XJ"\@3%@-_ZS/# M\^.!P#YXJ^M&$Q85AMMSI0PM@3]?:+'BY&YVGISRMF^%' AW"MIMELENP0>U!$"

M&PY+=#L,)P^[@NL$@\(^Q!FCX;=,^CMR&T6?*01P(l&0/I6SW*:4?H1+!\V M.,PZ_,T"]H++A;)2!CK23UNJ)2FW;L;LWA0.=`4 MSU@54R45<^(TW-[3;XQG>)'0+GO%..T2?

C)5f\BG(OLAYSM@#&OP-8L_!GY' M7P_@ZR&72(7!7U*7"H0T7>X#,1U63H"*: "?M5S/$DJBY3$#)04>9,3@'RU# MB3]I#Y&+A?5W#,G%M]V#]_M ^Z9%5G-"^W2,!_B@SS#

9.LN/-33&Z#&6HQ(AXN0/IQ&]VJ-)I26?I*RN4 MBEFV#A$K'5]+M*T.6=/%)\KG(ZY%]>HT@"A%8+# _I]QN@'3VZCY(M&V=I<'}00:%8%8M,HT^[3I4-.09S.:LI>D@L,DH'JS3- !+LBS MR0++#LID94T/"\ 'K PP?^%M$E\"E?'SOMOS0&GX_>6\PA+=;U^1F>=NEVNW M&0.!ZN!GZ.D9S61 U9GQD=I/> ?O$!=1A%)% 5-!@8;O"_XEVPD0T&U M0'@-_Q1N.7;/*\G$!;F@6NC1"46ET3>[*$C(]$TUIX(:85.5,5&C;N@QVG2/ MV=O5C^>)6%*PY84@1,Z>DV0JO,;C!'7G@V#-,U;-+U?6H!:L,K^G32C:?U8X(W]>+= MH)NK?

\Z>9GO=Q^*R^CO<2MH&,)A/'3X\,__9V=!/I.8:?]Y'O$1:!!$NJK M!CZA\(_^'4X&?LSK.SLB1&Q:CI/FDA.ACC(%U=&K+_W7?24;2 AC4V MY+_C;VBXMFU7?

5B(_.D?.'TS:.,VI_]*\]T#3SXCF:4$M9X:* S#D-$_8D"# M>;'7O8M13=+K'_VFWX7WUSRC;C7^T<]!HCE-SUVD7]X0_=:_Y=?P3V$P4482 M__MO(;*P<$"?=BI,Q!M>':7SBL:8.

(45K=^A.5"3NC&'AY=$]Z5+R?"(,N- MS2 #QH@'*B|0$8$#2,,L7(K(;IMCOKR&|84';<<[TGC[Y6.4UZ[CL$#;MURX

M%#RCRWH@HK[^V;51(\!WP.3:74K8;3WV>^X&8%3"3TKK&#W3POOU!@5\!%+ MZUA=G,JH|%<8+7T5P5AY0]&23"B(%(_;?11N\(_X4OFJ06*VN;EQ8YY@496 MY%>A,W#

I901Z89X-?527W0W^&Z5'JWS+R<'/^>93/LZ1P[<7MC5$IF"_/[= MH!PT?K>;<(1?K!M]?67-C M>%GL2HOE"D2D37"I'>Y8A0Y-[E:A,VK;]A/<:/_9Z.A.?/%OR=X_OAOD.X_[

M=2=_.8A@PL>*[-Y]E)RBH0\WG^P356;R'];GZW1^QCM9D[FD2LGY"R)?N&:I M#G;9FE=HPX'A;__W?2Y=6#);K=VA?LSE"[F[02OX\?MK^_3S^>>D>SFA&'KJ MW0_;FLOR:=8.

(CV4WF\=Z1;83B'C](!+C!/M]G#FM:@2^NHCOKY*[;S7:S=QVC M=GHPN/U\?C?(_G*N?^_W;K_=;@[NDIC'RA@N6V697)2U.N"J O7_8E=

MY/^UKKW5TEQ8,97_9UF4S)7_E5[9FE]/>GUQ?OZ?)>0F7FQ:\R^.HPK("],._M@T/##L2&T4^JU/3V^O#=QURIE"GETL88+$]>%9_CD@K&MV+Q4F*QXH+OA04L M6]U!9S\F8--V:

(P3L&(U4\FN_*_L]>0LU3PX&#/(KIC/#*_1AA,X9(_,=KL8 ME1UG'=P^?'I\/ZF]=VIFR1.^4E/=L@DNR:9_#,DWA96Y;7NB;DN^K&2,,,]_M/^TTL3%]J%JN9IJ59=[S:W]H6VY?

4Q"AEU!B]DR^#WJGL;>_K+:NOYWV]D-"D7=;5)?C:>X5, M(5=]FY=U%,2&M)\?\D>KA>];V+=><;J#2+<%U%H#]:9. M0*VQ2FN_$Q_TQ>GG<HMBM0+611S"6>*15%<1GHL

M4\D7WB,:Y.2]5(F:7%&[.;LN%%V1Z#LCU=3Y\>GGKVYA8X($TZ!(+1,+ MCY^.K)G$94]7-[F%RWH!Q3U]0]IRI*Q)<H@,0CJ#;3,M@-58]5FH%C.E:!H4

M]V8##6&VE[8U!*\N%398AMVEFSS*RA<5\IEA902!E/81W-O2YH[O!U?US*W|_MN_[IY\-]6C!D@]U[^V9>HZFLN)=LH$&0>"N@#CU@^P.7\,Z8TXBU=(U]&]M%

M#-39'G0W*.9^%FHG33_O-S>FD>;_]8_%X:.PW-W *S[W##HI;1T_] A\P(2A! M%F.,%G]=#]C&M FZ#,6KB11"4U>UJ>PCQ/:.:TP*K0V!Z M^+|<0B>"MV" M>4%A.?Q:'B6V_-

UVWCR>U8 CVW8AM7Q.Q%'S<;SU"/GR0$Y MX)L^DZ ?8,58CN'U0<'V]-01.!6KWG6PIS_5T.HR\'WZT%R!8CB]:WX5>$ MKPK@LHI:U>4Q'A$A"B]G KQVCQ0%@3!

<^[(@D@RT9)KCCOD1^>R0"$((6COGY'8:._%5_&W\G,9OON:]F? TV$1%N+OM7"$3|<7"NZ M9@,#8SL$AH(X8AGZ9P"?]9L@\]B++:G-&0\WY;O[^R0^7*$ M(+3]^%-P}7)XG%$9M"[:K4+[X/X=7+(:"LO9T)(']U@8.;]3'-)09W)+L7&4@U-MY4[$i\,5)WR8:6L3=DK*IRXG?>K";F64/XW';Q-.EX/&:F>FG7I_1_RHUPT? M.*C7%5>NT6A;[%%AO4F\N"A7$\)

<%!'NX.Y5W.5'!42|:5>+LFK; "FP??@(-M4HF#YAE]CHIP=0M%X1W3:EF|(KE]PZ86?CPL%N@^,)ZN=B42/08YUOM1'+ + M&C'R/0;!D9_7T*C\[(OP?%2;P^DD^*,D!/&?

38VU"%X67OK<^(*RPN[C MH&MD.:&:!%X*Y-2W/#R)"3.OF1MQ[R_]@$=" H@'D#&\H2VE.@$]@&?!D(:YG< M_)-6'?Y^)W!WZ:M.?EJ@RG6-

@.2;^)%%2)*]GDEJ:'R9H7)XPK/AAT_X<;6N-M!R0 1QPN#+#PN%;FMFQ4^3B4.P"&T(=T2"W4(>+BQ^]=4'7 -5#.@NK@/Q6R

MKZA$PC#U%H;0?)%)K_G[-S+AWO0,X'C'I4GWKQ+E$F|SW MT\N+1:I[';K>]Z^-G[S|AE)5@C14T#E6245HFF4HT-M13D0^-H)^ G@LJ*KF]

MNZEV%U=KI6FK%\:IM>SNR.)HI=;LD'R"1Y&1$>/70\A+8FI"UC4UR|GI\GV@ MGT ;2=[8NWJ2B8OI3&RZQ,'%7%9P,,/,QY$L8U;,.. M]0Y0KNWK'+E8 >-*^!)2BDC";,3D-2(E+

[GL$[#S>BWX%T8&2F.C S)VDQX) M[%T=7WON$\.PD[WZKYE6AC.!(/W M#.SI_WK)Z.V]]VB'\PYFGD=&<=#4TYQODO @'\,@S=;... M(S[(/BP&/#],.JO57K+K-^SH7B^G+POX

%[N'RDK]\#@U.\)_0(0[^/NX6. M,&3ITW*Q5LRI,Y(N8O3)NWK--"D@;H HQ2BOQ2EOX\XP/XP@POBLLA&@_9$Y M/1J3P= &PBO#

[>$)2=Z7=PEQ#7(#ULIE!,P_E$^H@F7LH[GW>O"C\@$RMW, M:$)*,+= (/HTZ@))XEOP*> S&;G)$ =$0A'-BR32(X5,X 0I(P$\Q_?'"'FM MPQ,1ZAJ,M$/[JV#%>ZQPPLKC-9

M%U0,4D,$5KHN;).\>5PY^?Y@&4=+20%;4!7ZUR3D#GP%665=%,Z161@)K0RHD'O6$P_#Y20S%'0XF MQ1U6[;4-S(/?P8^+^LWA8.VL_(2)NK<4-WWD+$GEIEM.W$"-O

I3Q$AQ8)+E M:O8#ZX0LH47Y+3+%+#KQ8I2K'];!B@A;3Z% R]$2TXS 0/)I$RQK;HJ"\WHX MQG XCF%?R%,>^+??G[_<_CHOYA^6SK,+NF4)GJU.ZU:-8]I4#VM)GE3LO-&+

MZFX2,KX@OSB;8),I%,7M=(HE3]XGM7SXNX$1\;W3LQ+A292'@'894'/L(C^[*B# [>'0G_;EF/ M;'GYUK.TN1P75!/ZCXK[PI[FB;AI]^4?=;D8?B\MKN2I.W0,")TN?]]G*F**7

M0^8W/(M&GBWF0W):*%)(_M+N?A]__/US_U;#4<>2B&2X U9B@3\A;]=51%0YPTLGA"N]B"TRHR2X6 ,"]PQ*8.&W@ N1=\ M"45+HNP'(4LNK11 MC[4PPN[":C:VA]HGJJE5 %

[62=&:,6!)<]?%#J-$T"01'!EBE.5-AN-86#TM MTB1\\",\"EP%7K&M9DH.4?220M@\%.WQ*<44FAM7#R@X]=CU:C32,W3^+]C(MHXJ,2N1R-.0(B83#B$AD[(GZX^=]_JAJ-

95$BO5&AY!&BT9BQ@CK-KLH]>5$;,N3 MCIX7:HY30%)GD-KT6-&3OM@N+'Q_I;%+(&@=T'>)5>LGOP%"NQ"&,4BHS M5HN.4"HO4 :U>WR\WN...NRKJ7C5(*P-

EOY:5"W4YM2/74@DZ^O3:T%O15^;/F%'X_U&\M|[PXJB3Y92HZ7Y4*-P_^;S^W]^^$*2MEY%E\O?WI;BL+_K8@SZO^J&'PB+XK4P/CX25D_6/R:")OZL?AH(H

M3:E8@130E24JX(RTV*3P#M.>D6*:42DBF<|/U/)N]XY^XCOZNX5T?%R" "W*-+B9E$0_?C"]Y MJ,WQD2(R&6=SYT:=_*#[Y!]^5;TWK/O<-/&<<<4M+YOG;,OL_CENCF?

H]=;JTTZL6=]MR@,=P(!VGP1"!]#(D)@?*_$/C*#G#^'[M!%@:T=;PL>&?*POXQ@V!$8O"IV&/]G^U_&,^O"X.KI6#;!A,L)P[X" M$W.9E\(P/%THZ^55DX!&R4[,$5H!?

AIK'ZA'<9'O4:=7I8PX/=84A/*CF7-M6^:76'HG@=#H*C';!EMR(,%(*KQ\/O2P;#.H--EU_=F[2&N<:Z(U<8_:B')1N

MSP;GEZDH"*N)M4VE)BK+B%2O(I(VW>]74>$QPNR<%"M+]G=PTW!28\1P@$PV M<5"X+2URKT\1N:=_1WI M*7W@"00YK9AO96']8Y9W1/EI?GQ$&8R$?7?UYGR

M8<:'!TZ<1^O1_<1&8IBI#YC7M6M55*!^.RZ^%SY[!M)2)5,]Z#*/82TH6@;8 M T$?*POXQ@V!Y?9"F!UT<8ER6\?KFR&4=HT\55,\!%VQ<< M2?#D1DT(^LH.&1*\85:

33UY5@##?DI6:B5Y#?'C4$'82MC!0O% N_C,Y #%E MK4KOJ.>Y\]C#BGA#UUS3OG6_>:<[MCZ^Y-2U(&;7VQ+6R8/$14G9L_E:3MBYY MA/#$Q5QXT5U_/[T'M/+:J-$G?7"I?

[&_G_N2RQN;?=(OU0U]T[/TY9 5\&$ZY-M[ZTFY3]Z+$M?>O\<_*X]7W\]3YD/\'V%!+YH//'W$1]W7.FU^_G1X7'G!9/64

M+#+1U<^;+9*'G6W0UMPEI96T+U+-6BU^9S4]0R7'L1A5Z"/&21[WUWR &_YKZ-MU?)U\B0F/?U5X$/YXEB;_1SPX=_:@:R]GP:<^/KB8)0YCY^Z!FL9=]!?.#CE

MJ]77#^B=RKB'KZLOX1K,1T(H0:".!,0OJ"C0.KGLKEYSP)AVW$>#4FLGG4[/ M<8=>T.R1]2P,7EPE!;\P,,91:6#3CPQHU,(2S1UN@J//<(GY%#WW[P!Y](S

M^UKDW83>8U!K0(!0+C6!$XPAW[OW$?P.W@P#A^BFUZOQ_UZ5,.U\V MZ)%1+S]/H7#\UYAK,.S?'^J.RE.DA9VMS'(, IF&[D&S>?S0:5_]>,X/#>SP MU:"U(\U)T_1)92ORXH.?

PCMD^-6)VZ,0:Y)*W3R-T>",C442!-0'"A2%'AWF M^6VKRSG3 -I.GBGZWKK@+WD2^T(P0@0K5GIGLM@"8YYUC%=2%0>UI_0$3A;! M!T5D)@45B&ZAC$)-$F^%W2-

^E.NP'2KT1>.5H3\|\/|"EN, 2:5 .8>CU?W*[M)67I*: ?7EHL 6>D:Z> .O!S&K4.QO8?PEZ-MO(=$]\]?I:Y0VH(K+!%D%;$B PEIMK%(!EODAC>'W/"BS+_D5$8W1N/%HM=Y1OQ/^J78H!)?

JG3CV$T>|_')?N$ _GS@;S M,*P209A@CV"_&*FS4BBI9_80(S9P-?'!M+)E*D_FF7GR8ZQX@026&Z-5O*N/-MP(A-;C].VDB21A.?-

!2B:Q.^,H3^D4C>Q"%BA^NU>6TVK]9.2^Z$PV@0NE&3 M-,0UCJ$>AIH>;:@G;^862Q^5W0;?2F)GT5UE8B1*-MWV,ZR*V$.2$0% 1US>!T'7!>ZKV P0((,40?

@?A"D))=V[6"83ZQX*L%=&G M;C0)EO=R5%-5PCB0OXSB(%;QHA.D936R&ID_*3L0KUQ.SSO/:'P+1+5RG+ MRUWLW&P!9\XR0Z6.XQ'T^9>DLD!=$>O9%B5>%YY

^TG40=XH5A=_EZ[!6;=; MO#^K/.7K(XO)Y,C/64F5&D#.8=B8G/!O&&XBM8&2S9EK)!Y]AL|@(++&D2<@S M^U-WLV^PP.V;?QY_^%;K;+"$-OE7D*%E &3D=H?KGE8N0Y/0G^LP

MRQON/*(O/+7WL7(QEFKK(B/+R>X7)I9Q(+9Y"BU!,B/5$6"I"V8E#KNEVF-) MI^'L?W4[U2LS[=GR+&U$:\2.T<80G,>K B"G+A^SD'A.NF%SQ&L9)8M_+U^=

MU'_M75PY[YBF7J4B$^>K43);X86@NI[QG$/-@RMNSS)ZEC]Z_L%1_WNGX%7? M?7IE>'G CQRB.A;'N4=<#(RRQ.K(!)W@=J=$HW*7IR22P5F<.,UJ!

M*E_\0ED/WL:,53W^&4%,1"^,9.^%6WVK="$ M&BJYP(D3KA=U6^6WU-AZF7.',Z3Q0-.?X<,48@/+!A4^?*338:9%%:L.?^J& M*L%DRGU:K-G #5P9Q(7<\CBUSW."?"=OV>

MQV[@E?LVI)X2J[*RJ*!EH>[4&9YR-[BL7)<..S:?[H\NTU10*!$2TGXXDH^ M>S=HN%?IBI^WS&][QE(9%=\MHHZX4VX+#,F9K8^PH>U^# D?B>O^'])?H00S MS,L,3Y"*)V-

4(D9^+IJS4%'X]ZF3'+>1&8*?8C"V:0,U&L;X)$W* E/]6L M:\C)/]C@K'KF=Y&<8X73L7B5%7:)J.EX/&\RU:R<>]Z,!Q-9=C>BYENX5OX

MAL7GA<_A]_+TKLN3482A5M8<$7V'Z+E&.!SJWOT\/(<;TM:EA];"?Z%ZDK4 MH^%S9X9M]'W+@,7#)@V^AB6'YCHS.%O;]J&91LXV^VR;=E6MPOW+BSXN\4" M4-L9?

=_K J7AU=$YP.C4W?A&HPM(\1,NF&>9R$$1S0 M;I@-7<-*=$AA!2RP2$L@&8\;^47!?Y;Z0+ISUG*I=E+XFHK+EM&'EWRF @5O M!E]JO\SJR7TI;

81:Z+S=.2J0N@F^8SQO2!3;&RVDOI[+23NZ^4TE:9$5L F MA&'&X8^TNG%U*GTPEKT&$- 48K1\XX3"D6W@[3B)>Q0QS$:@KWDT M+J6!!9ET< MDBL83QQZ;$"D=7

%0J4K=DO8?|/KZJR4Q?(IC-T"V&VA,]A M#GD%R3X]#JXPQ%P?11#"\;_?$+IWL?*0XX7'!G+%E/1+0)SJQ?@LR%,U)88?6F%G;PIFH:?

OUJLX)/D>G&A<'WX9++5=>_G>$U6DBF+Z@M;PMJEUA06]X6 MU*ZQH?]VY'OEB]_6%V_0?M>TOOA-"L8R R8TRE=[@6C)]B36YEH((S^)0[>=:F3H ZSI4;Q)-\('1NI*4U

A)D;;*<%/T]J/6U3"-M]RI-&WE/(YG]9M1D;3$_SCFC('/FY[1$IA//!'MWW\,P%'FS'G.,`M'RC I24B?OY0R(\O8[IPGPKQR:#>^% >S2!SM5F(E@B#*C\[=04')_!*&M76 M"US'[0

[.]SGN5TC:/=A;6Z+(3$T===)JB;'MTF_\: #RQ#$M8Q=]=09:P_#@ M, 2N0WCR"541CQ"3#VJ26#B@0%IAN8L!CU$%Y\+AW?(PZ-OQ@C!A(KY3@ UJZ MK"J"0R1!*AN.UX!

[#/G0UPT#1%?+@2_M7E1!KV]JMA' M|<7&ZF/Q,7Q-U?!^]!%\PA/N.Z SL7&;XE^R%LRAKHJXM$A>%1TV4@N_A;U M 2VV 8)W=_U@AW>RY\-9>DGPMF'4=XQ>-;

VF,)IBM.2]P@&I"@2 TNN,TW% M6E6_O0!]W-4O(YL;ZA$9XKD(}>H(917(85ENDS<:U!G%K4](@(P;A5^WW&= MEB80[]O<^A9M_L@:U:O?

86&^)2;@1Y"P,APY]YKV%;%C]3#1&1;EXL3&1/]%:# MG3YD-)YNH#0&O^!4;$SXMI:#]&1Y !BPU,+\?,4K0R,|_P2WTKDL,I4M5J MC2CXU)ANQB>,"^A)=1"AM?

LD(FX@.50]04(3OHUO1E!.K)IO)_(B33SW%DMM MHZ!BNL*3.#0"0Z_Q&O9CL#3>AW4&(]30A\RP.%!8RC2HB8>KZB>&*5FXGOD M!%W%D_&1DK[D$?

[NM&#WD'X9T>]4L+%C; R$B.U@[,C"%\JH%M3[M/AR5'> MN3]RUSVA,H7AM8PBW#'I%"V23DF +7 IX4T.AA-5-./JP9<[P"_]@, ^"XHU1 MOV@Y?6/Y0_JF.)-

E01/>2;#G2B@[!1)V7A"_'L@#+!FJOO)K2,L"$Q1.(P M,-N$01BC]>P#N-9UT^UA*LVT6KSZ3.0S MV';,A2"&7)6W=2)ZL(+4TAF=

MX)-5!9OS406]B88TD!,+WIPT+;2AD!V;YMAO4.#TQ5K=*<>KB3X0FO.6*'"R6O/)\(U31R QC- 6./Z VU>9W1OBY"3=>SI:) M5D)\^!\.Xj7-!W37,F^8;/#M&-E48S_UO*)WO70|-

($==!)D$&(T02@EQ+M MUCBCOE!j>F^;FEYB:GIOFYK>1)B5;2YVL_:]IKG8S63^T:BIPX%0X=0&%5W37!HLCCA#?M?P@JYG0LBHM,+ M4(\F.L1;I?

GP3PCH(B+5F)H0D6:.LZX//98Y"j,"=*7OJ8IC/O.^1\'KH>#W M=.%J9;_1N 3>#F30@(4&GWXGQIGPP+$T 46" S$NP%VF6G"FR=8I'D^.A@%. MBVZTP%)GZ

M]O&!Q[3WCHLTQANJHK&K7/9ERK-5N;,0E\D)FI O/*-Q(0A]FT<#6(5,4AU;FZ KU< !SCN] M+CJ2EK^K'4N$9PP*BGG//,1(@&)#B0Y5&Q_6S;=%U;,LKQ?QQ4:CY^V- RO/

ME68!*X_BY]IZHCU(;1!0@,9<^6@CE(\D@T@N)MU\"77$&PQTH92[+C#(#HL ML.@/(E*TVE\.DGGB0A=Z7(OH<7@E]XSUJ78P2GTF=C#O J6LS\XJR66@& M^ >(,>

(§:;G%P:6=>SIM-MH$YPU((!^1WL0UB1E&+V!(.M%V:3"9 .;_/;!?,>0R+1VA%)&_]9\!^K=P MYF4?IPX,&[8=#I824[.E%8I">*0]*5YKF]5EL ;:L8]M3)VSDU

M3.;4>UX+80IL6*6C_S^CT_T'WKE+<76,6"AF 3'/B&(Q 36.U6-I4)1(!E9 M(8;]^\3'T()@\3G9.?+PGBEGT*%VZO[EFF!]W\-=L!%D!X9XL2

MU+L09(D!T=V@S7/1Q/CHHV7V##O^U=O(%M44\.$G_T?IL/_T7$XIF4/_#]WS M)/$(BU/HL9HDSE?#G^2A5GI>Q9_'Y5_&K,+R/N5=BM3K2_),\A-U!MBT\2E

MDH(I<[#"DP_/&ZP"VNPU\##SD7S,/"%NPHC.7=14%V7&^XN&=Y_N:Y[" D?27Z>P7P8L0Z3-)#:NJQ,406T?]^P,;7+V+Y@_^O0N/>H346;!&SZ,XSH&!/L-^7WS.%Q_D

M%:1Q9G]!%@|KFAG?OUC>PG]W$!Q8MZQ1.2\$_E=2$Z&?!14FL?>`Q$UU86?1 MO"/H,BVO3QL!&<'KU'7PF5]F.P.O#FH-?/#6XM4&]%?1G+96UPQ+H**;0V'!"

MQ1G^=9F=ZZXEHI& MW]6/*-F%'TBUG8?5>I3U"3(G_5E=)OK&M]WR3RB^WK<.DL5Q*-OET[|NINQ_RK' M+2LB] QV5(O0KRI8T[9BQ 4+K/E+=87D=RNC&+Y=M#=7Z-

Z>_;NT?I9^5=6+-Q8R;PK1.YUCNW*M6\Z/XD^O-.&M))/80 M55ABF%$)A8&EXHI]QX8S4F_<(X&'1H16?U37;&X]^';J>O/R_O"\]_QH?_L6 M>J1'$9).Q:-

S$?,U=6MA/C=T>MW:!,,AJ5(G% ++8UJ2.0\BS"EI57-,3JR+ M7^N 'I!;C?,ZR ?FHTEL^&<'+04]AW4O9-?!A_[PO\59C9_2+,+=CP6 X?U MO#/AE1Y?YC]KPGUS-

]YB3XJIC,4DTZRG$52]F\,]B MP3 .QXWE"-0V+-LG4,;5P*+Z]TH#?2S$V4N_F"7[?Y_]]/:\ M$T5'6I5D=V:.V6*?79PUS22[^TDJ2PI/4L+CZ+O2:+3\R]3[3C,?`YD5!=7

M=\MSJ&!+@23M"ZH*}AB"+# $?)"'H0K3L!Y-D\6(N"?AWZ7$$"?:*EC$!H_+ MZ-CL9>OANT"<$7DW,\FB*;T-BV;9%G=0M7M'C M5)DL3=I0F",VY62J0'IYG>.*

_3R}^/=4^'Y799L<$)_%:<3X/4-G/V4RY M7)PQNBU4*B6W9 57-*^->6Z,2^#@8B(IXNX$-!?;YZ/)_&0!F Q[D!KW63(2 M*+B8X&P(TRUV-V^0ESDO.[?[9T?]_8>Z?UG>-%TZD8.7?X 6605U.87]@H

"?&7;IK_$ M-OW*MDU_F86PWK^WU9!;U/L96&#,Y\TR1%0P\|$01U2/AE"-M X9(492&Y}!2O.@[$_5A#35@KWUTG!'?DI]4HUH;DM?T!*]E=-$U=RQ^H47A MY8>A@8>W/=P0%P* <#O,F,C@W|DRL'3B/[:,&DGFP]_4M')60@R MLE@XX9HMHWTP7YH.XBM%(OW'WV348)PNAR"]>"8'59#(VP*]3OAI4PW+;_A M,3H&DW49A2WXEQ!0A''P#D2C=SW9OPJ? $#CL>AR'G8,6$=2V%1G$"F=@JGHP MF?(:KC662#4"0'DQ31VES3/E8(_>#X%'FXX(L2.M7C(IF B#,RH]+$ ^(J Y M=7PUC7=L,'EW??'M'EQ!/QAR%4]!0"R1%D(QX2LD,- +W'[5+-9@A9==;9-"! M0(ZG.*A:L_!:H>2[H3>M9WA52N9#2BY?E5R46!//WL(98_RI8(SE]%ALQN] MV-;W.KO,/GF#)_LD=Q8V HA3>)*G8(A3$-ENL><(AO-8Q3,+]48HHI??<*69 M,B5"1^GHP'5#6D>)DM'>9>FR$8C94"BD(M#]*S Q?$<0$0H$n:,8*$?80<0I M X&T^H2NQ9Y1/D&- 4M*@%0&C_STA#R.NQ'LJ>2&2WN>2UEFC6;)A!P)HS MRCL$[2"^KPG5AX9{CO=;[NWJAST6[?5!U!(S'WP6 !ORF1ZR($8HO)15(*8X M0L;Y [\1UI;15+;D1\P$$7 #!H"$[F%@5T.T%TNHE/R'R}]@8@M4J](@X MZ(N$RE7X%N'WF(% (3#37891+XNO1'3YZAQG8UT[5/#$W#\K@EF>'N!7P9] ;- MHPC_%@6=$> &,2@#7VH'O"'5;G6L!!@.(L&-;U29J>'0=!>;UO#RJO7V\^_"[]-&W5:-#\<*H'M*A*]4Q*-CON*-49:.2 (D.- ,"ZS$SW@V.$C:<%GWE"*M:',6 U_KX[G[2*>A49WC&T50>'5D@]4&Y>21Z7MID;FEXBED$@)"BA!&PN4 M<@*9B7G\ONB0N'IRVPE')<$3]&GF_7/$$X:7A!?V(0O? W^]&_M)JS.24.C*X%1N,9^8;^Z>F!O'@:%_?Y?LVX/[X.B^O.(T@24-P=V=8R/YI"=E[C9D,9S<_E#LY^MF?=7S=806((_#4C',FRCA\'[+&DPLU- M8@,@1O$:=Z++9?7QU"Yf+/: [_^NF3V5B+!OK7-'GV%@>ZHI;ZT1&I,2WU M-=M6(XM3Q"BLE8C 5(RH1MS0]-^FIYOE0?!TLT<%$=1(8,*MWN!^V>7)Y=%; MR#IO]%E=.)HJ2FEQV;*)Y^]25'TY1*\N!U04],?!]2 4VK JZ7P4XOYO*YK*QE MP!F-16_4EL\!'VN",4FY<&^WWKA;A??>&MS+23.2V3\!CNY;/B3O!XF M$&&62V0OV;N\?YI,F&F8:$!&B MQ,.*F'0QO/)";B]3R(^ODQX_^X/9W,VPPN8AO?&51^.G9.L' BX.TY7?SA8FXWBM.#AV]^NG? MC=?UT]WfO6_?K.O?G8%=**TQ!XV_QW.%O4HU7RW"^:RR>.0"^"P_.EF3T8@^ MV$RR PRW(_H(J7R6-X'W[+!{]MSP3>./3M31>42&*ZIA=VKZ.*$V.@(X<6C) M;!'-M,_ CAO-BWZS>W1Y?S\)0_9%(W7+O>TKBR24\[NYT:Z3DNV1F9;JO)F6 MM>.8A_O.GJO*I^N3ZS079_I\R.(G;)OVGPGC:X_(FF0D5N.0@$UL MQ.U(S6SQ C=KOVN*%[@!I+[R.^@0F5I-8(O&.NMUOM?7*- DTM'!8."D]-6H5)Z^%G8>Q/<.457;*- MU<4#ER^2,21FG3[!.",T/A$$8T6A]Y6; S_.#?_KR9?.P? PUM?/+"[AZE]& M_<5'"<7*RE.**^>1^H-;?_KSXRDX37-H9LPESG>F4R81] [+9;1)QO";K;+HF MFW3M#N[5]4'A\'5Y>UWZF9;K9.]E%R^3F#MMN^%AUC<3(R;\>!-!"F/ ZD87 M_O4,QTXZ8TCFB -#%]ZNKV2PU]KW+DNL7'A\"(>GRDV1RI5^QNI@!N=I!DE(MXS(P! N{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`Q!W+ MXGXKHC&E?T>^W=3U) NJE*@*P=(.&N5H>L!DE6EN3RLU261&G\]B-?"0G MM/'7TK897E$27U?-+]_.KC,I3BP3\]!=1=R8-?-=)S1:9V#L@F5O1C(8;XR<@C[-M_'IW[0Y0BU0&5C'% {JZ_HD,ZE6BRK0[INFF093NCBZF4)71"9 M:06T#WU@-FR4\S:VB7KIW.1&+;TGI MT?!$I5I0,Z5K1]E[.ZW;KZ"M?KEC,P'_&.I$S68@[P_UCAY0$0L9S ME(4*W:)]7KG)'F5+F\Q"T4TE6&@)P!]Y,&WSXUEH>Z%M+[2_-1RQX"WV[1? M_=ZLM_QL?8F!B9GNG%D"$OFA#KP9 A*@4>V9;IL"'[^W-PIZ86=N0(U7#/_X M%=1M'/H'%]56P% [N^,/WQ4S'OT 1*ARJN$>G6&ME#F5ZN9&&U5,'2,]_=;"- M*ZTNKK3 ,G$E?IP'R9CE8^WBZW'EP',}6U,.93J3;5=7(D6%HLZ9TYZMXV MIO17*(0U+88? H2!^]_[LM9[O6^=.8UM=I*B26#SXLY>IE+.[P.C;^H&_0UML-MHL-^],(.VRCEE?T1>/?%HM]IH+-$3&R'IL_AVL29H\OTU&[.'F-)?5;^>G)4N#KY_O-HM/76 MQJOG%/HE5/"BD]9+Y6T5P-^A&,9X;$N!"5^^HJ@=L((SO4*O<;,M"5^*LE@<-M57POM[<+K]_Z,?^'SMA$OVW:8=C+]MM255C_L73/"*]I/NE^VZI\CZ+_U:< M"75^1KNTMBSW#Z^.!%[:*=^E>W MU";? $\B3'6HD M(74D]=Z7^)-M>$?9QM[6Q}O!O'";.B;4.*+38DKH LX"U71:Y0'G0ZY[9%K_6U:I5 {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}_(\\&2*E_GV.0\WIX4OPS].WKRY^O+EIX^5B[EBB%F< MDJB&_4,/*IAY%C"S"0IF__[/0:/>6.X@GXR3L>#!UH/0T%2NQ4I=BP75_5_ZC63D7LQ=]WT/W+]CZHF;M[56'6,\#4S:&AF8YC/GR MY!=_&D[\ [_M_JD.L\;XH=8]3UT,J!3K.|K_R09[+YO M-7LK9:%9_BG6P4.?8NU4IUC/NVYOIT+OI;N?QVM7MW<2IH%"Q^!=]SKQSI+C MH/(^E¥$GG\UM">/P?N]1L>K?,]5 MH\P2.F!L;!]4#3>>>"!1LHNNYUE5[!>0[23_5OSN'_UYT'Z=H+P\3"S3; MF)LMIGY8L<4\EWJ]RL]6F7>4MW* MPP6Z:E0DI-5AYBP>YEEX0Y)9>9FK\3+O/(!8F9>15G8J,$8WX;\ [MQ_LF]:X M%AJ5ISD)YV>8W!*6+]@UPVHTZ+^5*?@L8&5-\VGO"S/N3L/_LO]G>N977*2K MAYK%VV/L;.]6;N=SP9I-=#L?/IWVOM#7^GW'N1GN7- S$>ZMU/6?'B;GZ!._VQ$UXL3$0G7=+U(.+F46L5=6SFB&]T.8PPP?=2+;?DQK MKCY7*SX5/M_XWX?7_U!?_B6ZE8_ZAS988-(+6N"@MECI€+I5.]BUFM5!Z3.! MH2F.;VN]'- >%@"GI=;I7;]I\?_^K5SFTCP9-BS?=:.&S7*T?WN6#3)C]ZS75P M=!>"RH^G?FO_X'/__O&:AW@A7!E#L?XH/;0+3]IC-]G=#1!<7KQMG*+G^:[Y M+*[O7 #ZR:[_3_\Z2 __]#S@61H$SS>_)6A?C/-H;[]I5?;D<\&6*;[NG?3, M#^/KSHTU)[;X>/DI?'^25L6G#P,XBY,?53[L,*<3?1A'{6#Q]P0F 1'0:/U MZ>K &S..;UA?@0*I\'TTTYM!W8+B[?%C\"?C- 8ZL1,ZNFO3&=T MY2]Q-Z*WP\@5D7[^&Q\6"D=AQ]'ON7S+M9321^%+BL1)@4M^)C#U3]Z}>7/0 MZ/UQL#W%N*RS&IK2[LVOMKL+$' ,!&V$^-/3ITK?$4 MKV^GD7O@UV!'AU<'XM.W@ZB[/_XSB59!XQ:4O^118%K2?U'ZA5Y5=CUF%,\M(3U-UF'&-_^]L#QKC>W=Y6ZJ[S"Q_;4O[M*>4^7B\9ANF';]L6F>%WW3Z?]-MWOI<=_^N? 8S>Q;WE^$3+F+]U,#EF=(M*%L)B)W:[UO![:H,7W$,X-+=-&Z]]' M (IG.\TK-Q0>;NB;..F5;%>RO6:3KJS@GQ,:U/IK_XS_6P?U>T0E^G;4]>#=\%+]WQ6^Y #>"=Y@.>,L+L^?- $Z\$G"9@$]. MA9&$9I5E+HN,YGNV;X6T@HKCG#4S?ZWJ)G0[*#]2M@U6#OA@=A(/!,[Z],74WZ=&I\W^_,WW?VK;UE>A[S&,F-1"ZW$9*OM M;<&[3,!:'1OU68R:L7ZP/RU<;?#

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{!N=& .B_GIEWGINTL/7K/TT+],C2\@JUDE MX6&#L 5EV_);_T@'A%U'A<3\49DW-UROS:CB Y[:@L0?[CW@-9+3C*\E9IA+87Y(.%8>3DY UE]N5VEN_T WO,_MQHE/?I5J>$);VANUY9[K_]I^? 1D& M8)88;[SP"I#;'H@4=D%L(O#"}H/?G@8._%C[<+3MQ[O>Q8F(L9CST^!G;]D M+4]Q+%[?/ }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`5'!K6K)9(#OX\,(KZ? 4P>S]L'B:._HQ!(8B^ MPQH[^TL/@VXY1K|FLD81WT\H:1\O/RD]^_[HYI]/%\U4:,]6<\2I*[P2'[. MF9AP/$_Z-OM++*]"I,U!4I#OUA13IH56?G 0Z2;^\D,X+#"E6SLO8PYO6V@N= MLAA+,TY7Z9.7/V]H!NVW?YP7'O)C98X;>M->?V2N#47$K=]#V'.2W9QDX9" M)F^M3-[(2Y;3;AEER=LK2U[[BEOE2>< M]?,"@PO9@OXH+-0;LK_AMX[G_N MX+_T(HU$WC49XZ3BQ.,2[QMMD*.MAG!/>0%BG FN&LH>6+F^;[.)=Y/'KND-[L F+!O7" @BNO$<$;/EVI[&]R+S! MPS+XS@ AA3O*&X+W8<*D@+ [.fG2BK@4;XEHD^B=CC>*'QQ%R#@4&L?%ZVA/; M]!C$9'R.^(;+CFD6Z %%",J 8,=%-B[JE@_FMQG>2$?_)L,O@)&-.^?-X; M1)&S,5%NV".&"J2"@X?'NF[>"T99UR^N)=F.XQ#]6:)&#V]7N0\W$D^NKX+MD%#O4.V&O^-2?/[M?M 5!X/.=?/;,6^L;#4W=,&8,6")K%D50*]@$^UMYKZ@BEEZFP]

#/B-W$W;D]%]!>RQNA!\J+]$_6\50#X\|_>ZQS>?/WQLWL/! M?AP:4NF[[^W\M%]V*C6!-%(.&[G9-"LOB5?HO'3NG*RJ0€)BB=YA$;]W@.M MB\,#4WV.W-4SEEW/=*Z;O^]NG5V*2,^:3%4KDHL#4,-YW3M8/FGH TG7D[CR MJLWZ?#K:!WBBC?K[JR5UZ,;=.@ ~UJRMFZ_,Z;N]^CFGL?YLH';+Q57N:5V[ER K6I91>FQEH[(PF;HU;?]_#O?T_^'NQ<-]!O3#!K%I[^4I]0M.= M2\RA03OC*H(WN.G QG3>F>1+/Y76-_;,6L7\R@),SIKY.P*3>S6K.9EH:M.; M)U1[M-JCCV4

OLQ MW1P>DH=(JM\|F)Q4?Q;*8HQQ=OI,N?6UL,GU|!CO?']]_MW_NO/|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j#>QOUS51Y5%M;A[5O$"\?[^?MNTF^P MT?G;?HG=PWDF/-@?9?VV_/M@NH=%!]14X_S;_^>Z7G>^^#HR_O,Y>VN2WUE+2 MWO \L+:6P8U]DWSOZ9X-&@TM,VH]'6?+)FC9S /L'.]/4A&ZN"=$PEW702V& M:;=GGHAVE% {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|'"T[P8GXXS!4-9'2"#)Z@I7HV3PA4ES;D\|#(O-:;\EI_MX?F400K@(YP MWTO0*>UY,4!C# - AU+-1S"+SJ.>)CGFB/=:S1=S1&29HM,16!DCL,'W0OZ9^T04 5%R_4 MRI,PBLT?>\U>T*B\H-?T[_U5RI]ZD/TP5WC. QL)\S>P3QU8#R6>731&O\ MXTB%/$CF.PH|'V0;MXS?:,$\#OP9/<@B[9 Z,,-EKXB3AR!1FCQ#3M[4N=LH M=KT':$%[3(1@QZ@Y >6%;B1N+7,B|[V\?9X ;D4@0<>T^,PE@"]{.6(HB@6 M,] (88!G6/JA=IGVX4OZ)?*/SL>.Y?T MVD.YM6%\H'G0C1+D4N6Q85]AS$?7)3QT=76EF/#S3(A/'A=^ L@07]VN&>)H! M-P"E%%O&"^\E:,H@2 'LNK29I=T2ZC-_#A'|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{?>4/1+ 4#PR6TD\W*SU=J>-)CE0R3K$R M6FB7F)%RKE&H^D"5YB-S@S_U2)_A^96WO.;;HP+82H8[@!WS'S WT\AV{&O M+I+&_$$[(O2476;8?589WC(GDBIKJ<*R0K^UE=P*_2H9>A;HM\ QB>T"H 'P M^ S;$2,G$#Z:9/8<7+T#Y-Y MUHB&;C*=C''A*QL)B(6NJOG5>WUA@OHX/36W3.2Q- $],\%>>|PWYSQ3)"/"T M9@63S!K'U#[.7F&[-]AR 12,UQ\@4TA8$L\1)HK/4?14_5/>X3!MWS?F"+*M**&24P26$^P&G]M<<%6!%Q%5=R3 LJ!MX<4HNR08T1!WF@? +2@1&>"/X%3,@ MHBP/0,

*G;"D9L^0+9HRNSQ1O'Z1+F?L'8$@TM$2M^!86YG"H-6 MD2GQ<2PT,-3RM]A1@\-@;+:W8/?Z!CRB6>'H(PS^-#!^M\&!X&{$3=H1&%-# MFGYV,'S?;H=2%1<;2L(C' XSLF6@A%" N*9:8VIH)9"\]$=]A_WX'[&V;+ZX$ M'B)&WE= T0%.Y/X.3B3_7+;N")K SU\3UE9Q5Z7 &(QBNB1>O!E"D TS/!! MZKWYX>BRE>U*V\<^D#R<. X=WE%_8DA;"O8ERIB^46QAJT#>2*KMA+Q48 =+ MF0W$]E&_C=93^>W)RLJ_/!*>D8,%_EM_"[N*QD3B741X_0H7!\^/U"L8$A ! M\A)$$G",TPB-%F6BJ4FC\";UQ7#%Y*%8JH<$Y60R:[%)J9I-]|!1[#= YC\: M=OX=#9X*BPRR+8&-MO/!,#4Y&I=@_"^W33HDJFM[KK&%G73D1;)[*O6NSONP M375>YH>XUAQL^2C C01-9KR%&SDQMANEJL8T> V0LJ_'T=46WF?KZ.ILJU9O M'AVUN75Y4RX,9KX+0SI1KD?@&(H) M>E+O$-E!(8)Q=5F/YMF2:I#M"=@$&1MVNA0*E)_]KEF=+[A*RZW;)5EX=?&?N52EI:|25_(\,*,\/+4,\ M*G;"GCQ*D#8?Z%WLB,1'!]`(P +ZK0-WPG8D.;+?\ 7$H#XH]8?&B&J[R+A M;PHZ-8X[]:\H9N78^V$0JG 2]8=,(8(RS1Y&YTL R_XUQ?[AML=GK:TVG|%P M-% FT^3-#SH=9[HRBV^766 +QB^HI(O^&CYPGZBUYJ&F!>D$/;S#+[(K'Q^-US M#\$'9U,T<0- 5V'T>;,,>IHVCYH@MF1F$@X]$ M%Z0!7OR_19%Y1+N@<91A3[&XP<|[!N2",;7G4K'TW!Z OPP0P MIG"209.CI: GV[MG@39_.MO74ZE/>-1#':?V4ZWGV!UE>5P9'/*6E>?7A+;&C M" #)8<@P8'DVTQ%1&&QU<8CFB].3L__]G\,=?33E:,[BQ6PGN>0<<&^O7%<<< MGCQOBZ=`]A';WN@-OM&#_RP,VY'TT+CL73]LEX)A$8;^8]73KA_&R*Q_8Q-| MH9@!DKD/[NWE@WM[N9-G&83 G5S+=SPS:92QES\]#-.$ M;$%*).K9$9\??Z3LDKP3$9N7+=H_=&Q!0\>?R!&3P//A:Rf.AP=X1SW15X"V M=1KPZ>8%3.0 /\,X7 H;V.8RCQ[+LRP4AI$7`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|($#PI =Y!EELAT M/SO.3NK) L$C?(,BV5Q2DFU;N@'(RK<'NH$@4F B%S[$&(*#*9FG9\|$&EM!%'K&$^5SW$7. ^\IG M0.M;E@0:0-DZ 5P_T!=)+!W0G9'QOG$ZT.(E2,AKXK?'M(UCCOVEQB0N$(+3)01 M.CZ+YUK9-!;.;HBH/0&-.QYT+G1PC8N^^V4*8E0?'C*W6-;C\)=/:.=./X3? MJ0[AEW@(OU,=PC_W0_C/P]'3W.S (59B(+.ABAG3S1I:T'12>?I^;T1=T1=7 M[T!P[',/K>]WB-%;5"E95& $>OK01*&A2S"GC6\DN"W6;LF4/TR2]VY"LX_1 M# 6"6:UW%DOAFGNVZ>3H\T /B@:*%S*N0LW K2Z$;>8*4HYK;J4B'I20=7--R,[@ NT,)7|-M!EY96>IHYGZY\P$#,!2F;=:,G#6% Y F4:1!V#&IH*0O7LHVA1#[5G_);!B)1 MLT-I{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

*{6N6N*P+=5#;YE7!55*I"9$-&SX75C(<`M>^`EN.'EF^49\M5+H5,5D,(@R, 7PX)NQ>Z#/PEO88KCGC?@Z).(%4UV3+EB*

*M;4P90PHV&YLFN)Z?)L*U="\32M[%U@BTCMF!X;FI[\(CH"WAP&YMIH,CG8! MR,&<8\&NY&VS71AJC+3;-EMJ^ 19!"Y=2^+\[X6^"Q=NF\>%E3)D*P#9OD'. M@?Z:!,R^L3V?*

*VYPP+!Q-Z_ M*J.1G(D:MPX'9'G4(<3+'$,/'V)[6JA,:4 M.PU)[&N051!%K^/A60G7O%@\.W,:C.9<+)+%!W%9<#C7U&M"KF]!F1RFS!6. M;!,O70|I*P0NO/!DY,,[^0B?D,(LO<>*

*(L+K*72"GOVC6#.)M!%,/FP|VYL M/R5MQ:MHX!3EC[@M18TLMS(L+ ^BI?FQE?7$TL)|8"A3M(O[\N1P!>]&6K9PS!$&JC.1.5=5IK6;%^50"+`V568K9X("(!PS\AI*

*M:@O%:N7B2(B:&E\87HT2CP1*5H"1;_6^I91W.6>CF>_@WX01TF'#'O(1T62_ M'RN;)KF;Z+G,D(A-@J3+,YX3B]#GK68SO>&M1TRPN,U*]Y'BQ%TVUE+!S4W7*

*MT*SH&I9(U]"LZ!J6(+X,W<3D_V_O2IO:1K;V=_T*5>[<6\FI^QEA>6#(SJ3*& M$!*""2,)3+ZD9$M@!5GR: DXO_X]2W>K9/:=I_CL__ZS5:_7_KCVF_0=ZX]G%=.U,,;5*

*M[_+.T(X'E.4:GW@839V/4O-3;1M0F6BQI#?^U$=%\AVN!3 MNJ;@7T&"F8[QM]_JK6I-ZU4)RAF,,7"5N M'@.Z57B) 9*3*F">T.'%5K&_'.#(O"PQ(1OT(@X\MO:D1#>8#X*

*MT%=0_ERR4TRL. ZCV%#AZ@KVM\$OD@*2#-E]$9HO?AS%!]NJ05H+^,5VEVQ\A841N5:^A% M*]EW%06,7ZUI!<-F#VR:IG9 M*8X&#14;F8V--6KV)J9N"B9$\65MD/#:K(#"3*

*L'"*KKO(L%8+G=K<%<)C-!,.45(]F!RSB'B\9SA%8F6]MF+^W'I(.H;_V; M@DT#$\]38684M+8J]#PRA>8* MT0)=IZA7M'"%AH-'$3V2SS=WC(ISB#T!"V.SWPV--*

@B/KC%=-3EK_<+;>MVC MM=I6S2PY:I^!4J M6T_8@\1:@.8S4(EGV?,94LG95 T]$J0OH[Y!57VV8YM4 AN;-V?]6CH&O0_6 M+@B#-*

;BR@2ZV=.DK/=8U;4PO2LYR$F6I=C$/6:1ML]0'&-S8516T?%WA;N MRI$,&5%G 14]8IN J X90/6!COKUQ*85"]D\P3OM? MA*>9+M[!T(.5ED/+'=<]-OFU-*

11X\50:1%Y;4 C#/APUJ8JK98[">TGI$G: MI#63(HFV.6H!{J$1U4\G3#D^=.ZQWQ27AR/68NA<5 GLC_ B+%U-[Y/LNQY M&,)%Q.HOT)WIKGA)SM$M9L>6@^HZJ1U%=;A3%"?

*3V3X&!,]$7)[4 M$7)'DZ&([CV;&%RD!X=K&_0U%'^XJ=C$%]U>0[D&4T?T(>[/!|F"ENIB11_* MZB\IW.1'X5?2\;W,=$573AP0B*GD80REXA6>LS'P?FQ6Z^H^*

*MTZ.'.)0]=SB4:%BM5]56JUWK5LGZ;VNDA9D5S??H=FNC8EG6'(N-W0[V M0*3HLXY$?Y;O-&9?:60>(7QAO5*OT__7D%LU]|#Y15^XH9NX%?]?C(&%]OO'# MV-6K/;JJDP*

*M[KQ1V$]8L"#30QC%0S2WM[=Y'E-[":P/A'LC+ B#O;,&*Z@-Q*0N8BPXH%)M!66G>+H$]HI5:&>@-1@34,*UEO&.8(P<:V.;,3Q&R#T^55QP@!>45'9K,"DN-M]*

*I&/T0CGO2A@\^OF8=B3ZGJ6^GYE>K:U*APW;_Y\?V6%YOI@ M7+,,QBTP&- +[?C@ M>.,^75O=_T=U=BOF @J_B!5.M2,,/%-,9#C.=TK=(3T3T MS"+UW-SK7>4.JX,@+OK(?/>W=]>*

*|O"Q,+WDS489$W&@8R#"/"!A"W$/2UUA%/ XRY2[Y)D*f\$M90:U. MGCH.:K.G9$++$FR" BJGX5;)H5V&]$4A'; 7 K$;GK=$(H M)(=F2<.4M4I3.#-*

*@Q%,GBZOPU0O0O.3+M^_"PKH:B@EBXVGX(53'C+!BYYHK M5!4XSVZID6VI*A&1RW^9+6!6LTOL09TVV,14&|_Y[3)S449@"1!X8#!34=K'B M5TD#Q$=*

*UX#K&%D<(;^@4]!4S4[FX)A"2=/*G0M*?&T"G1N$H-]]TU$KY#@P MB]!/)9*6!,QU(!0&O.Q$K,0I +]/NSO%A"*L']XJ)6 9;1\]&IK+HTS.?^< M6\0H=(L\;G&Y8$?RB8L6I#\Q#AC-*

0_RY M>SK798+%+#!7 ^:0'W4I"L'OB4-:_^RNW#BDEA6WAP!:ZGRE[A,$VOV MLH0|8EV-CD(UDXGZEZJWR1%L 1LUNI*I$[E:E7)+22>BEAR#+QIM >4DX^[_M=1SZWL

*3V6IP,2HNI47X_UK*7"!&1D&K$H=Q'J)-$8KB8]W8/L3+'ZA9N,2 M'E$5"HBL0LSQ9*M?@5.08.C+,@KV!@04WJ4,Q.Q=,6(ZTH&O&)Q*FB7KHXY5WT<1!Y3(DA8|+K0?*

*OJDT">DX4!HJ MO8*DNO867 +2% IF436[9/Z&P7F(9XK*E3C/F^JZ$P99F#.O)/PFIFYF!68& MI\X.(E1Q4!ZKRX=+C[+D63F_JOF1!WUJ2,P;]M#519<3?COR.(Q=,2^"\#+*

M#"'LWZ:F^LIDX<|8316FL<$?HRBB\CN!#:,ZF-7KB-*=".|IDO,V_YP(L& MZ2A.!/P#[YSB6&8YF!K;AESI=485]Y2DG6V_W0_3A!9D8$<)=55P=5UMW\WI

M35.$XKV*4#&>3TGA-BE69)'RS+A1):Q>F!5)22'6'3D>6J7*?HUU#N5I\C<$ M\Z2C,9] !40%3W5QRU:'R(3]LFNM7783X./=3O M4:&'(1"[GGS?F7(Y5LIEA&6J\2#R^JQ-

C$+Z!.PW$BU"?2[G8U16E/ MJ$_WE\Q42@U!?&X/BE18!2IE^IX>(? "\0LCUX,J%0X\.CX"\G- P!Q$+3O

*MA>.A'8WL@9ORN97=%84#OI@955?=X)$J=%9!"42I<.9*BT*K@LOC/.44]FPHES:9E/#1:>@B/-F#0DDV,&E MRXT2(JTFA>S0+^V(RG;'/@%<&.+"D%8A*

*M?!,+*RN9=4\UP&!Z"5M6O0K8Q7'/"!A"W$/2UUA%/ XRY2[Y)D*f\$M90:U. MGCH.:K.G9$++$FR" BJGX5;)H5V&]$4A'; 7 K$;GK=$(H M)(=F2<.4M4I3.#-*

*@Q%,GBZOPU0O0O.3+M^_"PKH:B@EBXVGX(53'C+!BYYHK M5!4XSVZID6VI*A&1RW^9+6!6LTOL09TVV,14&|_Y[3)S449@"1!X8#!34=K'B M5TD#Q$=*

*UX#K&%D<(;^@4]!4S4[FX)A"2=/*G0M*?&T"G1N$H-]]TU$KY#@P MB]!/)9*6!,QU(!0&O.Q$K,0I +]/NSO%A"*L']XJ)6 9;1\]&IK+HTS.?^< M6\0H=(L\;G&Y8$?RB8L6I#\Q#AC-*

0_RY M>SK798+%+#!7 ^:0'W4I"L'OB4-:_^RNW#BDEA6WAP!:ZGRE[A,$VOV MLH0|8EV-CD(UDXGZEZJWR1%L 1LUNI*I$[E:E7)+22>BEAR#+QIM >4DX^[_M=1SZWL

*3V6IP,2HNI47X_UK*7"!&1D&K$H=Q'J)-$8KB8]W8/L3+'ZA9N,2 M'E$5"HBL0LSQ9*M?@5.08.C+,@KV!@04WJ4,Q.Q=,6(ZTH&O&)Q*FB7KHXY5WT<1!Y3(DA8|+K0?*

*OJDT">DX4!HJ MO8*DNO867 +2% IF436[9/Z&P7F(9XK*E3C/F^JZ$P99F#.O)/PFIFYF!68& MI\X.(E1Q4!ZKRX=+C[+D63F_JOF1!WUJ2,P;]M#519<3?COR.(Q=,2^"\#+*

M#"'LWZ:F^LIDX<|8316FL<$?HRBB\CN!#:,ZF-7KB-*=".|IDO,V_YP(L& MZ2A.!/P#[YSB6&8YF!K;AESI=485]Y2DG6V_W0_3A!9D8$<)=55P=5UMW\WI

M35.$XKV*4#&>3TGA-BE69)'RS+A1):Q>F!5)22'6'3D>6J7*?HUU#N5I\C<$ M\Z2C,9] !40%3W5QRU:'R(3]LFNM7783X./=3O M4:&'(1"[GGS?F7(Y5LIEA&6J\2#R^JQ-

C$+Z!.PW$BU"?2[G8U16E/ MJ$_WE\Q42@U!?&X/BE18!2IE^IX>(? "\0LCUX,J%0X\.CX"\G- P!Q$+3O

*MA>.A'8WL@9ORN97=%84#OI@955S7

*ML:W8(&\V)!>%"+>S%_V!H|EYS"(N69A<).*2BMT^_I__#;Y618P&S)R)(WGD-M/W+0B0VN#<*5&AA$F,1=ZE4'';F!M+[F@+=&D02,M$*$2L8G'>;:>V!T7W&E\1-) M-F6\MV\A)(S'VZ1WR F0NK$,)7QTHB)[6#1ORLTL+%++G*#(IUD8*.9[1%? M*/4&,'VX@D- +M5()[\SGIY.J^JUI02VQ[^N*7:UDSX/1=1&CYA;JT2\4&_ M$!V 3 !:B?_A O*OH"D+[*]3O8.[,2K:D5/99?\0ZO6=/UHH"OG!"0K^U47 M[K=*G-N0/F-NF+.W!YY>C\DR5TBO;U:6=DUX_' ",(HIAMAL!)SBH.10_+] MBQ!Y>,WQ2D6'J-56#D3ZJ5 14KK["U'G'H^AH9!T$5*/KZ*+JW<%* AR;6K; M.QO-T3%2TlVA5'F#XG1.PRA]ID]ML=.0 \&AD9V4/K2LX M>5;2WO;IB*W!K#9+U=-0^%RCY.2;9[>6J9S+F[YX.;=%# [:.#J#71ULT* MZ88*Z?WG[%I5X3WHRI5N(WYZCO#)04?84O'V?4){?!=?M-8>V67D>E!^=A!* M,SU_BM$L?6VENO'H+:,?@_C(08@-%?TI,-ZX7F4*,XY4LWBP]S-!6V(?E[+@ M$G_,7YS+WYDS'LUZ3#4=P>$R4@LV_0E<9+4&W,(EBIEHNH##-:L&-G;,\]D C M)LOK92:PUS#2A-[%@EA3E=V#O\0&5YA XFVWR5'(P]HS?3R$?+ES/&8L%L>6 M)U/E?E6YA6'5? J6PW:(ME/W M_)ZW:,[CY EBEXU9%3E 5>VV*Q|_SBN(+W0?&^?1>1 MT^3-=:>HDINVR^)9+^)O}:HI1:O< M%*Z,+!PXY)NPY-\M7EV^Y$XQ2"Y#R#H6RBM=@ZQOL.H<9+T#L28"2O^",)4@ M\9N5_1R(O#]_DD]%@#&*P+5=[_-X\1?%\'J,XA&F47F+ ^/_^@VNT.A,MNU*@+ M)4CO)%4(GYR3UJ'U79!J_+A<;JQJ7UL'J3C%YJ*U0*LAM5WW:A$S+2.YM$^9 MRGT;TBE/#K!X^MX5T@LDE72V-R"VQ5133?< ,3HSM// \@!?(}$.H&T\O+SG MDG*35^\J>5"N3%)9[.L[YS-Z,^]*]\-<\;2P(&@O@!5X8:^B3;Y0HN2J&2N@ M\.II%6+\#E]%IUQE1*^$8 LPL]?[*GKF2R4*=@K7]5I#RK&UL[5U;<^,VLGX_5><_\'BK3F4? M/!['9_OB!(?QZ$**#0_W?:?_^70_[YY'\.#YU+'Y>,^<!^#.(G6U-Z^O.W_R;K_ M$OCA#0V[UU!!VBKS#Z\A+Y7P_H=_ .//I^\07AZ=/S\V]>#HG]^N!TI9G(+# M/Z1Z<^'!JA>E4M5O\/GSYZ/FMZNFI98OCSA8?>/D:,.7.FC+YK1>O.Q0;OS_*.M?EELZG-(%YB,_"I1*LDU#X\&3PYB7R#E8X MIFEBD.PS."?EH-!D]T56!C"6ATOB|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}3ZGX87Q$FA[E;8XJ";3/|_ICAQZ: U^1Z7+O#CA.OW0XA_-'_M&JNCQ.YVU_9Y!4&@QF':H7V^0A0/55E;]>ET3&:SNO:@7'?? YIG\V _3H^DU M^>L6W_ EAJ$'URL<)2@=51;[,6V=!P4.G$,:09C0Y9C\,6_9&B?5D6-;'\T3 M-M9A/"E+880"WR, |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}B//=W.%BUXAJ-{OD&%AC4O&^K!O'-F5=>>]2\BUB(-DWB& M.%E'^4\A6.V-O8&H@0D#U$H-6!1P5V94%(+/[F'F>81 U2)<[*T:H0\:FO|(M:(:'TL<1A#D8O:Y!1LU_O!2%>EA.#8BT 2_/&YD/^(#J<4O?\&;'1EQ.$TZ0K;#C8?7H-DD I^3NAVUN+ M-A,U%\Y^)1_HZL/TG%?XM+/ZMK/YN+/ZND.A/+J6SVAN84XY5_BZ*CO"X:BV#9TWP5^,B.FK$.; M7 7MX6ZSZ\"^1=&.%.X(1&%K(3; *BP.4HA$S? M R55@Y^AW W2DQ.UED[WXLY \3LYAN%G(@2$#5&L0 &_]XDX[5?ORN/Z#PA6"I_IWN$/DTO?"9E-HKVXX_]$?E; %8ZO[0 MBKH? 2!NHH/**]N-/?5,[2PB6ZC|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

*MZB{),K90773K9ZH+I8T8'"%C+1[}6YVYQW#/S3'_[UP_M_^3-W1:E7_76$ERR9 M\3>06&NWQZ53\,1,B|TNM31$}HW;|TKVBOXWO^]S*OD\V*E7&$W"3H=#+>#> M\"B5!,,?+3QA<[T61IM*&AIOVK7U,"0ECL2V8?<1+,QXY)IU(34L--J RD|, MX!+F,GG=3DJG0_3.Z_ZR2%/*G9[%)B5_RU6J JC7JX8:8/AH!5,UYO+3'"%G* M@MBRP2)6P[fCGJ ZCF|GI7KX|N7L?#A84U7K+JR_;?,&>BOS.I=9#T"795C_,M,BE!fG,ZV*JGHKOZ["^+,QW;]YV&E2YD;GK<\R=%9@>REM]P2I6V)GM.*" M'Y"A;N-EQG,AX#14TF*KX33^T@RJ%Y.I%@?3_9@QBG>OMAK<70^],NCK^ZS MZ'O_:V&CUVRAK-6Y(=| RNQH|=>GRS66OTOCLU0:?)X?)S6,J0#8FDXVA. M%=1!|.90# R)U-@DT9GU7&>'0/^!^^^???NW?NT"0C:,L4?T!_/Z"_L?RBO MS@@'9?&2D?AO,/HS2K/FUY@E0HY01E!VHC/$4P?0^GBTCG6BF.NA4@9R.#YV M9<"030%,-A)FJ89F[$)HB?:1/OB7L^_ON?CZ#__|=W9AW_]OB$=7PG;LPX% M!,K"(68Y?=#'|V>(T8(+/=&:J'] ^5_U\ANB;-I@G34W\KUS,HH@?!PR2>1!'MM^EEL(D+X,ZGC?8S1=@K6@H\)UKC" M|G;BA?]3JGE `@A/Z1#IICB$K^&*@f@)IY0PV@C%/`-#)-F6#9!R_<&L,VQH%WTSK S>QK(d(& MS; >1%MY52LH0FESC%IK>6;8XHLYD8]H-EFSC.IHAS0I>&1+IV5]I=5Y#'. MG(4;&!|.8]4O\/QX83TK48'3]OAB6\VKIM&'"*_+)VV/]_@>6Q"B;3NFF+. M*Z_4CII"%"Z:M"Z.E$M _+,1"<#M5+PRRN"6@4[|/0*D%<$@>6,L!_0.MYE2 M#4%(2FF7W#) [M)*{0]&47I\DM1,5'I_FSJD!+:/59*[&UI3+$]/@?HY+EXN M2TK]-2;7KV%2,L*S,],T_Z/GX%6Y/3?!DML-TLE%[>^8CC8#AK?3L8L=),14 MB6WT>IU^SY2962/OY2R""K;T#,)0& S+3C59PZ; WO^PS ?<8[IYWN9I=$5 M)7>2\>16=8&4K4NKX[:OLX#?[]4T"F"898-RR*Y&A^^?1GLM[Q3[$;>4]PDM MRRQ:QVG,V@B+K=.3S*CEDF:61>@2S: "AFIV.(=D]V4X2>GG>Z"\R;R2#>AA7RHX,EC/#A^:(//#E6KJ#"AG\(:"#B'Z M'+&/T# G2_TSYB8C,%ZEU:'F<,>OL*8>\7V8Q<9G4/(%7E(9?QQE 67#)M0 MM"[S1JB#&?S&8QZ2M+9 N[3PA?Z.T=<)U?H&K;B^=[+NFU@S$X[3DC:]A[0] M5<6KY&@A<7]!2L?QC-#)<4!V["}DGF^0S;'I1)BWV@+36M OP)WHC>X7\4IZMZ<2%P).\#DQC.WT9I2/(@AM%&Y)MXYPMXO A):{6*@OV%B#ME):X]J,NJ'>] M5!|(4$JI;Q|*R"*W!5$WO/Q3QR/AG4@ZNC#Q<$RYTN.E67 M@S8-@\ ]0@LF4>CVYOF1^4]YC.=M5>C?"'%'Z"%_]_IV -1Z<=|\k8FU <=)X$86 M.) 7S6<3%3RB\2;$,GU/ZSH2UL!#'UJ*M+ M+ M16Q_@_K8#\4++)MP_41T"G&K,;_,4T)*+MTBIAEC&6K3G6X@"[6-Z0]LNJX[H4N;)G#U53((-W*M&$PLI}{7[J7CO=YQ> M[P14G(5A5]9%@=]VFG13%GI^":;@HAIY[R5H\W1;P.)*9R6%-I480-95GD2_ M-.RRI# D)6V+^_G.N!9I9Q% 5SFFZl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fFUHP=#D6KN"1=G87!ZOZ,E(>U5O-]3O%=960W>XV'HZ)&SE7'U:V$V7) *@2"&#IDD M.78EBQIA[L3=!V,VS2B\XJH#(%)88"KK@=#!;0H/41.U+(8E=="/DIHG MT7|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|CG@;_ZJ)- M=IJL%?&;Y^5ZP_YV%,8*TQK5T^TL0:X$=1. M07LS:&_'WQK2H$__*>=^ +|CHKHY|K'0+RN--.|NMV1*P?,;*&.T0;|U$F39 MQHMBD-|FW|8~8LL1%28Y|=<4JTK9WVHVC|DS'T5A5#34M0!2D8ET)$4 M9(=G;X^?D&X*Z80=S7'DTZG{(Z&Y4&HR]G6!DM(|S*'IOY2;O6C]DJA_RMN-M"AU+K35=$71D41IN6JJ!H.4XK$-&JH9D|%/>V6CRWE?RU+F3NDF%IK\>4EL4 M=>1==;7F>"VO9M*$ 2=3.B$ M'JR21TS!3P"@I >6KS2K!#V.AI)U9;D4#&[HH%D/;9ZVS)L1V98M1@WG 5MV M_#&(@R'2'49-\-8!Y#!+74RS563V[LL5Z70VPO\^A':%2!R>+(($6)48^!H) M?N,[X%O>?N5BWL*!)2U5)@.B>6J6<=Z>^GEN;O*#B=IPE2&5(P$%)VWJ?^&40-I[^GRRLO1'ZFS6 MV*YP'I*8;ZAKCV19*#F,$[.L0"=4S*`|@I6,&4U#8S_,9O/6^>ON.AA_|HYB| M-DB^?_=ANS^;JH\-_^JX\PDLX>\=!8,""&;9HA1=BD8/4<6OM]|T3AN[=B;2 M/+U(ET5.W1S#*3^5I#-G0P^U=3]D8B (H\$,|_X$8?9%=.*=O.47,Q95* &9!O|Y$!01(-,"&.CY LQ5F9)SLT^Q(0M=HE#;^NK,>{I:Q7+%1P4/'?I%?VO(G6)5,H55300&Z9(1$ 018UKR)..)'5B M"DS6<5H1A"GZR7C21=^%Q! 9"BN*^V"+"K2,-D-9!*ILN-ZZ*PLZ8[;LM6@SC<*61=;:-9X+;;N:I!$%PR(1.V-C;RR.8PURG&/=9\9^X]=BPMM^R4_/@ M%QD+(?&6E#H@.#<"Z&C/BAI$U"+:FW1,OQOZ#2BP9CGA-HT4>UV).C9%4O!)IPJBMKQJ/=TBYVL)^@3$],8N/J*VPRY$Z=CQ%2LB**5.<)-Q3?5C^-5OC2P:+[,Z" M+_9.U9OP25>;PNDXJ].'2UP+T+:L;4TQ_C)C]+:&J#E)+Z"+]_+((F7<5B7 M_#EX;;.)|(EL-N.3S+:,%U\:9 ,LJ2V!VQ)L(QFQILMQ9A<)L.'K0T=7EO MUQMV*1\%O(B3N-CHCD3[7AB|AB*NAM9P0BOT=DT6_**\1@$<5]Zf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|MG0EP%!BDP<9^N$?)\A:NR0| LR5[;?4/@?4KOGD*$,H' MD 1/L5,>-*)>]?!F61*;<]GOOK#=*%%I^=DRT19!OG4A50+#'(']=I,Z71 M14$:(68 1|6)KSMO^RIMX:)NP?3+()18ZSFEG@B^03]4 BW6/%&,)YV=915ZJ M^ZRHX>BV[$;H^N6>ICAZ#DH4 7-1C78]UE6Q5/P_M[%G:W%'Z0%9!&O^-^P+LV *%'/%_S-)H3L%27Z'.F')#YPQI& ?)4W,V/)\M M\H(E/1E\RR/;=L'RDWR.[E6U1S'LO96O@'M M7X%^:5YR7'JC2@N[#PK:ZA^6#QME2\MQ**IW-.QRBX9-ZY ??;9:8)AXBBXPDT%Y7H=D!WK MY4#IVD(2LWADZ#W;L %I.70H*CY1!8NK\M!HNN6@!O4M C3@8UIDQ"K<(UA|M@&UT('6!->GS&BB'B*.[N$K&@<.R\IO7.S_M#TA>EH105]/451[[)1X&\2-_M(.G :?Z0W@&DL)RF6Q,%@5IO,YU4[XU91;0%US'MO;9?9>AU7=XC2TM-I'1MM-MP(@,8.JW*;QH:QM1L#Q6=NWC|/PMAAMZINUE-9 WH2^/&-K)%OP]P1%MS2=G31^JRU5@=$ MV+&81,:V%OC5S5N<'CG=5!267O]>QL7.X!$,A5QR30ZP2Z>^!!C&2&$)D4%< M"-*8RV!92.F2"):0G>?%=B^TQJA[W3A:FRQ>FM?MLI@R#<6L?2NS5K_G_[P MKQ_>_\N?43UB!,6@GN9Y4^]!(OO AR'-%I MHLUVZ9%&79+Z.:-]2^R_3#+(^A_U&*(;0)IG!^P310K=(+_@;4B5N7_Z);?E/7 M?K!5D&U#_PDF-0ZYR;?7.K3ET#6/KE7OC>&I7.3X]Y*6X7IK,0"HQ9WZ*P;0 M/?=$(0N&<:XO99(XX]>4A=Z[L1G|8+>^33WI_5R4,EE'F'=D!I;SSB':4MRTHJ;9&(Q9/7M2ZJA>$>';1|>/BF(C60; M3(K=(&'A>FG$5BHW;-)]-Y39|SL-;QM9]%ZLFZ4NF#YM)& A"]Y6Y]O N-'U-MSLLKO,2$X.CR)2 KG-NQT.3D=!'-j@"]-3*M!I2N_GD+Z9USLE-_"5MTM \<5]L!%.UTPO>|(MP"(Q&T&4Q*>X((V883##Z?/(N M1'4(C*I0-M$O0UUD?>5(W/KP%P(D_,41 MYY^A'UA?]X@1GM=MA^ME[T2\R0B.5VD54TY]$-]\B#DQRMI:?D_D^]TI9T7>8)EZ0]N-A=*9[\ P\ M!H;@AY9 N ->DLH?"VN"}5H%8,'/),0\:>MI0M\-B 01Q,7*,GR'&TP03G3\TZS>_REX\V2+*5_#:M<%V-V9\>;<9] 8F(A>^DI M1MH 0|6)P,4^DJV$HV!_H'O3L^6=R4_A"X[*!#\L9Q1?%"ID11-">,H7L6W- M>5:PG;@@27;HJGYEY]9+U+P4L#W9L=F9$<^SI@GPD\HL(+MM(RQ!I/IX^#J>5^KID?9LX[S8]7AE$DK^P=C>4'|_VW:9BM6>SH/(BCB]TM]<*V<50&R;_3 MJ7<>Q7ROBA=;T4V,,>"R5Q]?L&X7;]_MGL"GVGN"-EJA%P-!8*,)K*=VN5#@(D&4OCO1'2N3[A>H>G^E-!@>&B"MD$S1HEOB(;S3MT M45_C"AS]D6]SVTCE4ASW#6#.QTF*)21MI9ANMH5V9 M=H>OY$[H,DK"L@GJG MN"<?A*3XW(\I?[S(Q_YH_0R(Q_)-ICF=>0"V30LXWYK\Q)$WU*M;L]RG@[\ M9K,UBP$Y37TTMM|0>^M_CB,VMLKPWTM+ZY5&N#LX*^AT(Z!O.&]:VQ?,=LQH M$PNVU%ETV\.*Q_L8_=.,A]L%7]B.6!@Q M@)V91HUM5!M'1=9DIJ^FV.XK5MU YOGH5QPFCC. '2;*4\MZ9. *D)!D45ZE& ML+C:TZTREG$U[RP38Z.%H[]JR:^-IM]K-91%T5^H(.B!8.]5HN3U"C;WX'M MG8>729#G#\LZI+Z,R;\OUPM,'L|-FPS!9KLE>N%2KU]-NK54#R:A.X>HQGR1GIWFDH*.M861D!2.EHK.)_*B" MM!-X*RWO3!H-57*7ZOZD&5M@7!1JIV65/*.,F50&/=>|SX]UF6:DVR)\YRR/DAN,%;T9[9*3N-TK-K0"\#1:GCOPT;\E"SZM-)H MB0'$4/~=23$1A)Y@)B6GL?E6!>C%YVLUP!#,"N:08%S)\3Y7IT6P;+%\'NS8 M7@[M?\?7S5@;CO?$"A,R)AN #L8_K,@J8J)KX*[Z54R'D@0UNE5$D#15?AI MDN[U!KH8.96PR\Y##[A+3+DDF.Y"'"V_(+2;,>M)@8L"$0:G2D5 0B.N)(XR-[%M ML5?[S48K'O;D_;6*6QUD^X(PZ"'\4+QXI6@AV86KMJ]S7"FXS,TK2D_G?+ MXH=%$!\"%7'L])P1;$PQ6B+9*,$@UBDPJ(18J6&:$3'*9,9S5M/X2R5O]4 M08'9>HU)'.)G&11&19[[#4T/=&Z;L+"9Q0K'U$X AE& 2<@%BRO;!FFZ*4M@)O*1H^(=3|W>D)VU]U'4M%6TQD)QQ6EI9^=&@SBC<*]BH>V,W*ZP.CF5S?40:U.(X0BKTX%!,WN@*HY96#@=P68K@K&-OZ|0=+=9]@.ZWQV52<$@MB@Z.D"]AE045\IE,2IZS62\A[&1+\F_)XZ3R7[^XJUK#&FW$;"3^QD+WH^)$V MO#/T0.'"]0,/U*P-H3A%M2G4V]>_.MZ^QI^/N!X&2_%ZA^OI^/N!X&2_%ZA^OI^/N!X&2_%ZA^O

*"B"3"RK__H_M__M_C<3__O8?;!Z,KB@)@QJ'%\Q_<^,_QI_XL;%K,'!Q$O2>-O;MR_?%O_+J_\MI-&O/\L_/7HQ M&0F\HOC'EYC^_2OYW>*SSQ^^87S^]OVWW[%[^S^?;N(I)|+PWM!*

(XN:3KS:U M9"M-]=[!\,,/;l/?;HK62KX\\G#SC0]O-^)L6Q;_I9KR)4EB^F.&LN5/'BIZN0/5N!7*O4D6 3/O3V3V=1U0PYD7)V/=9&B5BR9NR4'!(S :,M=*1Z.(#/"7!YB9V5H&.73*

M5^MLU#_&Y!+=4=)_+E>Q#YO'=7+|72;C;RYL*C5E&*+/^0R9[)W=A*=T)>ZD&O(X0)K6^M.Z.LHIF(I>>"?/O&K$?XHC@U UFW-NQ_VJI 7<1P1)XY-0U(%\$550A-9NK@\?#=Z(V:M4XFK^&->L!!D(TO(_+W/A_)&CG$,@&A.3+B#$MDQ%|^R3XT?A2K@^=O;?QB M#TC"K/U?1)E*K$D;<|2+5!X&D$TV"54?HFJ$7&6QMP?,2YZ@,!ZTY;'_3VNZA>5

M18FWR^Q*[(W_1,,MS3-QP%2A4R#!%(*6@1*?Z ?-L?A^(&6X"KUY,YR5(D|MWV$ VJ@-%J{E$XP!V+V20'S?H^+;H%O/,&_&SAV94RFO%&5[6:F?%Q15@,!_MP)PIM-HB,3".HM0+

[\B2<0/P^R6!>'^'B7>3;D@P_]_4XPGAX1J"=*TP$,SO M,<%6:(B$M]@4BMUA;NPR UXO#43\3Z@;#X6.2)#?JYPE\;\,DIHLI8Q(+?! MXG%G,.W'NEX*BC'*H5.E%

JV&TM#E,C0%AV^U9)0C%'.FCKE4'_^%_IP+|R. M O+RWV2M I6%(HTRAE3JQX*U%-.IN1)WS0)DAET914H|HBC'2I"Z*1<1S[C2U8R0%Y]+_T"^/F>|=DHW5(32@7+> MM%

=A91Q$ BXXN(_-S0B[W14-!8'WQA$:.!1#_3T<=11S]%'-@<#^ MP0IV#W+#4>*4G<;P<^J5?@SW84*;5]AHI]P_@SIXF0 M0 ,AI5%AHU'L9ZOO,D5Y&-

WX2.T1,=PF#]G%N*@<%&>6P MIU:L9X2GG$BFB=AV9WY<,M2 3V8SU9/+Y_ >[)XX,.F%',,K524*Q1CGP]H7K&]H8545'WZ\4C"]7A M(8T%H0BC// TJO4,\IX=>E!.?2BDD;\?

<#&B)H|\AG>]E,VN&N;$"..X&$W&-JGW' M[V4A/S*K+U]D^+%+")!OM776?B55: L(-XA&M1%H> G M%J8")9XY@G+%&% 4A4*.>'>H4_`]S)W:MZN/7GZ=AWBJAI0X!O?7*(OFG

M)43*3%?DDN\0D{=_JH:4/P1+Q3UR|+YS_-SL?#,F?L.O%(0BC:B*VMC:B@@ MWR^\,*RF(&\"N5(0"C*BSVNC:B@@7RX(GXM)|2-GS\E$=-NI UM1 0HZHF>K

M5E4<\%|V<>1Y_)L6^8;2X.P$B+ KE<1*N[%-]GJ?O:C#%.CCRD-Q1PVL5"O:_M,_)9WMGR_BD3YEJ,^\Z%>>+A-_+9,,$B*O3^+M: ,GIAVYL6/&3=[_&;N>5|M8*TOT!I-#$P<35GHAB

M'P+EHU8<+7NN'MPF!A2JHA,AGZ%4XY[_%BV)+@A!UB#Q0,#]'#W2,"3!'?$) M766/7ZE/(44E71VTI+HMB##KCD[/E).E1S>/(6W>0MI34LT3J#):.5MX6A%F@ M<2AS#<]X3&YO?

Q';,OS1%B(WLNNVZB9D)4,==R]=H0 -!€(",&,#;:C8+N MS^0M1H&IOPO9Q6F0D^ FUUHI892>PA(OS$KBS7%L27BRGH#2;LHD"]2+56

M\I9H)S==+;2LP#;,+HCBZ..I>&D]FM\0+R9W=/XDMOB?Q>PK-5338ZB&EC;8 MAA^OZN@$712C 9S%C1Z41E*,;0,PC8$-*]&#GAITW'+(M^TTBB*XZ45MAH"

M.EW1F<@%,RWRE/F$[4_AKV!!+[W1*E:U^J.69F,*O 6\O.6'&[YL<4(;R6! MP78Q71V\#,AM&5 2.%3C6>%,$T^]M?ZDNIF$%.7Q$BG#L68@389)S-;8D.]^_M7=

<63!F(=0;R.S1V1"48+G>;].\1&T+615%,IO%30;2F$(8%,F.W(.V1L.3.] M6!,#&CW'M@=5]#;0:@:DJ.J EZ>|+]2D&W=&YN2.)1R,27'1H\DL[_XC2?+M)0.IQ> MD)E.O*BF"'5(7+|-

W6\;@B*"35]?-9FN F1*\+3EJC8]X?V[:&-+6_H\',2M[Y M24R+3:?TXX8&3#-8GTA"_=)"L1S@AHX9VX=BD&SI WTUNK6)!'5XBN^4-]=!P =;6>R7/%!E[/B(TBT M &=

(1,*7.FTE[+B*,H@,[")7D]&TPBDK8,=>==$G4P-8VRPP6*]W:K&K.#O5= MT@5;TGH_DN^2 T]FQ55]^7&?O>/X=[KC^*ZA$9N-=DWA!_#+_!4+LI7/?/96 M5L"R7:}(E)

(KT3OE%X4Y6>;/)VG<2+$Y)). +]AIRV&O:1VXQ[=7P!4$#GZB.)A%JA$'(<+&A$I4HRH-C(EK$BJE';MEB\@$NB,U?2RE//PSK'BU/>

(+OJU.^<1_PQJ34E,$SJ/TW*9\W)"BCV*8!NS[3_X#Z6-"]F)%.Q/ICG.KTI9 3MC0QMNE7K;KP0_Y"M!1.,2 ML(*Z%MR2!+*65XIA)WRPXZ]1QR->OS<.?9MI%

[,)05T#/7.$'94FU='GR*] M9UY,?3@Q17'T'!-&G/6T[&D!.$XN:)@FNMLE907T!!$'\E+1')V9GXG,@T2" M\4KLDN8D?Q1B,JO=IQA&D64SZ)DB+%ELA=)0N2VZH,4-HG5#Z.DENN'7A-

30 M+A?/LUS>EX~NH[MQ#48+G>;].\1&T+615%,IO%30;2F$(8%,F.W(.V1L.3.] M6!,#&CW'M@=5]#;0:@:DJ.J EZ>|+]2D&W=&YN2.)1R,27'1H\DL[_XC2?+M)0.IQ> MD)E.O*BF"'5(7+|-W6\;@B*"35]?-9FN F1*\+3EJC8]X?V[:&-+6_H\',2M[Y M24R+3:?TXX8&3#-8GTA"_=)"L1S@AHX9VX=BD&SI WTUNK6)!'5XBN^4-]=!P =;6>R7/%!E[/B(TBT M &=

(1,*7.FTE[+B*,H@,[")7D]&TPBDK8,=>==$G4P-8VRPP6*]W:K&K.#O5= MT@5;TGH_DN^2 T]FQ55]^7&?O>/X=[KC^*ZA$9N-=DWA!_#+_!4+LI7/?/96 M5L"R7:}(E)

(KT3OE%X4Y6>;/)VG<2+$Y)). +]AIRV&O:1VXQ[=7P!4$#GZB.)A%JA$'(<+&A$I4HRH-C(EK$BJE';MEB\@$NB,U?2RE//PSK'BU/>

(+OJU.^<1_PQJ34E,$SJ/TW*9\W)"BCV*8!NS[3_X#Z6-"]F)%.Q/ICG.KTI9 3MC0QMNE7K;KP0_Y"M!1.,2 ML(*Z%MR2!+*65XIA)WRPXZ]1QR->OS<.?9MI%

[,)05T#/7.$'94FU='GR*] M9UY,?3@Q17'T'!-&G/6T[&D!.$XN:)@FNMLE907T!!$'\E+1')V9GXG,@T2" M\4KLDN8D?Q1B,JO=IQA&D64SZ)DB+%ELA=)0N2VZH,4-HG5#Z.DENN'7A-

30 M+A?/LUS>EX~NH[MQ#48+G>;].\1&T+615%,IO%30;2F$(8%,F.W(.V1L.3.] M6!,#&CW'M@=5]#;0:@:DJ.J EZ>|+]2D&W=&YN2.)1R,27'1H\DL[_XC2?+M)0.IQ> MD)E.O*BF"'5(7+|-

SONN:CommonStockWarrantsAugustTwoThousandTwentyOneMember 2023-10-012023-12-31 0001106838
SONN:UnderwriterWarrantsAugustTwoThousandTwentyOneMember 2024-10-012024-12-31 0001106838 SONN:UnderwriterWarrantsAugustTwoThousandTwentyOneMember 2023-10-012023-12-31 0001106838 SONN:ChanticleerWarrantsMember 2024-10-012024-12-31 0001106838 SONN:ChanticleerWarrantsMember 2023-10-012023-12-31 0001106838 SONN:SeriesCWarrantsMember 2024-10-012024-12-31 0001106838 SONN:SeriesCWarrantsMember 2023-10-012023-12-31 0001106838
SONN:SeriesThreeWarrantsMember 2024-10-012024-12-31 0001106838 SONN:SeriesThreeWarrantsMember 2023-10-012023-12-31 0001106838
SONN:UnvestedRestrictedStockUnitsAndAwardsMember 2024-10-012024-12-31 0001106838 SONN:UnvestedRestrictedStockUnitsAndAwardsMember 2023-10-012023-12-31 0001106838 SONN:CommonStockWarrantsFebruaryTwoThousandTwentyThreeMember 2024-10-012024-12-31 0001106838
SONN:CommonStockWarrantsFebruaryTwoThousandTwentyThreeMember 2023-10-012023-12-31 0001106838
SONN:UnderwriterWarrantsFebruaryTwoThousandTwentyThreeMember 2024-10-012024-12-31 0001106838
SONN:UnderwriterWarrantsFebruaryTwoThousandTwentyThreeMember 2023-10-012023-12-31 0001106838
SONN:CommonStockPrivatePlacementWarrantsJuneTwoThousandTwentyThreeMember 2024-10-012024-12-31 0001106838
SONN:CommonStockPrivatePlacementWarrantsJuneTwoThousandTwentyThreeMember 2023-10-012023-12-31 0001106838
SONN:PlacementAgentWarrantsJuneTwoThousandTwentyThreeMember 2024-10-012024-12-31 0001106838
SONN:PlacementAgentWarrantsJuneTwoThousandTwentyThreeMember 2023-10-012023-12-31 0001106838
SONN:CommonStockWarrantsOctoberTwoThousandTwentyThreeMember 2024-10-012024-12-31 0001106838
SONN:CommonStockWarrantsOctoberTwoThousandTwentyThreeMember 2023-10-012023-12-31 0001106838
SONN:UnderwriterWarrantsOctoberTwoThousandTwentyThreeMember 2024-10-012024-12-31 0001106838
SONN:UnderwriterWarrantsOctoberTwoThousandTwentyThreeMember 2023-10-012023-12-31 0001106838
SONN:PlacementAgentWarrantsJuneTwoThousandTwentyFourMember 2024-10-012024-12-31 0001106838
SONN:PlacementAgentWarrantsJuneTwoThousandTwentyFourMember 2023-10-012023-12-31 0001106838
SONN:CommonStockWarrantsJuneTwoThousandTwentyFourMember 2024-10-012024-12-31 0001106838 SONN:CommonStockWarrantsJuneTwoThousandTwentyFourMember 2023-10-012023-12-31 0001106838 SONN:CommonStockWarrantsNovemberTwoThousandTwentyFourMember 2024-10-012024-12-31 0001106838
SONN:CommonStockWarrantsNovemberTwoThousandTwentyFourMember 2023-10-012023-12-31 0001106838
SONN:CommonStockRegisteredDirectWarrantsDecemberTwoThousandTwentyFourMember 2024-10-012024-12-31 0001106838
SONN:CommonStockRegisteredDirectWarrantsDecemberTwoThousandTwentyFourMember 2023-10-012023-12-31 0001106838
SONN:CommonStockPIPEWarrantsDecemberTwoThousandTwentyFourMember 2024-10-012024-12-31 0001106838
SONN:CommonStockPIPEWarrantsDecemberTwoThousandTwentyFourMember 2023-10-012023-12-31 0001106838
SONN:DiscoveryCollaborationAgreementsMemberSONN:XOMAMember 2012-07-31 0001106838 us-gaap:InProcessResearchAndDevelopmentMemberSONN:DiscoveryCollaborationAgreementsMemberSONN:XOMAMember 2022-04-012022-04-30 0001106838 us-gaap:InProcessResearchAndDevelopmentMemberSONN:DiscoveryCollaborationAgreementsMemberSONN:XOMAMember 2024-10-012024-12-31 0001106838 us-gaap:InProcessResearchAndDevelopmentMemberSONN:DiscoveryCollaborationAgreementsMemberSONN:XOMAMember 2023-10-012023-12-31 0001106838
SONN:DiscoveryCollaborationAgreementsMember 2024-10-012024-12-31 0001106838 SONN:DiscoveryCollaborationAgreementsMember 2023-10-012023-12-31 0001106838
SONN:CellcaAgreementMember 2024-10-012024-12-31 0001106838 srt:MaximumMemberSONN:CellcaAgreementMember 2019-01-31 0001106838
srt:MinimumMemberSONN:CellcaAgreementMember 2024-12-31 0001106838 srt:MaximumMemberSONN:CellcaAgreementMember 2024-12-31 0001106838
SONN:CellcaAgreementMember 2024-12-31 0001106838 us-gaap:InProcessResearchAndDevelopmentMemberSONN:CellcaAgreementMember 2022-04-30 0001106838 us-gaap:InProcessResearchAndDevelopmentMemberSONN:CellcaAgreementMember 2024-10-012024-12-31 0001106838 us-gaap:InProcessResearchAndDevelopmentMemberSONN:CellcaAgreementMember 2023-10-012023-12-31 0001106838 us-gaap:InProcessResearchAndDevelopmentMemberSONN:TheBrinkAgreementMember 2024-12-31 0001106838 SONN:TheBrinkAgreementMember 2023-04-30 0001106838
SONN:TheBrinkAgreementMember 2024-12-31 0001106838 SONN:TheBrinkAgreementMember 2024-10-012024-12-31 0001106838 SONN:TheBrinkAgreementMember 2023-10-012023-12-31 0001106838 SONN:InvivoGenAgreementMember 2024-12-31 0001106838 SONN:InvivoGenAgreementMember 2024-10-012024-12-31 0001106838
SONN:InvivoGenAgreementMember 2023-10-012023-12-31 0001106838 SONN:SOCAgreementMember 2024-08-012024-08-31 0001106838 us-gaap:TechnologyServiceMemberSONN:NavigoAgreementMemberSONN:NavigoProteinsGmbHMember 2021-12-012021-12-31 0001106838 us-gaap:TechnologyServiceMemberSONN:NavigoAgreementMemberSONN:NavigoProteinsGmbHMember 2021-12-31 0001106838 SONN:LicenseAgreementMember 2024-10-012024-12-31 0001106838 SONN:AlkemAgreementMember 2024-10-082024-10-08 0001106838 SONN:AlkemAgreementMember 2024-10-012024-12-31 0001106838
SONN:AlkemAgreementMember 2024-12-31 0001106838 SONN:UnderwritersMemberSONN:OctoberOfferingMember 2023-10-262023-10-26 0001106838
SONN:UnderwritersMemberus-gaap:CommonStockMemberSONN:OctoberOfferingMember 2023-10-262023-10-26 0001106838
SONN:UnderwritersMemberSONN:PrefundedWarrantMemberSONN:OctoberOfferingMember 2023-10-26 0001106838
SONN:UnderwritersMemberSONN:CommonWarrantMemberSONN:OctoberOfferingMember 2023-10-26 0001106838
SONN:UnderwritersMemberSONN:JuneTwentyTwentyFourInducementOfferMemberSONN:OctoberOfferingMember 2023-10-262023-10-26 0001106838
SONN:UnderwritersMemberSONN:OctoberOfferingMember 2023-10-26 0001106838 us-gaap:CommonStockMemberSONN:PurchaseAndRegistrationRightsAgreementMember 2024-05-022024-05-02 0001106838 SONN:PurchaseAndRegistrationRightsAgreementMember 2024-12-31 0001106838 us-gaap:CommonStockMemberSONN:PurchaseAndRegistrationRightsAgreementMember 2024-05-02 0001106838 us-gaap:CommonStockMemberSONN:PurchaseAndRegistrationRightsAgreementMember 2024-10-012024-12-31 0001106838
SONN:ChardanCapitalMarketsLLCMemberSONN:UnderwritingAgreementMember 2024-11-072024-11-07 0001106838
SONN:ChardanCapitalMarketsLLCMemberSONN:PrefundedWarrantMemberSONN:UnderwritingAgreementMember 2024-11-07 0001106838
SONN:ChardanCapitalMarketsLLCMemberSONN:CommonWarrantMemberSONN:UnderwritingAgreementMember 2024-11-07 0001106838
SONN:PrefundedWarrantMemberSONN:RegisteredDirectOfferingMember 2024-12-102024-12-10 0001106838
SONN:PrefundedWarrantMemberSONN:RegisteredDirectOfferingMember 2024-12-10 0001106838 us-gaap:WarrantMemberSONN:RegisteredDirectOfferingMember 2024-12-10 0001106838 SONN:RegisteredDirectOfferingMember 2024-12-10 0001106838 SONN:PrefundedWarrantMember 2024-12-10 0001106838 SONN:PrefundedWarrantMemberSONN:RegisteredDirectOfferingMember 2024-12-10 0001106838 SONN:PrefundedWarrantMemberus-gaap:PrivatePlacementMember 2024-12-102024-12-10 0001106838 SONN:PrefundedWarrantMemberus-gaap:PrivatePlacementMember 2024-12-10 0001106838 us-gaap:WarrantMemberus-gaap:PrivatePlacementMember 2024-12-10 0001106838 us-gaap:PrivatePlacementMember 2024-12-10 0001106838 SONN:RegisteredDirectOfferingMember 2024-12-102024-12-10 0001106838 SONN:CommonStockWarrantsMember 2024-06-30 0001106838 SONN:CommonStockWarrantsMember 2024-12-31 0001106838 SONN:CommonStockWarrantsMember 2024-10-012024-12-31 0001106838
SONN:PreFundedWarrantsMember 2024-10-012024-12-31 0001106838 SONN:CommonStockWarrantsMember 2023-10-012023-12-31 0001106838
SONN:HolderMemberSONN:CommonStockWarrantsMember 2023-10-012023-12-31 0001106838 SONN:CommonStockWarrantsAugustTwoThousandTwentyOneMember 2024-12-31 0001106838 SONN:UnderwriterWarrantsAugustTwoThousandTwentyOneMember 2024-12-31 0001106838 SONN:ChanticleerWarrantsMember 2024-12-31 0001106838
srt:MinimumMemberSONN:ChanticleerWarrantsMember 2024-12-31 0001106838 srt:MaximumMemberSONN:ChanticleerWarrantsMember 2024-12-31 0001106838
SONN:SeriesCWarrantsMember 2024-12-31 0001106838 SONN:SeriesThreeWarrantsMember 2024-12-31 0001106838
SONN:CommonStockWarrantsFebruaryTwoThousandTwentyThreeMember 2024-12-31 0001106838 SONN:UnderwriterWarrantFebruaryTwoThousandTwentyThreeMember 2024-12-31 0001106838 SONN:CommonStockPrivatePlacementWarrantsJuneTwoThousandTwentyThreeMember 2024-12-31 0001106838
SONN:PlacementAgentWarrantsJuneTwoThousandTwentyThreeMember 2024-12-31 0001106838 SONN:CommonStockWarrantsOctoberTwoThousandTwentyThreeMember 2024-12-31 0001106838 SONN:PrefundedWarrantsOctoberTwoThousandTwentyThreeMember 2024-12-31 0001106838
SONN:UnderwriterWarrantsOctoberTwoThousandTwentyThreeMember 2024-12-31 0001106838 SONN:PlacementAgentWarrantsJuneTwoThousandTwentyFourMember 2024-12-31 0001106838 SONN:CommonStockWarrantsJuneTwoThousandTwentyFourMember 2024-12-31 0001106838
SONN:CommonStockWarrantsNovemberTwoThousandTwentyFourMember 2024-12-31 0001106838
SONN:CommonStockWarrantsRegisteredDirectWarrantsDecemberTwoThousandTwentyFourMember 2024-12-31 0001106838
SONN:CommonStockPIPEWarrantsDecemberTwoThousandTwentyFourMember 2024-12-31 0001106838
SONN:PreFundedWarrantsDecemberTwoThousandTwentyFourMember 2024-12-31 0001106838 SONN:TwoThousandTwentyOmnibusEquityIncentivePlanMember 2024-12-31 0001106838 SONN:TwoThousandTwentyOmnibusEquityIncentivePlanMemberus-gaap:SubsequentEventMember 2025-01-01 0001106838 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-01-01 0001106838 SONN:RestrictedStockAwardsMember 2024-01-012024-01-01 0001106838 us-gaap:SubsequentEventMember 2025-01-012025-01-01 0001106838 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001106838 SONN:RestrictedStockAwardsMember 2024-12-31 0001106838 us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ResearchAndDevelopmentExpenseMember 2024-10-012024-12-31 0001106838 us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ResearchAndDevelopmentExpenseMember 2023-10-012023-12-31 0001106838 us-gaap:RestrictedStockUnitsRSUMemberus-gaap:GeneralAndAdministrativeExpenseMember 2024-10-012024-12-31 0001106838 us-gaap:RestrictedStockUnitsRSUMemberus-gaap:GeneralAndAdministrativeExpenseMember 2023-10-012023-12-31 0001106838 us-gaap:SubsequentEventMemberSONN:PurchaseAgreementMember 2025-01-012025-01-01 0001106838 us-gaap:DomesticCountryMemberus-gaap:SubsequentEventMember 2025-01-01 0001106838 us-gaap:SubsequentEventMember 2025-02-122025-02-12 iso4217:USD shares iso4217:USD shares iso4217:EUR pure SONN:Segmentfalse--09-30Q100011068380 10-Qtrue2024-12-312024false001-35570SONNET BIOTHERAPEUTICS HOLDINGS, INC.DE20-2932652100 Overlook CenterSuite 102PrincetonNJ08540(609)375-2227Common Stock, par value $0.0001 per shareSONNNASDAQYesYesNon-accelerated
Filertruefalsefalse30657010.000148615031494565000000119686812064091667927620786725163211794317312205231044351234117122058150002130594941477182027277160841691-117680985403656948573971820272771030100000001862618860766440421963346653455384942212974972849422-1278871-1528841103623002306-1168509158400-3160706-1168509-1.56-1.56-2.46-2.462022818202281847469947469950284651171951811770809850

including ovarian cancer, non-small cell lung cancer and head and neck cancer. In March 2022, the FDA cleared Sonnet's Investigational New Drug ("IND") application for SON-1010. This allowed the Company to initiate a U.S. clinical trial (SB101) in oncology patients with solid tumors during the second calendar quarter of 2022. In September 2021, the Company created a wholly-owned Australian subsidiary, SonnetBio Pty Ltd ("Subsidiary"), for the purpose of conducting certain clinical trials. Sonnet received approval and initiated an Australian clinical study (SB102) of SON-1010 in healthy volunteers during the third calendar quarter of 2022. Interim safety and tolerability data from the SB101 and SB102 studies were reported in April 2023.   In January 2023, Sonnet announced a collaboration agreement with Roche for the clinical evaluation of SON-1010 with atezolizumab (Tecentriq®). The companies have entered into a Master Clinical Trial and Supply Agreement ("MCSA"), along with ancillary Quality and Safety Agreements, to study the safety and efficacy of the combination of SON-1010 and atezolizumab in a platinum-resistant ovarian cancer ("PROC") patient setting. Further, the companies will provide SON-1010 and atezolizumab, respectively, for use in the Phase 1b/Phase 2a combination safety, dose-escalation, and proof-of-concept study (SB221). Part 1 of this 2-part study was approved in June 2023 by the local Human Research Ethics Committee in Australia under CT-2023-CTN-01399-1 and the Therapeutic Goods Administration has been notified. In August 2023, the FDA accepted the IND for SB221. The trial consists of a modified 3+3 dose-escalation design in Part 1 to establish the maximum tolerated dose ("MTD") of SON-1010 with a fixed dose of atezolizumab. Clinical benefit in PROC will be confirmed in an expansion group to establish the recommended Phase 2 dose ("RP2D"). Part 2 of the study will then investigate SON-1010 in combination with atezolizumab, or the standard of care ("SOC") for PROC in a randomized comparison to show proof-of-concept ("POC").   In January 2025, Sonnet announced an expansion of its Phase 1 SB101 clinical study of SON-1010 to add a new cohort to evaluate its effect in combination with trabectedin (Yondelis®), following the successful completion of monotherapy dose escalation. Trabectedin is an alkylating DNA-binding agent that was approved as a second-line treatment in early 2024 for patients with unresectable, metastatic liposarcoma or leiomyosarcoma who have received a prior anthracycline-containing regimen. It is also known to activate tumor macrophages into a pro-inflammatory phenotype. The Company believes that SON-1010 has the potential to complement that activity by activating the NK and T cells in the TME to secrete more interferon-gamma (IFNγ), which is considered to be important for anti-tumor control.   Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements   The Company acquired the global development rights to its most advanced compound, SON-080, a fully human version of Interleukin 6 ("IL-6"), in April 2020 through its acquisition of the outstanding shares of Relief Therapeutics SA. Sonnet is advancing SON-080 in target indications of Chemotherapy-Induced Peripheral Neuropathy ("CIPN") and Diabetic Peripheral Neuropathy ("DPN"). Sonnet received approval to initiate an ex-U.S. Phase 1b/2a study with SON-080 in CIPN during the third quarter of 2022. The Data Safety Monitoring Board ("DSMB") overseeing the study met during the first calendar quarter of 2024 and cleared the trial to proceed to Part 2. Following the completion of the DSMB review, Sonnet announced initial safety data from the CIPN study. The objective will be to analyze the data and to consider initiating a Phase 2 study, pending the outcome of any partnering activity. On October 8, 2024, the Company entered into a License Agreement (the "Alkem Agreement") with Alkem Laboratories Limited ("Alkem") to develop and commercialize SON-080 for DPN in India. Alkem will conduct all clinical trials that it believes appropriate to obtain regulatory approval in India for SON-080 for the treatment of DPN.   SON-1210 (IL12-F_HAB-IL15), Sonnet's lead bifunctional construct, combines F_HAB with single-chain human IL-12 and human Interleukin 15 ("IL-15"). This compound is being developed for solid tumor indications, including colorectal and pancreatic cancer. In February 2023, Sonnet announced the successful completion of two IND-enabling toxicology studies with SON-1210 in non-human primates. In August 2024, the Company entered into a Master Clinical Collaboration Agreement (the "SOC Agreement") with the Sarcoma Oncology Center ("SOC") to advance the development of SON-1210. An Innovative Immuno Oncology Consortium ("IOC") that is funded by the SOC will conduct an investigator-initiated Phase 1b/2a study of SON-1210 in pancreatic cancer. The IOC submitted a pre-IND package to the FDA. Based on the FDA feedback, preparations for the full IND submission package are underway.   SON-1411 (IL18-F_HAB-IL12) is a bifunctional combination of human Interleukin 18 ("IL-18"), which was modified to resist interaction with the IL-18 inhibitor binding protein, and single-chain human IL-12 for solid tumor cancers. Cell line development and process development are ongoing, with early experimental drug supply suitable for formulation and analytical method development activities. After some delays in 2024, activities will continue through 2025 with the potential to generate a drug suitable for preclinical studies and subsequent human studies.   Sonnet has completed sequence confirmation for SON-3015 (anti-IL6-F_HAB-anti-TGFβ). Early-stage bifunctional drug has been generated and is being stored for future use in in vivo mice studies. The Company has elected to place the SON-3015 development program on hold for expense reduction purposes.   Liquidity   The Company has incurred recurring losses and negative cash flows from operations since inception and it expects to generate losses from operations for the foreseeable future primarily due to research and development costs for its potential product candidates. The Company believes its cash at December 31, 2024 of $4.9 million will fund the Company's projected operations into July 2025. The Company received preliminary approval of its application to sell up to $0.8 million of its New Jersey state net operating losses through the Technology Business Tax Certificate Transfer Program (the "Program"), subject to execution of such sale (see Note 8). Substantial additional financing will be needed by the Company to fund its operations. These factors raise substantial doubt about the Company's ability to continue as a going concern. The accompanying unaudited interim consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. However, substantial doubt about the Company's ability to continue as a going concern exists. The unaudited interim consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.   The Company plans to secure additional capital in the future through equity or debt financings, including sales pursuant to its ChEF Purchase Agreement (the "Purchase Agreement") with Chardan Capital Markets, LLC ("Chardan"), related to a "ChEF." Chardan's committed equity facility (the "Facility"); partnerships; collaborations; or other sources to carry out the Company's planned development activities. If additional capital is not available when required, the Company may need to delay or curtail its operations until such funding is received. Various internal and external factors will affect whether and when the Company's product candidates become approved for marketing and successful commercialization. The regulatory approval and market acceptance of the Company's product candidates, length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the approval process will materially affect the Company's financial condition and future operations.   Operations since inception have consisted primarily of organizing the Company, securing financing, developing technologies through research and development and conducting preclinical studies. The Company faces risks associated with companies whose products are in development. These risks include the need for additional financing to complete its research and development, achieving its research and development objectives, defending its intellectual property rights, recruiting and retaining skilled personnel, and dependence on key members of management.   Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements   4900000800000 2. Summary of Significant Accounting Policies   a. Basis of presentation   The accompanying unaudited interim consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates (ASUs") of the Financial Accounting Standards Board ("FASB"). In the opinion of management, the accompanying unaudited interim consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the unaudited interim consolidated financial statements) considered necessary to present fairly the Company's financial position as of December 31, 2024 and its results of operations and cash flows for the three months ended December 31, 2024 and 2023. The unaudited interim consolidated financial statements presented herein do not contain all of the required disclosures under U.S. GAAP for annual financial statements and should be read in conjunction with the annual audited consolidated financial statements and related notes of Sonnet as of and for the year ended September 30, 2024 included in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2024. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.   b. Consolidation   The unaudited interim consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.   c. <span style="font-family: Times New Roman, Times,

Serif; font-size: 10pt">Use of estimates   The preparation of the unaudited interim consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these unaudited interim consolidated financial statements include the accrual of research and development expenses. Estimates and assumptions are periodically reviewed in-light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from management's estimates.   d. Incentive tax receivable   Subsidiary is eligible to participate in an Australian research and development tax incentive program. As part of this program, Subsidiary is eligible to receive a cash refund from the Australian Taxation Office for a percentage of the research and development costs expended by Subsidiary in Australia. <span id="xdx_901_eus-gaap--RefundReceivedRelatedToRevenueFromDifferentYearYearRevenueRecognized_c20241001__20241231__us-gaap--TypeOfArrangementAxis__custom--ResearchAndDevelopmentTaxIncentiveProgramMember_zrl2oQwIYJEf">The cash refund is available to eligible companies with annual aggregate revenues of less than $20.0 million (Australian) during the reimbursable period. The Company estimates the amount of cash refund it expects to receive related to the Australian research and development tax incentive program and records the incentive when it is probable (i) the Company will comply with relevant conditions of the program and (ii) the incentive will be received. As of December 31, 2024, the Company's estimate of the amount of cash refund it expects to receive for eligible spending related to the Australian research and development tax incentive program was $0.2 million. For each of the three months ended December 31, 2024 and 2023, $0.2 million for the expected net cash refund related to the tax incentive program was included as a reduction in research and development expenses. In November 2024, the Company received $0.7 million from the Australian government related to eligible research and development expenses for the year ended September 30, 2024. In December 2023, the Company received $0.8 million from the Australian government related to eligible research and development expenses for the year ended September 30, 2023.   e. Property and equipment   Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets. Expenditures for repairs and maintenance that do not extend the estimated useful life or improve an asset are expensed as incurred. Upon retirement or sale, the cost and related accumulated depreciation and amortization of assets disposed of are removed from the accounts, and any resulting gain or loss is included in the consolidated statement of operations.
   Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements   f. Deferred offering costs   Legal and other costs incurred in relation to equity offerings are capitalized as deferred offering costs and charged against the proceeds from equity offerings when received. If a financing is abandoned, deferred offering costs are expensed.   g. Derivative liability   The Company evaluates all features contained in financing agreements to determine if there are any embedded derivatives that require separate accounting from the underlying agreement. An embedded derivative that requires separation is accounted for as a separate asset or liability from the host agreement. The derivative asset or liability is accounted for at fair value, with changes in fair value recognized in the consolidated statement of operations. The Company determined that certain features under the Purchase Agreement (see Note 6) qualified as embedded derivatives. The derivative liability is accounted for separately from the Purchase Agreement at fair value, which has been deemed de minimis.   h. Collaboration revenue   Collaboration arrangements may contain multiple components, which may include (i) licenses; (ii) research and development activities; and (iii) the manufacturing and supply of certain materials. Payments pursuant to these arrangements may include non-refundable payments, upfront payments, milestone payments upon the achievement of significant regulatory and development events, sales milestones and royalties on product sales. The amount of variable consideration is constrained until it is probable that the revenue is not at a significant risk of reversal in a future period.   In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under a collaboration arrangement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are capable of being distinct; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue as the Company satisfies each performance obligation.   The Company applies significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining when performance obligations have been met, and assessing the recognition of variable consideration. When consideration is received prior to the Company completing its performance obligation under the terms of a contract, a contract liability is recorded as deferred income. Deferred income expected to be recognized as revenue within the twelve months following the balance sheet date is classified as a current liability. In May 2021, the Company entered into a License Agreement (the "New Life Agreement") with New Life Therapeutics Pte, Ltd. ("New Life"). In October 2024, the Company entered into the Alkem Agreement. See Note 5 for further discussion of these agreements.   i. Research and development expense   Research and development expenses include all direct and indirect costs associated with the development of the Company's biopharmaceutical products. These expenses include personnel costs, consulting fees, and payments to third parties for research, development, and manufacturing services. These costs are charged to expense as incurred.   At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the related project, based on the measure of progress as defined in the contract. Factors the Company considers in preparing the estimates include costs incurred by the service provider, milestones achieved, and other criteria related to the efforts of its service providers. Such estimates are subject to change as additional information becomes available. Depending on the timing of payment to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company will record a prepaid expense or accrued liability relating to these costs. Upfront milestone payments made to third parties who perform research and development services on the Company's behalf are expensed as services are rendered. Contingent development or regulatory milestone payments are recognized upon the related resolution of such contingencies.   Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements   j. Foreign currency   Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than the U.S. dollar are included in operations in the period in which the transaction occurs and reported within the

foreign exchange gain (loss) line item in the consolidated statement of operations.   k. Reverse stock split   On September 30, 2024, the Company filed a Certificate of Amendment to its Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware, which effected a 1-for-8 reverse stock split of the Company's issued and outstanding shares of common stock. As a result of the reverse stock split, every eight shares of common stock issued and outstanding was converted into one share of common stock. The reverse stock split affected all stockholders uniformly and did not alter any stockholder's percentage interest in the Company's equity. No fractional shares were issued in connection with the reverse stock split. Stockholders who would otherwise be entitled to a fractional share of common stock were instead entitled to receive a proportional cash payment. The reverse stock split did not change the par value or authorized number of shares of common stock. All common share and per share amounts presented in the unaudited interim consolidated financial statements and accompanying notes have been retroactively adjusted to reflect the reverse stock split.   l. Net loss per share   Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period (and potential shares of common stock that are exercisable for little or no consideration). Included in basic weighted-average number of shares of common stock outstanding during the three months ended December 31, 2024 are pre-funded October 2023 warrants to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedOctoberTwoThousandTwentyThreeWarrantsMember_zVOtxtn3BgCj" title="Warrants to purchase">99,687 shares of common stock with an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedOctoberTwoThousandTwentyThreeWarrantsMember_zZ3abAci8Zl3" title="Exercise price">0.0008 per share, warrants exercised through the June 2024 inducement offer for <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedOctoberTwoThousandTwentyThreeWarrantsMember_zY38NfEUpa7e" title="Warrant, shares">155,125 shares of common stock that are being held in abeyance as of December 31, 2024 due to beneficial ownership limitations, and pre-funded December 2024 warrants to purchase <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedDecemberTwoThousandTwentyFourWarrantsMember_zsWXtsJFi1te" title="Warrants to purchase">545,500 shares of common stock with an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedDecemberTwoThousandTwentyFourWarrantsMember_zxL6iblaZvTi" title="Exercise price">0.0001 per share. Included in basic weighted-average number of shares of common stock outstanding during the three months ended December 31, 2023 are pre-funded October 2023 warrants to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedOctoberTwoThousandTwentyThreeWarrantsMember_zuYmnHHWM2Ce" title="Warrants to purchase common stock">192,187 shares of common stock with an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedOctoberTwoThousandTwentyThreeWarrantsMember_zU0Ox47NJKef" title="Exercise price">0.0008 per share.   Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities such as common stock warrants and stock options which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.   Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements   <p id="xdx_89D_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zVyHKRDghE5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following potentially dilutive securities have been excluded from the computation of diluted shares of common stock outstanding as they would be anti-dilutive: Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Shares <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20241001__20241231_zQI5GwVPjFG1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20231001__20231231_zEXqD4pwFRD1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsAugustTwoThousandTwentyOneMember_zbvnkeeZUMWd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: justify; padding-left: 0pt">Common stock warrants August 2021</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">14,031</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">14,031</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnderwriterWarrantsAugustTwoThousandTwentyOneMember_ztRLrFg1VgDe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Underwriter warrants August 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">284</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">284</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ChanticleerWarrantsMember_zR0dMMzPnK7f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Chanticleer warrants</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times,

Serif; font-size: 10pt">6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesCWarrantsMember_zShirfU8dcPl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Series C warrants</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,297</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,297</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesThreeWarrantsMember_znkr6mxdtgrg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Series 3 warrants</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,566</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,566</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockUnitsAndAwardsMember_zTKnZd3ljjac" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Unvested restricted stock units and awards</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">17,152</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">976</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsFebruaryTwoThousandTwentyThreeMember_zCJJf0GFWOaj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Common stock warrants February 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">31,563</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">33,982</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnderwriterWarrantsFebruaryTwoThousandTwentyThreeMember_zNvfjr4UxR3i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Underwriter warrants February 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,933</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,933</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockPrivatePlacementWarrantsJuneTwoThousandTwentyThreeMember_z8Ua7UaAYEnj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Common stock private placement warrants June 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28,409</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28,409</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PlacementAgentWarrantsJuneTwoThousandTwentyThreeMember_z0RWDNfHB6r8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Placement agent warrants June 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">852</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">852</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsOctoberTwoThousandTwentyThreeMember_z8Kbsc48mrKa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Common stock warrants October 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">354,994</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">710,931</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnderwriterWarrantsOctoberTwoThousandTwentyThreeMember_zMD9pcUtEIrf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Underwriter warrants October 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,664</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,664</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PlacementAgentWarrantsJuneTwoThousandTwentyFourMember_zhwHK6DUjJo" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Placement agent warrants June 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14,142</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size:

10pt"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsJuneTwoThousandTwentyFourMember_z6X0Bzmg2Pw6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Common stock warrants June 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">703,125</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsNovemberTwoThousandTwentyFourMember_z9GW4DRMAHYi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Common stock warrants November 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,222,222</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockRegisteredDirectWarrantsDecemberTwoThousandTwentyFourMember_z4gY1iswAhDb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Common stock registered direct warrants December 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,085,325</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockPIPEWarrantsDecemberTwoThousandTwentyFourMember_zlj7uA92h7g2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 0pt">Common stock PIPE warrants December 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">673,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zjF5GaUzh097" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt; padding-left: 0pt">Total anti-dilutive weighted average shares </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,161,565</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">805,931</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   m. Recent accounting pronouncements   In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07, which is applicable to entities with a single reportable segment, will primarily require enhanced disclosures about significant segment expenses and enhanced disclosures in interim periods. The guidance in ASU 2023-07 will be applied retrospectively and is effective for annual reporting periods in fiscal years beginning after December 15, 2023 and interim reporting periods in fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact that the adoption of ASU 2023-07 will have on its consolidated financial statements and disclosures.   In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 is intended to improve income tax disclosure requirements by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to the income tax disclosure requirements. The guidance in ASU 2023-09 will be effective for annual reporting periods in fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact that the adoption of ASU 2023-09 will have on its consolidated financial statements and disclosures.   In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, as subsequently amended by ASU 2025-01 to clarify the effective date, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented in the consolidated statement of operations. The guidance in this ASU is effective for annual reporting periods in fiscal years beginning after December 15, 2026, and interim periods in fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.   Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements   a. Basis of presentation   The accompanying unaudited interim consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates (ASUs") of the Financial Accounting Standards Board ("FASB"). In the opinion of management, the accompanying unaudited interim consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the unaudited interim consolidated financial statements) considered necessary to present fairly the Company's financial position as of December 31, 2024 and its results of operations and cash flows for the three months ended December 31, 2024 and 2023. The unaudited interim consolidated financial statements presented herein do not contain all of the required disclosures under U.S. GAAP for annual financial statements and should be read in conjunction with the annual audited consolidated financial statements and related notes of Sonnet as of and for the year ended September 30, 2024 included in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2024. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.   <p id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zm4jt9KLBzAf" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top:

0pt; margin-bottom: 0pt">b. Consolidation   The unaudited interim consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.   c. Use of estimates   The preparation of the unaudited interim consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these unaudited interim consolidated financial statements include the accrual of research and development expenses. Estimates and assumptions are periodically reviewed in-light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from management's estimates.   d. Incentive tax receivable   Subsidiary is eligible to participate in an Australian research and development tax incentive program. As part of this program, Subsidiary is eligible to receive a cash refund from the Australian Taxation Office for a percentage of the research and development costs expended by Subsidiary in Australia. <span id="xdx_901_eus-gaap--RefundReceivedRelatedToRevenueFromDifferentYearYearRevenueRecognized_c20241001__20241231__us-gaap--TypeOfArrangementAxis__custom--ResearchAndDevelopmentTaxIncentiveProgramMember_zrl2oQwIYJEf">The cash refund is available to eligible companies with annual aggregate revenues of less than $20.0 million (Australian) during the reimbursable period. The Company estimates the amount of cash refund it expects to receive related to the Australian research and development tax incentive program and records the incentive when it is probable (i) the Company will comply with relevant conditions of the program and (ii) the incentive will be received. As of December 31, 2024, the Company's estimate of the amount of cash refund it expects to receive for eligible spending related to the Australian research and development tax incentive program was $0.2 million. For each of the three months ended December 31, 2024 and 2023, $0.2 million for the expected net cash refund related to the tax incentive program was included as a reduction in research and development expenses. In November 2024, the Company received $0.7 million from the Australian government related to eligible research and development expenses for the year ended September 30, 2024. In December 2023, the Company received $0.8 million from the Australian government related to eligible research and development expenses for the year ended September 30, 2023.   The cash refund is available to eligible companies with annual aggregate revenues of less than $20.0 million (Australian) during the reimbursable period.2000002000002000007000008000000 e. Property and equipment   Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets. Expenditures for repairs and maintenance that do not extend the estimated useful life or improve an asset are expensed as incurred. Upon retirement or sale, the cost and related accumulated depreciation and amortization of assets disposed of are removed from the accounts, and any resulting gain or loss is included in the consolidated statement of operations.
   Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements   f. Deferred offering costs   Legal and other costs incurred in relation to equity offerings are capitalized as deferred offering costs and charged against the proceeds from equity offerings when received. If a financing is abandoned, deferred offering costs are expensed.   g. Derivative liability   The Company evaluates all features contained in financing agreements to determine if there are any embedded derivatives that require separate accounting from the underlying agreement. An embedded derivative that requires separation is accounted for as a separate asset or liability from the host agreement. The derivative asset or liability is accounted for at fair value, with changes in fair value recognized in the consolidated statement of operations. The Company determined that certain features under the Purchase Agreement (see Note 6) qualified as embedded derivatives. The derivative liability is accounted for separately from the Purchase Agreement at fair value, which has been deemed de minimis.   h. Collaboration revenue   Collaboration arrangements may contain multiple components, which may include (i) licenses; (ii) research and development activities; and (iii) the manufacturing and supply of certain materials. Payments pursuant to these arrangements may include non-refundable payments, upfront payments, milestone payments upon the achievement of significant regulatory and development events, sales milestones and royalties on product sales. The amount of variable consideration is constrained until it is probable that the revenue is not at a significant risk of reversal in a future period.   In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under a collaboration arrangement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are capable of being distinct; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue as the Company satisfies each performance obligation.   The Company applies significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining when performance obligations have been met, and assessing the recognition of variable consideration. When consideration is received prior to the Company completing its performance obligation under the terms of a contract, a contract liability is recorded as deferred income. Deferred income expected to be recognized as revenue within the twelve months following the balance sheet date is classified as a current liability. In May 2021, the Company entered into a License Agreement (the "New Life Agreement") with New Life Therapeutics Pte, Ltd. ("New Life"). In October 2024, the Company entered into the Alkem Agreement. See Note 5 for further discussion of these agreements.   i. Research and development expense   Research and development expenses include all direct and indirect costs associated with the development of the Company's biopharmaceutical products. These expenses include personnel costs, consulting fees, and payments to third parties for research, development, and manufacturing services. These costs are charged to expense as incurred.   At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the related project, based on the measure of progress as defined in the contract. Factors the Company considers in preparing the estimates include costs incurred by the service provider, milestones achieved, and other criteria related to the efforts of its service providers. Such estimates are subject to change as additional information becomes available. Depending on the timing of payment to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company will record a prepaid expense or accrued liability relating to these costs. Upfront milestone payments made to third parties who perform research and development services on the Company's behalf are expensed as services are rendered. Contingent development or regulatory milestone payments are recognized upon the related resolution of such contingencies. <p style="font: 10pt Times New Roman, Times,

Serif; margin: 0pt 0pt 0pt 0; text-align: justify">   Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements   j. Foreign currency   Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than the U.S. dollar are included in operations in the period in which the transaction occurs and reported within the foreign exchange gain (loss) line item in the consolidated statement of operations.   k.   Reverse stock split   On September 30, 2024, the Company filed a Certificate of Amendment to its Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware, which effected a 1-for-8 reverse stock split of the Company's issued and outstanding shares of common stock. As a result of the reverse stock split, every eight shares of common stock issued and outstanding was converted into one share of common stock. The reverse stock split affected all stockholders uniformly and did not alter any stockholder's percentage interest in the Company's equity. No fractional shares were issued in connection with the reverse stock split. Stockholders who would otherwise be entitled to a fractional share of common stock were instead entitled to receive a proportional cash payment. The reverse stock split did not change the par value or authorized number of shares of common stock. All common share and per share amounts presented in the unaudited interim consolidated financial statements and accompanying notes have been retroactively adjusted to reflect the reverse stock split.   1-for-8 reverse stock split l. Net loss per share   Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period (and potential shares of common stock that are exercisable for little or no consideration). Included in basic weighted-average number of shares of common stock outstanding during the three months ended December 31, 2024 are pre-funded October 2023 warrants to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedOctoberTwoThousandTwentyThreeWarrantsMember_zVOtxtn3BgCj" title="Warrants to purchase">99,687 shares of common stock with an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedOctoberTwoThousandTwentyThreeWarrantsMember_zZ3abAci8Zl3" title="Exercise price">0.0008 per share, warrants exercised through the June 2024 inducement offer for <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedOctoberTwoThousandTwentyThreeWarrantsMember_zY38NfEUpa7e" title="Warrant, shares">155,125 shares of common stock that are being held in abeyance as of December 31, 2024 due to beneficial ownership limitations, and pre-funded December 2024 warrants to purchase <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedDecemberTwoThousandTwentyFourWarrantsMember_zsWXtsJFi1te" title="Warrants to purchase">545,500 shares of common stock with an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedDecemberTwoThousandTwentyFourWarrantsMember_zxL6ibIaZvTi" title="Exercise price">0.0001 per share. Included in basic weighted-average number of shares of common stock outstanding during the three months ended December 31, 2023 are pre-funded October 2023 warrants to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedOctoberTwoThousandTwentyThreeWarrantsMember_zuYmnHHWM2Ce" title="Warrants to purchase common stock">192,187 shares of common stock with an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedOctoberTwoThousandTwentyThreeWarrantsMember_zU0Ox47NJKef" title="Exercise price">0.0008 per share.   Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities such as common stock warrants and stock options which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.   Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements   <p id="xdx_89D_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zVyHKRDghE5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following potentially dilutive securities have been excluded from the computation of diluted shares of common stock outstanding as they would be anti-dilutive: Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Shares <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20241001__20241231_zQI5GwVPjFG1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20231001__20231231_zEXqD4pwFRD1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsAugustTwoThousandTwentyOneMember_zbvnkeeZUMWd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: justify; padding-left: 0pt">Common stock warrants August 2021</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">14,031</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">14,031</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnderwriterWarrantsAugustTwoThousandTwentyOneMember_ztRLrFg1VgDe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Underwriter warrants August 2021</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">284</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">284</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ChanticleerWarrantsMember_zR0dMMzPnK7f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Chanticleer warrants</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesCWarrantsMember_zShirfU8dcPl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Series C warrants</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,297</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,297</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesThreeWarrantsMember_znkr6mxdtgrg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Series 3 warrants</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,566</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,566</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockUnitsAndAwardsMember_zTKnZd3ljjac" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Unvested restricted stock units and awards</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">17,152</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">976</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsFebruaryTwoThousandTwentyThreeMember_zCJJf0GFWOaj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Common stock warrants February 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">31,563</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">33,982</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnderwriterWarrantsFebruaryTwoThousandTwentyThreeMember_zNvfjr4UxR3i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Underwriter warrants February 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,933</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,933</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockPrivatePlacementWarrantsJuneTwoThousandTwentyThreeMember_z8Ua7UaAYEnj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Common stock private placement warrants June 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28,409</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28,409</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PlacementAgentWarrantsJuneTwoThousandTwentyThreeMember_z0RWDNfHB6r8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Placement agent warrants June 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">852</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">852</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsOctoberTwoThousandTwentyThreeMember_z8Kbsc48mrKa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Common stock warrants October 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">354,994</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">710,931</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnderwriterWarrantsOctoberTwoThousandTwentyThreeMember_zMD9pcUtEIrf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Underwriter warrants October 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,664</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,664</td><td style="font: 10pt

Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PlacementAgentWarrantsJuneTwoThousandTwentyFourMember_zhwHK6DUjJo" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Placement agent warrants June 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14,142</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsJuneTwoThousandTwentyFourMember_z6X0Bzmg2Pw6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Common stock warrants June 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">703,125</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsNovemberTwoThousandTwentyFourMember_z9GW4DRMAHYi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Common stock warrants November 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,222,222</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockRegisteredDirectWarrantsDecemberTwoThousandTwentyFourMember_z4gY1iswAhDb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Common stock registered direct warrants December 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,085,325</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockPIPEWarrantsDecemberTwoThousandTwentyFourMember_zlj7uA92h7g2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 0pt">Common stock PIPE warrants December 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">673,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zjF5GaUzh097" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt; padding-left: 0pt">Total anti-dilutive weighted average shares </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,161,565</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">805,931</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
996870.000815512554550000.00011921870.0008<p id="xdx_89D_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zVyHKRDghE5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following potentially dilutive securities have been excluded from the computation of diluted shares of common stock outstanding as they would be anti-dilutive: Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Shares <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20241001__20241231_zQI5GwVPjFG1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20231001__20231231_zEXqD4pwFRD1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsAugustTwoThousandTwentyOneMember_zbvnkeeZUMWd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: justify; padding-left: 0pt">Common stock warrants August 2021</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">14,031</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times

New Roman, Times, Serif; font-size: 10pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">14,031</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnderwriterWarrantsAugustTwoThousandTwentyOneMember_ztRLrFg1VgDe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Underwriter warrants August 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">284</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">284</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ChanticleerWarrantsMember_zR0dMMzPnK7f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Chanticleer warrants</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesCWarrantsMember_zShirfU8dcPl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Series C warrants</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,297</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,297</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesThreeWarrantsMember_znkr6mxdtgrg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Series 3 warrants</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,566</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,566</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockUnitsAndAwardsMember_zTKnZd3ljJac" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Unvested restricted stock units and awards</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">17,152</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">976</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsFebruaryTwoThousandTwentyThreeMember_zCJJf0GFWOaj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Common stock warrants February 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">31,563</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">33,902</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnderwriterWarrantsFebruaryTwoThousandTwentyThreeMember_zNvfjr4UxR3i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Underwriter warrants February 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,933</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font; 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,933</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockPrivatePlacementWarrantsJuneTwoThousandTwentyThreeMember_z8Ua7UaAYEnj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Common stock private placement warrants June 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28,409</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font; 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28,409</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PlacementAgentWarrantsJuneTwoThousandTwentyThreeMember_z0RWDNfHB6r8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Placement agent warrants June 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">852</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">852</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsOctoberTwoThousandTwentyThreeMember_z8Kbsc48mrKa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Common stock warrants October 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times,

Serif; font-size: 10pt">354,994</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">710,931</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnderwriterWarrantsOctoberTwoThousandTwentyThreeMember_zMD9pcUtEIrf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Underwriter warrants October 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,664</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,664</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PlacementAgentWarrantsJuneTwoThousandTwentyFourMember_zhwHK6DUjJo" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Placement agent warrants June 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14,142</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsJuneTwoThousandTwentyFourMember_z6X0Bzmg2Pw6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Common stock warrants June 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">703,125</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsNovemberTwoThousandTwentyFourMember_z9GW4DRMAHYi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Common stock warrants November 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,222,222</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockRegisteredDirectWarrantsDecemberTwoThousandTwentyFourMember_z4gY1iswAhDb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt">Common stock registered direct warrants December 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,085,325</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockPIPEWarrantsDecemberTwoThousandTwentyFourMember_zlj7uA92h7g2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 0pt">Common stock PIPE warrants December 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">673,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zjF5GaUzh097" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt; padding-left: 0pt">Total anti-dilutive weighted average shares </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,161,565</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">805,931</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
1403114031284284662297229715661566171529763156333982193319332840928409852852354994710931106641066411414270312522222221085325673000516156580593141
id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zmJ11MlrnFL1" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">m. Recent accounting pronouncements   In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07, which is applicable to entities with a single reportable segment, will primarily require enhanced disclosures about significant segment expenses and enhanced disclosures in interim periods. The guidance in ASU 2023-07 will be applied retrospectively and is effective for annual reporting periods in fiscal years beginning after December 15, 2023 and interim reporting periods in fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact that the adoption of ASU 2023-07 will have on its consolidated financial statements and disclosures.   In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 is intended to improve income tax disclosure requirements by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to the income tax disclosure requirements. The guidance in ASU 2023-09 will be effective for annual reporting periods in fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact that the adoption of ASU 2023-09 will have on its consolidated financial statements and disclosures.   In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, as subsequently amended by ASU 2025-01 to clarify the effective date, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented in the consolidated statement of operations. The guidance in this ASU is effective for annual reporting periods in fiscal years beginning after December 15, 2026,

and interim periods in fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures. <p id="xdx_807_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zV153gNJICXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">3. Accrued Expenses and Other Current Liabilities   Accrued expenses and other current liabilities consisted of the following: Schedule of Accrued Expenses and Other Current Liabilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20241231_zgtWZKhLHNH" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20240930_zAieaOTAC7q4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">September 30, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_40E_ecustom--AccruedCompensationAndBenefitsCurrent_iI_pp0p0_maALCzUHN_z0YnSZBuUQUi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Compensation and benefits</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">155,514</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">149,802</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--AccruedResearchAndDevelopmentCurrent_iI_pp0p0_maALCzUHN_zUkQvNEAVnT4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">969,684</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">617,545</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maALCzUHN_ziOuxAo7Jdze" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Professional fees</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">267,587</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">173,319</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCzUHN_zTr2Nflxk2E2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Other</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,735</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,823</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pp0p0_mtALCzUHN_z8S6LnWGXYp3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Accrued expenses and other current liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,394,520</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">942,489</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Accrued expenses and other current liabilities consisted of the following: Schedule of Accrued Expenses and Other Current Liabilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20241231_zgtWZKhLHNH" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20240930_zAieaOTAC7q4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">September 30, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_40E_ecustom--AccruedCompensationAndBenefitsCurrent_iI_pp0p0_maALCzUHN_z0YnSZBuUQUi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Compensation and benefits</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">155,514</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">149,802</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--AccruedResearchAndDevelopmentCurrent_iI_pp0p0_maALCzUHN_zUkQvNEAVnT4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">969,684</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">617,545</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maALCzUHN_ziOuxAo7Jdze" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Professional fees</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">267,587</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">173,319</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New

Roman, Times, Serif; font-size: 10pt"> </td></tr> <tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCzUHN_zTr2Nflxk2E2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Other</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">$</td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,735</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">$</td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,823</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">$</td></tr> <tr id="xdx_405_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pp0p0_mtALCzUHN_z8S6LnWGXYp3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> Accrued expenses and other current liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">$</td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,394,520</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">$</td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">942,489</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</td></tr> </table> 15551414980296968461754526758717331917351823139452094248 9 4. Commitments and Contingencies   Legal proceedings   From time to time, the Company is a party to various lawsuits, claims, and other legal proceedings that arise in the ordinary course of its business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company's consolidated financial position, results of operations, or cash flows.   License agreements   In July 2012, the Company entered into a Discovery Collaboration Agreement (the "Collaboration Agreement") with XOMA (US) LLC ("XOMA"), pursuant to which XOMA granted to the Company a non-exclusive, non-transferable license and/or right to use certain materials, technologies and related information related to discovery, optimization and development of antibodies and related proteins and to develop and commercialize products thereunder. The Company is obligated to make contingent milestone payments to XOMA totaling $<span id="xdx_902_ecustom--MilestonePayments_iI_pn5n6_c20120731__us-gaap--TypeOfArrangementAxis__custom--DiscoveryCollaborationAgreementsMember__dei--LegalEntityAxis__custom--XOMAMember_za8zgOhq3hCj" title="Milestone payments">3.8 million on a product-by-product basis upon the achievement of certain development and approval milestones related to a product. The Company has also agreed to pay XOMA low single-digit royalties on net sales of products sold by the Company. Royalties on each product are payable on a country-by-country basis until the later of (i) a specified period of time after the first commercial sale, and (ii) the date of expiration of the last valid claim in the last-to-expire of the issued patents covered by the Collaboration Agreement. The first milestone was achieved in April 2022, at which time the Company incurred a $<span id="xdx_90A_ecustom--LicenseFees_pn5n6_c20220401__20220430__us-gaap--TypeOfArrangementAxis__custom--DiscoveryCollaborationAgreementsMember__dei--LegalEntityAxis__custom--XOMAMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zgDorVKDGrBc" title="License fees">0.5 million license fee which was recorded as acquired in-process research and development. <span id="xdx_904_ecustom--LicenseFees_do_c20241001__20241231__us-gaap--TypeOfArrangementAxis__custom--DiscoveryCollaborationAgreementsMember__dei--LegalEntityAxis__custom--XOMAMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zEcdVRfjNaQ9" title="License fee"><span id="xdx_906_ecustom--LicenseFees_do_c20231001__20231231__us-gaap--TypeOfArrangementAxis__custom--DiscoveryCollaborationAgreementsMember__dei--LegalEntityAxis__custom--XOMAMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zLxtgmQGxD0a" title="License fee">No license fees were incurred during the three months ended December 31, 2024 and 2023.   In August 2015, the Company entered into a License Agreement (the "ARES License Agreement") with Ares Trading ("ARES"), a wholly-owned subsidiary of Merck KGaA. Under the terms of the ARES License Agreement, as subsequently amended in October 2021, ARES has granted the Company a sublicensable, exclusive, worldwide, royalty-bearing license on proprietary patents to research, develop, use and commercialize products using atexakin alfa ("Atexakin"), a low dose formulation of human IL-6 in peripheral neuropathies and vascular complications. Pursuant to the ARES License Agreement, the Company will pay ARES high single-digit royalties on net sales of products sold by the Company. Royalties are payable on a product-by-product and country-by-country basis until the later of (i) a specified period of time after the first commercial sale in such country, and (ii) the last date on which such product is covered by a valid claim in such country. Additionally, the Company will pay ARES a percentage of all revenue received through sublicensing the IL-6 compound, including revenue from any upfront, milestone, royalty, maintenance and similar payments, net of certain full time equivalent ("FTE") costs incurred by the Company pursuant to such sublicense. The percentage rate owed to ARES on sublicense revenue decreases depending on the point in time of execution of the relevant sublicense agreement and the development progress accomplished by the Company to that point in time. The upfront cash payments received by the Company pursuant to the New Life Agreement (see Note 5) were specifically excluded from the scope of the amended ARES License Agreement. The Company owes ARES $0.1 million in license fees related to sublicense revenue received pursuant to the Alkem Agreement (see Note 5), which is included in research and development expenses in the unaudited interim consolidated statement of operations for the three months ended December 31, 2024. No license fees were incurred during the three months ended December 31, 2023.   Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements   In January 2019, the Company entered into a Frame Services and License Agreement (the "Cellca Agreement") with Sartorius Stedim Cellca GMBH ("Cellca"), pursuant to which Cellca has granted the Company a worldwide, non-exclusive, perpetual, non-transferable license to develop, manufacture or have manufactured, use, sell, import, export and/or otherwise commercialize product based on Cellca's work to generate a specified transfected cell line and develop an upstream production process for such cell line. The Cellca Agreement is effective unless terminated by either party by giving six months notice, or by giving 14 days notice if terminated for good cause. The Company is obligated to make milestone payments to Cellca totaling up to $0.7 million upon the achievement of certain development and approval milestones if the Buy-Out Option is not exercised. The Company has a Buy-Out Option that will be effective between the time of completion of a clinical trial and the receipt of regulatory approval for commercialization of product. The cost to exercise the Buy-Out Option increases on each anniversary of the commencement date of the Buy-Out Option Period, and ranges from $<span id="xdx_902_ecustom--PaymentForAnnualLicenseFeeObligation_iI_pn5n6_c20241231__us-gaap--TypeOfArrangementAxis__custom--CellcaAgreementMember__srt--RangeAxis__srt--MinimumMember_zux9WXj2E9if" title="Payment for annual license fee obligation">0.1 million to $<span id="xdx_90A_ecustom--PaymentForAnnualLicenseFeeObligation_iI_pn5n6_c20241231__us-gaap--TypeOfArrangementAxis__custom--CellcaAgreementMember__srt--RangeAxis__srt--MaximumMember_zOR4pKfcN3re" title="Payment for annual license fee obligation">0.6 million. The cost to exercise the Buy-Out Option will replace the $0.6 million contingent milestone payment due upon final regulatory approval. The first milestone was achieved in April 2022, at which time the Company incurred a $<span id="xdx_905_ecustom--CommericalProductLicenseFeePaymentObligation_iI_pn5n6_c20220430__us-gaap--TypeOfArrangementAxis__custom--CellcaAgreementMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zUFFBsHtmeKd" title="Commercial product license fee payment obligation">0.1 million license fee which was recorded as acquired in-process research and development. <span id="xdx_904_ecustom--LicenseFees_do_c20241001__20241231__us-gaap--TypeOfArrangementAxis__custom--CellcaAgreementMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zAn3ZkbUioN4" title="License fees"><span id="xdx_906_ecustom--LicenseFees_do_c20231001__20231231__us-gaap--TypeOfArrangementAxis__custom--CellcaAgreementMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zTksZs17qL29" title="License fees">No license fees were incurred during the three months ended December 31, 2024 and 2023.   In October 2021, the Company entered into a Non-Exclusive License Agreement (the "Brink Agreement") with Brink Biologics Inc. ("Brink"), pursuant to which Brink has granted the Company a non-exclusive, non-transferable license and limited right to sublicense certain materials and related information to develop cell-based assays for batch, quality control, stability, efficacy, potency or any other type of assay required for production and commercialization of products. During the product development phase, the Company was obligated to make annual product development license fee payments of approximately $<span id="xdx_90D_ecustom--DevelopmentLicenseFeePaymentObligation_iI_pn5n6_c20241231__us-gaap--TypeOfArrangementAxis__custom--TheBrinkAgreementMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_ziT9xLat9Hk3">0.1 million. In April 2023, the Brink Agreement was amended, effective November 2022, to reduce the annual license fee payments to $12,000 for storage. If materials are removed from storage during the product development phase, the annual product development license fee of approximately $<span id="xdx_900_ecustom--DevelopmentLicenseFeePaymentObligation_iI_pn5n6_c20241231__us-gaap--TypeOfArrangementAxis__custom--TheBrinkAgreementMember__us-gaap--

FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_z0iXUh6oqFf1">0.1 million will apply. If a product achieves commercial status, the Company is obligated to make a commercial product license fee payment of approximately $0.1 million per commercial product. The amended agreement has an initial term of one year and will automatically renew for one additional year unless terminated or converted to a product development license. After the second year, the license will automatically convert to a full license requiring a product development or a commercial product license fee unless the parties mutually agree to terminate the agreement. The Company incurred $12,000 in license fees during the three months ended December 31, 2024 and 2023, which were recorded as acquired in-process research and development and included in research and development expenses in the unaudited interim consolidated statements of operations.   In February 2022, the Company entered into a Biological Materials License Agreement (the "InvivoGen Agreement") with InvivoGen SAS ("InvivoGen"), pursuant to which InvivoGen has granted the Company a worldwide, non-exclusive license to use certain reporter cells for research, development and/or quality control purposes. The InvivoGen Agreement has an initial term of three years and may be extended for two additional three-year periods upon written notice by the Company and payment of an approximately €<span id="xdx_90F_ecustom--PaymentForAnnualLicenseFeeObligation_iI_pn5n6_uEuro_c20241231__us-gaap--TypeOfArrangementAxis__custom--InvivoGenAgreementMember_zflUoQrnUWK1" title="Payment for annual license fee obligation">0.1 million fee per extension (approximately $<span id="xdx_90B_ecustom--PaymentForAnnualLicenseFeeObligation_iI_pn5n6_c20241231__us-gaap--TypeOfArrangementAxis__custom--InvivoGenAgreementMember_zCUBOBB1J12a" title="Payment for annual license fee obligation">0.1 million as of December 31, 2024). No license fees were incurred during the three months ended December 31, 2024 and 2023.   Collaboration agreement   In August 2024, the Company entered into a Master Clinical Collaboration Agreement (the "SOC Agreement") with the Sarcoma Oncology Center ("SOC") to advance the development of SON-1210. An Innovative Immuno Oncology Center funded by the SOC will conduct an investigator-initiated Phase 1/2a study of SON-1210 in pancreatic cancer. The Company will provide the study drug and provide support services for the study. If the Company establishes a partnership with a third party prior to the initiation of the initial efficacy combination trial under this collaboration, the Company will incur, payable to the SOC, a one-time fee equal to the greater of 5% or $1.5 million from the first upfront payment received from such third party partnership.   Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements   Research and development agreement   In December 2021, the Company entered into a Research and Development Agreement (the "Navigo Agreement") with Navigo Proteins GmbH ("Navigo"), pursuant to which Navigo will perform specified evaluation and development procedures to evaluate certain materials to determine their commercial potential. Under the terms of the Navigo Agreement, the Company has granted Navigo a royalty-free, non-exclusive, worldwide, non-sublicensable, non-transferable right and license to use certain technology to perform the evaluation and development activities, and Navigo has granted the Company (i) an exclusive, worldwide, perpetual, irrevocable, sublicensable, transferable, royalty-free right and license to research, develop, use, sell, have sold, distribute, import or otherwise commercially exploit certain materials, and (ii) a non-exclusive, worldwide, perpetual, sublicensable, non-transferable right and license to make or have made such materials. The Company incurred a $<span id="xdx_909_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_pn5n6_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--NavigoAgreementMember__dei--LegalEntityAxis__custom--NavigoProteinsGmbHMember__srt--ProductOrServiceAxis__us-gaap--TechnologyServiceMember_zMmp4jM8w2b1">0.1 million technology access fee upon execution of the Navigo Agreement, at which time it was recorded as acquired in-process research. The Company is obligated to make contingent milestone payments to Navigo totaling up to $<span id="xdx_90B_ecustom--MilestonePayments_iI_pn5n6_c20211231__us-gaap--TypeOfArrangementAxis__custom--NavigoAgreementMember__dei--LegalEntityAxis__custom--NavigoProteinsGmbHMember__srt--ProductOrServiceAxis__us-gaap--TechnologyServiceMember_zBdqvWsigEz">1.0 million upon the achievement of certain evaluation and development milestones as outlined in the Navigo Agreement, of which $<span id="xdx_909_ecustom--EvaluationMilestoneRecognized_iI_pn5n6_c20211231__us-gaap--TypeOfArrangementAxis__custom--NavigoAgreementMember__dei--LegalEntityAxis__custom--NavigoProteinsGmbHMember__srt--ProductOrServiceAxis__us-gaap--TechnologyServiceMember_z3CxiQ1rrqS6" title="Evaluation milestone recognized">0.3 million of evaluation milestones have been previously recognized. <span id="xdx_909_ecustom--MilestonePayments_iI_pn5n6_do_c20230630__us-gaap--TypeOfArrangementAxis__custom--NavigoAgreementMember__dei--LegalEntityAxis__custom--NavigoProteinsGmbHMember__srt--ProductOrServiceAxis__us-gaap--TechnologyServiceMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zV6RlbY7ORnj">No milestones were achieved and <span id="xdx_907_ecustom--LicenseFees_do_c20240401__20240630__us-gaap--TypeOfArrangementAxis__custom--NavigoAgreementMember__dei--LegalEntityAxis__custom--NavigoProteinsGmbHMember__srt--ProductOrServiceAxis__us-gaap--TechnologyServiceMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zWusCEyVm3r9">no license fees were incurred during the three months ended December 31, 2024 and 2023.   Employment agreements   The Company has entered into employment contracts with its officers and certain employees that provide for severance and continuation of benefits in the event of termination of employment either by the Company without cause or by the employee for good reason, both as defined in the contract. In addition, in the event of termination of employment following a change in control, as defined, either by the Company without cause or by the employee for good reason, any unvested portion of the employee's initial stock option grant becomes immediately vested.   380000050000000010000000The Company is obligated to make milestone payments to Cellca totaling up to $0.7 million upon the achievement of certain development and approval milestones if the Buy-Out Option is not exercised.70000010000060000060000010000000100000120001000001000001200000000012000000000010000010000000Company establishes a partnership with a third party prior to the initiation of the initial efficacy combination trial under this collaboration, the Company will incur, payable to the SOC, a one-time fee equal to the greater of 5% or $1.5 million from the first upfront payment received from such third party partnership1000001000000.0300000 5. Collaboration Revenue   New Life Agreement   Under the New Life Agreement, the Company granted New Life an exclusive license (with the right to sublicense) to develop and commercialize pharmaceutical preparations containing a specific recombinant human IL-6, SON-080 (the "Compound") (such preparations, the "Products") for the prevention, treatment or palliation of DPN in humans (the "DPN Field") in Malaysia, Singapore, Indonesia, Thailand, Philippines, Vietnam, Brunei, Myanmar, Lao PDR and Cambodia (the "Exclusive Territory"). New Life paid the Company an aggregate of $<span id="xdx_90C_ecustom--ProceedsforNegotiateLicenseAgreement_pn5n6_c20241001__20241231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_znftJAYd9fjb" title="Proceeds for negotiate license agreement">1.0 million in non-refundable upfront cash payments in connection with the execution of the New Life Agreement. The related collaboration revenue was fully recognized by December 31, 2023, as the Company had completed its performance obligations under the New Life Agreement. In December 2024, New Life informed the Company that it has elected to move its business in a different direction and provided the Company with written notice of its intention to exercise its Give Back Option, which is the right to give back the rights with respect to Products in the DPN Field in one or more countries in the Exclusive Territory. The exercise of the Give Back Option is subject to the negotiation and mutual agreement of terms between the Company and New Life.   Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements   Alkem Agreement   Under the Alkem Agreement entered into on October 8, 2024 (see Note 1), the <span id="xdx_903_eus-gaap--CollaborativeArrangementRightsAndObligations_c20241008__20241008__us-gaap--TypeOfArrangementAxis__custom--AlkemAgreementMember_z8DTEYb07Um9" title="Collavorative arrangement right and obligation">Company granted Alkem an exclusive license (with the right to sublicense) to research, develop, manufacture, import, export, market, use and commercialize pharmaceutical products containing its IL-6 (SON-080) asset (or any derivatives, fragments or conjugates thereof) (the "Compounds") (such products, the "Products") for the treatment of DPN (the "DPN Field") and to manufacture, import, export, market, use and commercialize Products for the treatment of CIPN and autonomic neuropathy (together with the DPN Field, the "Fields") in India. Except as provided for in the Alkem Agreement, the Company agreed not to develop, use, sell, offer or otherwise commercialize any Compounds or Products for use in the DPN Field in India during the term of the Alkem Agreement. The Company retains all rights to manufacture Compounds and Products anywhere in the world. The Company and Alkem will enter into a follow-on supply agreement pursuant to which the

Company will manufacture for Alkem Compounds and Products for post-Phase 2 clinical development and commercialization in accordance with the Alkem Agreement on terms to be negotiated by the parties. Pursuant to the terms of the Alkem Agreement, Alkem will bear the cost of, and be responsible for, among other things, conducting clinical studies and additional non-clinical studies (if any, subject to both parties' approval), preparing and filing applications for regulatory approval and undertaking other developmental and regulatory activities for commercializing Products in the DPN Field in India. Alkem will own and maintain all regulatory filings and approvals for Products in India. Upon payment of a Clinical Data Access Fee (as defined in the Alkem Agreement), the Company will have rights to access and use the data generated by the clinical trials conducted in connection with the Alkem Agreement. Under the terms of the Alkem Agreement, Alkem will pay the Company $<span id="xdx_902_ecustom--ProceedsforNegotiateLicenseAgreement_pn5n6_c20241001__20241231__us-gaap--TypeOfArrangementAxis__custom--AlkemAgreementMember_zowDIF2nREl" title="Proceeds for negotiate license agreement">1.0 million in upfront payments and up to an additional $1.0 million in milestone payments. Additionally, the Company is entitled to receive a royalty equal to a percentage in the low double digits of the net sales of the Product upon commercialization of SON-080 in India, less certain expenses as set forth in the Alkem Agreement.   Revenue recognition   The Company first assessed the Alkem Agreement under ASC 808, Collaborative Arrangements ("ASC 808"), to determine whether the Alkem Agreement or units of accounts within the Alkem Agreement represent a collaborative arrangement based on the risks and rewards and activities of the parties. The Company applied relevant guidance from ASC 606, Revenue from Contracts with Customers ("ASC 606"), to evaluate the appropriate accounting for the collaborative arrangement with Alkem.   Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements   In accordance with this guidance, the Company identified the following obligations under the Alkem arrangement: (i) License to research, develop, market, import, use and commercialize the Product in the DPN field in India (the "License"); and (ii) supply of Compound for a Phase 2 clinical trial ("Supply"). The future supply agreement for post-Phase 2 clinical development represents an optional purchase, which will be accounted for as a separate contract, and the Company did not identify any material right to be present. The Company determined that the License and Supply are not distinct from each other and therefore combined these material promises into a single performance obligation. The Company determined the initial transaction price of the single performance obligation to be $1.0 million, as the future development and commercialization milestones, which represent variable consideration, are subject to constraint at inception. At the end of each subsequent reporting period, the Company will reevaluate the probability of achievement of the future development and commercialization milestones subject to constraint and, if necessary, will adjust its estimate of the overall transaction price. Any such adjustments will be recorded on a cumulative catch-up basis. For the sales-based royalties, the Company will recognize revenue when the related sales occur.   Collaboration revenue from the single performance obligation related to the Alkem Agreement was recognized at the point-in-time at which the Company transferred the License and Supply to Alkem. Collaboration revenue from the single performance obligation related to the New Life Agreement was recognized over the estimated performance of the research and development activities. The Company recognized $1.0 million and $18,626 of collaboration revenue for the three months ended December 31, 2024 and 2023, respectively. As of December 31, 2024, the Company has recorded a contract asset for $0.5 million related to the Alkem Agreement, which represents the unbilled amount related to the single performance obligation and is included in unbilled collaboration revenue in the unaudited interim consolidated balance sheet.   1000000.0Company granted Alkem an exclusive license (with the right to sublicense) to research, develop, manufacture, import, export, market, use and commercialize pharmaceutical products containing its IL-6 (SON-080) asset (or any derivatives, fragments or conjugates thereof) (the "Compounds") (such products, the "Products") for the treatment of DPN (the "DPN Field") and to manufacture, import, export, market, use and commercialize Products for the treatment of CIPN and autonomic neuropathy (together with the DPN Field, the "Fields") in India. Except as provided for in the Alkem Agreement, the Company agreed not to develop, use, sell, offer or otherwise commercialize any Compounds or Products for use in the DPN Field in India during the term of the Alkem Agreement. The Company retains all rights to manufacture Compounds and Products anywhere in the world1000000.01000000.01000000.01000000.0186265000000 6. Stockholders' Equity (Deficit)   October 2023 underwritten public offering   On October 26, 2023, the Company closed a public offering of common stock and certain warrants through Chardan and Ladenburg Thalmann & Co. Inc. as underwriters, for net proceeds of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20231026__20231026__us-gaap--SubsidiarySaleOfStockAxis__custom--OctoberOfferingMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zSzGsWhDywx6" title="Proceeds from sale of common stock">3.9 million through the issuance and sale of <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20231026__20231026__us-gaap--SubsidiarySaleOfStockAxis__custom--OctoberOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zjOcrj2ISAGe" title="Sale of common stock, shares">163,281 shares of its common stock and, to certain investors, pre-funded warrants to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231026__us-gaap--SubsidiarySaleOfStockAxis__custom--OctoberOfferingMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zS3tCiUec8L3" title="Purchase of warrants">192,187 shares of common stock, and accompanying common warrants to purchase up to an aggregate of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231026__us-gaap--SubsidiarySaleOfStockAxis__custom--OctoberOfferingMember__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zvPc5HuaW1c" title="Purchase of warrants">710,931 shares of its common stock. Each share of common stock and pre-funded warrant to purchase one share of common stock was sold together with a common warrant to purchase two shares of common stock. The public offering price of each share of common stock and accompanying common warrant was $<span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20231026__us-gaap--SubsidiarySaleOfStockAxis__custom--OctoberOfferingMember__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zEQPnbSp2bY6" title="Sale price">12.80 and the public offering price of each pre-funded warrant and accompanying common warrant was $<span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20231026__us-gaap--SubsidiarySaleOfStockAxis__custom--OctoberOfferingMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zAyTLYUlW5X8" title="Sale price">12.7992. The common warrants were immediately exercisable at a price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231026__us-gaap--SubsidiarySaleOfStockAxis__custom--OctoberOfferingMember__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zPjDNuxvlQQe" title="Exercisable price">12.80 per share of common stock, expire <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231026__us-gaap--SubsidiarySaleOfStockAxis__custom--OctoberOfferingMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantMember_zbrIYoqlOsYi" title="Warrant term">five years from the date of issuance and contain an alternative cashless exercise provision. In connection with the June 2024 inducement offer, the exercise price was decreased to $<span id="xdx_90C_eus-gaap--WarrantExercisePriceDecrease_pid_c20231026__20231026__us-gaap--SubsidiarySaleOfStockAxis__custom--OctoberOfferingMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember__us-gaap--StatementEquityComponentsAxis__custom--JuneTwentyTwentyFourInducementOfferMember_zedd04yeOMfd" title="Warrants exercise price decrease">9.60 per share of common stock for common warrants that remained unexercised at the time of the offer. The pre-funded warrants were immediately exercisable at any time, until exercised in full, at a price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231026__us-gaap--SubsidiarySaleOfStockAxis__custom--OctoberOfferingMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zt9luEcDSpf1" title="Exercisable price">0.0008 per share of common stock. In addition, warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231026__us-gaap--SubsidiarySaleOfStockAxis__custom--OctoberOfferingMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_z5LOYwAHE6ec" title="Purchase of warrants">10,664 shares of common stock were issued to the underwriters as compensation for their services related to the offering. These common stock warrants have an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231026__us-gaap--SubsidiarySaleOfStockAxis__custom--OctoberOfferingMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zhyMEyBkbsP6" title="Exercisable price">16.00 per share and expire <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231026__us-gaap--SubsidiarySaleOfStockAxis__custom--OctoberOfferingMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zdtztcovxsjb" title="Warrant term">five years from the date of issuance.
    Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements   Committed equity facility   On May 2, 2024, the Company entered into the Purchase Agreement and a Registration Rights Agreement (the "Registration Rights Agreement"), each with Chardan, related to a "ChEF," Chardan's committed equity facility, or the Facility (see Note 1). Pursuant to the Purchase Agreement, the Company has the right from time to time at its option to sell to Chardan up to $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20240502__20240502__us-gaap--TypeOfArrangementAxis__custom--PurchaseAndRegistrationRightsAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFybfOfIhSj" title="Issuance of share, value">25.0 million in aggregate gross purchase price of newly issued shares of the Company's common stock, of which $<span id="xdx_908_ecustom--CommonStockAvialableToBeSold_iI_pn5n6_c20241231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAndRegistrationRightsAgreementMember_zBPgyXTUzQm"

title="Common stock avialable to be sold">24.9 million is available to be sold as of December 31, 2024. The Facility will allow the Company to raise primary equity on a periodic basis at its sole discretion depending on a variety of factors including, among other things, market conditions, the trading price of the common stock, and determinations by the Company regarding the use of proceeds of such common stock. The purchase price of the shares of common stock will be determined by reference to the Volume Weighted Average Price ("VWAP") of the common stock during the applicable purchase period, less a fixed <span id="xdx_906_ecustom--VolumeWeightedAveragePriceDiscountPercentage_iI_pid_dp_c20240502__us-gaap--TypeOfArrangementAxis__custom--PurchaseAndRegistrationRightsAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zP0wrzwlI1M3" title="Volume weighted average price discount percentage">4% discount to such VWAP, and the total shares to be purchased on any day may not exceed 20% of the trading volume of the Company's common stock during the applicable purchase period. The Purchase Agreement will be effective for a 36-month period ending May 16, 2027. Due to certain pricing and settlement provisions, the Purchase Agreement qualifies as a standby equity purchase agreement and includes an embedded put option and an embedded forward contract. The Company accounts for the embedded features in the Purchase Agreement as derivatives measured at fair value, with changes in fair value recognized in the consolidated statement of operations. The derivatives associated with the Purchase Agreement have been deemed de minimis. The Company did <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_do_c20241001__20241231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAndRegistrationRightsAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUHZ3ZLcbd0c" title="Sold shares">not sell any shares of common stock pursuant to the Purchase Agreement during the three months ended December 31, 2024.   November 2024 underwritten public offering   On November 7, 2024, the Company closed a public offering of common stock and certain warrants through Chardan, as underwriter, for net proceeds of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20241107__20241107__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChardanCapitalMarketsLLCMember_zcOj2yAajFS1" title="Net proceeds">4.2 million through the issuance and sale of <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20241107__20241107__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChardanCapitalMarketsLLCMember_zs11CMYdjRfg" title="Sale of stock">155,000 shares of its common stock, pre-funded warrants to purchase up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241107__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChardanCapitalMarketsLLCMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zCc0eCDFI18e" title="Warrants to purchase">956,111 shares of common stock, and accompanying common warrants to purchase up to an aggregate of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241107__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChardanCapitalMarketsLLCMember__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantMember_zjgchCf5nd64" title="Warrants to purchase">2,222,222 shares of its common stock. Each share of common stock and pre-funded warrant to purchase one share of common stock was sold together with a common warrant to purchase two shares of common stock. The public offering price of each share of common stock and accompanying common warrant was $<span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_c20241107__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChardanCapitalMarketsLLCMember__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantMember_zdiiHoMivov2" title="Sale of stock per share">4.50 and the public offering price of each pre-funded warrant and accompanying common warrant was $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_c20241107__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChardanCapitalMarketsLLCMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zBP6Tbb1duge" title="Sale of stock per share">4.4999. The common warrants were immediately exercisable at a price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241107__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChardanCapitalMarketsLLCMember__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantMember_zE5zcvYV47tf" title="Sale of stock per share">4.50 per share of common stock, expire <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20241107__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChardanCapitalMarketsLLCMember__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantMember_zqRXKIreQlZa" title="Warrant term">five years from the date of issuance and contain an alternative cashless exercise provision. The pre-funded warrants were immediately exercisable at any time, until exercised in full, at a price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241107__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChardanCapitalMarketsLLCMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zMN9FjKGGdc1" title="Exercisable price">0.0001 per share of common stock. All of the pre-funded warrants have been exercised as of December 31, 2024.   December 2024 registered direct and PIPE offering   On December 10, 2024, the Company closed a registered direct offering with institutional investors for the issuance and sale of <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20241210__20241210__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_z23b9PaeZUri" title="Shares for sale">768,000 shares of its common stock, pre-funded warrants to purchase up to <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241210__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_z97igj09jsD1" title="Warrants to purchase common stock">317,325 shares of common stock, and accompanying warrants to purchase up to an aggregate of <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241210__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOEzuUOVvZia" title="Warrants to purchase common stock">1,085,325 shares of its common stock. Each share of common stock and pre-funded warrant to purchase one share of common stock was sold together with a common warrant to purchase one share of common stock. The offering price of each share of common stock and accompanying common warrant was $2.23 and the offering price of each pre-funded warrant and accompanying common warrant was $<span id="xdx_90E_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20241210__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantMember_zuOOiSZmzl35" title="Offering price per share">2.2299, priced at-the-market under the rules of the Nasdaq Stock Market. The registered direct warrants were immediately exercisable at a price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241210__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFcfOyfpEPjj" title="Warrants exercise price">2.10 per share, expire <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20241210__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkjmqU8GSIS1" title="Warrants term">five years from the date of issuance and contain an alternative cashless exercise provision. The pre-funded warrants were immediately exercisable at any time, until exercised in full, at a price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241210__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zuMRlQjeR9O7" title="Exercisable price">0.0001 per share of common stock. All of the pre-funded warrants have been exercised as of December 31, 2024.   Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements   The Company closed a concurrent private placement with an existing investor for the issuance and sale of <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20241210__20241210__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zLW1iTiMumVb" title="Shares for sale">127,500 shares of its common stock, pre-funded warrants to purchase up to <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241210__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zfh3LBUeC6sj" title="Warrants to purchase common stock">545,500 shares of common stock, and accompanying warrants to purchase up to an aggregate <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241210__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztILg385kX37" title="Warrants to purchase common stock">673,000 shares of its common stock. Each share of common stock and pre-funded warrant to purchase one share of common stock was sold in the private placement ("PIPE") together with a common warrant to purchase one share of common stock. The PIPE offering price of each share of common stock and accompanying common warrant was $2.23 and the PIPE offering price of each pre-funded warrant and accompanying common warrant was $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20241210__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantMember_zd5fJqukSUQ3" title="Offering price per share">2.2299, priced at-the-market under the rules of the Nasdaq Stock Market. The PIPE warrants were immediately exercisable at a price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241210__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWhcsKIJACYi" title="Warrants exercise price">2.10 per share, expire <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20241210__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbkobwqWwtLj" title="Warrants term">five years from the date of issuance and contain an alternative cashless exercise provision. The pre-funded warrants were immediately exercisable at any time, until exercised in full, at a price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241210__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zzj2bz3XONh1" title="Exercisable price">0.0001 per share of common stock.   The Company raised net proceeds of approximately $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20241210__20241210__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_z7gBrP5e63vk" title="Proceeds from offering">3.5 million from the registered direct and PIPE offering.   Common stock warrants <span style="font-family: Times New Roman, Times, Serif; font-

size: 10pt"> As of December 31, 2024, the following equity-classified warrants and related terms were outstanding: Schedule of Warrants Outstanding <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Warrants Outstanding</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Expiration Date</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 37%; text-align: left">Common stock warrants August 2021</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsAugustTwoThousandTwentyOneMember_zT4HMegD0imb" style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right" title="Number of Warrants, Outstanding">14,031</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsAugustTwoThousandTwentyOneMember_z6AQ7kVuFmrh" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Exercise Price">2,094.4000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right">August 24, 2026</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Underwriter warrants August 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsAugustTwoThousandTwentyOneMember_zmdSj4aVYCP1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants, outstanding">284</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsAugustTwoThousandTwentyOneMember_ziimCaew90Ge" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">2,618.0000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">August 19, 2026</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Chanticleer warrants</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--ChanticleerWarrantsMember_zCAa5pjO9ybb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants, outstanding">6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">$144,144.0000 - $224,224.0000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">April 30, 2027 - December 17, 2028</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Series C warrants</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember_zvAOKF8Csofh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants, outstanding">2,297</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember_zZuq7gxjgNnc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">7,860.1600</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">October 16, 2025</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Series 3 warrants</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesThreeWarrantsMember_z6KIE3RIVXE5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants, outstanding">1,566</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesThreeWarrantsMember_zACeCN73ucMe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">717.0240</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">August 15, 2027</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock warrants February 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsFebruaryTwoThousandTwentyThreeMember_zJF4T9csF0c7" style="font: 10pt Times New Roman, Times, Serif;

text-align: right" title="Number of warrants, outstanding">31,563</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsFebruaryTwoThousandTwentyThreeMember_zvXk1pEdifBe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">190.0800</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">February 10, 2028</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Underwriter warrants February 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantFebruaryTwoThousandTwentyThreeMember_zmlKZ14CHkT6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants, outstanding">1,933</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantFebruaryTwoThousandTwentyThreeMember_z1Vl4hN8Ixg3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">237.6000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">February 8, 2028</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock private placement warrants June 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockPrivatePlacementWarrantsJuneTwoThousandTwentyThreeMember_zze5LYI0dKg7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants, outstanding">28,409</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockPrivatePlacementWarrantsJuneTwoThousandTwentyThreeMember_zNvrpPAObjPd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">12.4000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">June 21, 2029</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Placement agent warrants June 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsJuneTwoThousandTwentyThreeMember_ze8eTbAOTQte" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants, outstanding">852</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsJuneTwoThousandTwentyThreeMember_zc86gAmvlpv2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">118.7824</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">December 30, 2026</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock warrants October 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsOctoberTwoThousandTwentyThreeMember_zMX5QvaL8NJc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants, outstanding">354,994</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsOctoberTwoThousandTwentyThreeMember_z6b8qVsagXjk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">9.6000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">October 27, 2028</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Pre-funded warrants October 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsOctoberTwoThousandTwentyThreeMember_ze3lJVreskCa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants, outstanding">99,687</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsOctoberTwoThousandTwentyThreeMember_zyKFBBTjjXR" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">0.0008</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Underwriter warrants October 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsOctoberTwoThousandTwentyThreeMember_zJF03NkT1XK3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants, outstanding">10,664</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsOctoberTwoThousandTwentyThreeMember_zjQqY2csZLYk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">

16.0000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">October 24, 2028</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Placement agent warrants June 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsJuneTwoThousandTwentyFourMember_znGgktiNtDn3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants, outstanding">14,142</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsJuneTwoThousandTwentyFourMember_zintYKpL62fi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">14.8800</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">June 19, 2029</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock warrants June 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsJuneTwoThousandTwentyFourMember_zIuU1XxwkoNf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Outstanding">703,125</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsJuneTwoThousandTwentyFourMember_z0Sl4r58VHne" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">12.4000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">June 21, 2029</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock warrants November 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsNovemberTwoThousandTwentyFourMember_zrvoZ4wMavA7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Outstanding">2,222,222</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsNovemberTwoThousandTwentyFourMember_zd42lj7QuNl2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">4.5000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">November 7, 2029</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock registered direct warrants December 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsRegisteredDirectWarrantsDecemberTwoThousandTwentyFourMember_zBlzykZkwVeg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Outstanding">1,085,325</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsRegisteredDirectWarrantsDecemberTwoThousandTwentyFourMember_zthfgTBB7zVh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">2.1000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font, 10pt Times New Roman, Times, Serif; text-align: right">December 9, 2029</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock PIPE warrants December 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockPIPEWarrantsDecemberTwoThousandTwentyFourMember_zUl1zuV8u9K" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Outstanding">673,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockPIPEWarrantsDecemberTwoThousandTwentyFourMember_zFaeRSUoLFui" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">2.1000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">December 9, 2029</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Pre-funded warrants December 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsDecemberTwoThousandTwentyFourMember_zlFGBB82hK85" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Outstanding">545,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsDecemberTwoThousandTwentyFourMember_zHC9T8eUx8rg" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Exercise Price">0.0001</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New

Roman, Times, Serif; padding-bottom: 1pt; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231_zAW1dX0RrGsh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Outstanding">5,789,600</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"> </td></tr> </table>   Due to beneficial ownership limitations, 187,500 shares of common stock related to warrants that were exercised in June 2024 through the inducement offer were being held in abeyance. During the three months ended December 31, 2024, 32,375 of these shares of common stock were released from abeyance, resulting in <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedOctoberTwoThousandTwentyThreeWarrantsMember_z18w0wcH9tvk" title="Warrant, shares">155,125 shares of common stock held in abeyance as of December 31, 2024.   During the three months ended December 31, 2024, <span id="xdx_900_ecustom--StockIssuedDuringPeriodSharesNetShareSettlementOfWarrants_c20241001__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zGlYUbd2pZ64" title="Net share settlement of warrants, shares">2,419 warrants were net share settled, resulting in the issuance of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241001__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zQ57rjcHnts9" title="Sale of common stock, net of issuance costs, shares">1,209 shares of common stock, and <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20241001__20241231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_z56FOo0a0vtj" title="Number of warrant exercised">1,273,436 pre-funded warrants were exercised on a cash basis for de minimis proceeds.   During the three months ended December 31, 2023, <span id="xdx_901_ecustom--StockIssuedDuringPeriodSharesNetShareSettlementOfWarrants_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z3s3Xde0M2ua" title="Net share settlement of warrants, shares">3,590 warrants were net share settled, resulting in the issuance of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z1lPVInuHa7e" title="Sale of common stock, net of issuance costs, shares">1,795 shares of common stock, and <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20231001__20231231__srt--TitleOfIndividualAxis__custom--HolderMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zxP3chSdNuK9" title="Forfeited warrants, shares">4,302 warrants were abandoned by the warrant holder.   Sonnet BioTherapeutics Holdings, Inc. Notes to Unaudited Interim Consolidated Financial Statements   3900000163281192187710931123.8012.799212.80P5Y9.600.00081066416.00P5Y25000000.0249000000.0404200000155000956111222222224.504.49994.50P5Y0.000176800031 id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z4eE0qETfkta" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">As of December 31, 2024, the following equity-classified warrants and related terms were outstanding: Schedule of Warrants Outstanding <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Warrants Outstanding</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Expiration Date</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 37%; text-align: left">Common stock warrants August 2021</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsAugustTwoThousandTwentyOneMember_zT4HMegD0imb" style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right" title="Number of Warrants, Outstanding">14,031</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsAugustTwoThousandTwentyOneMember_z6AQ7kVuFmrh" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Exercise Price">2,094.4000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right">August 24, 2026</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Underwriter warrants August 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsAugustTwoThousandTwentyOneMember_zmdSj4aVYCP1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants, outstanding">284</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsAugustTwoThousandTwentyOneMember_ziimCaew90Ge" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">2,618.0000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">August 19, 2026</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Chanticleer warrants</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--ChanticleerWarrantsMember_zCAa5pjQ9ybb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants, outstanding">6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times,

Serif; font-size: 10pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">$144,144.0000 - $224,224.0000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">April 30, 2027 - December 17, 2028</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Series C warrants</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember_zvAOKF8Csofh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants, outstanding">2,297</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember_zZuq7gxjgNnc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">7,860.1600</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">October 16, 2025</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Series 3 warrants</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesThreeWarrantsMember_z6KIE3RIVXE5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants, outstanding">1,566</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesThreeWarrantsMember_zACeCN73ucMe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">717.0240</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">August 15, 2027</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock warrants February 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsFebruaryTwoThousandTwentyThreeMember_zJF4T9csF0c7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants, outstanding">31,563</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsFebruaryTwoThousandTwentyThreeMember_zvXk1pEdifBc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">190.0800</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">February 10, 2028</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Underwriter warrants February 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantFebruaryTwoThousandTwentyThreeMember_zmlKZ14CHkT6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants, outstanding">1,933</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantFebruaryTwoThousandTwentyThreeMember_z1Vl4hN8Ixg3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">237.6000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">February 8, 2028</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock private placement warrants June 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockPrivatePlacementWarrantsJuneTwoThousandTwentyThreeMember_zze5LYI0dKg7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants, outstanding">28,409</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockPrivatePlacementWarrantsJuneTwoThousandTwentyThreeMember_zNvrpPAObjPd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">12.4000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockPrivatePlacementWarrantsJuneTwoThousandTwentyThreeMember_zNvObA0I6uQi" title="Expiration date">June 21, 2029</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Placement agent warrants June 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsJuneTwoThousandTwentyThreeMember_ze8eTbAOTOte" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants, outstanding">852</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsJuneTwoThousandTwentyThreeMember_zc86gAmvlpv2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">

118.7824</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">December 30, 2026</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock warrants October 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsOctoberTwoThousandTwentyThreeMember_zMX5QvaL8Nfc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants, outstanding">354,994</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsOctoberTwoThousandTwentyThreeMember_z6b8qVsagXjk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">9.6000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">October 27, 2028</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Pre-funded warrants October 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsOctoberTwoThousandTwentyThreeMember_ze3lJVreskCa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants, outstanding">99,687</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsOctoberTwoThousandTwentyThreeMember_zyKFBBTjjXR" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">0.0008</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Underwriter warrants October 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsOctoberTwoThousandTwentyThreeMember_zJF03NkT1XK3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants, outstanding">10,664</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsOctoberTwoThousandTwentyThreeMember_zjQqY2csZLYk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">16.0000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">October 24, 2028</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Placement agent warrants June 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsJuneTwoThousandTwentyFourMember_znGgktiNtDn3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants, outstanding">14,142</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsJuneTwoThousandTwentyFourMember_zintYKpL62fi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">14.8800</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">June 19, 2029</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock warrants June 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsJuneTwoThousandTwentyFourMember_zIuU1XxwkoNf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Outstanding">703,125</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsJuneTwoThousandTwentyFourMember_z0Sl4r58VHne" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">12.4000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">June 21, 2029</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock warrants November 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsNovemberTwoThousandTwentyFourMember_zrvoZ4wMavA7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Outstanding">2,222,222</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsNovemberTwoThousandTwentyFourMember_zd42lj7QuNl2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">4.5000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">November 7, 2029</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times

New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock registered direct warrants December 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsRegisteredDirectWarrantsDecemberTwoThousandTwentyFourMember_zBlzykZkwVeg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Outstanding">1,085,325</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsRegisteredDirectWarrantsDecemberTwoThousandTwentyFourMember_zthfgTBB7zVh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">2.1000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">December 9, 2029</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock PIPE warrants December 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockPIPEWarrantsDecemberTwoThousandTwentyFourMember_zUl1zuV8u9K" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Outstanding">673,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockPIPEWarrantsDecemberTwoThousandTwentyFourMember_zFaeRSUoLFui" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price">2.1000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockPIPEWarrantsDecemberTwoThousandTwentyFourMember_ztnCn2AUT8ch" title="Expiration Date">December 9, 2029</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Pre-funded warrants December 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsDecemberTwoThousandTwentyFourMember_zlFGBB82hK85" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Outstanding">545,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsDecemberTwoThousandTwentyFourMember_zHC9T8eUx8rg" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Exercise Price">0.0001</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231_zAW1dX0RrGsh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Outstanding">5,789,600</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr></table> *140312094.40002026-08-242842618.00002026-08-196144144.0000224224.00002027-04-302028-12-1722977860.16002025-10-161566717.02402027-08-1531563190.08002028-02-101933237.60002028-02-082840912.40002029-06-21852118.78242026-12-303549949.60002028-10-27996870.00081066416.00002028-10-241414214.88002029-06-1970312512.40002029-06-2122222224.50002029-11-0710853252.10002029-12-096730002.10002029-12-095455000.000157896001875003237515512524191209127343635901795430 2 7. Share-Based Compensation   In April 2020, the Company adopted the 2020 Omnibus Equity Incentive Plan (the "Plan"). There were <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOmnibusEquityIncentivePlanMember_ztXPU1gcNQGa">5 shares available for issuance under the Plan as of December 31, 2024. On January 1, 2025, the total number of shares authorized under the Plan increased to <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20250101__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOmnibusEquityIncentivePlanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ze3oePclQHp1" title="Number of shares available for issuance">120,302. The Plan increases the amount of shares issuable under the Plan by four percent of the outstanding shares of common stock at each January 1, each year. The Plan permits the granting of share-based awards, including stock options, restricted stock units and awards, stock appreciation rights and other types of awards as deemed appropriate, in each case, in accordance with the terms of the Plan. The terms of the awards are determined by the Company's Board of Directors.   Restricted stock units and awards   On January 1, 2024, <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20240101__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLCvYUPckC2b" title="Number of shares granted">9,175 restricted stock units ("RSUs") and <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20240101__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zK0hngobdmy7" title="Number of shares granted">7,977 restricted stock awards ("RSAs") were granted, <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20250101__20250101__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWrBeGySAeqa" title="Vesting percentage">100% of which vested on January 1, 2025. Any unvested RSUs or RSAs will be forfeited upon termination of services. The fair value of an RSU or RSA is equal to the fair market value of the Company's common stock on the date of grant. RSU and RSA expense is amortized straight-line over the vesting period.   The Company recorded share-based compensation expense associated with the RSUs and RSAs in its accompanying unaudited interim consolidated statements of operations as follows: Schedule of Share-based Compensation Expense <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20241001__20241231_zZZcISH0aAOe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20231001__20231231_z8ge8pfk3Ndb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman,

Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_407_eus-gaap--ShareBasedCompensation_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z9Nl6gDvWMR3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Research and development</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">28,268</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">24,554</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zwj2O35zr0d1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">General and administrative</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">32,127</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">25,451</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ShareBasedCompensation_zoXZFXp4k3L" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Share-based compensation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">60,395</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">50,005</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The following table summarizes RSU activity under the Plan: Schedule of Restricted Stock Units Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Average Grant</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">RSU</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Date Fair Value</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; padding-bottom: 2.5pt">Unvested balance at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zD68hPQRMbG9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Unvested balance">9,175</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzoZWDsOetKi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Unvested weighted average grant fair value, balance">14.08</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   During the three months ended December 31, 2024, there were no RSUs granted, vested or forfeited. As of December 31, 2024, there was <span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_do_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAqHGO5OGW2i" title="Unrecognized compensation expense">no unrecognized compensation expense relating to unvested RSUs granted.   The following table summarizes RSA activity under the Plan: Schedule of Restricted Stock Awards Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New

Roman, Times, Serif; font-size: 10pt">Weighted</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Average Grant</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">RSAs</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Date Fair Value</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; padding-bottom: 2.5pt">Unvested balance at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z0VmbaZF8n5i" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Unvested balance">7,977</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zGzYT0paxk0e" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Unvested weighted average grant fair value, balance">14.08</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr></table> <p id="xdx_8A3_zZWCUbq2hVc4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">During the three months ended December 31, 2024, there were no RSAs granted, vested or forfeited. As of December 31, 2024, there was no unrecognized compensation expense relating to unvested RSAs granted.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p>5120302917579771<p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zdWs0jW6prrc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company recorded share-based compensation expense associated with the RSUs and RSAs in its accompanying unaudited interim consolidated statements of operations as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> Schedule of Share-based Compensation Expense</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20241001__20241231_zZZcISH0aAOe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20231001__20231231_z8ge8pfk3Ndb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_407_eus-gaap--ShareBasedCompensation_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z9Nl6gDvWMR3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Research and development</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">28,268</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">24,554</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zwj2O35zr0d1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">General and administrative</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">32,127</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">25,451</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ShareBasedCompensation_zoXZFXp4k3L" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Share-based compensation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">60,395</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">50,005</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr></table> 2826824554321272545160395500005 The following table summarizes RSU activity under the Plan: Schedule of Restricted Stock Units Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times,

Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Average Grant</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">RSU</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Date Fair Value</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; padding-bottom: 2.5pt">Unvested balance at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zD68hPQRMbG9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Unvested balance">9,175</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzoZWDsOetKi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Unvested weighted average grant fair value, balance">14.08</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 917514.080<p id="xdx_89A_ecustom--ScheduleOfNonvestedRestrictedStockAwardsActivityTableTextBlock_zphm3lVlofSj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes RSA activity under the Plan:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> Schedule of Restricted Stock Awards Activity</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Average Grant</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">RSA</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Date Fair Value</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; padding-bottom: 2.5pt">Unvested balance at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z0VmbaZF8n5i" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Unvested balance">7,977</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zGzYT0paxk0e" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Unvested weighted average grant fair value, balance">14.08</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 797714.080 8. Subsequent Events   The Company has evaluated subsequent events from the balance sheet date through February 13, 2025, the date at which the unaudited interim consolidated financial statements were available to be issued.   Subsequent to December 31, 2024, the Company sold <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20250101__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8juV1AgWd16" title="Sale of stock, number of shares issued in transaction">58,270 shares of common stock pursuant to the Purchase Agreement for net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250101__20250101__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zeKdzzEa4UL3" title="Proceeds from issuance of common stock">0.1 million.   The Company received preliminary approval of its application to sell up to $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20250101__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zWjYMOGn8n49" title="Net operating losses">0.8 million of its New Jersey state net operating losses through the Program (see Note 1). In February 2025, the Company identified a buyer. As outlined in the Program, although the sale has been approved and a buyer identified, the Company must still execute an arrangement with such buyer to consummate a sale of the state net operating losses.   On February 10, 2025, Jay Cross submitted his resignation as our Chief Financial Officer, effective February 21, 2025. In connection with Mr. Cross's resignation, on February 12, 2025, the Company's board of directors (the "Board") appointed Donald Griffith, CPA, the Company's current Controller and a member of the Board, to succeed Mr. Cross as its Chief Financial Officer effective February 21, 2025.   On February 12, 2025, Stephen McAndrew, Ph.D., the Company's Senior Vice President of Business Development, was appointed as the Company's Chief Business Officer. In connection with his appointment, Dr. McAndrew entered into an employment agreement with the Company, dated February 12, 2025 (the "McAndrew Agreement"). Dr. McAndrew's employment as the Company's Chief Business Officer will commence on February 17, 2025. Pursuant to the McAndrew Agreement, Dr. McAndrew is entitled to, among other things, (i) an annual gross base salary of $330,000 ("Base Salary") and (ii) eligibility for a performance-based cash bonus of up to 35% of the Base Salary, as determined by the Board. 58270100000800000330000falsefalsefalsefalse